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Abstract 
The aim of this thesis was to better characterise migraine through more detailed investigation 
of selected headache-related factors and to compare these factors with those seen in other 
commonly occurring recurrent headaches. The factors investigated in this thesis were 
neurochemical profile; cervical musculoskeletal impairments; and patient experience, 
represented by pain and disability characteristics, emotional state and other personal factors. 
This thesis had six objectives: first, to describe how headaches are defined in clinical trials; 
second, to compare levels of brain neurochemicals in migraine to controls; third, to explore 
the relationship between brain neurochemicals and relevant disease characteristics of 
migraine; fourth, to characterise cervical musculoskeletal impairments and patient experience 
in migraine compared to non-migraine headaches and controls; fifth, to characterise the six-
month clinical course of migraine and non-migraine headaches and the factors associated 
with the clinical course; and lastly, to examine changes in disability over six months in 
migraine and non-migraine headaches. 
To set the stage for characterising migraine and comparing it with non-migraine headaches 
including tension-type headache (TTH) and cervicogenic headache (CGH), it was first 
necessary to determine how these headaches were defined in clinical trials. Whilstthe 
International Classification of Headache Disorders (ICHD) has been widely considered the 
reference standard for classification and diagnosis of headaches, the extent of its application 
in research wasunknown.In Chapter Two, a systematic review was conducted with the aim of 
exploringand describingthe definitions of study populations in clinical trials of frequent 
recurrent headaches including TTH, CGH and cluster headache. Data extracted from each 
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study which defined the study population included the ICHD diagnostic criteria as reported in 
theeligibility criteria and baseline characteristics of participants. This review 
demonstratedthat there was general adherence (205 out of 229 studies, 89.5%) to the ICHD 
criteria in defining study populations. However, whilst study populations were diagnosed 
mostly through interview, clinical examination and diary entry, over half of all studies 
(127/229, 55.5%) did not specify the method used to define the study population. 
Furthermore, reporting of inclusion criteria differed between headache types: pain intensity 
was most commonly reported for migraine and tension-type headache studies (n = 123, 
66.1% and n = 21, 67.7%, respectively), episode frequency for cluster headache studies (n = 
5, 71.4%), and neck-related pain for cervicogenic headache studies (n = 3, 60%). Few studies 
described the extent to which study populations demonstrated ICHD features at baseline. The 
findings of Chapter Two provide insight into applicability of results of clinical trials to 
clinical populations and highlight the need for detailed reporting of participant selection in 
research. 
The levels of brain neurochemicals in migraine and the relationship between neurochemicals 
and clinicalcharacteristics were explored ina case-control study (Chapters Three and Four). 
Twenty individuals withmigraine and 20 age- and gender-matched controls were recruited. In 
Chapter Three, the levels of neurochemicals, particularly gamma-aminobutyric acid (GABA), 
were comparedbetween individuals with migraine and controls using proton magnetic 
resonance spectroscopy (1H-MRS). Usingaspecialised technique called Mescher-Garwood 
point resolved spectroscopy, two significantfindings were demonstrated. First, individuals 
with migrainehad higher GABA levels[median (IQR)1.41 (1.31–1.50)institutional units] 
compared to age- and gender-matched controls [1.18 (1.12–1.35)institutional units, p = 
0.002]. Second, brain GABA levels hadgood diagnostic accuracy in classifying individuals as 
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having migraine [area under the curve = 0.84 (95% confidence interval, CI, 0.71 to0.96), p< 
0.001]. Specifically, brain GABA levels of 1.30 institutional units or higher had a positive 
likelihood ratio of +2.67 to indicate migraine, with a sensitivity of 84.2% and specificity of 
68.4%. These findings imply a putative role of GABA in the pathophysiology of migraine 
and suggest the potential of GABA as a biomarker for migraine. 
In Chapter Four, the process of validating GABA as a migraine biomarker was continued.In 
this chapter,the association between brain GABA levels and clinical characteristics,including 
pain, central sensitisation symptoms, emotional state, and headache-related disability, in 
individuals with migraine were explored in a case-control design.Fair positive associations 
were found between GABA levels and pain scores (ρ = .47, p = 0.04) and between GABA 
levels and symptoms of central sensitisation (ρ = .48, p = 0.03). GABA levels were not 
associated with headache history, frequency, duration or intensity, with symptoms of 
emotional state, nor with levels of disability (p> 0.05).These findings corroborate the role of 
GABA in migraine pathophysiology and its potential as a biomarker. These findings also 
provide preliminary evidence for the usefulness of measuring pain and central sensitisation in 
characterising migraine. 
To characterise cervical musculoskeletal impairments and patient experience in different 
headache types, we conducted a cross-sectional study in Chapter Five. The aim of this study 
was to compare the prevalence and severity of these factors between migraine and non-
migraine headaches. Forty people with migraine, 45 people with non-migraine headaches 
(TTH and CGH), and 40 controls participated. Fewer participants in the migraine group [n=4 
(10%)] had cervical articular impairment compared to the non-migraine group [n=26 (58%); 
p < 0.001].Further, migraine and non-migraine groups did not differ on cervical muscle 
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impairment measures. Participants in the migraine group[median (IQR) 7.0 (6.0–7.0)]had 
more intense pain (numerical rating scale 0–10)than non-migraine[5.0 (4.0–7.0)p = 0.009]. 
Similarly,the migraine group [43(31–53) out of 90]had higher disability scoreson Headache 
Disability Questionnairethan the non-migraine group [27 (20–42); p = 0.006].Additionally, a 
combination of the following variableshad 80.0% sensitivity and 75.6% specificity in 
identifying migraine: no pain on manual examination of the cervical spine, less change in 
deep cervical extensors thickness during contraction measured using real-time ultrasound 
imaging, less frequent headaches, and higher disability scores. Thus Chapter Five presents 
new evidence that a combination of tests can differentiate migraine from non-migraine 
headaches. 
In Chapter Six, we followed the same participants from the cross-sectional studyover 6 
months in a longitudinal cohort design.The aim of this study was to characterisemigraine, 
based on its clinical courseover 6 months. A secondary aim was to examine the extent to 
which the clinical course was associated with demographic and headache characteristics, 
cervical musculoskeletal impairments, and other personal factors.Participants underwent 
physical examination of cervical musculoskeletal impairments at baseline, completed an 
online diary daily for 6 months, and self-report questionnaires at baseline, 1, 3 and 6 months 
after enrolment. Headache frequency, intensity and activity interference varied from month-
to-month for all headache types.However, day-to-day variability in headache intensity and 
activity interference differed between migraine and non-migraine headaches, with greater 
volatility demonstrated in migraine. A multifactorial model comprising migraine headache 
group, receiving physical treatment, pain on manual examination of the upper cervical joints, 
higher scores on disability questionnaires, and lower level of physical activity explained 
27.7% of the variation in disability at 3 months (p = 0.040). Likewise, a multifactorial model 
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comprising headache group, age, headache intensity, activity interference, pain on manual 
examination of the upper cervical joints, disability scores and level of physical activity 
explained 32.3 % of the variation in disability at 6 months (p = 0.031). Of these factors, pain 
on manual examination of the upper cervical joints increased the odds of non-improvement in 
disability by nearly 6 times [odds ratio (95% CI) = 5.58 (1.14 to 27.42); p = 0.034]. These 
results therefore suggest that the clinical course of migraine is more volatile than non-
migraine headaches and that factorsinfluencing this clinical course include headache features, 
cervical joint dysfunction, disability and physical activity. 
The final objective of examining short- to medium-term changes in disability in different 
headachetypes was investigated inChapter Seven.The internal responsiveness of four 
commonlyused questionnaires was evaluated by calculating effect size, and external 
responsiveness was calculated using receiver operating characteristic curve analysis.The 
Headache Impact Test-6 and Headache Disability Questionnaire were the most responsive 
questionnaires for individuals with both migraine and non-migraine headaches. At short-term 
(3 months), effect sizes (84% CI) ranged from 0.31 (0.07 to 0.56) to 0.47 (0.11 to 0.82), 
while at medium-term (6 months), effect sizes ranged from 0.40 (0.06 to 0.74) to 0.60 (0.26 
to 0.94). Headache Disability Questionnaire generally had the greatest external 
responsiveness to change in headache frequency at both short- and medium-term [areas under 
the curve (95% CI) 0.52 (0.32 to0.72) to 0.69 (0.49 to 0.89). These findings add to the 
evidence presented in Chapter Four by demonstrating that the HIT 6 and the HDQ are 
usefulquestionnaires to use in clinical practice. 
Collectively, this thesis provides deeperinformation regardingthe nature and characteristics of 
migraine compared with non-migraine headaches, including TTH and CGH.This thesis has 
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established the potential of GABA as a biomarker for migraine, and thus implies the possible 
role of GABA in the disease process. In addition to exploring the neurochemical profile, this 
thesis has also characterised migraine according to cervical musculoskeletal impairments and 
patient experience embodying disability, pain, central sensitisation, and other personal 
factors. The implications for clinical practice are to assess cervical musculoskeletal 
impairments and patient experience to facilitate diagnosis and prognostication, and to educate 
patients on the nature of their headaches. Findings from the thesis may also be used by 
guideline developers, providing stimulus for further discussions regarding the definition of 
migraine and the reporting of participant selection criteria, with reference to this definition, in 
clinical trials. Future research directions are identified in validating GABA as a biomarker for 
migraine and elucidating its pathophysiology. By characterising migraine more fully, findings 
from this thesis will inform the development of effective treatments that possibly could be 
targeted at GABA or at the clinical characteristics found to be present in migraine. Ultimately 
this should achieve better health outcomes for people with migraine and other headaches. 
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Chapters Two to Seven appear in journal publication format, each of these chapters contains 
its own abstract, introduction, methods, results, discussion, conclusion, and reference list. 
Similarly, Chapters One and Eight each has its own reference list. Appendices for specific 
chapters appear at the end of the thesis. 
The aims of this thesis can be found in the abstract, Chapter One and Chapter Eight. Chapter 
One serves as the introductory chapter for the thesis and therefore presents concepts related to 
Chapters Two to Seven. Chapter Eight serves as the concluding chapter and summarises the 
findings and their implications to headache definitions, clinical practice and future research. 
The studies presented in Chapters Two to Seven were granted ethics approval by The 
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CHAPTER ONE 
Current Understanding of Migraine and  
Recurrent Non-Migraine Neck-Related Headaches 
1
This is Meg. She’s that girl who makes plans with friends 
then cancels at the last minute, giving the migraine excuse. 
“Migraine Meggy”, she’d be teased, but then her friends 
realised it really wasn’t funny! 
Meg’s friends thought that migraine was just a bad headache; but it’s more 
than that. Sure, Meg gets headaches –severe, throbbing headaches that are 
unrelenting for a day or two each time. But aside from headaches, Meg’s 
migraines make her vomit and intolerant to light, so much so that she had to 
install block out curtains. During her migraine attacks, Meg lies still in her 
dark room, debilitated and frustrated, waiting for her symptoms to pass or for 
science to find a cure. 
[Excerpt from Three-Minute Thesis Presentation (3MT®) by Maria Eliza Ruiz Aguila; 
Winner,Faculty of Health Sciences 3MT® 2014] 
The more we know about characteristics of frequently occurring headaches, the more Meg 
and her friends might understand these conditions. With better understanding, we might also 
move closer to effective targeted headache treatments. Thus the aim of this thesis was to 
further characterise migraine and other headaches that most frequently present in primary 
care namely tension type headache and cervicogenic headache. This was achieved by firstly 
exploring conventions in classification and diagnosis. The next step was an exploration of the 
neurochemical profile of migraine, which yielded new findings about migraine biochemistry. 
The final step was to investigate cervical musculoskeletal impairments, clinical 
characteristics and elements of a patient’s experience that characterise migraine and 
distinguish it from other headache types. 
Illustration by David Val Christian B. Agoncillo, 2014 
forpresentations related to studies in this thesis 
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This introductory chapter provides a background on the current understanding of migraine 
and other frequently presenting recurrent headaches. In the first section, headaches, in 
general, and migraine, tension-type headache and cervicogenic headache, in particular, are 
defined according to the most accepted classification system, the International Classification 
of Headache Disorders. These definitions directly influence prevalence estimates of these 
recurrent neck-related headaches. Therefore the next section discusses the prevalence and 
associated burden of these headaches. Next, an overview of the clinical features and course of 
these headaches is discussed, followed by a depiction of cervical musculoskeletal 
impairments which may be common to migraine, tension-type headache and cervicogenic 
headache. Pathophysiologic mechanisms which may relate with the clinical features and 
course of migraine, tension-type headache and cervicogenic headache are then briefly 
described. This section on pathophysiology also includes a summary of extant evidence on 
neurochemical profile in migraine. The current understanding of the clinical features and 
pathophysiology of these recurrent headaches directly influences their assessment. Therefore 
the previous sections set the stage for the subsequent section on assessment of these 
headaches. To broaden the perspective on the pain experience of patients with migraine, 
tension-type headache and cervicogenic headache, a section is provided describing factors 
that may influence patient experience, and the importance of measuring these factors and the 
impact of headache on patients’ lives. 
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Current understanding of migraine and recurrent non-migraine neck-
related headaches 
1.1. Headache definition, classification and diagnosis 
The term “headache” refers to a symptom of many disorders and is characterised as either a 
painful or nonpainful discomfort of the entire head, including the face and upper neck (1). 
“Headache” may also refer to an independent disorder characterised by headache and other 
associated symptoms. Because the term “headache” may be used inconsistently, a consensus 
on headache terminology is necessary to facilitate communication in research and clinical 
practice. 
The first demonstration of a consensus in headache terminology was with the publication of a 
classification system for headache disorders in 1962 (1). This classification system was based 
on aetiology of headaches and comprised brief definitions of a limited number of headache 
types. Headaches were then classified as “vascular headache” or “muscle-contraction” 
headache, and so forth. This system eventually was perceived to be inadequate and confusing 
(2). Headache practitioners acknowledged the need for a better classification system that 
would operationally define headache types. Thus the International Classification of Headache 
Disorders (ICHD) emerged (3). ICHD was the first classification system to be accepted 
internationally as the uniform approach to the classification and diagnosis of headache 
disorders in clinical practice and research (4). The operational definitions in ICHD 
wereoriginally based on clinical descriptions of headache attacks and mostly based on expert 
opinion, in the absence of published evidence at that time. Increased evidence from clinical 
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trials and longitudinal and epidemiological studies of, genetics, neuroimaging, and 
pathophysiology from have since contributed to the evolution of ICHD.  
The ICHD, now its third edition, beta version (ICHD-3 beta),is the reference standard for 
headache classification and diagnosis (5, 6). ICHD reflects research evidence on which 
headache types should be classified, which rules to apply to diagnose the headache types, and 
how to organise these headache types. The current ICHD divides headaches into three 
groups; primary headache, secondary headache and other headaches not better classified as 
primary or secondary headache. This third group includes painful cranial neuropathies and 
other facial pain. Across the three parts of ICHD are 14 main headache types, each defined 
operationally with key clinical criteria required for its diagnosis. Primary headaches are those 
whose aetiologies are unknown and which exist independent from any other medical 
condition (7), such as migraine, tension-type headache (TTH) and cluster headache. In 
contrast, secondary headaches are those whose aetiologies are known, attributed to another 
medical disorder, such as headaches due to trauma, vascular disorder, infection, and disorder 
of the neck (such as cervicogenic headache, CGH). Thus primary headaches, like migraine 
and TTH, are classified and diagnosed based on headache features whilst secondary 
headaches, such as CGH are classified and diagnosed based on headache features, the 
presence of the causative disorder and evidence for causation of the headache by the 
causative disorder (8). 
Definitions for migraine and non-migraine headaches, such as TTH and CGH, have been 
refined over the three editions of the ICHD. Whilst the diagnostic criteria for these headaches 
have not fundamentally changed from the first to the third editions of ICHD, these criteria 
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have been revised to reflect current evidence and to improve applicability of the criteria (9). 
The current diagnostic criteria for migraine, TTH and CGH are presented in Table 1. 
The diagnostic criteria in Table 1 specifying the minimum number of attacks or episodes for 
classification of migraine, TTH and CGH connote the recurrent nature of these headaches. 
The diagnostic criteria also illustrate how TTH and CGH are relatively “featureless” 
compared to migraine, as many of the diagnostic features of TTH and CGH refer to absence 
of symptoms (10). 
Compared to the clear definitions of migraine and TTH since the first ICHD, it was only 
since the second ICHD that CGH has been recognised as a discrete headache. Prior to this, 
ICHD referred to “headache…associated with disorder of …neck…” (3). This was despite 
the introduction of the term “cervicogenic headache” by Sjaastad and colleagues in 1983 (11) 
to refer to headaches provoked by head or neck movements. The non-use of the term 
“cervicogenic headache” as a headache classification in the first ICHD reflected the view that 
CGH was not considered sufficiently proven in the absence of a neck disorder (12). Aside 
from the ICHD definition, an even more specific definition of CGH is provided by the 
Cervicogenic Headache International Study Group (CHISG) (13). A comparison between the 
ICHD and the CHISG definitions of CGH is presented in Table 2. The required criteria for 
diagnosis differ between the two classification systems. For example, ICHD required clinical 
evidence of cervical lesion whilst the CHISG required diagnostic blockade. The CHISG 
criteria also lists other characteristics of less importance for diagnosis which are not included 
in the ICHD criteria. 
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Table 2. Comparison of diagnostic criteria for cervicogenic headache 
The International Classification of Headache 
Disorders, 3rd edition (beta version) 
Diagnostic Criteria Cervicogenic Headache International 
Study Group 
Cephalalgia. 2013;33:629–808. Headache. 1998;38(6):442–445. 
Required criterion: Clinical, laboratory and/or imaging 
evidence of a disorder or lesion within the cervical 
spine or soft tissues of the neck known to be able 
to cause of headache 
Clinical, laboratory and/or 
imaging evidence of a 
cervical lesion 
At least two of the following: 
• Headache has developed in temporal
relation to the onset of the cervical disorder
or appearance of the lesion 
• Headache has significantly improved or
resolved in parallel with improvement in or
resolution of the cervical disorder or lesion 
• Cervical range of motion is reduced and
headache is made significantly worse by
provocative manoeuvres 
• Headache is abolished following diagnostic
blockade of cervical structure or its nerve 
supply 
Evidence of causation of 
the headache by the 
cervical spine lesion 
At least one of the following (in decreasing 
importance) : 
• Headache pain similar to the usually
occurring one induced subjectively
and/or iatrogenically (part of
confirmatory combination of criteria)
o by neck movement and/or
sustained awkward head
positioning,(may be the 
sole criterion for neck
involvement), and/or 
o by external pressure over 
the upper cervical or
occipital region on the
symptomatic side 
• Restriction of cervical range of motion 
• Ipsilateral neck, shoulder, or arm pain 
of a rather vague non-radicular nature
or, occasionally, arm pain of a
radicular nature 
Evidence by diagnostic anaesthetic blockades 
(part of confirmatory combination of criteria) 
Unilaterality of the head 
pain, without sideshift 
Part of confirmatory combination of criteria for 
scientific work 
Other characteristics that 
are not part of 
confirmatory combination 
of criteria 
Moderate-severe, non-throbbing, and non-
lancinating pain, usually starting in the neck 
Episodes of varying duration 
Fluctuation, continuous pain 
Only marginal effect or lack of effect of 
indomethacin  
Only marginal effect or lack of effect of 
ergotamine and sumatriptan 
Female sex 
Not infrequent occurrence of head or indirect 
neck trauma by history, usually of more than 
only medium severity 
Various attack-related phenomena, only 
occasionally present, and/or moderately 
expressed when present  
• Nausea 
• Phonophobia and photophobia 
• Dizziness 
• Ipsilateral “blurred vision”
• Difficulties on swallowing 
• Ipsilateral oedema, mostly in the
periocular area 
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For purposes of this thesis, study populations for migraine and non-migraine headaches (TTH 
and CGH) were defined using the ICHD diagnostic criteria. For CGH, ICHD was used 
instead of CHISG criteria for consistency with the other headache types, as ICHD lists 
criteria for migraine, TTH and CGH. We also could not fulfil CHISG criteria in our protocols 
because we did not include diagnostic blockade, which is required to confirm diagnosis using 
CHISG criteria. 
Efforts continue toward further improving the ICHD to mirror the advancing state of 
evidence on headaches. Thus far, the ICHD has been a useful tool in understanding 
headaches and in developing and evaluating new headache treatments. The ICHD has been 
deemed useful to clinicians when a patient’s diagnosis is uncertain, and to researchers, in 
selecting patients for clinical trials (4). Being internationally accepted, the ICHD represents 
agreement among headache practitioners in headache classification. As such, ICHD 
facilitates the conduct of epidemiological studies on the prevalence and disability rates of 
certain headache types. Consequently ICHD contributes to the appreciation of headaches as a 
public health concern. 
Despite continuous efforts to improve the classification system, there remain challenges in its 
use related to the nature of the classification system itself and the nature of the headaches. 
First, diagnosis based on headache features as in ICHD may be challenging because 
symptoms may overlap between headache types (14). Further one headache type may coexist 
with one or more other headache types (15) which may influence the ability to detect a 
headache diagnosis (16). Symptom overlap or coexistence of other headaches may be the 
reason for at least 50% of migraine cases being misdiagnosed as other headache types, such 
as episodic tension-type headache (17), sinus headache or stress-related headache (18). 
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Second, the decision rules in the ICHD present diagnostic criteria for each headache types 
as a combination of clinical features. For example, diagnosis for migraine without aura 
requires that two criteria be met, at least two of four symptoms for one criterion be present, 
and at least one of two symptoms in another criterion be present (see Table 1) (8). These 
decision rules increase the sensitivity of the ICHD but also increases the heterogeneity of 
the possible clinical presentations of a particular headache diagnosis. Another criticism for 
such a system is its complexity may be confusing and consequently influence reliability of 
diagnosis (19). 
Despite these challenges in headache diagnosis, the ICHD remains the most widely 
accepted classification system for headache diagnosis. In fact, guidelines for clinical trials 
of headaches recommend using the ICHD in selecting participants such that all participants 
fulfil the diagnostic criteria for the headache being studied (20-22). Such guidelines allow 
standardisation of study populations despite the complex presentations of headaches. In the 
clinics, however, the extent of use of ICHD for diagnosis is unknown. This may be 
interesting to know as the ICHD is not designed to be used for day-to-day clinical practice 
for obvious headache cases but only when the diagnosis is uncertain (8).Chapter Two presents 
the extent of application of ICHD in defining study populations in treatment efficacy trials. 
Diagnosis could be improved by a better understanding of mechanisms, especially of the 
primary headaches. Elucidating pathophysiological mechanisms of migraine and TTH, for 
example, could add objective criteria to the classification system. These could include 
biological markers, presented in ChaptersThree and Four,for migraine. As well, other 
clinical features beyond those currently listed in the ICHD diagnostic criteria could be 
explored to improve diagnosis and improve understanding of headaches. Thus we compared 
clinical features between headache groups in Chapters Five and Six. 10
1.2. The prevalence of migraine and non-migraine headaches 
Headaches are among the most prevalent disorders in the world. Prevalence studies estimate 
that half to three quarters of adults aged 18 to 65 years in the world have had a headache in 
the last year (23), with about half (47%) having an active headache disorder (24).Three of the 
most prevalent headaches are migraine and non-migraine headaches, namely TTH and 
CGH. Of these three, migraine and TTH are the most prevalent, affecting more than 10% of 
the world population (25). It is therefore not surprising that migraine, TTH and the 
combination of these are the top three headaches seen in primary and specialist clinics (23). 
Migraine ranks seventh in global prevalence among all disorders according to the 2013 
Global Burden of Disease Study, affecting nearly 850 million individuals (25). Among 
headaches, migraine ranks second, with a total prevalence of 10%, and 11% among adults 
(24). Females are two to three times as likely as males to have migraine (14). Thus the 
prevalence of migraine among adults is different between females (mean = 16.6%) and males 
(mean = 7.5%) (26). The most common age of onset of migraine is between 20 to 30 years 
(27). Its prevalence increases with age, peaks at around 40 years, after which the prevalence 
declines, especially for women (14). 
TTH is more prevalent than migraine, ranking second among all disorders according to the 
2013 Global Burden of Disease Study, affecting about 1.6 billion individuals (25). Unlike 
migraine, females are only slightly more affected by TTH than males, with a male:female 
ratio of 4:5 (14). Thus the prevalence of TTH among adults is also only slightly different 
between females (mean = 22.36%) and males (mean = 16.9%). (26) Compared to migraine,
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TTH has a later age of onset between 25 and 30 years (14). Its prevalence peaks between 30 
and 39, increases until 50 years, and slightly declines with age. 
The third most prevalent headache seen in primary and specialist care is CGH (28). 
Compared to the epidemiological studies for migraine and TTH, only a few have investigated 
CGH. Of the few prevalence studies on CGH, most were clinic-based studies that calculated 
prevalence rates of CGH as defined by ICHD or the CHISG, resulting in varied prevalence 
estimates. In a small study using modified ICHD criteria, prevalence of CGH was estimated at 
17.8% among adults with frequent headaches aged 20 to 59 years (29). Another clinic-based 
study among adults with idiopathic headaches (30) that used ICHD criteria (3) reported CGH 
prevalence to be 16.1%. Larger studies resulted in smaller prevalence estimates. For example, 
prevalence was estimated by Sjaastad and colleagues (31) to be 4.1% for adults aged 18 to 65 
years old fulfilling the CHISG criteria (32). In the only population study of CGH prevalence 
to date [(33) cited in (34)], even lower prevalence estimates were reported: 0.4% using the 
ICHD criteria (3) and 1% applying five criteria of the CHISG (32). The varied prevalence 
estimates for CGH nevertheless indicates that CGH is among the most frequently seen 
headaches in the clinics. 
1.3. The burden of migraine and non-migraine headaches 
Headaches cause substantial burden on the individual and the society. On the individual level, 
burden arises from the pain and other symptoms associated with the headache (35). These 
symptoms may reduce functional ability, which may, in turn, reduce work productivity and
pay. Work loss for individuals with headaches is estimated at 4.2 days per year, with 70% of 
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this time lost due to reduced effectiveness at work (36). This cost of headaches on work 
productivity and income is highlighted because headaches are more prevalent in the work 
productive years. For individuals with recurrent headaches, the burden caused by the 
headache is not only present when symptoms are active but also in between headache 
episodes. Individuals with headaches may need to modify their lifestyle and defer social 
activities in attempt to prevent another headache episode. 
On the societal level, burden arises from direct treatment costs and the indirect costs of 
reduced work productivity. Between direct and indirect costs, direct costs are estimated to be 
lower because 50% of individuals with headaches worldwide do not consult health 
professionals (23), Therefore the burden of headaches is believed to be underestimated (14). 
Nevertheless, the burden due to the two most prevalent headaches, migraine and TTH, has 
been characterised in a number of population studies. 
Migraine is the sixth most disabling condition in the world in 2013, making it the most 
disabling headache, based on years lived with disability (YLDs) (25). Disability calculated 
using YLDs considers prevalence and severity of health loss. Migraine is more disabling than 
TTH based on YLDs, causing more than 28 billion YLDs, compared to more than 2 million 
YLDs for TTH (25). A slightly different picture is presented when disability is calculated 
using frequency, duration of headache episode and intensity. Using this calculation, TTH 
was found to cause disability at least as much as, if not more than, as migraine (24). It is 
apparent then that migraine and TTH are the two most disabling headaches, migraine for its 
higher severity than TTH, and TTH, for its higher prevalence than migraine. 
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No epidemiologic study has focused on disability due to CGH. Yet evidence from clinic-
based studies and randomised controlled trials indicates that individuals with CGH 
experience disability comparable with that in migraine and TTH. In a retrospective clinic-
based study, 32–65% of patients with chronic and recurrent CGH perceived the impact of 
their headache on function and relationships to be considerable or debilitating (37). The area 
of function most affected in 87% of the patients was loss of productivity in paid work. The 
considerable disability associated with CGH was also demonstrated at baseline by 
participants of randomised controlled trials when measured using different patient-report 
questionnaires(38-41). 
This thesis characterises disability in migraine (Chapter Four), how it differs from non-
migraine headaches (Chapter Five), how it changes over time (Chapters Six) and its 
measurement using patient-report outcomes (Chapter Seven). Collectively, the studies in 
these chapters sought to broaden understanding of the burden of different headache types on 
the individual level. 
1.4. Clinical presentation and course of migraine and non-migraine headaches 
Headache disorders that affect most individuals at least at one point of their lives (23) are 
usually non-life threatening, mild or infrequent (42). In contrast, headaches that recur have 
varied clinical presentations that may not be fully captured in the ICHD criteria (Table 1). 
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1.4.1. Clinical presentation of migraine and non-migraine headaches (TTH and 
CGH) 
1.4.1.1. Clinical presentation of migraine 
Migraine presents as two main subtypes: migraine without aura and migraine with aura (8). 
Both subtypes may occur a few episodes in a month (i.e., episodic migraine) or as many as 15 
or more days in a month (i.e., chronic migraine) (8). Migraine with aura differs from 
migraine without aura in that the headache in migraine with aura is preceded, accompanied 
or, in rare cases, followed by transient neurologic symptoms. For both migraine subtypes, the 
headache phases, and aura phase in the case of migraine with aura, are preceded by prodrome 
(or premonitory) symptoms (8, 43). The prodrome symptoms may be general, such as 
anorexia, neck pain or stiffness, or food cravings, or psychogenic, such as mood change, 
fatigue, irritability, or neurogenic, such as difficulty concentrating, repetitive yawning (44-
47). Prodrome symptoms may also include those also associated with the headache phase 
such as nausea, photophobia, or phonophobia (46). It is estimated that as much as 86.9% of 
people with migraine experience these prodrome symptoms (45, 46). These symptoms may 
again appear after the headache phase, as postdrome (or resolution) symptoms. Other typical 
postdrome symptoms include weakness, lightheadedness and mild residual head discomfort 
(43, 48). Postdrome symptoms appear to be as prevalent as prodrome symptoms, with as 
much as 80% of people with migraine experiencing at least one postdrome symptom (46). 
Further, nausea and/or vomiting during the headache phase and aggravation of the headache 
by routine physical activity are considered the most characteristic symptoms of migraine 
without aura, distinguishing it from other headache types (49, 50). 
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1.4.1.2. Clinical presentation of TTH 
TTH may also occur a few episodes in a month (i.e., episodic TTH) or as many as 15 or more 
days in a month (i.e., chronic TTH). (8). Of those features of TTH listed in Table 1, the 
feature ‘not aggravating the headache by routine physical activity’ is considered its most 
characteristic symptom, and that which most distinguishes it from migraine (49, 51, 52). 
Unlike migraine, prodrome and postdrome symptoms are believed to be not typical of TTH 
(53). The absence of prodrome and postdrome symptoms is consistent with the 
characterization of TTH as a “featureless” headache (51). However, a clinical study reported 
prodrome symptoms similar to those in migraine in as many as 87% of patients with episodic 
TTH(44). In the same study, significantly fewer patients with TTH reported general 
prodrome symptoms such as food craving, feeling cold, and diarrhoea than patients with 
migraine. The similarity in prodrome symptoms between migraine and TTH led some authors 
tohypothesise that these two headache types are not distinct entities and instead are the same 
headache from the opposite severity spectrum (54, 55). This hypothesis is discussed later in 
section 1.6.5. Still, similar features between migraine and TTH necessitate in-depth 
characterisation of these headaches to arrive at a correct diagnosis and effective treatment. 
Such characterisation is the focus of Chapter Five of this thesis. 
Aside from TTH features listed in Table 1, another feature common to patients with TTH is 
increased pericranial tissue tenderness that is present during the headache phase and even 
between headache episodes (8). Among patients with TTH, increased tenderness [mean 
tenderness score 25.6 (SD 5.8) out of 48] was demonstrated in cephalic and neck muscles and 
the coronoid and mastoid processes (56). Pericranial tenderness is thought to increase with 
16
headache frequency (57), although this was not replicated when data on headache frequency 
were prospectively collected (56). 
1.4.1.3. Clinical presentation of CGH 
Whilst the scientific community is in general agreement as regards the clinical presentation of 
migraine and TTH, the same cannot be said for CGH. Table 2 demonstrates this, with the 
ICHD criteria differing from the CHISG criteria on clinical features that are considered 
diagnostic for CGH (8, 13). Although the unilaterality of the headache that does not shift 
sides is a confirmatory diagnostic criterion for CGH according to the CHISG criteria but not 
for ICHD, this feature is recognised by ICHD as a typical presentation of CGH (8). Similarly, 
ICHD recognises CGH as being typically reproduced by external pressure on the cervical 
spine (8). Alternatively, pain radiating to the shoulder and arm, moderate, non-throbbing 
pain, and history of neck trauma have also been suggested as being the most characteristic 
associated symptoms of CGH (58). 
It is therefore relevant to determine the extent to which patients demonstrate the above-
named features that are believed to be characteristic of migraine non-migraine headaches, 
specifically TTH and CGH. Doing so would characterise these headaches better and possibly 
clarify their distinction. With this in mind, we determined the extent to which study 
populations in treatment efficacy trials demonstrated these characteristics, and other ICHD 
criteria, in a systematic review presented in Chapter Two. To date, no study has investigated 
how study populations are defined and therefore to whom evidence from the trials should 
apply. Chapter Two fully explores this question. 
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1.4.2. Overlaps and variability in clinical presentation of migraine and non-
migraine headaches (TTH and CGH) 
Despite the characteristic features of each headache type, migraine and common non-
migraine headaches, such as TTH and CGH, may have overlapping symptoms (14). For 
example, characteristic features of migraine such as photophobia and aggravation of the 
headache by physical activity are also present in 65% and 53%, respectively, in patients with 
TTH (52). Other diagnostic criteria for migraine, namely headache episodes lasting 4 to72 
hours, unilaterality, pulsating quality, and aggravation of headache by physical activity, were 
also demonstrated by patients with TTH (33%, 11%, 23%, and 17%, respectively) (59). 
Additionally, photophobia and phonophobia were also demonstrated in patients with TTH 
(18% for both symptoms) (59) and CGH (19% and 28%, respectively) (60); and nausea and 
vomiting were also present in CGH (up to 45.5% and 21.2%, respectively) (28). Conversely, 
muscle tenderness, which is typically associated with TTH, was present to a notable degree in 
patients with migraine (tenderness scores of 10–18 out of 24) (57). Headache provoked during 
passive accessory intervertebral movement examination of the cervical spine, considered 
diagnostic for CGH, was also present in 95% of patients with migraine and 100% of patients 
with TTH (61). Moreover, all three headaches may present as unilateral headache that does 
not shift sides (62). Despite the presence of features diagnostic for other headache types, it 
must be noted that patients examined in the studies cited above still fulfilled the ICHD 
diagnostic criteria for their respective headache types. Still, the overlapping symptoms may 
make diagnosis challenging in some cases. 
An individual with one headache type may also present with features characteristic of one or 
more other headaches if these headaches coexist (63). It is estimated that 94% of individuals 
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with migraine have coexisting TTH (64). The coexistence between migraine and TTH has 
been well recognised, that it has been included in the list of chronic overlapping pain 
conditions by the National Institutes of Health and the United States of America Congress 
(65). A population study, for example, demonstrated overlap of TTH with migraine without 
aura in 83% of the sample and with migraine with aura in 75% of the sample (59). Similarly, 
CGH has been shown to coexist with migraine and/or TTH in 1.8% of a population (31). 
Aside from possible overlap in features between headache types, clinical presentation of 
migraine, TTH and CGH may also be variable within the individual and between individuals 
with the same headache type (49). Individuals with the same headache type may have 
different clinical features considering the nature of the ICHD criteria where a combination of 
features is used as basis for diagnosis. Therefore, not all diagnostic features are expected to 
be present in individuals with a particular headache type. As well clinical presentations may 
vary within the same individual and still fulfil the ICHD criteria for that particular headache 
type. Of the three headache types, it is apparent from the classification rules in Table 1 that 
clinical presentations that migraine has more variable symptoms than the non-migraine 
headaches. 
The apparent overlap of headache classifications and variability of headache features 
provides another important reason to improve characterisation of migraine as distinct from 
non-migraine headachessuch as TTH and CGH. Such characterisation of migraine was 
explored in Chapters Five and Six. 
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1.4.3. Clinical course of migraine and non-migraine headaches 
1.4.3.1. Clinical course of migraine 
Aside from understanding the typical clinical features of migraine and non-migraine 
headaches, understanding their clinical courses may also aid in characterising them better. 
Evidence suggests that migraine does not progress. A 12-year retrospective study showed that 
migraine episodes ceased in 29% of patients experiencing episodic migraine, and of those 
who continued to experience migraine episodes 80% reported reduced frequency and. more 
than 50% reported milder intensities, 1.6% developed chronic migraine (66). Similarly, a 
prospective study showed that headache frequency decreased by more than 25% in almost 
50% of patients whilst 16% reported an increase in headache frequency by more than 25% 
(67). 
1.4.3.2. Clinical course of TTH 
Similar to migraine, evidence suggests that TTH generally does not progress (68). Population 
studies showed that 45 to 48% remitted into less frequent or no headaches, 16 to 75% had an 
unchanged frequency and 25 % progressed from episodic to chronic TTH (69, 70). Whilst 
TTH does not seem to progress, TTH persists throughout young adulthood(71) or possibly 
throughout life (72). Larger population studies are needed to know if TTH remits at some 
point. 
Whether migraine and TTH remit or progress is predicted by non-modifiable and modifiable 
factors. For migraine, the most commonly cited factor in literature for progression of 
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migraine is high frequency, with headaches occurring 10–14 days per month having 20 times 
the risk for progression compared to a frequency ≤ 4 days per month (73).Persistence of 
chronic tension-type headache is associated with coexistence of other headaches (74), 
medication overuse (74, 75), older age at baseline, duration longer than 6 years (75). 
Other factors associated with progression of migraine or TTH to chronic daily headaches in 
population studies are low level of education, arthritis, female, diabetes, previously married, 
obese, and white people (76). Odds ratios for these factors for headache progression were 
highest for low level of education [odds ratio (95% confidence interval) 3.35 (2.1 to 5.3)] and 
lowest for white people [0.77 (0.6 to 1.0) for non-white people compared to white people]. Of 
these factors, obesity was the most notable as it was also associated with five times higher 
risk of developing new chronic daily headache, suggesting its importance as a potential target 
of intervention to modify outcome in headaches (77). Conversely, remission after one year 
from chronic to episodic headache was associated with higher education, diabetes, non-white 
people, being married,and increasing age for females (78). Odds ratios for these factors for 
remission was highest for higher education [odds ratio (95% confidence interval) 0.21 (0.1 to 
0.5) for low education level] and lowest for increasing age for females [1.04 (1.01 to 1.06)]. 
It is difficult to explain how diabetes could be associated with remission. Nonetheless, 
diabetes being a factor for both remission from and progression to chronic daily headache 
suggests its potential as another target of intervention in headaches. For migraine, other factors 
associated with remission are lower headache frequency [0.29 (0.11 to 0.75) for headaches 
occurring 25–31 days per month compared to 15–19 headache days per month], absence of 
allodynia [0.29 (0.11 to 0.75)] and non-use of preventive medications [0.41 (0.23 to 0.75) for 
preventive medication use] (78). 
21
1.4.3.3. Clinical course of CGH 
In contrast to the studies done on clinical course of migraine and TTH, only one study to date 
exclusively investigated the course of cervicogenic headache, observed in a cohort who had 
whiplash injury. In this study by Drottning and colleagues (79), recovery from CGH was 
shown to be slow, with 35% of patients still having CGH and further restrictions in cervical 
range of motion six years after the whiplash injury. The authors hypothesised that it may take 
as long as 10 years for the patients to be fully symptom-free. The trajectory of this slow 
recovery showed a steep drop in the initial months followed by a slow decline, without 
reaching full freedom from symptoms at six years. Results of this study suggest non-recovery 
from CGH to be associated with younger age (mean age 44 years old versus 62 in those who 
recovered from CGH); being female (82 % versus 71% in those who recovered). More 
longitudinal studies with larger sample size of participants without associated whiplash injury 
are needed to clarify the course of CGH. Given the trajectory of recovery shown in this study, 
it would be interesting to validate the short-term course in individuals with CGH. In this 
thesis, we investigated the six-month course of CGH and TTH compared with migraine in 
Chapter Six. 
Less is known too about short-term clinical course of migraine. One longitudinal 
observational study has shown that clinical characteristics of migraine remain stable over 3 
months, with a general trend toward improvement in disability (80). Additionally, improved 
disability had a moderate positive association with headache frequency in 3 months. Further 
evidence is required to build on these findings by identifying the short-term variations in 
headaches. Thus Chapter Six of this thesis characterises how migraine changes over 6 
months. 
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1.5. Cervical musculoskeletal impairments in migraine and non-migraine headaches 
1.5.1. Rationale for considering cervical musculoskeletal impairments in 
migraine and non-migraine headaches such as TTH and CGH 
An understanding of impairments that are associated with particular headache types may help 
further elucidate their pathophysiologic mechanisms. Among impairments that can be present 
in both migraine and non-migraine headaches are those that affect the cervical 
musculoskeletal system. This is due to the bidirectional relationship between nociceptive 
input from the upper cervical spine and the brainstem, resulting from the convergence of 
trigeminal and cervical afferents on to common neurons in the TCC. Cervical 
musculoskeletal impairments may include neck pain and tenderness, deviations from normal 
cervical articular movement and function and deviation from normal cervical muscle 
structure and function. 
The proposed role of cervical musculoskeletal impairments in TTH is illustrated by its former 
descriptor ‘muscle contraction headache’. This term reflects the hypothesised origin of TTH 
and the involvement of the muscles in the head and neck (8).Similarly, CGH is recognised as 
a neck-related headache and its classification requires association of neck-related symptoms 
and signs of impairments (8). Further studies characterising the nature of cervical 
musculoskeletal impairments in migraine and non-migraine headaches are needed to 
determine any similarity and difference between these headaches. 
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1.5.2. Neck pain 
Understanding the nature of neck pain in headaches is particularly important because of the 
widespread global prevalence of and disability due to neck pain itself (25).Neck pain has 
been shown in population and clinical studies to be prevalent in individuals with migraine or 
non-migraine headaches. Prevalence rates for coexisting neck pain with migraine ranged 
from 16.7 % to as high as 72.6% (81-85).The association between migraine and chronic neck 
pain ranged from odds ratio (95% confidence interval) 4.25 (3.84 to 4.70) (81) to 5.4 (5.2 to 
5.6) (83). Whether neck pain is a comorbidity or is part of the migraine picture is still 
contentious. One study supporting the notion that neck pain is part of the migraine episode 
reported neck pain during the headache phase of the migraine in 69.4% of the patients (86). 
Neck pain was also present among 36.1% of individuals with non-migraine headaches (82). 
The frequent coexistence of neck pain in migraine and non-migraine headaches suggest the 
relevance of specifying other impairments of the cervical spine that may be associated with 
the headaches. 
1.5.3. Cervical articular impairments 
Cervical articular impairment, as used in this thesis, comprises restricted cervical range of 
motion along the cardinal planes of movement and painful or restricted joint dysfunction 
demonstrated during manual examination of the upper cervical spine or on rotation in flexion 
at C1-C2 segment. There is strong evidence for the presence of cervical articular impairment 
in headaches, especially for CGH. Their presence in CGH is expected and is among the 
diagnostic criteria for CGH (8, 13). Cohort studies have demonstrated worse cervical articular 
impairments in patients with pure CGH (87, 88) or CGH coexisting with one or more other 
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headaches (89) compared to individuals with migraine, TTH and controls. These impairments 
included less cervical spine range of flexion (87), extension (87, 88) and rotation (88), and 
pain on manual examination of the upper three cervical spine(87, 88). Individuals with CGH 
also had significantly reduced range of motion at C1-C2 segment compared to individuals 
with migraine and those with mixed headaches (90). These results from cohort studies were 
consistent with a meta-analysis of studies, which further showed medium to large effect sizes 
for differences in these impairments between individuals with CGH and controls (91). 
Cervical rotation with cervical flexion showed the largest effect size [standardised mean 
difference = 22.23 (95% confidence interval 22.73 to 21.73)] in favour of decreased range in 
individuals with CGH compared to controls (91). 
Evidence of cervical articular impairment is scant for TTH but suggests restrictions in 
cervical range of motion in both episodic and chronic TTH. Specifically, restrictions in 
cervical flexion, and right lateral flexion and rotation were demonstrated in episodic TTH 
compared to controls (92) whilst restrictions in cervical rotation were demonstrated in 
chronic TTH compared to episodic TTH and controls (93). In both studies, the groups which 
demonstrated restrictions in cervical mobility also had reduced flexor head posture. This may 
explain the difference in findings for episodic TTH and cervical mobility between the two 
studies. One study also reported referred head pain on manual examination of the upper 
cervical spine in 14 out of 14 participants with TTH (61). More studies are required to 
validate these results. 
Evidence of cervical articular impairment in migraine has been inconsistent. There is 
evidence for restricted cervical rotation and upper cervical rotation in flexion in women with 
episodic or chronic migraine compared to controls (94) and the presence of symptomatic 
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upper cervical joints in 80–100% of participants with migraine (61, 94). However, these 
findings conflict with those indicating no cervical articular impairment in migraine compared 
to controls (87, 88). 
1.5.4. Cervical muscle impairments 
Cervical muscle impairments in migraine and non-migraine headaches are also relevant to 
characterise in relation to cervical articular impairment due to the role of the cervical 
muscles, especially the deep muscles, in supporting the cervical joints. Cervical muscle 
impairments may be deviations from normal physical structure, muscle behaviour 
(comprising motor control aspects of contraction), and muscle function (including strength 
and endurance). 
1.5.4.1. Impairments in cervical muscle physical structure 
Impairments in the structure of the cervical muscles have been observed in individuals with 
TTH and CGH. In individuals with chronic TTH, atrophy of the rectus capitis posterior 
muscleswas detected using magnetic resonance imaging(95). In individuals with CGH, 
atrophy of the semispinalis capitis was also observed as reduced cross sectional area 
measured using real-time ultrasound at C2 level on the symptomatic side in CGH(88). This 
atrophy was not observed for other cervical extensors, namely,the longissimus capitisand 
trapezius muscles of the cervical extensors, nor in migraine, TTH or controls. Muscle atrophy 
in CGH was hypothesised to be associated with nerve supply coming from the dorsal rami of 
the upper cervical nerves. 
26
1.5.4.2. Impairments in cervical muscle behaviour 
Impairments in muscle behaviour during contraction have strong evidence for CGH although 
these have also been demonstrated in TTH and migraine. In CGH, large effect sizes 
[standardised mean difference = -1.86 (95% confidence interval -2.74 to 0.99) were reported 
for CGH compared to controls in terms of timing and activation of the deep cervical flexors 
tested using the cranio-cervical flexion test (91). These findings were confirmed in more 
recent studies that showed increased activity in the sternocleidomastoid in CGH, not 
observed in migraine, TTH and controls (88). Similar impairments in muscle behaviour were 
demonstrated in chronic TTH, where significantly lower pressure scores were achieved 
during the cranio-cervical flexion test compared to controls (96). 
Whilst cranio-cervical flexion test did not reveal impairments in muscles in migraine, one 
impairment in muscle behaviour observed in episodic and chronic migraine was significantly 
higher coactivation of cervical extensors during maximal cervical flexion compared to 
controls(97, 98).Similarly, higher coactivation of antagonistic muscles was demonstrated in 
chronic TTH during cervical flexion, and also during cervical extension (99).Whether or not 
the increased muscle activity observed in these headache types is associated with any 
comorbid cervical musculoskeletal disorder remains to be investigated. 
1.5.4.3. Impairments in cervical muscle function 
Impairments in cervical flexor function have been consistently demonstrated in CGH 
compared to controls. These have been characterised as significantly worse than controls, 
with large effect sizes indicating weaker cervical flexors [standardised mean difference = 
27
-0.93 (95% confidence interval -1.33.to 0.54)] and lower cervical flexor endurance 
[standardised mean difference = -1.56 (95% confidence interval -2.83 to 0.29)] in CGH (91). 
These findings were confirmed in a more recent, larger cohort study (88). 
One study (100) demonstrated similar findings for cervical extensors in CGH with large 
effect sizes, indicating weaker cervical extensors [standardised mean difference = -1.01 (95% 
confidence interval -1.59to -0.42)](91). Cervical extensor endurance in traumatic CGH was 
also lower than controls (100). Aside from impaired strength and endurance, less extensibility 
of the upper trapezius, scalenes and suboccipital extensors was also demonstrated in CGH, 
not present in migraine with aura and controls (87). 
Whilst some studies did not find impairments in cervical muscle function in TTH and 
migraine compared to CGH, there is evidence for weakness of cervical extensors in TTH 
compared to controls (101). Moreover, there is also evidence for weaker cervical 
extensorsand of slower peak force generation for cervical flexion and left lateral flexion in 
episodic migraine compared to controls (97). 
Other cervical musculoskeletal impairments have been shown to be present in migraine, TTH 
and/or CGH, including forward head posture (87, 93, 102), active trigger points (92, 93, 103), 
and pressure pain threshold on sites relevant to cervical symptoms (87) but these are beyond 
the scope of this thesis. Nevertheless, the cervical musculoskeletal impairments described 
previously for migraine, CGH and TTH remain to be elucidated as to their role in headache 
pathophysiology. Future studies may investigate whether these impairments are a prodrome, 
comorbidity, cause, result, or feature of the headache phase. A step toward understanding the 
nature of these impairments is exploring other cervical musculoskeletal impairments that may 
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be present in migraine and non-migraine headaches. This gap is particularly true for 
migraine, where evidence of cervical musculoskeletal impairments is not as conclusive as for 
TTH and CGH. The need to investigate cervical musculoskeletal impairments and their 
assessment further is also suggested by an expert panel of physiotherapists which 
nevertheless recommended a comprehensive examination of musculoskeletal impairments in 
headaches (104). These findings point to the need for more evidence comparing cervical 
musculoskeletal impairments in migraine and non-migraine headaches, especially for 
impairment in cervical extensor function. Thus Chapters Five and Six describe cervical 
musculoskeletal impairments in migraine and compare these with non-migraine headaches. 
1.6. Overview of pathophysiology of migraine and non-migraine headaches 
1.6.1. Common anatomy and physiology of headaches 
Despite the different possible presentations and causes of headaches, it is believed that all 
headaches involve the activation of the trigeminocervical complex (TCC) in the brainstem 
(105, 106). Within the TCC, trigeminocervical neurons receive input from the periphery 
through the trigeminal nerve, the upper three cervical nerves (Figure 1) and other cranial 
nerves such as the facial, glossopharyngeal and vagus nerves (105, 106). The TCC makes 
direct ascending connections with different areas in the brainstem, including the superior 
salivatory nucleus and the ventrolateral periacqueductal grey (PAG), the rostral ventromedial 
medulla (RVM), the nucleus cuneiformis, and with higher structures including several 
hypothalamic and thalamic nuclei, which in turn make ascending connections with the cortex 
(Figure 2). Thus activation of the second order neurons in the trigeminocervical neurons 
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results in transmission of nociceptive information to higher-order neurons in the thalamus. 
This in turn, leads to activation of other higher-order pain centres in the cortex, such as the 
frontal cortex, sensory cortex, insula, and cingulate cortex, resulting in headache (107). 
Figure 1.The trigeminocervical nucleus, spanning the brainstem and spinal cord. It receives 
afferents from the spinal tract of the trigeminal nerve and from the upper cervical 
spinal nerves. It sends input to supraspinal centres through the trigeminothalamic 
tract. Reprinted from The Lancet Neurology, Vol. 8, Bogduk N &Govind J, 
Cervicogenic headache: an assessment of the evidence on clinical diagnosis, 
invasive tests, and treatment, pp 959–968, 2009, with permission from Elsevier. 
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Figure 2. Overview of the peripheral and central nociceptive system involved in the 
transmission and modulation of headache. Reprinted from Headache Currents, Vol. 
2, Bartsch T, Goadsby PJ, Anatomy and physiology of pain referral patterns in 
primary and cervicogenic headache disorders, pp 42–48, 2005, with permission 
from SAGE Publications. 
For chronic headaches, regardless of the headache type, there is also a common nociceptive 
processing system that involves the peripheral and central nociceptive pathways. Peripheral 
mechanisms involve the activation and sensitisation of peripheral nociceptors and Aδ and C 
fibres (108, 109). The activation may be due to ischaemia, mechanical stimuli or chemical 
mediators (110)whilst the peripheral sensitisation may be due to dysfunctional nociceptive 
processing. The exact nature of the peripheral sensitisation remains unknown but may 
involve increased nociceptive input from the periphery (for example the pericranial muscles, 
as depicted in Figure 3), resulting in plastic changes in the trigeminal nucleus. As a 
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consequence, the normally inhibitory effect of low-threshold Aβ fibres on nociceptive 
transmission in the spinal dorsal horn is altered to a pain stimulatory effect, and the response 
to nociceptive Aδ and C fibres is potentiated. The amplified nociceptive stimulation of 
supraspinal structures, such as the TCC and in the thalamus, results in central sensitisation 
(111). It appears that this central sensitisation also involves the activation of descending 
modulating pathways in the RVM and in the PAG such that nociceptive input is amplified 
and the anti-nociceptive input that would normally inhibit pain in a healthy nociceptive 
system is inhibited. Together, these mechanisms may induce and maintain the chronic 
headache. Central sensitisation due to amplified nociceptive input and disinhibition from the 
descending modulating systems may result in clinical features such as hyperalgesia, increased 
sensitivity to typically noxious stimuli. Additionally, when the TCC is sensitised, stimulus 
that are normally noxious such as movement or touch may trigger a headache. This increased 
sensitivity to typically non-noxious stimuli, allodynia, is manifested, for example, as 
hypersensitivity during shaving or when wearing glasses (110, 112). 
32
Figure 3.Dysfunctional nociceptive processing in chronic headaches. Important alterations 
from the normal nociceptive state are presented in bold. V, Trigeminal nerve; C2 
and C3, second and third cervical segment of the spinal cord; PAG, periaqueductal 
grey; RVM, rostral ventromedial medulla. Reprinted from Cephalalgia, Vol. 20, 
Bendtsen L, Central sensitization in tension-type headache — Possible 
pathophysiological mechanisms, pp 486–508, 2000, with permission from SAGE 
Publications. 
Beyond the TCC, there are other anatomic structures and functional interactions involved in 
the pathophysiology of the different headache types. Mechanisms that are specific for each 
headache type are believed to be manifested as differences in clinical features. Different 
theories have been proposed for the pathophysiology of specific headache types but so far 
these are still inadequate in clarifying the entire range of possible features of a headache 
within and between individuals or the definite mechanisms that initiate, propagate and 
terminate the headache. Until these features and mechanisms are conclusively elucidated, 
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headache assessment, diagnosis and treatment may remain nonspecific and inadequate. Thus 
pathophysiology of headaches remains a dynamic research area. The current widely known 
pathophysiologic theories for migraine, TTH and CGH are briefly discussed in sections 
1.6.2–1.6.4 below. 
1.6.2. Overview of pathophysiology of migraine 
1.6.2.1. Role of the trigeminovascular system 
The currently accepted theory on the pathophysiology of migraine implicates the activation 
and sensitisation of the trigeminovascular system. (TGVS) (Figure 4) (111, 113). The TGVS 
consists of the trigeminal ganglion (TG) projecting peripherally to cerebral blood vessels and 
dura mater innervated by the trigeminal nerve and centrally to the TCC in the brainstem and 
spinal cord. Peripheral nociceptive input in migraine comes from nociceptors and nociceptive 
A-δ and C fibres innervating the intracerebral blood vessels and dura mater (113).
Nociceptive input is then transmitted to the trigeminal nerve, the trigeminal ganglion, and 
synapses on second-order neurons in the TCC (53). 
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Figure 4.Pathophysiology of migraine.The key pathways for the pain are the 
trigeminovascular input from the meningeal vessels, which passes through the 
trigeminal ganglion and synapses on second-order neurons in the trigeminocervical 
complex in the brainstem. These neurons, in turn, decussates in the brainstem and 
form synapses with neurons in the thalamus. Reproduced with permission from 
Goadsby PJ, Lipton RB, Ferrari MD. Migraine — Current understanding and 
treatment.N Engl J Med. 2002;346:257–270. Copyright Massachusetts Medical 
Society. 
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1.6.2.2. Mechanisms responsible for headaches phases 
The exact mechanisms responsible for the premonitory, aura, headache, and postdrome 
phases of headaches, and transitioning between these phases, remain unclear. Current 
evidence suggests that mechanisms for these phases overlap (43). During the premonitory 
phase, it is generally believed that the central nervous system mediates the release of 
dopamine and activity of and therefore blood flow in the hypothalamus increase (114). This 
increased activity in the hypothalamus is part of a bigger picture of brain excitability before 
the headache phase. Just before or during the aura phase, regional cortical cerebral blood flow 
decreases, usually starting posteriorly and progressing anteriorly (8). This decrease in blood 
flow is above the threshold for ischaemic injury. The decrease in blood flow gradually 
progresses into increased blood flow over a period of hours. This change in regional cortical 
cerebral blood flow is believed to be due to cortical spreading depression (CSD). In CSD, a 
slow short-lasting depolarization wave propagates across the cortex that is followed by a 
period of inactivity. In migraine forms that do not have auras, a similar mechanism is 
postulated to be present but inactive. Animal studies suggest that CSD could be the 
mechanism activating the TGVS. This probable link provides an explanation for the headache 
that follows aura in migraine. As previously described, the headache phase of migraine 
involves activation and sensitisation of meningeal nociceptors and afferents say by 
mechanical stimuli. The sensitisation of meningeal afferents provides a mechanism that may 
explain the throbbing nature of the migraine headache as well as the exacerbation of the 
headache during events (e.g., coughing or sudden head movements) that increase intracranial 
pressure (111). Experiments showed that activation of the meningeal nociceptors may initiate 
a cascade of events leading to the release of inflammatory mediators. This neurogenic 
inflammation then results in the sustained activation and sensitisation of the meningeal 
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afferents, which then activates and sensitises second-order and third-order trigeminocervical 
neurons. Activation of the trigeminocervical neurons then activates different areas of the 
brain, resulting in headache. After the headache phase, symptoms occur comprising the 
postdrome phase. The few studies about postdrome phase suggest that this phase is linked 
with persistent changes in brain activity past the headache phase (115). These changes 
include bilateral posterior cortical hypoperfusion, midbrain and hypothalamic activation, and 
increased blood flow in the visual cortex. The overlap of postdromal symptoms with 
premonitory symptoms sets the scene for further investigation of the nature of postdromal 
symptoms.Therefore it is thought that migraine is fundamentally due to an abnormality in 
central processing of not necessarily abnormal input. Yet in some cases, as described earlier, 
meningeal nociceptors may also be involved (Figure 2). The exact mechanisms of 
sensitisation in migraine remain unknown. 
1.6.2.3. Role of neurochemicals in migraine pathophysiology 
Another area in migraine pathophysiology that remains inadequately understood is the 
relationship between migraine and alterations in neurochemicals in the central nervous 
system, particularly the possible imbalance between excitatory and inhibitory 
neurotransmission (116, 117). The activation of the TGVS is thought to release calcitonin 
gene-related peptide (CGRP) and substance P which, in turn, cause further vasodilation and 
neurogenic inflammation through the secretion of inflammatory mediators such as serotonin, 
adenosine diphosphate, platelet-activating factor, nitric oxide, and interleukins. The 
vasodilation and neurogenic inflammation further sensitise the neurons in the TG, followed 
by the neurons in the TNC in the brainstem (116). It is through this mechanism that CGRP, in 
particular, is postulated to transmit nociceptive information. 
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As regards excitatory-inhibitory neurotransmitter imbalance, there is evidence of a number of 
anomalies in metabolism of excitatory neurotransmitters in migraine compared with controls. 
These include higher glutamate-to-glutamine ratios in the occipital cortex (118) and altered 
levels of N-acetyl-aspartylglutamate in the anterior cingulate cortex as well as the insula 
(119). In contrast to evidence for excitatory neurotransmitters in migraine, the role of the 
principal inhibitory neurotransmitter gamma aminobutyric acid (GABA) has only been 
indirectly demonstrated, at best. For example, increased salivary GABA levels have been 
reported in people with migraine without aura during attacks, compared to interictal periods 
and to people with non-migraine headaches (120). These results suggested that increased 
GABA metabolism may somehow be a protective mechanism to limit symptomatic episodes. 
Increased levels of GABA in the cerebrospinal fluid (CSF) have also been demonstrated in 
people with migraine compared to controls (121). The increased CSF GABA was purported 
to be indicative of increased GABA concentration in the brain due to ischemia. 
Despite these findings, the role of GABA in migraine has not yet been fully established 
because of the lack of studies directly measuring GABA levels in the brain (122). Thus the 
possible role of GABA in pathophysiology was investigated in a study presented in Chapter 
Three in this thesis, where GABA levels in the brain were compared between migraine and 
controls. 
1.6.3. Overview of pathophysiology of a non-migraine headache: TTH 
Details of mechanisms of TTH, especially of its initiation, are still under debate. The 
prevailing theory is that both peripheral and central nociceptive mechanisms contribute to 
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TTH, with peripheral nociceptive mechanisms being most likely responsible for episodic 
TTH whereas central nociceptive mechanisms being most likely responsible for chronic TTH 
(8, 93). An example of activation of the peripheral system in TTH is a slightly increased 
muscle activity, which may result in microtrauma of muscle fibres and tendon, causing 
accumulation of chemical mediators. Such events may then activate and sensitise the Aδ and 
C fibres (123) and eventually cause increased myofascial tenderness, a feature of a specific 
subtype of TTH (8). Prolonged nociceptive impulses from the myofascial tissues result in 
summation of such impulses leads to sensitisation of the second-order neurons of the 
trigeminal nerve and second and third cervical segment of the spinal cord. This, in turn, 
results in increase nociceptive transmission to the supraspinal structures such as the thalamus 
and sensory cortex, and decreased supraspinal nociceptive modulation (108) resulting in 
headache. 
The role of central sensitisation in TTH is only recently recognised. As such, central 
sensitisation represents additional shared anatomic and physiologic substrates between TTH 
and migraine and fuels the debate on whether migraine and TTH are distinct headache types 
or belong to the same headache type with opposing severities. The arguments for and against 
this view of migraine and TTH being indistinct headache types are presented later in section 
1.6.5. 
1.6.4. Overview of pathophysiology of a non-migraine headache: CGH 
Compared to migraine and TTH, pathophysiologic mechanisms for CGH are better 
understood. The most important differentiator of CGH from migraine and TTH is the 
perception of pain in the head referred from a disorder in the cervical spine (34). The 
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mechanism for referral of pain from the cervical spine to the head involves the convergence 
between afferents from the upper cervical nerve roots and trigeminal afferents on common 
neurons in the TCCin the brain stem (Figure 1) (58, 106). Information received in the TCC 
from the upper cervical spine may relate to changes in muscle (spasm or tension), head and 
neck posture, neck strain, or nerve irritation. Such information on dysfunction in the upper 
cervical spine can cause sensitisation of the TCC. 
However, the role of the cervical spine as a generator of the headache in CGH and its 
diagnosis still lacks consensus (124, 125). One argument against the cervical spine as a 
headache generator is the shared cervical musculoskeletal impairments between CGH and 
other headache types(29, 88, 126), as described earlier in section 1.5. Another argument is 
that not all patients with upper cervical spine impairments complain of headache (125). For 
these reasons, it is possible that the cervical spine and a central mechanism are required to 
produce CGH (125, 127). Correspondingly, central sensitisation has been demonstrated in 
chronic forms of CGH, as previously described. Central sensitisation was evidenced by 
bilateral and generalised hyposensitivity, manifested as higher thermal detection thresholds 
(128). These results need to be validated in larger studies to hopefully clarify the exact 
mechanisms of central sensitisation in CGH. 
1.6.5. Alternative hypothesis on shared pathophysiology of migraine and TTH: 
Continuum theory 
Migraine and TTH are classified as two distinct headache types in the ICHD. However, many 
have challenged this notion that migraine and TTH are two distinct entities and instead have 
proposed that they are the same disorder in opposite ends of the severity spectrum, with 
40
migraine in the more severe end of the spectrum, and TTH in the less severe end (55). This 
alternative view has been referred to as the convergence hypothesis(54) or continuum severity 
model (129).  
1.6.5.1. Arguments for the continuum severity model 
A review of the diagnostic features of migraine and TTH (Table 1) may be interpreted by 
proponents of the convergence hypothesis as supporting their position. The diagnostic 
features of TTH are mostly absence or milder expressions of the diagnostic features of 
migraine (8, 51). Other overlaps between migraine and TTH have been noted, which to some, 
provide evidence for the convergence hypothesis. These overlaps include similarities in 
clinical features where features considered diagnostic for migraine are present in TTH and 
features typically associated with TTH are present in migraine [e.g. (63)]. One study revealed 
that the convergence hypothesis is demonstrated more in young adults with chronic 
headaches (129). Some prodrome symptoms are also similar between migraine and TTH (44). 
Having similar clinical features also challenge the notion of distinct pathophysiologic 
mechanisms for these two headache types, and therefore their being distinct headache types. 
Cady and colleagues propose that episodic TTH may evolve to migraine with increasing 
severity and central sensitisation(54). Response to treatment has also been cited as a 
similarity between the two with both being responsive to sumatriptan especially for migraine 
with neck pain (130). Another argument for the convergence hypothesis is the coexistence of 
migraine and TTH (e.g. 94% of individuals in a population study (64). 
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1.6.5.2. Arguments against the continuum theory 
Despite these similarities between migraine and TTH supporting the convergence hypothesis, 
there is evidence that migraine and TTH differ in their epidemiologic profile, specifically in 
terms of age and sex distribution. Notwithstanding the difference in epidemiologic profile, 
the strongest evidence for migraine and TTH being distinct lies on their genetic heritability. 
Migraine has been shown to have as high as 50% heritability, with identified genetic markers 
for familial hemiplegic migraine (117). Similarly, a genetic population study showed 
concordance for ETTH and having no TTH among monozygotic twins (131). 
1.6.6. Gaps in evidence on pathophysiology addressed in this thesis 
The debate on whether migraine and TTH are distinct entities or not is still ongoing. Further 
genetic profiling of these two headache types is critical in resolving the question on their 
being distinct. Until genetic biomarkers are fully elucidated, an enhanced clinical 
characterisation of the migraine and TTH may help in understanding how similar or distinct 
they are. Moreover, characterisation of the natural course of these two headaches, especially 
in cases which have coexisting diagnostic features for both, would help identify their 
distinction. To contribute to this debate, this thesis presents a characterisation of cervical 
musculoskeletal impairments and pain and disability in migraine versus non-migraine 
headaches (including TTH) in Chapter Five and a comparison of their clinical course over 6 
months in Chapter Six. 
Further evidence on the pathophysiology of migraine, TTH and CGH is required toward a 
full understanding of the exact mechanisms causing the headache. For migraine, the 
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propagation and termination of each attack also remains to be fully elucidated. The need to 
fully understand the pathophysiology of headaches also highlights the need to identify 
biomarkers for these headaches(111). Therefore the potential of one neurochemical, GABA, 
as a biomarker is explored in Chapters Three and Four. Further, hypotheses regarding 
pathophysiologic mechanisms might be generated by comparing clinical characteristics in 
these headaches. Thus the clinical characteristics of migraine are compared with non-
migraine headaches in Chapters Five and Six.Among the characteristics examined to better 
understand pathophysiology was the extent of central sensitisation symptoms measured using 
patient-report outcomes. 
1.7. Assessment to characterise migraine and non-migraine headaches 
1.7.1. Interview 
Because diagnosis using the ICHD involves differentiating one headache type from others 
primarily based on headache features, the most essential element of assessment is therefore 
patient history, through interview (132). For example, the clinician asks about headache 
frequency, location, quality and accompanying symptoms. The clinician then integrates and 
evaluates information from patient history to determine whether the headache is most likely 
primary or secondary. History is particularly critical for primary headaches like migraine and 
TTH which are not associated with objective clinical features that would allow objective 
basis for diagnosis. Based on patient history, the clinician determines if the headache is 
primary or secondary. This step in the diagnosis may require physical and neurological 
examination (133). Once the clinician has determined whether the patient has primary or 
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secondary headache, the clinician then determines the most likely headache diagnosis. The 
ICHD lists “Not better accounted for by another ICHD-3 diagnosis” as the final criterion for 
all headache types to remind clinicians to always consider other possible diagnoses (8). 
1.7.2. Headache diary 
Information on headache features from an interview may be supplemented through headache 
diaries (17). The advantage of the headache diary is that it prospectively collects headache 
symptoms and responses to the headache. The prospective collection of information reduces 
the recall bias which may be present during interview. The headache diary is also useful in 
closely following the behaviour of symptoms over time. (133). Doing so may help 
scrutinisevariability in patient symptoms.  
1.7.3. Physical examination tests for cervical musculoskeletal impairments 
An international panel of clinical and research physiotherapy experts has recommended a 
number of physical examination tests that may be useful in assessing patients with headaches, 
regardless of headache type (104). This recommendation is presumably related to evidence of 
the prevalence of cervical musculoskeletal impairments in headaches, as discussed earlier in 
section 1.5. The physical examination tests deemed useful or extremely useful by the expert 
panelwere manual joint palpation, cervical flexion-rotation test,active range of cervical 
movement,passive physiological intervertebral movements, reproduction and resolution of 
headache symptoms, cranio-cervical flexion test,combined movement tests, head forward 
position, trigger point palpation, muscles tests of the shoulder girdle, and screening of the 
44
thoracic spine. It was not specified whether these tests are useful for diagnosis or for 
assessing treatment outcomes. 
Of these tests, manual examination at C1/C2 segment of cervical spine and measurement of 
muscle length of the pectoralis minor muscle demonstrated discriminative ability for CGH 
versus migraine with aura and controls with a sensitivity of 80% (87). This finding was 
corroborated by another cohort study showing discriminative ability of a combination of 
manual examination of C0/C1 to C3/C4 segments, cranio-cervical flexion test and cervical 
extension range of motion measurement for CGH compared to migraine, TTH and controls 
with a sensitivity of 100% and specificity of 94% (88). In addition, flexion rotation test was 
also found to have good diagnostic accuracy for CGH versus migraine and mixed headache 
forms when used by an experienced examiner (area under the curve = 0.85 (95% 
confidence interval 0.75 to 0.95); p< 0.001). (90). Aside from tests found discriminatory for 
cervicogenic headache, tests for cervical muscle behaviour and function, especially of the 
cervical extensors, require further investigation. 
1.7.4. Self-report questionnaires 
Self-report questionnaires may be used to elicit information directly from the patient about 
the nature of his or her headache experience. The outcomes that can be assessed in headaches 
using self-report questionnaires may include quality of life, satisfaction about the treatment, 
pain beliefs, to name a few (133). The use of self-report questionnaires is consistent with 
recognising that headache is a subjective experience. 
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1.7.5. Assessment of migraine and non-migraine headaches used in this thesis 
Participants of studies presented in Chapters Six and Seven of this thesis completed a 
headache diary to provide information about their headache symptoms and disability of 
participants over 6 months. Information from the diary supplemented information obtained 
from the participants during the interview and using a self-report questionnaire. Self-report 
questionnaires were used in this thesis to assess personal factors that possibly influence the 
patient experience. These self-report questionnaires are presented in Appendices 4 and 5. The 
outcomes collected from the self-report questionnaires are presented in Chapters Four 
through Seven of this thesis. Of the tests found discriminatory for CGH and recommended by 
the expert panel for headaches, we employed manual joint palpation, the cranio-cervical 
flexion test, the cervical flexion-rotation test and active range of cervical movement to 
characterise migraine and their distinction from non-migraine headaches. These tests are 
briefly described in Appendix 5. Findings from these assessments of cervical musculoskeletal 
impairments in migraine and non-migraine headaches are reported in Chapters Five and Six. 
In an attempt to fill the gap in evidence about cervical muscle behaviour and function, 
especially of the extensors, we also included such tests in the physical examination of 
participants in the studies presented in Chapters Five and Six. 
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1.8. Recognising factors that influence the patient experience in headaches 
1.8.1. The importance of assessing more than the diagnostic criteria 
Existing headache classification systems were designed to focus on describing headache 
features and associated symptoms of each headache episode. Whilst such information is 
generally considered adequate for diagnosis, it is arguably inadequate for understanding the 
impact of the symptoms on the person (133). In headaches that persist and recur like 
migraine, TTH and CGH, the impact of the headache may extend to all domains of life and 
factors other than the headache symptoms may influence the patient experience of the pain 
(133). Therefore other factors influencing the headache experience and the response to the 
headache must be assessed to enhance the understanding of the patient experience. 
1.8.2. Factors influencing the patient experience 
1.8.2.1. Disability 
Disability pertains to how a health condition affects the person on the ability to function at 
home, at work or socially and how the person responds to the condition (133). The World 
Health Organisation defines disability in the International Classification of Functioning, 
Disability and Health (ICF) as an umbrella term for a person’s functioning in society that 
encompasses impairments, activity limitation and participation restriction (134). Impairments 
are deviations from typical body structure or function, activity limitations are restrictions in 
the ability to perform daily activities in a manner that is considered efficient and competent, 
and participation restriction is the inability to perform roles expected by society according to 
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a person’s context (134). Defining disability in this manner recognises that a health condition 
affects a person according to biomedical factors that are present and personal and 
environmental factors that may influence the person’s response to these biomedical 
factors(133). Disability must therefore be assessed because it cannot be fully explained by 
headache frequency, intensity and symptoms (135). The headache research community seems to 
agree with the recommendation of measuring disability and functioning as a secondary outcome 
measure in headache trials (20, 21). Some even argue that disability is the most important 
indicator of severity of the disorder (136) as disability may differ even among individuals with 
the same type and severity of headache. 
1.8.2.2. Pain 
When assessing pain in patients with headaches, we recognise that the person is living 
through an unpleasant and complex experience (137). The complexity of the pain experience 
rests on its subjective nature and the involvement of different dimensions contributing to the 
pain experience. The sensory-discriminative dimension contributes the sensation of the 
nociception. This in, turn, is modified by the cognitive-evaluative dimension contributes the 
meanings attached to the pain from past experiences or knowledge, and the motivation-
affective dimension contributes to emotions associated with the pain which relates with the 
escape or attack response to the pain. 
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1.8.2.3. Central sensitisation symptoms 
A construct related to pain is central sensitisation. The occurrence of central sensitisation was 
presented in an earlier section. Briefly, central sensitisation involves the hypersensitivity of 
the central nervous system to stimuli which may or may not be known to cause pain (138). 
Examples of manifestations of central sensitisation in patients with headaches are 
hyperalgesia (139) such as headaches associated with increased tenderness to palpation, and 
cutaneous allodynia (112) such as experiencing pain or any unpleasant sensation on the skin 
during a headache episode attack when tying the hair in a ponytail or being exposed to heat in 
the kitchen. 
1.8.2.4. Personal factors contributing to the headache experience 
The broad view of disability, as defined above, has implications on assessing a diverse range 
of information from patients with headaches. A comprehensive assessment may take into 
account factors including biomedical factors such as head pain characteristics and associated 
symptoms, and personal and environmental factors including but not limited to the extent of 
comorbidities, sleep quality, level of physical activity, and emotional state and response to 
pain such as depression, anxiety and stress, Such comprehensive assessment would allow 
better understanding of the patient’s experience of the headache and therefore contribute to 
managing that experience. In keeping with a patient-focused management approach, the 
assessment of these factors should also include information that are coming directly from the 
patient and that are meaningful to the patient. 
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1.8.3. Biomedical and personal factors assessed in this thesis 
A comprehensive assessment of the patient experience, incorporating biomedical and 
personal factors, was done in this thesis. For cross-sectional and cohort studies presented in 
this thesis (Chapters Four through Seven), headache characteristics were assessed through an 
interview and through a self-report questionnaire. Additional biomedical factors assessed 
using self-report questionnaires were pain and central sensitisation. Other biomedical factors 
assessed in studies presented in Chapters Five andSix were cervical musculoskeletal 
impairments using physical examination tests. These tests were previously shown to be 
discriminatory for CGH (87, 88, 90) and recommended by an international panel of experts as 
appropriate for people with headaches (104). Personal factors were assessed using self-report 
questionnaires in studies presented in Chapters Four, Five and Six. These personal factors 
were comorbidities, sleep quality, level of physical activity, and emotional state. Lastly, 
disability was assessed using headache-specific and generic questionnaires in studies 
presented in Chapters Four through Six. The meaningfulness of assessing disability was 
further investigated in Chapter Seven by looking at how disability changes over six months 
and the ability of the questionnaire to detect clinically relevant change. Such 
multidimensional assessment may improve characterisation of each headache type, 
particularly if there are notable differences between headaches types. Whether such 
differences exist between migraine and non-migraine headaches, namely TTH and CGH, was 
explored in this thesis. 
50
1.9. Summary 
In summary, migraine and non-migraine headaches,specifically TTH and CGH, are the most 
prevalent headaches which have in common some pathophysiologic mechanisms and clinical 
features related to cervical musculoskeletal impairments. Migraine, TTH and CGH cause 
significant disability partly due to a lack of full understanding of their pathophysiological 
mechanisms, their clinical characteristics that may help distinguish them, and other factors 
that may influence the impact of the headache. As such, headache classification and diagnosis 
of these headaches may be difficult for some cases. A comprehensive snapshot of the state of 
the art in the application of the headache classification system in defining migraine, TTH and 
CGH populations in headache trials is reviewed in Chapter Two. Results of this review 
guided the definition of our study populations in studies presented in this thesis. A candidate 
biomarker for migraine was investigated in Chapter Three. The good diagnostic accuracy of 
the candidate biomarker for migraine stimulated the continuation of its validation as a 
biomarker in Chapter Four by determining its association with clinical characteristics of 
migraine. The clinical characteristics that correlated with the candidate biomarker in Chapter 
Four were included as outcome measures in the cohort study characterising migraine and 
non-migraine headaches in Chapter Five. The findings in Chapter Five that disability differed 
between migraine and non-migraine headaches and changed over 6 months in Chapter Six led 
to investigating the meaningfulness of measuring disability over time in migraine and non-
migraine headaches in Chapter Seven. Therefore this thesis substantiates the current standard 
in classifying headaches, adds new evidence on the pathophysiologic mechanisms of 
migraine and the clinical course of migraine and non-migraine headaches, and confirms and 
augments what is known about the extent of cervical musculoskeletal impairments and 
disability in migraine and non-migraine headaches. 
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1.10. Aims of the thesis 
The broad aim of this thesis was to characterise migraine on the basis of its neurochemical 
profile, cervical musculoskeletal impairments and patient experience as distinguished from 
non-migraine headaches. 
The objectives were to: 
1. Describe how headaches are defined in clinical trials (Chapter Two)
2. Compare levels of brain neurochemicals in migraine to controls (Chapter Three)
3. Explore the relationship between brain neurochemicals and relevant disease
characteristics of migraine (Chapter Four)
4. Characterise cervical neck impairments and patient experience in migraine compared to
non-migraine headaches and controls (Chapter Five)
5. Characterise the six-month clinical course of migraine and non-migraine headaches and
the factors associated with the clinical course (Chapter Six)
6. Examine changes in disability over six months in migraine and non-migraine headaches
(Chapter Seven)
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Abstract 
Background: Clear definitions of study populations in clinical trials may facilitate application 
of evidence to clinical populations. This review aimed to explore definitions of study 
populations in clinical trials on migraine, tension-type headache, cluster headache, and 
cervicogenic headache. 
Methods: We performed a systematic review of clinical trials investigating treatment efficacy 
for migraine, tension-type headache, cluster headache, and cervicogenic headache. We 
extracted data on diagnosis, inclusion criteria and baseline headache characteristics. 
Results: Of the 229 studies reviewed, 205 studies (89.5%) defined their populations in 
adherence to the International Classification of Headache Disorders (ICHD) criteria. Some 
studies (n = 127, 55.5%) specified diagnosing through interview, clinical examination and 
diary entry. The most commonly reported inclusion criteria were pain intensity for migraine 
and tension-type headache studies (n = 123, 66.1% and n = 21, 67.7%, respectively), episode 
frequency for cluster headache studies (n = 5, 71.4%), and neck-related pain for cervicogenic 
headache studies (n = 3, 60%). Few studies reported details on the extent to which diagnostic 
criteria were present at baseline. 
Conclusions: ICHD is routinely used in defining populations in headache studies. Details of 
baseline headache characteristics were not as consistently reported.  
Key words: Patient selection, International Classification of Headache Disorders, migraine, 
tension-type headache, cluster headache, cervicogenic headache 
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Introduction 
Migraine, tension-type headache, cluster headache (1) and cervicogenic headache (2) are 
among the most commonly seen headaches in primary care and specialist clinics. Effective 
treatment of these headaches relies on correct diagnostic classification. Increased headache 
research over the past two decades (3) has contributed to improving the classification system 
for headaches such as the International Classification of Headache Disorders (ICHD). The 
ICHD, now on its third edition (beta version), provides a framework to standardize headache 
classification (4,5) and addresses the challenge of distinguishing headache types. A 
classification framework such as ICHD is important to ensure homogeneity of participants in 
clinical studies investigating treatment efficacy. 
Despite this improvement, classification of headaches using ICHD may be 
challenging for certain cases given that the classification system is based on clinical features 
(6). For one, a headache type may coexist with one or more other headache types (7). Further, 
symptoms vary within and between individuals with the same headache type (8). 
Additionally, some headache features may overlap, especially for frequent recurrent and 
disabling headaches such as migraine, tension-type headache, cluster headache and 
cervicogenic headache (6,9). It is therefore important to examine how study populations are 
defined in clinical trials. Details on definitions of study populations may confer better 
understanding of current criteria used to classify headaches. This understanding, in turn, 
would potentially increase awareness on the nature of headaches between study populations 
and guide to whom the inferences from the trials could be applied. 
The primary objective of this systematic review, therefore, was to explore and 
describe the definitions of study populations in clinical trials. In particular, this review aimed 
to explore the eligibility criteria for study populations of frequent recurrent headaches, 
namely migraine, tension-type headache, cluster headache, and cervicogenic headache. The 
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secondary objective of this review was to describe baseline characteristics of participants 
enrolled in clinical trials in terms of headache features listed as ICHD diagnostic criteria. 
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Methods 
Protocol registration 
The protocol for this systematic review was registered with PROSPERO (registration number 
CRD42014009167). 
Eligibility criteria 
We included research articles that were intervention studies (controlled studies or prospective 
cohort studies) that described participants as having ‘primary headache’, ‘migraine’, ‘tension-
type headache’, ‘cluster headache’ or ‘cervicogenic headache’. Inclusion was limited to 
studies published in English in peer-reviewed journals from the time of introduction of 
ICHD-II in 2004. When this second edition of classification was released, it was 
recommended for use as standard definitions of headaches for clinics and research (4).  
We excluded articles that had cohorts other than the diagnoses of interest for this 
review and articles that presented data for the same cohort as an earlier publication already 
included in the review. 
Information sources 
Relevant articles were identified by searching the following electronic databases from 2005 
to April 2015: Cochrane Library, Medical Literature Analysis and Retrieval System Online 
(MEDLINE), Cumulative Index to Nursing and Allied Health Literature (CINAHL). The 
Allied and Complementary Medicine Database (AMED), Embase, Physiotherapy Evidence 
Database (PEDro), and Web of Science. In addition, researchers scanned the “related 
articles” link of databases and SCOPUS to identify reports citing the included studies. 
Search strategy 
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We used a sensitive search strategy using a combination of Medical Subject Headings 
(MeSH) and words “primary headache” OR “migraine” OR “tension-type headache” OR 
“cluster headache” OR “cervicogenic headache” and related terms. The search was limited to 
‘peer-reviewed publication, 2005 to 2015’ and ‘humans’ (Appendix A) and conducted by a 
single investigator (MA). 
Study selection 
Two reviewers (MA and GD) removed duplicate citations and independently determined 
eligibility of retrieved articles by applying the inclusion criteria through title and abstract 
screening in EndNote™ X7.3 (Thomson Reuters. Endnote. New York: Thomson Reuters; 
2015). Two other reviewers (TR and AL) were consulted for articles that did not clearly meet 
the inclusion criteria. The full text of the remaining citations was retrieved and independently 
assessed by two reviewers (MA and AL or TR or KM or MD). Disagreement between the 
reviewers on study selection was resolved by a third researcher (TR or AL). 
Data extraction 
A data extraction spreadsheet was designed and pilot tested by all reviewers. Data were 
extracted independently by two reviewers (MA and AL or TR or KM or MD). Disagreement 
between the reviewers on extracted data was resolved by a third researcher (TR or AL). 
Data extracted included study and participant characteristics (Appendix B). Study 
characteristics included research design, sample size, intervention and control, method of 
headache diagnosis, and inclusion and exclusion criteria for the study. Participant 
characteristics comprised demographic information and headache features of the participants 
at baseline. Headache features included the diagnostic criteria for the each headache type 
according to ICHD-II (4). Studies were grouped by diagnosis for descriptive analysis. Data 
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on the process of diagnosis and inclusion criteria used in the clinical studies were analyzed to 
define the patient populations. Frequency distribution of studies that reported the ICHD 
clinical features as baseline characteristics of participants, and the means and standard 
deviations of these features or percentage of participants demonstrating these reported 
baseline characteristics were also described. 
Results 
Two hundred twenty nine studies met the selection criteria for this review (Figure 1). The list 
of studies included in this review appears as Appendix C. Of these studies, 222 (96.9%) were 
randomized controlled trials and 7 (3.1 %) were controlled clinical trials. Sample sizes ranged 
from 11 to 1935 [mean (SD) 243.31 (336.30)] (Table 1), with a total of 48661 participants 
across all studies. Migraine was the most studied headache type while cervicogenic headache 
was the least studied. Most investigated pharmacologic interventions (n = 158, 69.0%). Non-
pharmacologic interventions (n = 71, 31.0%) included complementary and alternative 
medicine (n = 29, 12.7%), psychotherapeutic intervention (n = 15, 6.6%), neurostimulation 
and nerve blockade (n = 16, 7.0%). 
Definition of study population and selection of participants in clinical trials 
Two hundred ten studies (91.7%) used a classification system to define their study 
populations, with 205 studies (89.5%) reporting adhering to the ICHD. One hundred twenty 
seven studies (55.5%) diagnosed participants through interview, clinical examination and 
diary entry (Table 2). It is unclear how diagnoses were arrived at or how the classification 
system was used in the other 102 studies as these details were not provided. 
Not all clinical features listed as ICHD diagnostic criteria for the headache types were 
routinely specified among the inclusion criteria (Figure 2). For migraine studies, the most 
75
commonly reported inclusion criteria was pain intensity (n = 123, 66.1%) and the least 
common was pulsating quality of headache (n = 22, 11.8%). For tension-type headache 
studies, the most commonly reported inclusion criteria were pain intensity (n = 21, 67.7%) 
and frequency of attacks (n = 17, 54.8%) while the least common were bilateral location, 
non-pulsating quality of headache and not affected by physical activity (all n = 7, 22.6%). For 
cluster headache studies, the most commonly reported inclusion criteria were frequency of 
attacks (n = 5, 71.4%) and severity, location and duration of headache (n = 4, 57.1%). For 
cervicogenic headache studies, the most commonly reported inclusion criteria were pain 
referred from the neck (n = 4, 80% of cervicogenic headache studies) and evidence of 
cervical spine or muscle disorder (n = 3, 60% of cervicogenic headache studies). No 
cervicogenic headache study specified improvement or resolution of pain in parallel with the 
resolution of the neck disorder or lesion as an inclusion criterion. 
Other inclusion criteria unrelated to the ICHD criteria but necessary to control for 
potential confounders were frequently used in the headache studies. In general, participants 
were included in studies if they belonged to a specific age group (mostly 18 to 65 years old), 
were younger than 50 years old on their first headache attack, were experiencing a single 
headache type or able to differentiate attacks according to headache types, were experiencing 
headaches for at least 1 year, and had no comorbidities such as malignancy or depression. 
Other selection criteria for study populations were related to the intervention investigated. 
For example, many studies excluded participants who were pregnant or lactating, had taken 
or were responsive to certain medications, or were taking other medications considered to be 
prophylactic or contraindicated to the intervention. 
Description of participants at baseline in terms of ICHD criteria 
Not all clinical features listed as ICHD criteria for the headache types were routinely reported 
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as baseline characteristics of participants in the studies (Table 3). Nevertheless, among the 
migraine studies that reported the baseline clinical features, the most reported characteristics 
were severity of the headache (n = 64, 34.4%) and presence of photophobia and/or 
photophobia (n = 44, 23.7%). Where reported, most participants demonstrated moderate to 
severe pain intensity (92.5% of participants) and photophobia and/or phonophobia (79.4% of 
participants) at baseline. For tension-type headache studies, the baseline headache 
characteristic most reported was severity of the headache (n = 15, 46.9%). It was not possible 
to pool severity data because different headache intensity scales were used. For cluster 
headache studies, only two ICHD clinical features were reported as baseline characteristic of 
participants: duration and frequency of attacks. Participants in the cluster headache studies 
had about 3 attacks per day lasting for about an hour. For cervicogenic headache, the only 
clinical feature reported as baseline characteristic of participants was abolition of headache 
following nerve blockade (n = 1, 20%). 
On further examination of the reported baseline characteristics of participants, there 
was little to no information describing the extent to which participants demonstrated the 
clinical features that were thought to least overlap with other headache types. For migraine 
studies, nausea and/or vomiting, photophobia and phonophobia, and aggravation of the attack 
by routine physical activity (8, 10) were reported in less than a quarter of the studies. 
Similarly, the following features were not reported as baseline characteristics: headaches not 
aggravated by routine physical activity for tension-type headache (8, 11, 12); presence of 
autonomic symptoms for cluster headache (13); and pain, referred from the neck and 
evidence of a cervical spine lesion for cervicogenic headache (2). 
Discussion 
This review reveals that the ICHD is routinely used to define study populations in headache 
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studies, suggesting consensus and endorsement among researchers of ICHD in providing a 
framework for selecting participants. The use of a common framework such as the ICHD in 
defining study populations, in turn, allows for better comparison and synthesis of data across 
clinical trials. The methods of applying the ICHD criteria varied between studies, with most 
conforming to the “gold standard” for diagnosing headaches of using the ICHD through 
interview and physical examination (14). 
Study populations across studies were homogenous beyond their headache features 
because participants were also selected based on other criteria. These selection criteria, such 
as being of a certain age at first headache episode and enrolment in the study, gender, health 
status, medication use, and frequency of attacks, were apparently used to fit outcomes of 
interest and to control for potential confounders. Whereas these selection criteria do not 
reflect the validity of the diagnostic criteria used in the studies, they conform to guidelines for 
clinical trials (15,16). The use of these guidelines in conjunction with the ICHD reflects how 
well these tools complement each other in defining study populations. While study 
populations were generally selected based on headache features listed in the ICHD, results of 
this review did not make it possible to describe the extent to which these features were 
demonstrated by participants at baseline. Few studies have provided this level of detail. Of 
the ICHD features reported at baseline, the most reported were intensity, severity and 
frequency of headaches. These headache features were consistent with some of the 
recommended outcome measures for headache trials (15-18). 
It is reasonable to think that not all headache features were reported as baseline 
characteristics because the researchers of the studies already mentioned adhering to the ICHD 
criteria in selecting the participants. Although selection criteria provide some information on 
participant characteristics, further details on baseline headache characteristics may be helpful. 
Because diagnosing using the ICHD is based on combinations of headache features, details 
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on which and to what extent headache features were demonstrated at baseline would clarify 
participant features and potentially improve understanding and confidence in headache 
classification in studies. Ultimately, such details may aid translation of research findings to 
clinical populations. 
Nevertheless, this large review presents a comprehensive snapshot of the landscape of 
definitions of study populations in headache trials. The limitations of this review were that 
we could not pool data for meta-analysis due to lack of standardization of outcome measures 
used and we did not assess risk of bias within studies. However, these were redundant 
because this review did not aim to evaluate treatment efficacy nor report pooled effect sizes 
for treatment outcome. A step forward may be to explore the importance and impact of 
reporting baseline headache characteristics of participants in headache trials. 
In summary, study populations of treatment efficacy studies investigating migraine, 
tension-type headache, cluster headache, and cervicogenic headache were generally defined 
based on the ICHD criteria. It is unclear to what extent participants demonstrated the ICHD 
criteria at baseline. This review provides a comprehensive snapshot of how study populations 
are defined in headache trials. Results of this review also provide a starting point for 
discussing the level of detail in reporting diagnostic headache features at baseline in clinical 
trials. 
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Article Highlights: 
• Definitions of study populations in most treatment efficacy studies of frequent
recurrent headaches, namely, migraine, tension-type headache, cluster headache, and
cervicogenic headache strictly adhered to the International Classification of Headache
Disorders.
• It is unclear to what extent participants demonstrated the diagnostic criteria at baseline
as few studies provided this level of detail.
• Results of this review provide a starting point for discussing the level of detail in
reporting diagnostic headache features at baseline in clinical trials.
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Figure Legends 
Figure 1. Flow diagram of study selection 
Figure 2. ICHD diagnostic criteria reported as inclusion criteria for study populations 
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Table Legends 
Table 1. Characteristics of studies and participants in the review 
Table 2. Process of diagnosing headaches used in clinical studies 
Table 3. ICHD diagnostic criteria described among baseline characteristics of participants 
with recurrent headache  
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 Figure 1. Flow diagram of study selection 
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Table 1. Characteristics of studies and participants in the review 
Study characteristics  
Design  
RCT (n, %) 222 (96.9) 
CCT (n, %) 7 (3.1) 
Number of participants (mean, SD) 243.31 (336.30) 
Headache classification studied [n (%) of total studies 
reviewed] 
 
Migraine  186 (81.2) 
Tension-type headache  31 (13.5) 
Cluster headache  7 (3.1) 
Cervicogenic headache  5 (2.2) 
Participant characteristics  
% Female (mean, SD) 78.74 (17.88) 
Age, years (mean, SD) 39.43 (0.48) 
History of headaches, years (mean, SD) 11.2 (12.85) 
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Table 2. Process of diagnosing headaches used in clinical studies 
Process of Diagnosis n (%) Studies 
Use of classification system  
Used a classification system 210 (91.7) 
ICHD 205 (89.5) 
Guidelines for controlled studies of drugs in 
migraine by the International Headache 
Society Clinical Trial Subcommittee  
3 (1.3) 
Silberstein-Lipton criteria for chronic migraine  2 (0.9) 
Sjaastad criteria for cervicogenic headache 2 (0.9) 
Did not report 19 (8.3) 
Method of Diagnosis    
Interview 81 (35.4) 
Clinical examination 55 (24.0) 
Diary 40 (17.5) 
Diagnosed by health professional/s 26 (11.4) 
Questionnaire 15 (6.6) 
Diagnostic and laboratory tests 13 (5.7) 
Self-identified 2 (0.9) 
“Screening” 12 (5.2) 
Did not report 102 (44.5) 
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Table 3. ICHD diagnostic criteria described among baseline characteristics of participants 
with recurrent headache  
 
ICHD Clinical Features n (%) Studies 
that Measured and 
Reported  the  Feature  
as Baseline 
Characteristic  
 
Mean (SD) of the 
Reported Headache 
Feature or  
% of Participants 
Demonstrating the 
Feature at Baseline 
A. MIGRAINE    
Headache attacks lasting 4-72 hours (untreated or 
unsuccessfully treated) 
29 (15.6) 21.31 (18.14) hours 
Unilateral location 11 (5.9) 59.8% 
Pulsating quality 8 (4.3) 85.9% 
Moderate or severe pain intensity 64 (34.4) 92.5% 
Aggravation by or causing avoidance of routine 
physical activity 
6 (3.2) 76.91 
Nausea and/or vomiting 36 (19.4) 52.4% 
Photophobia and phonophobia 44 (23.7) 79.4% 
At least 5 attacks   
B. TENSION-TYPE HEADACHE   
Headache occurring on ≥15 days/month on average 
for >3 months (≥180 days/year) 
1 (3.1) 21 days 
Headache lasting from 30 minutes to 7 days 5 (15.6) 11.46 (4.89) hours 
Bilateral location 0 (0)  
Pressing/tightening (non-pulsating) quality 1 (3.1) 67% 
Mild or moderate intensity 14 (45.2) 5.81 (1.70) (out of 10) 
Not aggravated by routine physical activity such as 
walking or climbing stairs 
0 (0)  
No nausea or vomiting (anorexia may occur) 1 (3.1) 100% 
No more than one of photophobia or phonophobia 1 (3.1) 100% 
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ICHD Clinical Features n (%) Studies 
that Measured and 
Reported  the  Feature  
as Baseline 
Characteristic  
 
Mean (SD) of the 
Reported Headache 
Feature or  
% of Participants 
Demonstrating the 
Feature at Baseline 
C. CLUSTER HEADACHE   
Severe or very severe unilateral orbital, supraorbital 
and/or temporal pain lasting 15-180 
minutes if untreated 
3 (50) 82.75 (37.89) minutes 
Conjunctival injection and/or lacrimation 0 (0)  
Nasal congestion and/or rhinorrhoea 0 (0)  
Eyelid oedema 0 (0)  
Forehead and facial sweating 0 (0)  
Forehead and facial flushing 0 (0)  
Sensation of fullness in the ear 0 (0)  
Miosis and/or ptosis 0 (0)  
A sense of restlessness or agitation 0 (0)  
Attacks have a frequency between one every other 
day and 8 per day for more than half the 
time when the disorder is active 
1 (16.67) 3.33 (0.77) per day 
D. CERVICOGENIC HEADACHE   
Pain, referred from a source in the neck and 
perceived in one or more regions of the 
head and/or face 
0 (0)  
Clinical, laboratory and/or imaging evidence of a 
disorder or lesion within the cervical spine 
or soft tissues of the neck known to be, or 
generally accepted as, a valid cause of 
headache 
0 (0)  
Abolition of headache following diagnostic blockade 
of a cervical structure or its nerve supply 
using placebo- or other adequate controls 
1 (20) 61.0 (5.4%) 
Pain resolves within 3 months after successful 
treatment of the causative disorder or lesion 
0 (0)  
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CHAPTER THREE 
Elevated Levels of GABA+ in Migraine Detected Using 1H-MRS 
Chapter Three is the peer reviewed version of the following article: Aguila ME, Lagopoulos 
J, Leaver AM, Rebbeck T, Hübscher M, Brennan PC, Refshauge KM. Elevated levels of 
GABA+ in migraine detected using 1H-MRS. NMR Biomed. 2015; 28:890–7. doi: 
10.1002/nbm.3321, which has been published in final form at 
http://onlinelibrary.wiley.com/doi/10.1002/nbm.3321/full. This article may be used for non-
commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving. 
Supplementary methods and results on levels of excitatory and other brain chemicals in migraine 
detected using proton magnetic resonance spectroscopy are presented in Appendix 3.
The study protocol for the study presented in this chapter appears as Appendix 4. 
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Abstract Summary 
Gamma-aminobutyric acid (GABA) has been implicated in several pain conditions 
yet no study has systematically evaluated GABA levels in migraine using 1H-MRS. Accurate 
detection, separation and quantification of GABA in people with migraine could elucidate the 
role of this neurotransmitter in migraine pathophysiology. Such information may eventually 
be useful in diagnosis and development of more effective treatment for migraine. The aims of 
this study were therefore to compare the concentration of GABA+ in people with migraine 
with asymptomatic individuals and to determine the diagnostic potential of GABA+ in 
classifying people as having migraine or not. 
In this case-control study, GABA+ levels in the brain were determined in 19 
participants with migraine and 19 matched controls by 1H-MRS using MEGA-PRESS 
sequence. The diagnostic accuracy of GABA+ for detecting migraine and the optimal cut-off 
value were determined by receiver operating characteristic analysis.  
GABA+ levels were significantly higher (P=0.002) in people with migraine [median 
1.41 (interquartile range 1.31-1.50) institutional units] compared with controls [median 1.18 
(interquartile range 1.12-1.35) institutional units]. GABA+ concentration appears to have 
good accuracy in classifying individuals as having migraine or not [area under the curve 
(95% CI) = 0.837 (0.71 – 0.96), P< 0.0001)]. The optimal GABA+ cut-off value for migraine 
was 1.30 institutional units, with a sensitivity of 84.2%, specificity of 68.4% and positive 
likelihood ratio of +2.67. 
Outcomes of this study suggest altered GABA metabolism in migraine. These results 
add to the scarce evidence on the putative role of GABA in migraine and provide basis to 
further explore the causal relationship between GABA+ and the pathophysiology of migraine.  
This study also demonstrates that GABA+ concentration has good diagnostic accuracy for 
migraine. These findings offer new research and practice directions for migraine diagnosis.  
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Abbreviations  
1H-MRS = proton magnetic resonance spectroscopy  
AUC = area under the curve  
Cr = creatine 
CSD = cortical spreading depression  
CSF = cerebrospinal fluid  
FWHM = full-width at half maximum 
GABA = gamma-aminobutyric acid 
GAD = glutamic acid decarboxylase  
Glx = glutamate + glutamine 
GM = grey matter 
ICHD = International Classification of Headache Disorders  
IQR = interquartile range  
IU = institutional units  
MEGA-PRESS = Mescher-Garwood point resolved spectroscopy  
MP-RAGE = magnetization prepared – rapid acquisition gradient echo  
ROC = receiver operating characteristic  
TGVS = trigeminovascular system 
WM = white matter 
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INTRODUCTION 
Migraine is the third most prevalent disorder in the world and causes more than 22 
million years of healthy life lost due to disability according to the 2010 Global Burden 
of Disease Study (1).  Despite its high prevalence, chronicity and consequent 
disability, diagnosis of migraine is based on a set of signs and symptoms (2) that are 
not specific to migraine (3), but overlap with other headache classifications. The lack 
of specificity in migraine diagnosis is, in part, because diagnostic markers (4) related 
to neurobiological mechanisms (5) are lacking. These uncertainties in diagnosis 
impact on treatment of migraine, which many consider to be inadequate (6). It follows 
that identification of specific diagnostic markers may improve understanding of the 
neurobiological mechanisms of migraine and open new avenues for development of 
effective therapeutics.  
The pathophysiological events that are widely accepted as contributory to the 
symptoms of migraine include cortical spreading depression (CSD)as well as 
activation and sensitisation of the trigeminovascular system (TGVS) (5). CSD is 
described as a wave of a brief, intense excitation of neurons and glial cells in the 
central nervous system followed by a long, slowly propagating wave of inhibition (7, 
8). The development of CSD triggers changes in cortical blood flow, featuring an 
initial increase in cortical blood flow, followed by a period of reduced cortical blood 
flow (9). CSD activates and sensitises the TGVS pain pathway, resulting in headache 
(5).    
Despite recent evidence supporting these pathophysiological bases for 
migraine, the mechanisms of activation, propagation and termination of these events 
remain unclear. One way to gain insight about the neurobiological mechanisms of 
migraine is to investigate the role of excitatory and inhibitory neurotransmitters. It has 
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been hypothesised that an imbalance between excitatory and inhibitory mechanisms 
results in the pathophysiological events leading to migraine (5, 10). Whilst the role of 
excitatory neurotransmitters in migraine has been explored (11, 12), inhibitory 
neurotransmission has received less attention. To date, only one other study has 
reported in vivo concentrations of the inhibitory neurotransmitter, gamma-
aminobutyric acid (GABA), in people with migraine (13). Thus the role that GABA 
assumes in the pathophysiology of migraine remains poorly understood. 
GABA is widely distributed and is the most abundant inhibitory 
neurotransmitter in the brain (14). Consequently, GABA has been implicated in 
neuronal excitability and cortical functions such as modulation of pain (15). 
Understanding the role of GABA in migraine is therefore important because 
alterations in both neuronal excitability and pain processing constitute CSD and 
TGVS activation and sensitisation in migraine (5).  
Earlier investigations of GABA in migraine using indirect methods that 
sampled saliva, cerebrospinal fluid (CSF) and blood have consistently reported 
increased GABA levels. Increased salivary GABA has been reported during the ictal 
period in people with migraine without aura, compared with headache-free periods, 
and compared with non-migraine controls (16). Similar results were reported as early 
as 1975 where elevated GABA levels were measured in the CSF during migraine 
attacks and not present when the participants were free of migraine headaches (17). 
Platelet GABA levels were found to be similar in people with migraine during 
headache free periods and controls, but were not measured during migraine attacks 
(18). Taken together, these studies suggest that GABA concentrations could be 
increased in the brain in people with migraine.  
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Direct measures of GABA are now possible using proton magnetic resonance 
spectroscopy (1H-MRS). Until recently, detecting GABA using 1H-MRS was difficult 
due to spectral overlap between GABA and other neurometabolites (19), resulting in 
large estimation errors. Recent technological advances now allow resolution of such 
spectral overlaps using specialised sequences such as Mescher-Garwood point 
resolved spectroscopy (MEGA-PRESS) (20). However, GABA resolved using such 
editing techniques contain substantial macromolecule contamination and as such is 
denoted as GABA+ and referred to as such in this study. The aims of this study were 
to determine and compare GABA+ concentration detected by 1H-MRS using MEGA-
PRESS sequence in people with migraine and asymptomatic individuals and to 
determine the diagnostic potential of GABA+ in classifying people as having 
migraine or not.  
 
MATERIALS AND METHODS 
Design and outcome measure 
In this cross-sectional case-control study, we compared GABA+ levels in the brainin 
people with migraine with asymptomatic controls using 1H-MRS. To eliminate 
possible confounding, the migraine and control groups were matched for age and 
gender. Area under the receiver operating characteristic (ROC) curve, optimal cut-off 
value, sensitivity, specificity, and positive likelihood ratio of concentration of 
GABA+ for migraine were also determined. This research was granted ethics 
approval by the Human Research Ethics Committee of the University of Sydney 
(Protocol Number 15048). 
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Participant inclusion 
Twenty participants with migraine were matched for age and gender with 
asymptomatic controls. Participants were recruited through advertisements posted at 
university, consumer support groups and primary care sites from 27 May to 15 August 
2013. Participants were aged between 19 and 64 years.  
Participants in the migraine group were included if they were diagnosed with 
migraine by their attending neurologist/physician, fulfilled the International 
Classification of Headache Disorders (ICHD)-II criteria for migraine (21), and had at 
least one migraine attack per month. Participants in the control group were included if 
they did not experience regular headaches and had no headache in the last three 
months.  
Participants in both groups were excluded if they: had non-migrainous 
headaches according to ICHD-II criteria; had a history of neck injury, claustrophobia, 
or severe depression (i.e., Depression Anxiety Stress Scales-21 score >21); were 
pregnant; had conditions that would compromise spectroscopy data (e.g. implants, 
tattoo, dental braces); or used medications known to alter GABA levels. 
We conducted initial telephone screening of study volunteers to determine 
eligibility. We then interviewed and physically examined all potential participants to 
confirm classification according to ICHD-II criteria and to exclude those with non-
migrainous or mixed classification headache. Participants with migraine provided 
information on history of migraine, frequency of episodes, typical location of 
headache, and headache intensity in the last month and in the last 24 hours. All 
participants provided written informed consent prior to participation. 
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Magnetic resonance spectroscopy data acquisition 
Imaging was conducted at the Brain and Mind Research Institute imaging centre on a 
3-Tesla GE Discovery MR750 scanner (GE Medical Systems, Milwaukee, 
Wisconsin) using an 8-channel phased array head coil. The following images were 
acquired in order: (a) three-dimensional sagittal whole-brain scout for orientation and 
positioning of the subsequent 1H-MRS scans. To aid in the anatomical localisation of 
sampled voxels, (b) a T1-weighted magnetization prepared – rapid acquisition 
gradient echo (MP-RAGE) sequence producing 196 sagittal slices was acquired 
(TR=7.2ms; TE=2.8ms; flip angle = 10°; matrix 256x256; 0.9mm isotropic voxels) 
and (c) single voxel 1H-MRS using MEGA-PRESS acquisition (20)(TR=1800ms; 
TE=68ms; NEX (phase cycling)=8; number of acquisitions=256; number of 
points=4096; spectral width=5000; voxel size=3x3x3 cm3;total scan time=8:24)with 
two chemical shift-selective imaging pulses for water suppression. Spectra were 
shimmed to achieve full-width at half maximum (FWHM) of <13Hz. Anatomical 
localisation of the voxel placement was based on the Talairach and Tournoux brain 
atlas (22)and positioning was guided by the T1-weighted image.The centre of the 
voxel was defined on the T1-weighted image on the midline sagittal plane 
andpositioned at the posterior cingulate cortex in a location that encompassed 
Brodmannareas 23 and 3. The superior-posterior most edge of the voxel extended into 
the precuneus (Brodmannarea 7) and inferiorly into the retrosplenial cortex 
(Brodmannarea 29 and 30). To cover asmuch grey matter (GM) as possible and 
ensure the voxel did not encroach within the lateral ventricles or the splenium of the 
corpus callosum, it was then rotated (in the sagittal plane) and translated to the left (in 
the axial plane). The final position of the rotated voxel was lateral to the midline 
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posterior cingulate and posterior andsuperior to the splenium of the corpus callosum 
(see Figure 1). 
Following 1H-MRS acquisition, data were transferred offline for post 
processing of GABA+ using the Gannet software toolkit (23) In brief the data were 
first processed using the GannetLoad module which parses variables from the data 
headers and applies a line broadening of 3 Hz. Next, individual spectra were 
frequency- and phase-corrected using Spectral Registration (24). The data were then 
processed by the GannetFit module, which employs a single Gaussian model to fit the 
edited GABA+ signal and evaluates GABA+ concentration in institutional units (IU) 
relative to water. The quality of the data was determined by the overall “Fit Error” 
index of each subject. This index represents the standard deviation of the fitting 
residual divided by the amplitude of the fitted peaks, and thus a measure of the signal-
to-noise ratio. Only spectra with a relative Fit Error of GABA+ below 10% were used 
for the subsequent statistical analyses. There was no statistical difference between the 
Fit Error, FWHM or the number of rejected shots between the two groups. Next, the 
Tarquin software package was used to estimate glutamate + glutamine (Glx) from the 
MEGA-edited spectra from edited on and off shots using the following parameters: 
sampling frequency=5000; transmitter frequency=127MHz; data points=4096; water 
cut off=45Hz; reference signal=H2O. Unsuppressed water data served as the internal 
reference for all water scaling. Next, the coordinates of the acquisition voxels for each 
participant were determined using the SAGE (Spectroscopy Analysis GE) software 
package and the reconstructed acquisition voxels for all participants were corrected 
for grey matter. GM correction was achieved by segmenting each participant’s 
structural image into GM, white matter (WM) and CSF using the FAST4 algorithm as 
implemented in FSL (25) and volume fractions were calculated. All statistical 
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analyses were conducted on GM-corrected GABA+. Finally, the radiographers, 
neuroimaging expert who read the spectroscopy data and the neuroradiologist were 
blinded to group allocation.   
 
Statistical analyses 
The calculated sample size (n=17 per group) was based on a hypothesised true mean 
difference of 0.2 IU between groups and an estimated within group standard deviation 
of 0.2 IU with a significance level of 0.05 with 80% power. Allowing for about 15% 
attrition, we determined sample size to be 20 per group. 
Descriptive statistics (median and interquartile range, IQR) were used to 
report participant demographics and headache characteristics given the nonparametric 
distribution of the data. GABA+ and Glx levels were compared between participants 
with migraine and their matched asymptomatic controls using Wilcoxon Signed 
Ranks Test. Pairs were excluded from analyses if either case or control data were 
missing.  
The ROC curve was drawn and the sensitivity, specificity and area under the 
curve (AUC) were calculated to determine the diagnostic potential of GABA+ in 
discriminating between people with migraine and controls. An AUC of 1 would 
indicate that GABA+ correctly classifies all participants as having migraine or not, 
and an AUC of 0.5 or less would indicate that GABA+ has no discriminatory value 
(26). Interpretation of AUC varies and we used the following scale in interpreting the 
discriminative ability of GABA+ for migraine: AUC greater than or equal to 0.90 as 
excellent; AUC greater than or equal to 0.80 and less than 0.90 as good; AUC greater 
than or equal to 0.70 and less than 0.80 as fair; and AUC of less than 0.70 as poor. 
The optimal cut-off value for GABA+ was calculated by finding the minimum 
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distance on the ROC curve to the top of the y-axis, representing the point on the curve 
closest to an ideal point where sensitivity and specificity are equal to one (27). 
Positive likelihood ratio for the optimal cut-off value was calculated using the formula 
sensitivity divided by one minus specificity. 
Statistical analyses were conducted using Statistical Package for Social 
Sciences® statistical software, version 21 (SPSS Inc., Chicago, Illinois, USA) for 
Windows. 
 
RESULTS 
Participants 
Twenty people with migraine and 20 age- and gender-matched controls participated in 
this study. Figure 2 describes the flow of participants through the study and reasons 
for exclusion of volunteers. Spectroscopy data were of sufficient quality to allow 
analysis from 19 participants each from migraine and control groups.    
Twenty eight (70%) participants were female. The median age and IQR were 
31.5 and 28-47.2 years, respectively (Table 1). Participants with migraine reported, on 
average, symptoms for more than 15 years and experienced approximately three 
episodes in a month. Average headache intensity in the preceding month was rated 
moderate to severe, and in the preceding 24 hours, rated none to moderate. No 
participant in the migraine group had migraine-related symptoms on the day of 
spectroscopy and none were taking GABAergic drugs for at least a month prior to 
participation in the study (Table 1).   
 
Outcomes  
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The concentration of GABA+ in participants with migraine was significantly higher 
[median (IQR)] 1.41 (1.31-1.50) IU] than their age-matched controls [median (IQR)] 
1.18 (1.12-1.35) IU]; P=0.002)   (Figure 3). There was no difference in Glx between 
migraine and control groups (P=0.313).  
GABA+ concentration appears to have good accuracy for classifying 
individuals as having migraine or not [AUC (95% confidence interval) = 0.837 (0.71 
– 0.96), P<0.0001)] (Figure 4).  
The optimal GABA+ cut-off value for the detection of migraine was 1.30 IU, 
with sensitivity of 84·2%, specificity of 68·4% and positive likelihood ratio of +2.67 
(Table 2).   
Post-hoc analyses demonstrate no statistically significant correlation between 
GABA+ concentration and age (correlation coefficient = -0.007, P = .950) and 
headache severity (correlation coefficient = .313, P = 192), thus excluding these 
variables as potential confounders. 
 
DISCUSSION 
This study is the first to provide direct evidence for the postulated role of GABA+ in 
migraine pathophysiology. Utilising the MEGA-PRESS sequence specific for 
resolving GABA+, we obtained accurate in vivo levels of GABA+ not previously 
possible (20).In so doing, our results demonstrated higher concentration of GABA+ in 
participants with migraine compared with their matched controls.  
Our findings are consistent with previous work showing increased GABA 
concentration in the human cerebral cortex during painful stimulation (15), and 
corroborate earlier biochemical studies that suggested GABA levels may be increased 
in the brain, based on indirect methods of measurement (16, 17). Further, our results 
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show that GABA+ levels are elevated during the interictal period. Our results differ 
from those of an earlier study that reported no significant differences in GABA 
concentration between people with migraine and controls (13). This difference in 
findings is potentially because the spectroscopy technique we used was specific for 
GABA+.  
Results of post hoc analyses showing no statistically significant correlation 
between GABA+ concentration and headache severity differ from an earlier report of 
lower GABA levels in people with migraine with severe headaches(13). We think this 
difference in findings may be explained by the lack of variability in headache 
intensities of our participants (Table 1). Whether similar results would be obtained 
from people with migraine with characteristics different from the participants of this 
study remains to be investigated.   
There are several methodological limitations associated with our study that 
warrant further discussion. Firstly, the MEGA-PRESS technique, which we employed 
to detect GABA, is not able to separate pure GABA from the macromolecule 
component that arises from spins coupled at 3 and 1.7ppm. As such, the GABA+ 
signal we report needs to be interpreted with caution, as it is likely to have 
macromolecule contamination.  Next, the GABA+ signal in our study represents total 
GABA within the acquired voxel and is derived from both intra- and extracellular 
pools. This limits conclusions that can be made as to the relationship between the 
GABA 1H-MRS signal and direct inhibitory processes. Further, we cannot explain the 
cause or mechanism of increased GABA+ levels because of the cross-sectional design 
of our study. However, the possibilities are that the increased GABA+ concentration 
could be the result of a previous migraine attack, a characteristic brain state prior to an 
attack or a feature of the “migraine brain” that initiates an attack. Of these, we 
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speculate that the increased GABA+ level in migraine contributes to the initiation or 
propagation of symptoms of migraine. This supposition is based on recent evidence 
that GABA causes vasodilation during the interaction between neurons, blood vessels 
and astrocytes during CSD and TGVS activation (9, 28, 29). We further propose that 
the increased GABA+ level is linked with the hypothesised altered excitability of 
cortical neurons during the interictal period (30). This is consistent with suggestions 
of increased GABA resulting from neurogenic inflammation (31), as is believed to 
occur in migraine.  Finally, data on the consumption of substances that may affect 
GABA concentrations such as nicotine (cigarette), alcohol and caffeine were not 
collected. 
Potential explanations for the increased GABA+ concentration could be an 
increase in the number of GABAergic neurons, changes in intracellular (e.g. increased 
pre-synaptic GABA due to changes in GABA synthesis or receptor expression, 
degradation or reuptake) or extracellular GABA levels (15, 32). Of these possibilities, 
we propose that the increased GABA+ level is due to an increase in intracellular 
GABA synthesis resulting from an altered function of its synthesising enzyme, 
glutamic acid decarboxylase (GAD) (33). This enzyme appears to be expressed only 
in GABAergic neurons and therefore is a good marker for neurons that use GABA as 
a neurotransmitter.  
Results of ROC curve analysis demonstrate that GABA+ has good predictive 
ability for migraine, identifying people with GABA+ concentrations equal to or 
greater than 1.30IU as having migraine. These findings indicate the utility of GABA+ 
as a potential biomarker for migraine and are likely to contribute to more specific 
migraine diagnosis and possibly even targeted and individualised treatment. At 
present, no biomarker for migraine has been systematically validated (4). Further 
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research could determine the validity of GABA+ in discriminating between people 
with migraine, other headache types and controls. The cut-off value calculated from 
this study may be used in further investigations aimed at identifying objective 
diagnostic biomarkers for migraine.  
This study provides new information on altered GABA+ in migraine and 
contributes to clarifying the neurobiological mechanisms of migraine. GABA has 
been previously shown to cause vasodilation during neurovascular coupling (29), as in 
that which occurs during CSD and TGVS activation (9).Given the link between 
GABA and the generally accepted theories of migraine pathophysiology, evidence 
from this study indicates that GABA+ could be a candidate diagnostic marker for 
migraine. Future research could also include investigations on the mechanisms 
causing the increased GABA+ in migraine through randomised controlled trials of 
drugs targeting GAD and on the nociceptive function of the increased GABA through 
longitudinal studies.  
 
CONCLUSIONS 
Our results demonstrate altered GABA+ metabolism in migraine when measured 
using magnetic resonance sequences specifically tailored to resolve GABA+. Our 
study thus adds to the scarce evidence on the putative role of GABA in migraine and 
provides basis to further explore the causal relationship between GABA+ and the 
pathophysiology of migraine. Results of this study also suggest good diagnostic 
accuracy for GABA+ for migraine and offer new research directions for migraine 
diagnosis.  
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Table 1.Characteristics of participants (n =40) 
PARTICIPANT CHARACTERISTICS GROUP 
 MIGRAINE 
(n=20) 
CONTROL 
(n=20) 
Demographic characteristics   
Age [median (IQR)] (years) 33 (28.25-47.25) 30 (26.5 – 47.5) 
Gender (female) [n(%)} 14 (70) 14 (70) 
Headache Characteristics    
History of migraine [median (IQRa)] (months since first 
episode)   
180 (60-288)  
Frequency of headache in a month [median (IQR)] (n)   2.75 (1.5-8.5)  
Episode duration [median (IQR)] (hours)   48 (24-48)  
Average headache intensity last month [median (IQR)] (0-10)b   6 (6-8)  
Average headache intensity last 24 hours [median (IQR)] (0-
10)b   
1.5 (0-6)  
Migraine Medications   
Non-steroidal anti-inflammatory drugs (number of participants) 
(n)  
6  
Triptans (number of participants) (n)  4  
Paracetamol (number of participants) (n)  4  
Beta blockers (number of participants) (n)  2  
Selective serotonin reuptake inhibitor (number of participants) 
(n)  
1  
 
aIQR = interquartile range 
bHeadache intensity: Numerical rating scale 0-10; 0=no pain, 10 = worst possible pain 
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Table 2. Distribution of GABA+ values in migraine (n=20) and control groups (n 
=20) 
 Migraine group Control group 
GABA+  > 1.3IUa 16 6 
GABA+  < 1.3IU  3 13 
Missing data 1 1 
 
aIU = institutional units 
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Figure Legends 
Figure 1. Fitted GABA+ resolved data using MEGA-PRESS. (A) Raw GABA edited 
spectrum highlighting GABA+, Glx signals. (B) Modelled data (red), raw 
GABA+ signal (blue) and residuals (black) exemplifying the accuracy of 
the data fit. (C) Representative water data [inset: unedited raw data at 
3.0ppm highlighting creatine (Cr) and choline peaks]. (D) T1-weighted 
structural image showing the anatomical localisation of 3x3x3 
cm3acquisition voxel. (E) Processed GABA+-edited difference spectrum 
before (green) and after (blue) frequency and phase correction. (F) Cr 
signal over the duration of the experiment. The y-axis represents the 
frequency (in ppm) of the Cr signal and shows that there is negligible drift 
over this period.  
 
Figure 2.  Flow of participants through the study. 
 
Figure 3.Concentration of GABA+ in participants with migraine and asymptomatic 
controls. Data are presented as box plots, where the boxes represent values 
between the 25th and 75th percentiles (interquartile range, IQR), the line 
within the box, the median, and the bars outside the box (whiskers), the 
range of data. Outliers are plotted as circles (1.5×IQR or more below the 
25th or above the 75th percentile) and stars (3×IQR or more below the 
25th or above the 75th percentile). 
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Figure 4.  Receiver operating characteristic curve evaluating GABA+ in people with 
migraine and controls.  Area under the curve = 0.837 (95% confidence 
interval 0.71-0.96), P< 0.0001 
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 Figure 1.Fitted GABA+ resolved data using MEGA-PRESS. (A) Raw GABA edited 
spectrum highlighting GABA+, Glx signals. (B) Modelled data (red), raw 
GABA+ signal (blue) and residuals (black) exemplifying the accuracy of the data 
fit. (C) Representative water data [inset: unedited raw data at 3.0 ppm highlighting 
creatine (Cr) and choline peaks]. (D) T1-weighted structural image showing the 
anatomical localisation of 3 x 3 x 3 cm3 acquisition voxel. (E) Processed GABA+-
edited difference spectrum before (green) and after (blue) frequency and phase 
correction. (F) Cr signal over the duration of the experiment. The y-axis represents 
the frequency (in ppm) of the Cr signal and shows that there is negligible drift 
over this period.  
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 Figure 2.Flow of participants through the study. 
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Figure 3.Concentration of GABA+ in participants with migraine and asymptomatic controls. 
Data are presented as box plots, where the boxes represent values between the 
25th and 75th percentiles (interquartile range, IQR), the line within the box, the 
median, and the bars outside the box (whiskers), the range of data. Outliers are 
plotted as circles (1.5×IQR or more below the 25th or above the 75th percentile) 
and stars (3×IQR or more below the 25th or above the 75th percentile). 
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 Figure 4.Receiver operating characteristic curve evaluating GABA+ in people with migraine 
and controls.  Area under the curve = 0.837 (95% confidence interval 0.71-0.96), 
P< 0.0001 
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CHAPTER FOUR 
The Association Between Clinical Characteristics of Migraine and 
Brain GABA Levels: An Exploratory Study 
Chapter Four is the peer reviewed version of the following article: Aguila ME, Rebbeck T, 
Leaver AM, Lagopoulos J, Brennan PC, Hübscher M, ,Refshauge KM. The association 
between clinical characteristics of migraine and brain GABA levels: An exploratory 
study.JPain.2016; 17:1058–67.doi:10.1016/j.jpain.2016.06.008, which has been published in 
final form at http://www.jpain.org/article/S1526-5900(16)30109-2/fulltext; with permission 
from the American Pain Society. 
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Abstract 
Migraine is prevalent and disabling yet is poorly understood.  One way to better understand 
migraine is to examine its clinical characteristics and potential biomarkers such as gamma-
aminobutyric acid (GABA).  The primary objective of this study was to explore whether 
relevant disease characteristics of migraine are associated with brain GABA levels. Twenty 
adults fulfilling the established diagnostic criteria for migraine and 20 age- and gender-
matched controls completed this cross-sectional study. Pain, central sensitization, negative 
emotional state, and perceived disability were measured using Short-form McGill Pain 
Questionnaire-2, Central Sensitization Inventory, Depression Anxiety Stress Scales-21, and 
Headache Impact Test-6, respectively.  Secondary analysis of brain GABA levels of the same 
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cohort measured using proton magnetic resonance spectroscopy was conducted. The migraine 
group had significantly higher scores on pain, central sensitization and disability than the 
control group.  Correlation analyses showed fair positive association between GABA levels 
and pain and central sensitization scores. No association was found between GABA levels 
and emotional state and disability. These findings are preliminary evidence supporting the 
use of questionnaires and GABA levels in characterizing migraine better and broadening the 
diagnostic process. These findings also strengthen the rationale for the role of GABA in 
migraine pathophysiology and corroborate the potential of GABA as a migraine biomarker. 
 
Perspective 
Higher pain and central sensitization scores were associated with increased brain GABA 
levels in individuals with migraine. These findings offer preliminary evidence for the 
usefulness of measuring pain and central sensitization in migraine and provide some support 
for the possible role of GABA in migraine pathophysiology and its potential as a diagnostic 
marker.  
 
Key Words  
GABA, migraine disorders, headache, central sensitization, disability, questionnaires 
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Introduction 
Migraine is among the most prevalent and disabling chronic conditions globally [43]. 
Despite the burden that migraine imposes on the individual and society [26,27], its 
underlying mechanisms remain poorly understood. Consequently, migraine diagnosis is 
nonspecific [44] and its treatment may be inadequate [41]. A better understanding of 
migraine, and ultimately its diagnosis and treatment, may be gained by deeper investigation 
of characteristic clinical features and their relationship with potential biomarkers.  
One possible biomarker for migraine is gamma-aminobutyric acid (GABA). GABA is 
the predominant inhibitory neurotransmitter in the central nervous system [13] and is an 
important regulator of the balance between excitation and inhibition in the brain [30]. As 
such, GABA has been implicated in clinical conditions thought to involve an imbalance 
between excitatory and inhibitory processes.  Interestingly, recent studies have also implied 
that GABA mediates excitatory actions as well, for example in the development of epilepsy 
[45]. We have recently published findings that brain GABA levels are significantly higher in 
people with migraine compared to age- and gender-matched controls and have demonstrated 
that GABA has good diagnostic potential for migraine [1]. These findings were the first 
direct evidence for the putative role of GABA in migraine and its potential as a migraine 
biomarker. Following the three-stage model suggested by Hlatky and colleagues [22] to 
validate biomarkers, it is then necessary to establish migraine characteristics associated with 
GABA and finally to determine that screening using the biomarker leads to targeted treatment 
and eventually reduces disease burden.  The second stage of validation might be furthered by 
exploring associations of GABA levels with important clinical characteristics.  
Four important clinical characteristics of migraine are pain, central sensitization, 
negative emotional state and disability. Pain is important in migraine diagnosis to an extent 
that pain characteristics help distinguish migraine from other headache types [19,20]. 
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Headache pain that is moderate to severe, throbbing and unilateral is characteristic of 
migraine [20]. Central nervous system sensitization involves decreased pain thresholds and 
exaggerated responses to noxious and nonnoxious stimuli [9]. Sensitization is commonly 
manifested in migraine as hyperalgesia [10] and cutaneous allodynia [9] such as pain when 
combing the hair, exposed to heat or cold, or wearing eyeglasses [28]. Symptoms of negative 
emotional states such as depression, stress and anxiety have been reported to be more 
frequent in people with migraine compared to controls [8,46] and associated with the 
tendency to perceive normal bodily sensations as disturbing [46].  Level of disability based 
on scores on self-report questionnaires has been consistently reported to be higher in people 
with migraine than people with other headache types [e.g. 33,40] and those without 
headaches [24]. An example of disability which differentiates migraine from other headache 
types is the avoidance of physical activity or reported aggravation of symptoms by routine 
physical activity during a migraine episode [19,20].   
It is possible that pain, central nervous sensitization, emotional state, and disability 
are associated with GABA levels in migraine.  First, pain has been shown to be modulated by 
GABA [13] and therefore any change in pain may be associated with changes in GABA 
levels. Second, central nervous system sensitization in migraine is theoretically linked with 
GABA levels considering one proposed pathophysiological mechanism for migraine. It has 
been hypothesized that a cortical excitatory – inhibitory imbalance in migraine leads to 
headache and other symptoms [42].  GABA may have a putative role in this imbalance. 
Third, symptoms of emotional states have been shown to involve the GABA system.  There 
is abundant evidence from human and animal studies that anxiety and depression are 
associated with reduced GABAergic function, yet recent animal studies indicate that 
symptoms of depression reduce when GABA action through GABA-B receptors is blocked 
[32]. Fourth, disability in migraine may be viewed as a manifestation of dysregulation in 
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brain and/or body systems that may have developed in the course of repeated migraine 
episodes [4]. GABA is a potential mediator in this dysregulation, given its role in regulating 
excitatory-inhibitory balance in the brain [30].  The potential relationships between GABA 
levels and central nervous sensitization, emotional state, and disability have not been 
investigated in migraine.   
The primary aim of this study was to explore whether relevant clinical characteristics 
of migraine including pain, central nervous system sensitization, emotional state and 
headache-related disability are associated with brain GABA levels. A secondary aim of this 
study was to compare clinical characteristics, particularly central nervous sensitization and 
emotional state, between people with migraine and asymptomatic controls. By exploring the 
relationship of clinical characteristics with GABA levels, we aim to build on the process of 
validating GABA as a migraine biomarker, inform migraine diagnosis and better understand 
migraine. 
 
Methods 
Design 
A secondary analysis of a previous cross-sectional case-control study that compared 
GABA levels between people with migraine and age-and gender-matched controls [1] was 
performed to explore the association between GABA levels and migraine clinical 
characteristics. This research was granted ethics approval by the Human Research Ethics 
Committee of the University of Sydney (Project Number 2012/581). 
 
Participants 
Participants with migraine were eligible for the original study if they were diagnosed 
with migraine by their attending neurologist/physician and if their headache features fulfilled 
132
the International Classification of Headache Disorders (ICHD)-II criteria for migraine [19]. 
Participants in the control group were included if they did not experience recurrent 
headaches, had never experienced a migraine episode, and were not experiencing significant 
pain nor pain longer than 3 months at the time of the study. Participants in the control group 
were matched to the migraine group for age and gender. Participants in both groups were 
excluded if they used medications known to alter GABA levels. Complete inclusion and 
exclusion criteria and other details of participant recruitment are described elsewhere [1]. In 
brief, participants were recruited through advertisements posted at university, consumer 
support groups and primary care sites.  
 
Procedures 
We conducted initial telephone screening of potential participants to determine their 
eligibility. All participants in the migraine group then underwent an interview and physical 
examination to confirm classification according to ICHD-II criteria and to exclude headache 
participants with non-migrainous or mixed classification headache. Controls were also 
interviewed and physically examined.   
Participants with migraine provided information on headache characteristics including 
history of migraine, frequency of episodes, typical duration of each migraine episode, and 
headache intensity in the last month using the visual analogue scale (VAS: with anchors at 0 
and 10: 0 = no pain, 10 = worst pain possible). In addition, participants described the location 
of their headache, associated symptoms, and any medication and/or treatment received.  
All participants satisfying the inclusion and exclusion criteria completed self-
administered paper-and-pen questionnaires that were arranged in a standardized manner to 
ensure consistency. Questionnaires, described below, included information about pain and 
central nervous system sensitization experience, emotional state, and disability. Completed 
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questionnaires were checked for any misunderstood or inadvertently missed item. 
Participants then underwent proton magnetic resonance spectroscopy to determine brain 
GABA levels. All participants provided written informed consent prior to participation.  
 
Outcomes 
Brain GABA Levels 
Brain GABA levels were measured in institutional units by single-voxel proton magnetic 
resonance spectroscopy using the Mescher-Garwood point resolved spectroscopy sequence 
(TR = 1800 ms; TE = 68 ms; number of excitations (phase cycling), 8; number of 
acquisitions, 256; number of points, 4096; spectral width, 5000; voxel size, 3 × 3 × 3 cm3; 
total scan time, 8 min 24 s).  The voxel was positioned lateral to the midline posterior 
cingulate, and posterior and superior to the splenium of the corpus callosum (Figure 1). 
Spectroscopy was performed during the interictal period for participants in the migraine 
group; no one had migraine-related symptoms on the day of testing. Details of the full 
spectroscopy methods and parameters are reported elsewhere [1]. 
 
Clinical Characteristics Based on Self-Report Questionnaires 
Migraine pain characteristics were described using the Short-form McGill Pain 
Questionnaire-2 (SF-MPQ-2) comprising 22 pain quality descriptors scored for intensity on a 
0 to 10 Likert scale. SF-MPQ-2 has been validated for use for neuropathic pain [12], as is 
thought to be present in migraine [3]. For this study, the top and bottom quartiles of intensity 
scores were considered to reflect the words that people with migraine used the most and least, 
respectively, to describe their headache.  SF-MPQ-2 also provided information on the 
multidimensional nature of the migraine pain experience by generating summary scores for 
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continuous, intermittent, neuropathic and affective pain subscales, aside from the total SF-
MPQ-2 scores. 
Presence of symptoms of central nervous system sensitization was measured using the 
Central Sensitization Inventory (CSI) [31]. The CSI is a highly reliable and valid screening 
tool for central sensitivity syndromes (CSS), that is, diseases that have central sensitization as 
a common feature [34]. Scores of >40 indicate possible CSS, with higher CSI scores 
reflecting a higher degree of sensitization. CSI discriminates people with central sensitivity 
syndromes, including migraine, from those without pain, with a sensitivity = 81%; specificity 
= 75% [34] and from those with chronic pain without central sensitivity symptoms 
(sensitivity = 83%; specificity = 55%) [35].  
Emotional state was measured using the Depression Anxiety Stress Scales-21 (DASS-
21) [29]. The DASS-21 is a short, valid and highly reliable instrument providing depression, 
anxiety and stress scores based on frequency and severity of symptoms [21]. It has been used 
to investigate the association of negative emotional state with migraine [6,18,36].  
Perceived levels of disability were measured using the Headache Impact Test-6TM 
(HIT-6), a brief questionnaire on the impact of the headache on work and daily activities 
[25]. The HIT-6 was shown to have high reliability and good validity in discriminating 
migraine from other headaches [25]. 
 
Statistical Analyses 
Spearman’s rho and Kendall’s tau correlations were used to explore associations 
between GABA levels and normally and non-normally distributed clinical characteristics, 
respectively, in individuals with migraine. Correlation coefficients were interpreted as 
follows: greater than.75, good to excellent relationship; 0.50 to 0.75, moderate to good 
relationship; 0.25 to 0.50, fair relationship; and 0.00 to 0.25, little or no relationship [39]. 
135
These correlation analyses were performed after normality of the distribution of data was 
tested using the Shapiro-Wilk statistic.  
We conducted area under the receiver operating characteristic (ROC) curve analysis 
for clinical characteristics that had at least a fair association with GABA levels and that might 
be useful in discriminating migraine. To this end, we computed for optimal cut-off value, 
area under the curve, sensitivity, and specificity of the questionnaire score. Based on these 
calculations, we interpreted diagnostic accuracy to be excellent, good, fair or poor [47].  
Descriptive statistics (frequency, mean and standard deviation, SD, median and 
interquartile range, IQR) of headache characteristics and self-report questionnaire scores 
were used to report clinical characteristics.  The Wilcoxon signed rank test was used to 
determine differences in clinical characteristics based on questionnaire scores between 
migraine and control groups given that not all were normally distributed. Pairs were excluded 
from analysis if either case or control data were missing. Glass’s  was calculated to 
compare the difference between mean scores of the migraine and control groups. 
Statistical analyses were conducted using Statistical Package for Social Sciences® 
statistical software, version 21 (SPSS Inc., Chicago, Illinois, USA) for Windows. 
Significance level was set at 0.05. 
As this was an exploratory study using secondary analysis of brain GABA levels from 
a previous cross-sectional case-control study [1], the sample size of this present study was 
based on that of the previous study (n = 40). This sample size was powered to detect group 
differences in brain GABA levels. 
Results 
Participants 
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Twenty people with migraine and 20 age- and gender-matched controls participated in 
this study. The median age (IQR) of the migraine group was 33 (28–47) years while the 
median age of the control group was 30 (26–48) years. Fourteen out of 20 (70%) participants 
of each group were female. The average duration of migraine symptoms was 15 years, with a 
frequency of three to five times per month (Table 1). Migraine characteristics of the 
participants (Table 1) were consistent with the ICHD diagnostic criteria for migraine. Most 
participants reported more than one location of headache, with 85% reporting temporal 
location and 80% reporting frontal location (Figure 2).   
Participants most commonly chose aching (95%), tiring-exhausting (80%), throbbing 
(75%), sickening (70%), and sharp (65%) from the SF-MPQ-2 to describe their headaches 
(Figure 3). More than half the participants with migraine (55%) were not taking migraine 
medications at the time of assessment and had neither sought physical treatment such as 
physiotherapy nor alternative treatment such as acupuncture (Table 1).  
Of all the variables considered, only the following variables were normally 
distributed: history of migraine, intensity of headache in the last month, and scores on HIT-6, 
CSI, MPQ-continuous, MPQ-affective, and MPQ Total scores.  
 
Association between Clinical Characteristics and GABA Levels among People with 
Migraine 
There was fair positive association between GABA levels and pain scores, 
specifically total SF-MPQ-2 scores (ρ = .47, P = 0.04) and SF-MPQ-2 scores on intermittent 
(τ = .33, P = 0.04), neuropathic (τ = .37, P = 0.03) and affective (ρ = .49, P = 0.03) pain 
subscales (Table 2 and, Figure 4A). There was also fair positive association between GABA 
levels and scores on the CSI (ρ = .48, P = 0.03) (Figure 4B). GABA levels were not 
associated with headache history, frequency, duration or  intensity, continuous pain domain 
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on MPQ, depression, anxiety and stress scales of DASS-21, nor levels of disability (P > 0.05; 
Table 2).  
Of those variables having fair association with GABA levels, only CSI scores were 
suitable for ROC analysis because both migraine and control groups had scores greater than 0 
on the CSI. Results of this analysis revealed that CSI appears to have good accuracy for 
classifying individuals as having migraine or not [AUC (95% confidence interval) = 0.88 
(0.76-1.00), P <0.001)] (Figure 5).   The optimal CSI cut-off score to distinguish people with 
migraine from those who do not get regular headaches was 22.5, with sensitivity of 95%, 
specificity of 80% and positive likelihood ratio of +4.75.  
 
Clinical Characteristics of Migraine and Control Groups Based on Self-Report 
Questionnaires 
There were significant differences between groups for scores on all of the self-report 
questionnaires (Table 3).   The two groups differed the most in their scores on HIT-6 scores, 
SF-MPQ-2 continuous pain and CSI, as shown by their respective Glass’s . Notably, there 
was no statistically significant between-group difference for the anxiety scale of DASS-21.  
Participants from both groups had scores categorized as “normal” for this scale. 
 
Discussion 
Our results show that pain and central sensitization scores had a fair positive 
association with GABA levels in migraine. These results support a putative role for GABA in 
migraine pathophysiology particularly where migraine presents with moderate to severe 
headache and central nervous system sensitization.  This association between these migraine 
features and GABA also provides some further support in validating GABA as a potential 
biomarker for migraine. 
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GABA levels were associated with three of the four summary scales of pain quality 
and severity contained in the SF-MPQ-2, namely intermittent, neuropathic and affective pain. 
People with higher pain scores on SF-MPQ-2 scores tended to have higher GABA levels. 
These results give rise to the question whether the observed relationship between GABA 
levels and pain scores are characteristic of migraine or of any pain condition. We believe that 
the association between increased GABA levels and higher pain scores indicates a change in 
brain chemistry specific to migraine or chronic episodic headache for three reasons. First, we 
measured GABA levels during the interictal period, when participants were free of headache. 
Second, two participants in the control group had mild pain in the limb. Third, increased 
GABA levels in migraine oppose the decreased GABA levels reported in other pain 
conditions from previous studies, although measured from different brain regions (from the 
insula in fibromyalgia [15] and thalamus in people with spinal cord injury with neuropathic 
pain compared to those without neuropathic pain [17]. The association between GABA levels 
and pain scores also implies that SF-MPQ-2 may be used as a basis for
inferring about GABA levels when spectroscopy data are unavailable. Interestingly, GABA 
levels were not associated with headache intensity based on participant rating of their usual 
headaches. We speculate that the difference in findings is because participants considered 
pain differently when presented with words on the SF-MPQ-2 than when asked to rate their 
usual headaches.  Using the SF-MPQ-2, participants rated the intensity associated with the 
specific words. On the other hand, when asked to rate the intensity of their usual headaches, 
participants could be thinking of the whole headache experience, how the headache affected 
their lives or how long they had been dealing with the symptoms.   
Increased GABA levels were associated with higher central sensitization scores. This 
means that increased GABA levels are most likely to be higher when central sensitization 
symptoms are more frequent. One possible explanation for this relationship may be the role 
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of GABA in regulating excitatory-inhibitory balance in the brain [30].  The increased GABA 
levels in migraine may cause abnormal excitability of the trigeminovascular system, as 
previously postulated for migraine [1,42]. This explanation is plausible given that most of the 
participants reported having photophobia and/or phonophobia, both considered clinical 
expressions of sensitization [7,10,42]. We have previously reported that glutamate + 
glutamine measured from the same cohort did not differ between the migraine and control 
groups [1]. These findings support the role of increased GABA in the altered excitability of 
the brain.  Another possible explanation for the relationship between increased GABA levels 
and higher sensitization is based on the role of GABA in neurovascular coupling.  GABA has 
been shown previously to cause vasodilation during neurovascular coupling [23] where 
cortical blood flow adjusts according to cortical activity. Neurovascular coupling may be 
impaired in migraine, leading to the progression of migraine symptoms. Therefore the 
relationship between increased GABA levels and higher central sensitization scores may also 
be indicative of a role for GABA in migraine symptoms. Further, results of ROC curve 
analysis indicate that people with CSI scores > 22.5 are nearly five times more likely to have 
migraine than those with scores below this. This cutoff score is lower than the previously 
reported CSI cutoff score of 40 to identify central sensitization syndromes [34,35], suggesting 
the possible specific use of the CSI for migraine identification. The CSI provides information 
beyond ICHD criteria and therefore broadens the diagnostic process and enhances the 
clinician’s appreciation of the patient’s experience. 
GABA levels were not associated with headache characteristics, emotional state and 
perceived disability in this cohort. Our results differ from a previous report showing lower 
GABA levels in more severe headache [2]. The lack of association in this present study may 
be due to the timing of our GABA measurement (interictal period) and also possibly because 
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our participants were more homogenous with generally more frequent and more severe 
headaches than the cohort reported on by Bigal and colleagues [2].  
The homogeneity of headache characteristics of the migraine cohort was ideal for 
investigating potential disease biomarkers [38] and therefore was one of the strengths of this 
study. We also believe that we were able to detect an association between GABA and pain 
and central sensitization partly because GABA levels were measured from the cingulate 
cortex, previously shown to have altered functioning in pain states [14]. Localizing the voxel 
in this region also allowed the use of a large voxel to maximize signal-to-noise ratio for 
GABA [1].  
Although this study provides new insights on migraine characterization and the role of 
GABA in pathophysiology, some limitations should be considered. First, GABA levels were 
measured from just one region to achieve good signal quality in a short acquisition time. We 
do not know if increased GABA levels, and therefore their association with clinical 
characteristics, are different in other brain regions. Second, spectroscopy was done during the 
interictal period so it is not possible to tell if GABA levels are also increased during the ictal 
period. It seems reasonable to speculate, however, that GABA levels might also be altered if 
measured during the ictal period. This speculation is based on a previous proposal that the 
brain in migraine changes in function and structure over time due to repeated migraine 
episodes [4]. These changes may include a dysregulation of the excitatory-inhibitory balance 
in the brain involving GABA. Correspondingly, we speculate that GABA levels measured 
during the ictal period might also be associated with symptoms of central sensitization and 
pain. Third, this study was intended to be exploratory and therefore was not set up for 
multivariate analyses and adjustment for multiple comparisons. For the same reason, we did 
not design the study to include the presence or absence of aura symptoms nor the varied 
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medications of the participants as covariates in the analyses. Lastly, DASS-21 and HIT-6 
scores of our participants had insufficient variability for rigorous analysis. 
Further studies are therefore required to confirm the results of our study. Larger, 
longitudinal cohort studies may investigate the association between GABA levels and clinical 
characteristics in migraine and other headache types during the ictal and interictal periods. 
Additional factors that may be related with GABA levels in migraine may be investigated 
such as other neurotransmitters, presence or absence of aura, and medications.  Similarly, it 
will be useful to determine whether questionnaires can differentiate migraine from other 
headache types. Further studies can also build on results of this study to validate GABA as a 
biomarker and address the lack of established biomarkers for migraine [11].  
Nevertheless, results of this study strengthen the rationale for the role of GABA in 
migraine pathophysiology and thus add to the understanding of migraine.  The association of 
pain and central nervous system sensitization symptoms with GABA levels in migraine 
suggests that patients’ subjective reports correlate with brain chemistry. Hence assessing 
these clinical characteristics using SF-MPQ-2 and CSI is useful, allows more specific 
characterization of migraine. It is hoped that a better understanding of migraine will 
eventually pave the way for effective targeted treatment options.  
 
Conclusions 
Increased GABA levels were associated with increased pain and more frequent 
central sensitization symptoms in migraine.  These findings contribute to the understanding 
of migraine.  These findings also provide early evidence for the usefulness of measuring 
GABA and pain and central sensitization in characterizing migraine better and broadening the 
diagnostic process.  In addition to enhancing diagnosis and assessment, using self-report 
questionnaires in clinical practice may facilitate understanding of a patient’s headache 
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experience.  This new information on the association of clinical characteristics of GABA 
levels in migraine brings us a step closer to demonstrating the validity of GABA as a 
migraine biomarker. 
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Figure Legends 
Figure 1. Placement of the single voxel in the (A) axial, (B) coronal, and (C) sagittal planes 
for proton magnetic resonance spectroscopy analysis  
 
Figure 2. Typical locations of headache as reported by participants with migraine (visual 
representation according to percentage of participants reporting the site of pain) 
 
Figure 3. Top and bottom five pain descriptors chosen by participants with migraine to 
describe their headaches (n = 20) 
 
Figure 4. Scatterplot with regression line showing positive association between brain GABA 
levels and scores on (A) Short-form McGill Pain Questionnaire-2 (ρ = .47, P = 
0.04) and (B) Central Sensitization Inventory (ρ = .48, P = 0.03) in the migraine 
group (n = 20) 
  
Figure 5. Receiver operating characteristic curve evaluating CSI scores of people with 
migraine and controls.  Area under the curve = 0.88 (95% confidence interval 
0.76-1.00), P<0.001 
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Table Legends 
Table 1. Descriptive migraine characteristics (n = 20) 
 
Table 2. Association of GABA levels and clinical characteristics of migraine using 
Spearman’s rho, ρ, or Kendall’s tau, τ, correlation coefficient (P values) 
 
Table 3. Comparison of clinical characteristics based on self-report questionnaires between 
migraine and control groups (n = 40) 
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 Figure 1. Placement of the single voxel in the (A) axial, (B) coronal, and (C) sagittal planes 
for proton magnetic resonance spectroscopy analysis  
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 Figure 2.Typical locations of headache as reported by participants with migraine (visual 
representation according to percentage of participants reporting the site of pain) 
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 Figure 3.Top and bottom five pain descriptors chosen by participants with migraine to 
describe their headaches (n = 20) 
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Figure 4. Scatterplot with regression line showing positive association between brain GABA 
levels and scores on (A) Short-form McGill Pain Questionnaire-2 (ρ = .47, P = 
0.04) and (B) Central Sensitization Inventory (ρ = .48, P = 0.03) in the migraine 
group (n = 20) 
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 Figure 5.Receiver operating characteristic curve evaluating CSI scores of people with 
migraine and controls. Area under the curve = 0.88 (95% confidence interval 
0.76-1.00), P<0.001 
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Table 1.  Descriptive migraine characteristics (n = 20) 
 MEAN (SD) MEDIAN (IQR) n % 
Migraine history (years since first episode) 17.6 (14.6) 15 (5.0-24.0)   
Frequency of headache in a month (n) 5.1 (5.2) 2.8 (1.5-8.5)   
Episode duration (hours) 38.6 (21.8) 48.0 (24.0-48.0)   
Average headache intensity last month (0-10) 6.4 (1.8) 6.0 (6.0-8.0)   
Unilateral   13 65 
With aura   9 45 
Nausea   18 90 
Vomiting   6 30 
Photophobia / Phonophobia     
Both photophobia and phonophobia   13 65 
Photophobia alone   6 30 
Phonophobia alone   0 0 
Neither photophobia nor phonophobia   1 5 
Physical activity intolerance   15 75 
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Table 2. Association of GABA levels and clinical characteristics of migraine using 
Spearman’s rho, ρ, or Kendall’s tau, τ, correlation coefficient (P values) 
 GABA LEVELS 
 Correlation Coefficients (P values)1 
Headache characteristics  
Migraine history ρ = -.40 (0.08) 
Frequency of headache in a month  τ = .16 (0.33) 
Episode duration  τ = -.01 (0.94) 
Average headache intensity last month ρ = .17 (0.48) 
Pain and sensitization  
SF-MPQ-2 Total score ρ = .47 (0.04)2 
SF-MPQ-2 Continuous pain score ρ = .21 (0.38) 
SF-MPQ-2 Intermittent pain score τ = .33 (0.04)b 
SF-MPQ-2 Neuropathic pain score τ = .37 (0.03)b 
SF-MPQ-2 Affective descriptors ρ = .49 (0.03)b 
CSI Total score ρ = .48 (0.03)b 
Emotional state  
DASS-21 Depression Score τ = -.14 (0.42) 
DASS-21 Anxiety Score τ = .17 (0.34) 
DASS-21 Stress Score τ = -.13 (0.43) 
Disability (HIT-6 score) ρ = .06 (0.79) 
 
1 Spearman's rho, ρ; Kendall’s tau, τ  
2 Correlation is significant at the 0.05 level (2-tailed) 
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Highlights 
• Increased GABA levels were associated with increased pain and more frequent
central sensitization symptoms in migraine.
• Results provide preliminary evidence for the possible involvement of GABA in
migraine pathophysiology.
• GABA is a potential biomarker for migraine.
• Measuring clinical characteristics of migraine using self-report questionnaires may be
useful in characterizing migraine better and broadening the diagnostic process.
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CHAPTER FIVE 
Characterizing Cervical Musculoskeletal Impairments and 
Patient Experience in Migraine as Distinguished from 
Non-Migraine Headaches 
Chapter Five has been submitted as: 
Aguila ME, Leaver AM, Hau SA, Ali K, Ng K, Rebbeck T. Characterizing cervical 
musculoskeletal impairments and patient experience in migraine as distinguished from non-
migraine headaches. Submitted to The Journal of Headache and Pain. 
The study protocol for the study presented in this chapter appears as Appendix 5. 
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Abstract 1 
Background:Symptoms of migraine may vary and overlap with those of other recurrent 2 
headache types, including tension-type headache and cervicogenic headache. Thus diagnosis 3 
and treatment of migraine may potentially be challenging. Cervical musculoskeletal 4 
impairments may help characterize migraine further but available evidence is inconsistent. 5 
Patient experience of disability and multidimensional pain is also important to detail to 6 
possibly differentiate migraine from other recurrent headaches.This research aimed to 7 
distinguishmigraine from non-migraine headaches(tension-type headache and cervicogenic 8 
headache) based on cervical musculoskeletal impairment and patient experience. 9 
Methods:In this cross-sectional study, participants with migraine and non-migraine 10 
headaches and headache-free controlsunderwent physical examination for cervical 11 
musculoskeletal impairment and completed questionnaires on patient experience (disability, 12 
multidimensional pain, central sensitization, and emotional state). 13 
Results:Fewer participants in the migraine group [n (%) 4 (10%)] had cervical articular 14 
impairment than the non-migraine group [26 (58%); p < 0.001]. Headache groups did not 15 
differ on cervical muscle impairment measures when considered independently. Migraine 16 
group had more intense pain [median numeric rating scale/10 (IQR)] 7.0 (6.0–7.0) versus 5.0 17 
(4.0–7.0); p = 0.009] and higher disability scores [e.g. Headache Disability Questionnaire 18 
43/90 (31–53) versus 27/90 (20–42); p = 0.006] than the non-migraine group. A combination 19 
of no pain on manual examination of the cervical spine, less change in deep cervical 20 
extensors thickness during contraction, less frequent headaches, and higher disability scores 21 
had 80.0% sensitivity and 75.6% specificity in identifying migraine. 22 
Conclusions: Less cervical musculoskeletal impairment and higher pain and self-reported 23 
disability, considered independently, distinguished migraine from non-migraine headaches. 24 
New evidence is presented on cervical muscle behavior measured using the deep cervical 25 
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extensor test and self-reported disability as part of a combination of clinical characteristics 26 
that distinguishes migraine. Thus results suggest the value of assessing impairments and 27 
disability in migraine for differential diagnosis. 28 
29 
Key words: migraine, tension-type headache, cervicogenic headache, disability, cervical 30 
spine, musculoskeletal impairment 31 
32 
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Background 33 
The most common recurrent headaches that present to primary care clinicians and specialists, 34 
namely migraine, tension-type headache (TTH) [1] and cervicogenic headache (CGH) [2], are 35 
among the most disabling headache types. One critical element in reducing the burden of 36 
headaches is effective targeted headache treatment. Effective headache treatment, in turn, 37 
requires a clear understanding of underlying disease mechanisms, well-defined distinction of 38 
clinical features between headache types, and ultimately, accurate diagnosis. 39 
Distinguishing migraine from other headache types is relevant because migraine is the 40 
most disabling headache globally [3], yet is underdiagnosed [4]. Contributing to this 41 
difficulty in diagnosis are the complex and varied presentations of migraine within and 42 
between individuals and its possible coexistence with other headache types [4, 5]. Migraine 43 
features may also overlap with those of other headaches, plausibly due to the common 44 
involvement of the trigeminocervical complex in the brainstem in different headache types, 45 
including TTH and CGH [6, 7].The bidirectional interaction between nociceptive input from 46 
the upper cervical spine and the trigeminocervical complex [8, 9] are hypothesized to result 47 
in cervical symptoms that are commonly associated with recurrent headaches [10, 48 
11]. Consequently, cervical musculoskeletal impairment has been treated in headaches, 49 
although with variable evidence on effects [9]. To date, it is unknown whether these 50 
characteristics distinguish migraine from other frequently presenting recurrent headache 51 
types. 52 
Therefore a conceivable way to better distinguish migraine, in addition to those listed 53 
as diagnostic criteria in International Classification of Headache Disorders (ICHD) [5], is by 54 
assessing symptoms and musculoskeletal impairments arising from the cervical spine [10, 55 
12]. It is plausible that migraine differs from non-migraine headaches in terms of cervical 56 
impairments. Migraine primarily involves central nociceptive processing while episodic non-57 
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migraine headaches, specifically TTH and CGH, are hypothesized to be primarily initiated by 58 
peripheral nociceptive mechanisms [5, 7, 13]. By clarifying whether or not cervical 59 
musculoskeletal impairment distinguished migraine, we improve the understanding of 60 
migraine especially when its presentation is complex. This improved understanding, then, 61 
would help address the issue of underdiagnosis of migraine. 62 
To build on knowledge from previous studies and clarify the distinction of migraine 63 
from other frequently presenting recurrent headaches, a comprehensive examination of 64 
cervical musculoskeletal impairment is warranted. A recent Delphi study that assembled a 65 
panel of expert physiotherapists recommended the use of tests for cervical musculoskeletal 66 
impairment in headache assessment, including tests previously reported as discriminatory for 67 
CGH [14]. Moreover, impairment of the cervical extensor muscle group in headache was 68 
proposed to require further investigation [15]. Additionally, cervical musculoskeletal 69 
impairment in headaches will be better understood when differentiated from those in 70 
headache-free controls, considering the high prevalence of neck pain in the general 71 
population [3]. 72 
In addition to understanding cervical musculoskeletal impairment in headaches more 73 
thoroughly, understanding symptoms from a multidimensional biopsychosocial perspective 74 
may potentially assist in distinguishing migraine from other headaches. Currently, the ICHD 75 
lists unidimensional characteristics of pain, such as quality and severity, among the criteria 76 
for classifying headaches [5]. However, these pain characteristics may overlap between 77 
headache types. For example, 35.1% of individuals with TTH reported moderate to severe 78 
headaches [16], which are severity ratings typically associated with migraine [5]. Therefore, 79 
a multidimensional assessment of pain, complemented by information about disability and 80 
other characteristics that modulate the pain experience, such as central sensitization 81 
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mechanisms [17] and emotional states [18], may provide the opportunity to understand the 82 
patient experinece better and distinguish migraine from other headache types. 83 
This study therefore aimed to determine if migraine can be distinguished from 84 
frequently presenting non-migraine headaches (TTH and CGH) based on a comprehensive 85 
assessment of cervical musculoskeletal impairment and patient experience. Clarifying the 86 
distinction between migraine and non-migraine headaches would contribute to a better 87 
understanding of frequently presenting headaches, an enhanced diagnostic framework, and 88 
eventually research directions for better, targeted treatments for these headache types. 89 
90 
Methods 91 
Design 92 
In this cross-sectional study, we compared characteristics between people with migraine, 93 
those with non-migraine headaches and headache-free controls. This research was granted 94 
ethics approval by the Human Research Ethics Committee of The University of Sydney 95 
(Project Number 2014/536). 96 
97 
Participants 98 
We recruited volunteers aged 18 to 65 with recurrent headache and headache-free controls 99 
through advertisements posted at community bulletins, social media, and primary and 100 
specialist care clinics. Participants in the headache group were included if they had headaches 101 
for at least one year and had at least one headache episode in the previous month. Headache 102 
participants were further classified into the migraine group (fulfilling the criteria for 103 
migraine only and not those for other headache types) or non-migraine group (with primary 104 
diagnosis of TTH and/or CGH, with or without comorbid migraine) using the ICHD-3 beta 105 
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criteria [5]. Participants in the control group were included if they had not experienced any 106 
headache in the past 3 months. 107 
Exclusion criteria for the headache groups were other known secondary headache 108 
classifications without a known pathogenesis in the neck, such as tumor, substance 109 
withdrawal, etc., and psychiatric disorders. Exclusion criteria for the control group were 110 
severe neck pain, recent head or neck surgery, or conditions requiring medical attention or 111 
affecting performance of daily activities. 112 
113 
Procedure 114 
All participants underwent initial telephone screening to confirm their eligibility. All eligible 115 
participants provided written informed consent prior to participation.Eligible participants then 116 
completed questionnaires that provided information about demographic and headache 117 
characteristics as well as their disability and multidimensional pain experience. Participants 118 
also attended one assessment session for interview about headache features and physical 119 
examination of cervical musculoskeletal impairment. Physical examination was done by a 120 
physiotherapist with 20 years of experience for the headache groups and by two novice 121 
physiotherapists for the control group. All examiners were trained by a specialist 122 
musculoskeletal physiotherapist with clinical and research expertise in cervical spine 123 
disorders. Participants were independently classified into migraine and non-migraine 124 
groups by two researchers using the ICHD-3 beta criteria. Disagreements were resolved by a 125 
third researcher. The process was overseen by a neurologist and a specialist physiotherapist 126 
who were blinded to the headache diagnoses of participants and who did not conduct the 127 
physical examination. 128 
129 
Outcomes 130 
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Cervical musculoskeletal impairment comprised cervical articular impairment and cervical 131 
muscle impairment. Cervical articular impairment was measured using the range of motion 132 
measures, flexion rotation test [19] and manual examination of the upper cervical spine with 133 
passive accessory intervertebral movements (PAIVMs) [12, 20]. The Cervical Range of 134 
Motion Instrument (CROM) 3 (Performance Attainment Associates, (Roseville, MN, USA) 135 
was used to measure flexion, extension, lateral flexion and rotation, summed to obtain the 136 
composite score. The flexion rotation test was deemed positive if headache was provoked and 137 
the range of movement was ≤ 32o [21]. Manual examination of the cervical spine was deemed 138 
positive if headache was provoked. 139 
Cervical muscle impairment was assessed in terms of muscle function (relating to 140 
strength and endurance) and muscle behavior (relating to motor control). Cervical flexor and 141 
extensor strength was measured using the Lafayette Manual Muscle Tester (Model 01163) 142 
handheld dynamometer [22]. Cervical extensor and flexor endurance was measured using the 143 
protocol published by Edmondston and colleagues [23]. Upper limits for sustained isometric 144 
contraction were set at 60 seconds for flexors and 200 second for extensors [23]. Ratios of 145 
extensor to flexor strength and endurance were calculated. 146 
Muscle behavior of the deep flexor and deep extensor muscles were assessed using 147 
the cranio-cervical flexion test [24], cervical extensor test [25], and the deep cervical extensor 148 
(DCE) test. The DCE test  measures changes in thickness of the deep cervical 149 
extensor muscle group during low-load using ultrasound imaging [26]. Performance on the 150 
cranio-cervical flexion test was scored using the performance index, which was calculated 151 
based on the number of times the participant could hold the pressure level achieved for 10 152 
seconds [24]. The cervical extensor test was scored through video analysis of the 153 
performance of the participant. The performance of correct movement patterns in maintaining 154 
the start position and during the eccentric and concentric phases of movement were scored on 155 
173
a scale of 0–4, with lower scores indicating better performance. The aggregate score, which is 156 
the total of scores for all phases, was reported. 157 
In contrast to the cervical extensor test, the DCE test measures changes in thickness of 158 
the deep cervical extensor muscle group during low-load contractions using ultrasound 159 
imaging [26]. Thickness of the deep cervical extensors was measured from real-time 160 
ultrasound images from the top edge of the lamina to the leading edge of the first fascial 161 
plane above the facet joint or spinous process at C4 level [26]. Measurements were done with 162 
the muscles at rest and during submaximal contraction. Measurements were taken from the 163 
symptomatic side for participants with side-locked headaches. For participants whose 164 
headaches were bilateral and for control participants, measurements from the left and right 165 
muscle groups were averaged and recorded as the measure for both sides. Analyses of the 166 
DCE test were based on the change in thickness of the muscles from the relaxed state to the 167 
contracted state and the percentage change in thickness (that is, the difference between 168 
contracted and relaxed state divided by the relaxed state multiplied by 100%). 169 
Aspects of patient experience assessed in this studycomprised disability, 170 
multidimensional pain, central sensitization, and emotional state using the Henry Ford 171 
Headache Disability Inventory (HDI) [27], Headache Disability Questionnaire (HDQ) 172 
[28],Headache Impact Test-6TM (HIT-6) [29], World Health Organization Disability 173 
Assessment Schedule 2.0 (WHODAS) [30], Short-form McGill Pain Questionnaire-2 (SF-174 
MPQ-2) [31], Central Sensitization Inventory (CSI) [32], and Depression Anxiety Stress 175 
Scales-21 (DASS-21) [33]. 176 
177 
Statistical analysis 178 
The calculated sample size (n = 32 per group) was based on a hypothesized mean difference 179 
of 20 degrees in range of cervical extension and 20 Newtons in strength between migraine 180 
174
and non-migraine groups [10] and an estimated within-group standard deviation of 35 181 
units,with a significance level of 0.05 with 80% power. Allowing for about 20% attrition, we 182 
determined the sample size to be 40 per group. 183 
Distributions of data were examined through visual inspection and using the Shapiro-184 
Wilk test and summarized using descriptive statistics. Comparisons of the continuous 185 
variables between migraine, non-migraine and control groups were computed using one-way 186 
ANOVA followed by Fisher’s least significant difference (LSD) post-hoc test when there was 187 
an overall significance. Kruskal-Wallis test was used when the assumption of homogeneity of 188 
variance was not met (Levene’s test, p< 0.05), followed by pairwise-comparisons using 189 
Mann-Whitney Test with Bonferroni correction. Additionally, comparisons for headache 190 
characteristics and pain and disability questionnaire scores between the migraine and non-191 
migraine groups only were computed using the T-test or Mann-Whitney Test, as appropriate. 192 
Comparisons of categorical variables between the three groups were computed using the Chi 193 
square test, followed by post-hoc test with modified Bonferroni correction when there was an 194 
overall significance.For characteristics that were significantly different between headache 195 
groups, area under the receiver operating characteristic (ROC) curve analysis was used. The 196 
discriminative ability of these characteristics were examined by computing for optimal cutoff 197 
value, area under the curve (AUC), sensitivity, specificity, and positive likelihood ratio. 198 
Stepwise discriminant analysis was used to identify the combination of characteristics that 199 
distinguished migraine from non-migraine headaches. The criteria for entry and removal of 200 
variables into the model were a significance level of p< 0.05 and p< 0.10, respectively, of 201 
Wilks lambda.Statistical analyses were conducted using Statistical Package for Social 202 
Sciences® statistical software, version 24 (SPSS Inc., Chicago, Illinois, USA) for Windows. 203 
Significance level was set at 0.05. 204 
205 
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Results 206 
Participants 207 
Forty people with migraine, 45 people with non-migraine headache, and 40 controls 208 
participated in this study. The non-migraine group comprised 26 participants with 209 
predominantly CGH, 16 participants with predominantly TTH, and three participants with 210 
both cervicogenic and TTHs. The flow of participants through the study and reasons for 211 
exclusion of volunteers are shown in Figure 1.The demographic and headache characteristics 212 
of the participants are presented in Table 1 and Table 2, respectively. There were significant 213 
differences between the migraine and non-migraine groups in headache characteristics. The 214 
migraine group had longer history of headache [median (interquartile range, IQR) 18.50 215 
(10.50–24.50) years versus 9.00 (4.00–20.00) years; p = 0.002], higher average headache 216 
intensity in the last month [7.00 (6.00–7.00) versus 5.00 (4.00–7.00); p = 0.009], and less 217 
frequent headaches in a month [3.00 (1.00–5.00) versus 8 (3.50–13.00); p < 0.001] than the 218 
non-migraine group. More participants in the migraine group compared to the non-migraine 219 
group had unilateral headache [n (%) 32 (80.00%) versus 20 (44.44%); p = 0.001] and 220 
experienced vomiting [20 (50.00%) versus 13 (28.89%); p = 0.046], and photophobia and/or 221 
phonophobia [36 (90.00%) versus 26 (57.78%), p = 0.001] with their headaches. 222 
223 
Cervical musculoskeletal impairment 224 
There were significant differences between groups in cervical range of extension, pain on 225 
flexion rotation test, manual examination of the upper cervical joints, and ratio of extensor-226 
flexor strength (Table 3). Post-hoc analyses revealed that the migraine differed from the non-227 
migraine group but not from the control group on cervical articular impairments. Specifically, 228 
fewer participants in the migraine [4 (10.00%)] and control groups [6 (15%)] tested positive 229 
on the flexion rotation test compared to participants in the non-migraine group [17 230 
176
(37.78%)] (p = 0.003–0.018). Similarly, fewer participants in the migraine group [4 (10.00%)] 231 
and control group [0 (0%)] had their headaches provoked on manual examination of the 232 
upper cervical joints compared to participants in the non-migraine group [n (%) 26 (57.78%)] 233 
(p< 0.001). The migraine group had lower ratio of extensor-flexor strength than the control 234 
group [1.51 (1.16–1.85) versus 2.15 (1.66–2.64);(p< 0.001)]. The migraine group did not 235 
differ from the non-migraine group on all cervical muscle impairment measures (p> 0.05). 236 
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Table 1. Demographic characteristics of participants (n = 125)* 237 
Median (IQR) or n (%) p 
values† 
Migraine 
(n = 40) 
Non-Migraine 
(n = 45) 
Control 
(n = 40) 
Age 42.00 (28.50–49.50) 29.00 (27.00–42.00) 31.50 (22.00–50.50) 0.06 
Gender (female) 32 (80.00%) 40 (88.89%) 31 (77.50%) 0.35 
Body mass index 23.44 (21.18–27.62) 22.48 (20.64–27.06) 23.12 (21.26–24.79) 0.69 
Marital status 0.48 
Single / Divorced / 
Widowed / Separated 
20 (50.00%) 28 (62.22%) 21 (52.50%) 
Married / De facto 20 (50.00%) 17 (37.78%) 19 (47.50%) 
Region of birth 0.048 
Oceania 27 (67.50%) 24 (53.33%) 16 (40.00%) 
Other geographic region 13 (32.50%) 21 (46.67%) 24 (60.00%) 
Level of education 0.08 
University degree 33 (82.50%) 40 (88.89%) 29 (72.50%) 
No university degree 6 (15.00%) 4 (8.89%) 11 (27.50%) 
No information provided 1 (2.50%) 1 (2.22%) 
Occupation 0.001 
Professional 13 (32.50%) 26 (57.78%) 13 (32.50%) 
Student 9 (22.50%) 12 (26.67%) 20 (50.00%) 
Other occupation 18 (45.00%) 7 (15.56%) 7 (17.50%) 
238 
Abbreviation: IQR, interquartile range 
NOTE. Bold numbers indicate statistical significance (p< 0.05) or statistically significant difference from the other groups on 
post-hoc analyses 
* For continuous variables, values are presented as median (IQR); for categorical variable, valuesare presented as frequency (%)
†pvalues for Kruskal-Wallis Testfor continuous variables between three groups; p values for Chi-square test for categorical
variables between three groups
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Table 2. Headache characteristics of participants with recurrent headaches (n = 85)‡ 239 
Median (IQR) orn (%) p values§ 
Migraine 
(n = 40) 
Non-Migraine 
(n = 45) 
History of headache (years since first 
episode) 
18.50 (10.50–24.50) 9.00 (4.00–20.00) 0.002 
Frequency of headache in a month  3.00 (1.00–5.00) 8 (3.50–13.00) <0.001 
Episode duration , minimum (hours) 3.50 (1.50–24.00) 4 (2.00–24.00) 0.96 
Episode duration , maximum (hours) 60.00 (30.00–72.00) 24.00 (12.00–72.00) 0.11 
Average headache intensity last month 
(0-10)** 
7.00 (6.00–7.00) 5.00 (4.00–7.00) 0.009 
Unilateral location 32 (80.00%) 20 (44.44%) 0.001 
Throbbing / pulsating quality 31 (77.50%) 27 (60.00%) 0.08 
Associated with nausea 35 (87.50%) 32 (71.11%) 0.07 
Associated with vomiting 20 (50.00%) 13 (28.89%) 0.046 
Associated with 
photophobia/phonophobia 
36 (90.00%) 26 (57.78%) 0.001 
Associated with physical activity 
intolerance 
17 (42.50%) 18 (40.00%) 0.82 
Pharmacologic treatment (number of 
participants, n, %) 
Paracetamol 14 (35.00%) 17 (37.78%) 0.06 
Non-steroidal anti-inflammatory 
drug 
18 (45.00%) 20 (44.44%) 0.58 
Tricyclic antidepressant 6 (15.00%) 3 (6.67%) 0.47 
Triptan 19 (47.50%) 10 (22.22%) 0.006 
Botulinum toxin 8 (20.00%) 11 (24.44%) 0.48 
Beta blocker 4 (10.00%) 3 (6.67%) 0.42 
Selective serotonin reuptake 
inhibitor 
5 (12.50%) 6 (13.33%) 0.64 
Proton pump inhibitor 4 (10.00%) 6 (13.33%) 0.42 
Anticonvulsant 5 (12.50%) 7 (15.56%) 0.29 
Contraceptive 7 (17.50%) 10 (22.22%) 0.99 
240 
Abbreviation: IQR, interquartile range 
NOTE. Bold numbers indicate statistical significance (p<0.05) 
‡For continuous variables, values are presented median (IQR); for categorical variables, valuesare presented as 
frequency (%) 
§pvalues for Mann-Whitney Testfor continuous variables between groups; p values for Chi-square test for
categorical variables between groups
** Headache intensity: Numerical rating scale 0–10; 0= no pain, 10 = worst possible pain
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Measurement of patient experience using self-report questionnaires 242 
There were significant differences between groups on all questionnaire scores (Table 4). 243 
Post-hoc analyses revealed that the migraine group had significantly higher scores than the 244 
non-migraine group on HDI Total Score [median (IQR) 40 out of 100 (21–56) versus 24 out 245 
of 100 (14–44), p = 0.029] and HDQ score [43 out of 90 (31–53) versus 27 (20–42), p = 246 
0.006]. For all other questionnaires, the control group had significantly lower scores than the 247 
headache groups;however there was no difference between headache groups. 248 
Total scores on HDI appeared to have good diagnostic value in classifying individuals 249 
as having migraine and not non-migraine headache (AUC = 0.80; 95% confidence interval, 250 
CI, 0.73 to 0.88; p< 0.001). The optimal HDI cutoff score to distinguish people with migraine 251 
from non-migraine headaches was 19 out of 100, with sensitivity of 80.0% and specificity of 252 
67.1%, and positive likelihood ratio of 1.72. Similarly, HDQ score appeared to have good 253 
diagnostic value in classifying individuals as having migraine or not (AUC = 0.82; 95% CI 254 
0.75 to 0.90; p<0.001). The optimal HDQ cutoff score to distinguish people with migraine 255 
from non-migraine headaches was 27.5 out of 90, with sensitivity of 80.0%, specificity of 256 
74.1%, and positive likelihood ratio of 3.09. 257 
181
Ta
bl
e 
4.
 C
om
pa
ris
on
 o
f s
co
re
s o
n 
se
lf-
re
po
rt 
qu
es
tio
nn
ai
re
s b
et
w
ee
n 
pa
rti
ci
pa
nt
 g
ro
up
s (
n 
= 
12
5)
 
25
8 
M
ig
ra
in
e 
(n
 =
 4
0)
 
N
on
-M
ig
ra
in
e 
(n
 =
 4
5)
 
Co
nt
ro
l 
(n
 =
 4
0)
 
M
ea
n 
(S
D
) 
M
ed
ia
n 
(IQ
R)
 
M
ea
n 
(S
D
) 
M
ed
ia
n 
(IQ
R)
 
M
ea
n 
(S
D
) 
M
ed
ia
n 
(IQ
R)
 
p 
va
lu
es
**
*  
D
is
ab
ili
ty
 
H
D
I T
ot
al
 S
co
re
††
†  
39
.4
5 
(2
3.
01
) 
40
.0
0 
(2
1.
00
–5
6.
00
) 
30
.4
9 
(2
1.
78
) 
24
.0
0 
(1
4.
00
–4
4.
00
) 
0.
02
9 
H
D
Q
‡‡
‡  
41
.6
0 
(1
5.
68
) 
43
.0
0 
(3
1.
00
–5
3.
00
) 
31
.6
7 
(1
6.
04
) 
27
.0
0 
(2
0.
00
–4
2.
00
) 
0.
00
6 
H
IT
-6
 T
ot
al
 sc
or
e§
§§
 
62
.1
0 
(5
.6
0)
 
62
.0
0 
(5
8.
00
–6
5.
50
) 
58
.6
7 
(6
.3
4)
 
60
.0
0 
(5
4.
00
–6
3.
00
) 
0.
06
 
W
H
O
D
A
S 
2.
0 
O
ve
ra
ll 
sc
or
e‡
‡‡
 
13
.6
5 
(1
3.
20
) 
10
.4
2 
(4
.1
7–
19
.7
9)
 
11
.6
2 
(1
0.
39
) 
6.
25
 (4
.1
7–
20
.8
3)
 
1.
09
 (3
.5
6)
 
0.
00
 (0
.0
0–
0.
00
) 
0.
70
 
Pa
in
 SF
-M
PQ
-2
 T
ot
al
 sc
or
e*
**
*  
2.
25
 (1
.7
1)
 
1.
98
 (0
.9
5–
2.
66
) 
1.
96
 (1
.3
9)
 
1.
64
 (1
.0
0–
2.
59
) 
0.
08
 (0
.2
0)
 
0.
00
 (0
.0
0–
0.
02
) 
0.
55
 
C
en
tr
al
 se
ns
iti
za
tio
n 
CS
I T
ot
al
 sc
or
e†
††
†  
35
.7
8(
14
.0
3)
 
34
.5
0 
(2
6.
50
–4
5.
50
) 
37
.1
6 
(1
2.
03
) 
37
.0
0 
(3
1.
00
–4
2.
00
) 
18
.8
0 
(8
.8
6)
 
18
.5
0 
(1
2.
00
–2
5.
50
) 
<0
.0
01
 
Em
ot
io
na
l s
ta
te
‡‡
‡‡
 
D
A
SS
-2
1 
D
ep
re
ss
io
n 
sc
or
e 
2.
55
 (3
.6
4)
 
1.
00
 (0
.0
0–
3.
50
) 
2.
16
 (2
.3
2)
 
1.
00
 (0
.0
0–
4.
00
) 
0.
85
 (1
.6
1)
 
0.
00
 (0
.0
0–
1.
00
) 
0.
00
2 
D
A
SS
-2
1 
A
nx
ie
ty
 sc
or
e 
2.
18
 (3
.3
9)
 
1.
00
 (1
.0
0–
3.
00
) 
2.
04
 (2
.3
4)
 
1.
00
 (0
.0
0–
3.
00
) 
0.
93
 (1
.4
2)
 
0.
00
 (0
.0
0–
1.
50
) 
0.
00
4 
D
A
SS
-2
1 
St
re
ss
 sc
or
e 
5.
35
 (4
.0
7)
 
4.
50
 (2
.5
0–
8.
00
) 
4.
91
 (3
.7
9)
 
4.
00
 (2
.0
0–
6.
00
) 
2.
55
 (2
.8
8)
 
1.
50
 (0
.0
0–
4.
50
) 
0.
00
1 
25
9 
A
bb
re
vi
at
io
ns
: C
SI
, C
en
tra
l S
en
sit
iz
at
io
n 
In
ve
nt
or
y;
 D
A
SS
, D
ep
re
ss
io
n 
A
nx
ie
ty
 S
tre
ss
 S
ca
le
s-
21
; H
D
I, 
Th
e 
H
en
ry
 F
or
d 
H
ea
da
ch
e 
D
isa
bi
lit
y 
In
de
x;
 H
D
Q
, H
ea
da
ch
e 
D
isa
bi
lit
y 
Q
ue
sti
on
na
ire
; H
IT
-6
, H
ea
da
ch
e 
Im
pa
ct
 T
es
t-6
; I
Q
R,
 in
te
rq
ua
rti
le
 ra
ng
e;
 S
D
, s
ta
nd
ar
d 
de
vi
at
io
n;
 S
F-
M
PQ
-2
, S
ho
rt-
fo
rm
 M
cG
ill
 P
ai
n 
Q
ue
sti
on
na
ire
-2
; W
H
O
D
A
S,
 W
or
ld
 H
ea
lth
 O
rg
an
iz
at
io
n 
D
isa
bi
lit
y 
A
ss
es
sm
en
t S
ch
ed
ul
e 
N
O
TE
. B
ol
d 
nu
m
be
rs
 in
di
ca
te
 st
at
ist
ic
al
 si
gn
ifi
ca
nc
e 
(p
<0
.0
5)
 o
r s
ta
tis
tic
al
ly
si
gn
ifi
ca
nt
 d
iff
er
en
ce
 fr
om
 th
e 
ot
he
r g
ro
up
s o
n 
po
st-
ho
c 
an
al
ys
es
 
**
* p
va
lu
es
 fo
r A
N
O
V
A 
fo
r C
SI
 sc
or
es
; p
va
lu
es
 fo
r M
an
n-
W
hi
tn
ey
 T
es
t f
or
 S
F-
M
PQ
-2
, H
D
I, 
H
D
Q
 a
nd
 H
IT
-6
 sc
or
es
; p
va
lu
es
 fo
r K
ru
sk
al
-W
al
lis
 T
es
tfo
r W
H
O
D
A
S 
an
d 
D
A
SS
 sc
or
es
 
††
†H
D
I T
ot
al
 S
co
re
s a
nd
 W
H
O
D
A
S 
O
ve
ra
ll 
Sc
or
es
 ra
ng
e 
fro
m
 0
 to
 1
00
, w
ith
 h
ig
he
r s
co
re
s r
ef
le
ct
in
g 
gr
ea
te
r d
is
ab
ili
ty
 c
au
se
d 
by
 th
e 
he
ad
ac
he
 
‡‡
‡ H
D
Q
 sc
or
es
 ra
ng
e 
fro
m
 0
 to
 9
0,
 w
ith
 h
ig
he
r s
co
re
s r
ef
le
ct
in
g 
gr
ea
te
r d
isa
bi
lit
y 
ca
us
ed
 b
y 
th
e 
he
ad
ac
he
 
§§
§  H
IT
-6
 sc
or
es
 ra
ng
e 
fro
m
 3
6 
to
 7
8;
 a
 sc
or
e 
<4
9 
in
di
ca
te
s l
itt
le
 o
r n
o 
im
pa
ct
 (g
ra
de
 1
); 
a 
sc
or
e 
of
 5
0 
to
 5
5 
in
di
ca
te
s m
od
er
at
e 
im
pa
ct
 (g
ra
de
 2
); 
a 
sc
or
e 
of
 5
6 
to
 5
9 
in
di
ca
te
ss
ub
sta
nt
ia
l i
m
pa
ct
 (g
ra
de
 3
), 
an
d
sc
or
e>
60
 in
di
ca
te
s s
ev
er
e i
m
pa
ct
  (
gr
ad
e 
4)
.
**
**
SF
-M
PQ
-2
 T
ot
al
 S
co
re
s r
an
ge
 fr
om
 0
  (
no
 p
ai
n)
 to
 1
0 
(w
or
st 
pa
in
 p
os
si
bl
e)
 
††
††
CS
I s
co
re
s r
an
ge
 fr
om
 0
 to
 1
00
, w
ith
 h
ig
he
r s
co
re
s r
ef
le
ct
in
g 
a 
hi
gh
er
 d
eg
re
e 
of
 se
ns
iti
za
tio
n 
‡‡
‡‡
D
A
SS
 sc
or
es
 ra
ng
e 
fro
m
 0
 (n
or
m
al
) t
o 
21
 (e
xt
re
m
el
y 
se
ve
re
) 
Combination of characteristics predictive of migraine 260 
Discriminant analysis of characteristics revealed significant differences between the migraine 261 
and non-migraine groups (Wilk’s lambda = 0.60, Chi square =49.22, p< 0.001). The 262 
discriminant function for characteristics explained 100% of the variance in the groups (p< 263 
0.001). A combination of no pain on manual examination of the cervical spine, less change 264 
on the DCE test, less frequent headaches, and higher disability scores predicted migraine 265 
(Table 5). This prediction model for migraine correctly classified 80.0% of the original 266 
grouped cases with a sensitivity of 80.0% and specificity of 75.6% for migraine (Table 6). 267 
268 
269 
Table 5. Discriminant function coefficients (standardized coefficients) for characteristics with 270 
highest predictive ability for migraine 271 
Characteristics Discriminant Function 
Coefficient 
Pain on manual examination of the upper cervical 
joints 
0.736 
Frequency of headache 0.523 
Headache Impact Test Total Score -0.513
Percent change in thickness of deep cervical extensor 
muscle from relaxed state on symptomatic side 
0.468
272 
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Discussion 276 
Our results provide information on characteristics that distinguished migraine from non-277 
migraine headaches. Our results indicate that cervical articular impairmentwas worse in 278 
people with non-migraine headaches than in people with migraine, while cervical muscle 279 
impairmentwas not different between headache groups. In contrast, headache intensity and 280 
self-reported disability were worse in migraine than non-migraine headaches. A combination 281 
of information on cervical musculoskeletal impairment, headache characteristic and self-282 
reported disability distinguished migraine from non-migraine headaches. These 283 
characteristics that distinguished migraine from non-migraine headaches may be assessed to 284 
enhance diagnosis especially for complex presentations of migraine. 285 
Cervical articular impairment was significantly less in the migraine group than the 286 
non-migraine group in our study, as would be expected. Specifically, both the flexion rotation 287 
test [19] and headache provocation with upper cervical spine manual examination [12, 288 
20] more frequently had positive findings in participants with non-migraine headaches than289 
those with migraine. Our results therefore corroborate previousstudies that demonstrated 290 
impairments on these tests in people with non-migraine headache, specifically CGH,but not 291 
in people with migraine and controls [10,12, 34]. Interestingly, more than half of the 292 
participants in both headache groups in the present study reported neck pain.The coexistence 293 
of neck pain in headaches is consistent with the hypothesized bidirectional interaction 294 
between nociceptive input from upper cervical spine and the trigeminocervical complex [8]. 295 
Our findings therefore support examining the upper cervical joints to differentiate migraine 296 
from non-migraine headache when neck pain coexists. Doing so would augment the ICHD 297 
diagnostic criteria, especially when diagnosing headaches whose clinical features are 298 
characteristic of more than one headache type. 299 
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In contrast to cervical articular impairment, measures of cervical muscle function and 300 
behavior were not different between groups. These results contrast with results of previous 301 
studies that showed these impairments to be present in CGH group but not in migraine and 302 
control groups [10, 12, 34]. One reason for this difference may be the heterogeneity of our 303 
non-migraine group, which comprised participants with predominant tension-type and/or 304 
CGH, including 22 participants with comorbid migraine. The heterogeneity of the non-305 
migraine group could have diluted any difference in cervical musculoskeletal impairments 306 
between headache types. Another possible explanation for the lack of significant difference in 307 
cervical muscle impairment between headache groups may be due to the different 308 
experimental protocols used. For example, the equipment we used for measuring strength was 309 
different from those used in previous studies [10, 34]. We used a dynamometer which is often 310 
available in clinics but may not have been as sensitive as the equipment used in previous 311 
studies. This is the first cross-sectional study that evaluated the DCE test, to potentially 312 
complement existing evidence on impairment in deep cervical flexors performance in CGH. 313 
Given the lack of difference demonstrated between headache groups, examination of the 314 
behavior of cervical extensors cannot be recommended at this point in time. In our 315 
assessment using the exploratory DCE test using ultrasound imaging, we imaged the 316 
extensor muscles at C4 level. Subsequent revised protocols of this test have demonstrated a 317 
significant difference when the muscles were imaged higher to the proposed source of 318 
symptoms in the spine, namely at C2 level [35]. 319 
Nevertheless, the finding that cervical muscle impairment was not significantly 320 
different between migraine and non-migraine groups is worth noting and exploring further. 321 
Despite the lack of statistically significant difference between groups, cervical spine joint and 322 
muscle impairmentswere generally worse in non-migraine headache, consistent with our 323 
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hypothesis and previous studies [10, 34].Further work on cervical muscle impairment is 324 
recommended, utilizing refined protocols and pure headache groups. 325 
The results also demonstrated that people with migraine had significantly higher pain 326 
ratings and disability scores than those with non-migraine headaches. While numerical rating 327 
scales of pain intensity were able to distinguish headache types, SF-MPQ-2 and CSI did not 328 
appear to do so, suggesting that multidimensional pain and central sensitization experience 329 
may be similar in migraine and non-migraine headaches. We also did not find DASS-21 330 
scores to be differentiators of headache types in this cohort, despite previous studies showing 331 
an association of negative emotional states with high levels of pain and disability [36]. The 332 
high pain rating and disability scores in migraine are consistent with previous studies [37] 333 
and with the ICHD definition of migraine as a more intense headache [5]. These results are 334 
also consistent with migraine ranking in the top ten disabling conditions globally and the 335 
highest headache type on this list [3]. The high disability profile associated with migraine can 336 
help distinguish it from non-migraine headaches. Factors that account for the higher disability 337 
in migraine versus other headache types may be explored in prospective qualitative and 338 
longitudinal cohort studies. 339 
As well, the disability scores from self-report questionnaires had acceptable 340 
discriminative ability. This raises a possible role for the use of these questionnaires in the 341 
diagnostic workup of people with migraine.Of the disability questionnaires tested in this 342 
study, HDI and HDQ appear to be the best questionnaires to use in distinguishing migraine 343 
from non-migraine headaches. The diagnostic utility for both HDI and HDQ is promising, 344 
given their AUC values on ROC curve analyses of 0.80 and 0.82, respectively. These AUC 345 
values suggest that HDI and HDQ could be used to distinguish migraine from non-migraine 346 
headaches. Both HDI and HDQ measure the severity of the interference of the headache with 347 
daily activities and the presence of the emotional aspects of disability [27, 28]. Results of this 348 
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study therefore indicate that these aspects of disability measured by HDI and HDQ are better 349 
differentiators of headaches than the frequency of interference of the headache with daily 350 
activities measured by other disability questionnaires [29, 30] tested in this study. 351 
When combined tests were considered, we found that a combination of no pain on 352 
manual examination of the cervical spine, less change in cervical extensor thickness during 353 
contraction,less frequent headaches, and higher self-reported disability distinguished 354 
migraine from non-migraine headaches. These results support the combined assessment of 355 
aspects of cervical joint function and muscle behavior together with a comprehensive 356 
symptom and disability profile as being useful in differentiating migraine from non-migraine 357 
headache. This combined assessment is easy to perform and is clinically feasible. Moreover, 358 
this combined assessment could complement the presently used model of diagnosing 359 
primarily based on headache features to characterize associated impairments and disability. 360 
Further, the presence of cervical musculoskeletal impairmentin migraine, although less than 361 
in non-migraine, and the disability and multidimensional pain profile in migraine may also 362 
inform research directions for modifiable targets of alternative migraine interventions. 363 
364 
Conclusions 365 
Less cervical musculoskeletal impairmentand higher pain and disability, when measured 366 
independently,distinguished migraine from non-migraine headaches. A combination of these 367 
characteristics and less frequent headaches distinguished migraine with acceptable sensitivity 368 
and specificity. Results support the assessment of cervical musculoskeletal impairment and 369 
patient-reported outcomes to better characterize and differentially diagnose migraine from 370 
non-migraine headaches. Assessing these characteristics could complement diagnosis using 371 
existing diagnostic criteria for migraine. 372 
373 
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CHAPTER SIX 
Six-Month Clinical Course and Factors Associated with 
Non-Improvement in Migraine and Non-Migraine Headaches 
Chapter Six is the peer reviewed version of the following article: Aguila ME, Rebbeck T, 
Pope A, Ng K, Leaver AM. Six-month clinical course and factors associated with non-
improvement in migraine and non-migraine headaches, which has been accepted for 
publication with revisions in Cephalalgia (16 June 2017). 
The study protocol for the study presented in this chapter appears as Appendix 5. 
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Abstract: 
Background: Evidence on medium-term clinical course of recurrent headaches is scarce. This 
study explored the six-month course and factors associated with non-improvement in 
migraine compared with tension-type headache and cervicogenic headache. 
Methods: In this longitudinal cohort study, the six-month course of headaches was 
prospectively examined in participants (n=37 with migraine; n=42 with tension-type or 
cervicogenic headache). Participants underwent physical examination for cervical 
musculoskeletal impairments at baseline. Participants also completed questionnaires on pain, 
disability and other self-report measures at baseline and follow-up, and an electronic diary 
for 6 months. Course of headaches was examined using mixed within-between analyses of 
variance and Markov chain modeling. Multiple factors were evaluated as possible factors 
associated with non-improvement using regression analysis. 
Results: Headache frequency, intensity, and activity interference in migraine and non-
migraine headaches were generally stable over 6 months but showed month-to-month 
variations. Day-to-day variations were more volatile in the migraine than the non-migraine 
group, with the highest probability of transitioning from any headache state to no headache 
(probability = 0.82–0.85). The odds of non-improvement in disability was nearly 6 times 
higher with cervical joint dysfunction [odds ratio (95% CI) = 5.58 (1.14–27.42]. 
Conclusions: Headache frequency, intensity, and activity interference change over 6 months, 
with day-to-day variation being more volatile in migraine than non-migraine headaches. 
Cervical joint dysfunction appears to be associated with non-improvement for disability in 6 
months. These results may contribute to strategies for educating patients to help align their 
expectations with the nature of their headaches. 
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Introduction 
Migraine and other common recurrent headaches such as tension-type headache (TTH) and 
cervicogenic headache (CGH) may present as episodic attacks, yet persist over time (1-3). To 
date, knowledge of how these headaches change over time is not fully understood. Evidence 
from a few longitudinal population-based and clinic-based studies has demonstrated the 
variable clinical course of migraine and TTH, in particular, in the long term. Specifically, 
migraine and TTH have been shown to remit in most people, follow a stable course in others, 
and progress to higher frequency episodes or other poorer outcomes in a few (4-6). For those 
cases in whom headaches progressed, the following have been identified as predictors: age at 
onset younger than 20, female, low education and socioeconomic status, white people, head 
injury, high attack frequency, obesity, medication overuse, stressful life events, caffeine 
overuse, sleeping problems, and other pain syndromes (6-8). Correspondingly, predictors for 
remission or recovery from headache have been identified, including less severe headaches at 
baseline, absence of anxiety and of sleep problems (8), episodes not triggered by alcohol, 
absence of associated symptoms (4), and short headache duration (5). 
However, less is known about how recurrent headaches change and their associated 
factors in the medium term, which is often considered more important to patients. One 
longitudinal observational study has shown that clinical characteristics of migraine remain 
stable over 3 months, with a general trend toward improvement in disability (9). Additionally, 
improved disability had a moderate positive association with headache frequency in 3 
months. Further evidence is required to build on these findings by identifying the short- to 
medium-term variations in headaches. Specifically, information regarding day-to-day 
variation in headaches will be relevant to patients with recurrent episodic headaches such as 
migraine and non-migraine headaches that present frequently to primary care (TTH and 
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CGH). For many of these patients, daily function is disrupted even on non-headache days 
because of the unpredictability of their headaches (10) despite undergoing treatment (9). 
Knowledge of the medium-term course of common recurrent headaches such as 
migraine, TTH and CGH will further characterize these headaches and, ultimately, contribute 
to a greater understanding of their entire clinical course. By knowing the behavior of their 
headaches in the medium term, patients could form realistic expectations accordingly, which, 
in turn, could positively influence the way they manage their headaches and reduce their 
disability. Characterization of migraine and non-migraine headaches could be further 
broadened when physical impairments that have been reported to be present and treated in 
these headaches, such as cervical musculoskeletal impairments (11-14), are considered. For 
example, upper cervical joint dysfunction, as conceivably suggested by the presence of light-
headedness, was associated with poor outcome in CGH after one year of active treatment 
(15). This might be the case for migraine as well; however, this has not been demonstrated. 
Understanding which factors are associated with poorer short- or medium-term outcomes 
could assist in mediating or managing these factors toward a more favorable clinical course 
(7). 
Therefore, the primary aim of this study was to describe and compare the medium-
term clinical course of migraine and non-migraine headaches in terms of headache frequency, 
intensity, and activity interference. A secondary aim was to explore factors that are associated 
with non-improvement in perceived disability, headache frequency and intensity in the 
medium-term. 
Methods 
Design 
In this longitudinal observational cohort study, we investigated the clinical course of different 
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headache types and factors that predicted this clinical course by following groups of people 
with migraine and non-migraine headaches for a period of 6 months. This research was 
granted ethics approval by the Human Research Ethics Committee of The University of 
Sydney (Project Number 2014/536). 
Participants 
We recruited volunteers aged 18 to 65 with recurrent headache through advertisements posted 
at community bulletins, social media, and primary and specialist care clinics. Participants 
were included if they had headaches for at least one year and had at least one headache 
episode in the previous month. Participants were excluded if they had known secondary 
headache classifications (e.g. tumor, substance withdrawal etc.) or psychiatric disorders. 
Participants were then classified into the migraine group (fulfilling the criteria for migraine 
only and not those for other headache types) or non-migraine group (with primary diagnosis 
of TTH and/or CGH, with or without comorbid migraine) using the ICHD-3 beta criteria 
(14). 
Procedure 
All participants underwent initial telephone screening to confirm their eligibility. All eligible 
participants provided written informed consent prior to participation. Eligible participants 
then completed questionnaires at baseline regarding demographic and headache 
characteristics, as well as patient-reported outcomes such as multidimensional pain, 
disability, and other health measures. Multidimensional pain and disability assessment 
included the Short-form McGill Pain Questionnaire-2 (SF-MPQ-2) (16), Central Sensitization 
Inventory (CSI) (17), Henry Ford Headache Disability Inventory (HDI) (18), Headache 
Disability Questionnaire (HDQ) (19), Headache Impact Test-6TM (HIT-6) (20), and World 
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Health Organization Disability Assessment Schedule 2.0 (WHODAS) (21). Other health 
measures comprised those previously shown to predict long-term course of headaches. These 
included the Depression Anxiety Stress Scales-21 (DASS-21) (22) to assess negative 
emotional states, the Self-Administered Comorbidity Questionnaire (SCQ) (23) to assess 
comorbidities (4), the Pittsburgh Sleep Quality Index (PSQI) (24) to assess sleep (6), and the 
International Physical Activity Questionnaire (IPAQ) (25) to measure physical activity (4). 
Participants then attended one assessment for interview and physical examination, in 
which headaches were classified and data for cervical musculoskeletal impairments were 
collected. Headache classification used ICHD-3 beta criteria (14) independently done by two 
researchers. Cervical musculoskeletal impairment data comprised joint dysfunction and 
cervical muscle behavior. These impairments were shown to be different between migraine 
and non-migraine headache groups in our previous cross-sectional work. Joint dysfunction 
was assessed through manual examination of the upper cervical spine with passive accessory 
intervertebral movements (PAIVMs) (26) and the flexion-rotation test (27). Manual 
examination of the cervical spine was deemed positive if headache was provoked. The 
flexion rotation test was deemed positive if headache was provoked and the range of 
movement was ≤ 32°. Cervical muscle behavior was assessed using the extensor under load 
test, a new technique that measures changes in thickness of the deep cervical extensor during 
low-load using ultrasound imaging (28). 
Participants then filled out an electronic diary daily for 6 months, beginning the day 
after their physical examination. Participants recorded the presence of headaches daily and 
provided information on headache intensity using the numerical rating scale (NRS: with 
anchors at 0 and 10: 0 = no headache, 10 = worst headache possible), and interference of the 
headache with normal daily activities on a scale of not at all (0), a little bit (1), moderately 
(2), quite a bit (3), and extremely (4). The diary was administered and data were collected 
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and managed using the Research Electronic Data Capture (REDCap) application (Research 
Electronic Data Capture, Nashville, Tennessee, USA) (29) hosted at The University of 
Sydney. Participants also completed the pain and disability questionnaires at 1 month, 3 
months, and 6 months after their physical examination. 
Statistical Analysis 
The sample size of the present study was based on the sample size of our previous cross-
sectional study (currently under review) (n = 40 per group). This sample size was powered to 
detect group differences in cervical musculoskeletal impairments, which was the focus of the 
cross-sectional study. 
Distributions of data were examined through visual inspection by a statistician and 
using the Shapiro-Wilk test. Accordingly, demographic and headache characteristics, and 
questionnaire scores were summarized as mean and standard deviation (SD). Additionally, 
baseline clinical characteristics between the migraine and non-migraine groups were 
compared using Student t test, (for continuous variables) or Chi square test (for categorical 
variables). The month-to-month variation in the clinical course of headaches over 6 months 
and between-group comparisons were examined using mixed within-between analyses of 
variance (ANOVA). The day-to-day variation in clinical course of headaches over 6 months 
was examined using Markov chain modeling (30). Details of the day-to-day variations 
derived from Markov chain modeling included the probabilities of transitioning from a given 
headache intensity and activity interference state to another or the same state on the next day. 
This approach models the randomness in headache behavior. For Markov chain modeling, 
intensity was described as ‘no headache’ (NRS 0/10), ‘mild’ (NRS 1–3/10), ‘moderate’ (NRS 
4–6/10), or ‘severe’ (NRS ≥ 7/10) to simplify the categories. Markov chain modeling also 
generated simulated models of the clinical course of headache intensity and activity 
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interference in 30 days in hypothetical individuals with headaches. 
The relationship between the dependent variable, absence of clinically meaningful 
improvement (i.e., non-improvement of headaches) and independent variables, namely 
demographic and headache characteristics, cervical musculoskeletal impairments, and scores 
on multidimensional pain, disability, and other health measures  were explored using logistic 
regression analyses. In the absence of a standard definition of non-improvement of 
headaches, we defined the primary dependent variable, for the purpose of regression 
analyses, to be < 2.5 point reduction in HIT-6 scores (disability) (31). Secondary dependent 
variables were < 50% reduction in headache frequency (32) and < 15% reduction in headache 
intensity (33). The relationship between dependent and independent variables was initially 
explored using univariate logistic regression analyses. Independent variables with p < 0.2 
based on the Wald Chi square statistic on univariate analyses were entered into multiple 
regression analyses using the ‘enter’ method. In all analyses, headache group was added as an 
independent variable. Dependent variables were presented as short-term changes (Month 3 
minus Month 1) and medium-term changes (Month 6 minus Month 1). Month 1 was 
considered as the baseline for the change scores in dependent variables; this allowed 
collection of prospective data from the headache diary for 1 month to serve as baseline data 
for headache characteristics. 
Statistical analyses were conducted using R studio version 3.3.0 2016 (R Foundation 
for Statistical Computing, Vienna, Austria) and Statistical Package for Social Sciences® 
statistical software, version 23 (SPSS Inc., Chicago, Illinois, USA) for Windows. 
Significance level for statistical analyses other than univariate logistic regression was set at 
0.05. 
Results 
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Participants 
Forty people with migraine and 45 people with non-migraine headache [mean age (standard 
deviation) = 37.15 (12.88) years] participated in this study. The flow of participants through 
the study and reasons for exclusion from analyses are shown in Figure 1. Demographic, 
headache and clinical characteristics of participants at baseline are presented in Table 1. The 
migraine group had longer history of headache [mean (SD) 20.44 (12.90) years versus 13.44 
(12.76) years; p = 0.014], less frequent headaches in a month [4.93 (5.89) versus 9.74 (7.66); 
p = 0.002], and higher average headache intensity per month [6.46 (1.65) versus5.57 (1.64); p 
= 0.014] than the non-migraine group. More participants in the migraine group were taking 
triptan than the non-migraine group [n (%) 19 (47.50%) versus 10 (22.22%) participants; p = 
0.014]. Fewer participants in the migraine group had cervical musculoskeletal impairments 
than the non-migraine group. For example, 4 (10.00%) participants from the migraine group 
reported pain on manual examination of the upper cervical joints compared to 26 (57.78%) 
participants from the non-migraine group. 
Clinical course of migraine and non-migraine headaches 
Headache characteristics changed over 6 months for both headache groups without fully 
remitting nor progressing (Figure 2). Headache frequency fluctuated from month to month in 
both headache groups (Figure 2A; p = 0.001), with the migraine group showing more 
fluctuations than the non-migraine group (p = 0.005). The migraine group consistently had 
fewer headaches per month than the non-migraine group. 
Average headache intensity fluctuated from month to month over 6 months for both 
headache groups (Figure 2B; p = 0.042), but this fluctuation was not significantly different 
between the two headache groups (p = 0.94). Average headache intensity oscillated around 
NRS 4/10 (moderate intensity) for both groups. Considering day-to-day fluctuation in 
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headache intensity, Markov chain analysis showed that every headache intensity state could 
be reached from any headache intensity state for both headache groups (Figure 3). The day-
to-day transition between headache intensity states of the migraine group ranged from a 
probability of 0.02 (from mild headache to severe headache the next day) to 0.82 (from no 
headache to remaining without headache the next day) (Figure 3A). 
In contrast, the day-to-day transition between headache intensity states of the non-
migraine group ranged from a probability of 0.04 (from no or mild headache to severe 
headache the next day) to 0.76 (from no headache to remaining without headache the next 
day) (Figure 3B). The migraine group generally had the greatest probabilities of transition 
from any headache state to no headache. The transition probabilities for headache intensity 
differed significantly between the headache groups (p < 0.001), with the migraine group 
showing more volatility. Based on the transition probabilities, any headache intensity would 
have higher probabilities to have no headache the following day in migraine. In contrast, any 
headache intensity would have higher probabilities of staying the same or having no 
headache the following day in non-migraine headaches. The day-to-day volatility of headache 
intensity in the migraine group was highlighted when modeled using Markov chains (Figure 
4). 
Average activity interference caused by headaches fluctuated from month to month 
for both headache groups (Figure 2C; p = 0.002) but this fluctuation was not significantly 
different between the two headache groups (p = 0.12). The activity interference for both 
groups oscillated around NRS 1.5 / 4 (headaches interfered a little bit to moderately with 
normal daily activities). Considering the day-to-day fluctuation in activity interference, 
Markov chain modeling showed that every interference state could be reached from any 
interference state for both headache groups (Figure 5). The day-to-day transition between 
activity interference states of the migraine group ranged from a probability of 0.01 (from no 
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interference to extreme interference) to 0.85 (from no interference to remaining without 
interference) (Figure 5A). In contrast, the day-to-day transition between activity interference 
states of the non-migraine group ranged from 0.01 (from no interference to extreme 
interference the next day) to 0.81 (from no interference to remaining without interference the 
next day) (Figure 5B). The migraine group generally had the greatest probabilities of 
transition from any interference state to no interference. The transition probabilities for 
activity interference differed significantly between the headache groups (p < 0.001). The day-
to-day fluctuation in activity interference was highlighted by simulation models derived from 
Markov chain analysis (Figure 6). 
Factors associated with non-improvement of migraine and non-migraine headaches as to 
headache-related disability, headache frequency and intensity 
The univariate analysis revealed that receiving physical treatment, pain and disability at 
baseline, and physical activity level were independently associated with non-improvement in 
headache disability in the short-term (Table 2) and headache intensity, pain, disability scores 
and physical activity level were associated with non-recovery in the medium term (Table 3). 
Multifactorial models were associated with non-improvement in headache-related 
disability at short- and medium-term. The full model containing migraine headache group, 
receiving physical treatment, pain on manual examination of the upper cervical joints, higher 
scores on disability questionnaires (namely HIT-6, HDQ and WHODAS), and lower level of 
physical activity was statistically significant for predicting non-improvement in headache-
related disability at short-term (p = 0.040) and explained 27.7% of the variation in disability 
(Table 4). However, no independent variable made a unique statistically significant 
contribution to this model. Likewise, the full model containing headache group, age, average 
headache intensity, average activity interference, pain on manual examination of the upper 
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cervical joints, scores on disability questionnaires (namely HIT-6, HDQ and WHODAS), and 
level of physical activity was statistically significant for predicting non-improvement in 
headache-related disability at medium-term (p = 0.031) and explained 32.3 % of the variation 
in disability (Table 5). Of these predictors, pain on manual examination of the upper cervical 
joints made a statistically significant contribution to this model (p = 0.034). Specifically, the 
odds of non-improvement in disability was nearly 6 times higher when pain on manual 
examination was present than when it was absent [odds ratio (95% CI) = 5.58 (1.14–27.42]. 
In contrast, none of the variables examined in this study were associated with non-
improvement in headache frequency or intensity after 3 or 6 months (Tables 2–5). 
Discussion 
This study demonstrated three main findings on the 6-month clinical course and factors 
associated with outcome in migraine and non-migraine headaches. First, the clinical course of 
headache characteristics in migraine and non-migraine headaches showed month-to-month 
variability, but generally did not remit nor progress. Second, day-to-day variations in 
headache intensity and activity interference were more volatile in the migraine group than the 
non-migraine group. Third, a number of demographic, clinical and patient-related factors 
were associated with persistent disability over 3 and 6 months. These findings further 
characterize and differentiate migraine and non-migraine headaches, thus informing clinical 
practice and research. 
The month-to-month variation in headache frequency, intensity, and activity 
interference in migraine and non-migraine headaches changed, but did not fully remit nor 
progress. These results are consistent with existing evidence for the 3-month clinical course 
of migraine (9) and show a similar trend as the prevailing knowledge on the long-term 
clinical course of changes in migraine (4, 34). Headache intensity fluctuated around moderate 
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intensity for both headache groups, challenging the typical picture of migraine as a more 
severe headache than non-migraine headaches (14). Analogously, activity interference caused 
by headaches over 6 months hovered between little to moderate interference for both 
headache groups. This range of activity interference contrasts with the high levels of 
disability associated especially with migraine and TTH (35). On closer consideration, such 
disparities in intensity and activity limitation ratings are understandable and may be partly 
attributed to measuring intensity and activity interference prospectively using a headache 
diary. First, retrospective rating by patients tends to overestimate headache intensities 
compared with information from diaries (36). Second, the perceived impact of the headache 
on daily activities measured each day could be lower compared to perceived disability over 
extended periods as captured by self-report questionnaires. 
This study also presents new evidence that characterizes the day-to-day variation in 
headache intensity and activity interference as being more volatile in migraine than in non-
migraine headaches. This greater volatility in migraine, as demonstrated by Markov chain 
analyses, is related to the higher probability of having no headache on the following day 
regardless of the current headache state. Further, the different possible scenarios of 
transitioning between headache states imply that the extent of volatility may be different 
between individuals with similar headache diagnoses, undergoing their usual treatment, and 
having the same level of headache intensity and activity interference on a particular day.  
This study also presents preliminary evidence that factors influencing non-
improvement in disability in 6 months include headache features, cervical joint dysfunction, 
disability and physical activity. This preliminary evidence presents prospective directions for 
future research. Of note is cervical joint dysfunction which appears to be associated with non-
improvement in disability in both migraine and non-migraine groups yet was less frequent in 
the former (10.00% versus 57.78%). The lack of factors significantly associated with non-
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improvement in frequency and intensity may most likely be indicative that no factor 
significantly influences those outcomes in the short-to medium-term. The same can be said 
for non-improvement in disability in the short-term. However, the multifactorial model for 
disability explains 27.7% and 32.3% of the variability in the model in the short- and medium-
term, respectively. The association of these factors with disability needs to be further 
investigated in larger cohort studies with pure headache groups. Prospective studies may also 
explore other factors that would influence non-improvement in disability. 
Results of this study inform headache management. First, information about the 
month-to-month and day-to-day variation in features of migraine and non-migraine 
headaches can form part of patient education. Importantly, educating patients about the most 
likely behavior of their headaches will help them align their expectations. This information 
could also be reassuring for patients who perceive the unpredictability of their headaches as 
disabling and disquieting (10, 37). Second, the small but statistically significant month-to-
month variation in headache characteristics over 6 months justifies continued monitoring of 
symptoms as part of headache management. Third, the association of cervical joint 
dysfunction with non-improvement in headache-related disability in 6 months reveals the 
usefulness of cervical joint assessment and, if necessary, targeting any impairments to help 
reduce disability in the short- to medium-term. 
The study aimed to describe the shorter-term clinical course of migraine and non-
migraine headaches with participants having their usual headache management, when 
interventions were not standardized. As such, we did not control for intervention and other 
possible confounding factors that could influence the course of headaches. Prospective 
clinical trials are indicated to investigate those other factors to build on evidence from this 
study. Such trials can also use evidence presented here concerning the 6-month clinical 
course of migraine and non-migraine headaches when selecting outcome measures. Further 
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studies involving pure headache groups and collecting longitudinal data on possible variables 
influencing non-improvement are also required to validate our results. Investigating the 
underlying mechanisms explaining the difference in month-to-month and day-to-day 
variation between migraine and non-migraine headaches also remains an area for future 
investigation. 
In conclusion, headache frequency, intensity, and activity interference show month-
to-month and day-to-day variations over 6 months in individuals with migraine and non-
migraine headaches who are already receiving treatment. Day-to-day variations in headache 
intensity and activity interference are more volatile in migraine compared with non-migraine 
headaches. Cervical joint dysfunction measured using manual examination appears to be 
associated with non-improvement in headache-related disability in 6 months. These results 
will contribute to strategies for patient education regarding the nature of their headaches, and 
also carry implications for outcome measure selection in prospective clinical trials. 
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Clinical Implications: 
• Headache frequency, intensity and activity interference show variations over 6 months,
but generally do not fully remit nor progress, in individuals with migraine and non-
migraine headaches.
• Day-to-day variation in headache intensity and activity interference is more volatile in
migraine than non-migraine headaches.
• Individuals with migraine or non-migraine headaches who have cervical spine
dysfunction are nearly 6 times more likely not to recover in terms of headache-related
disability within 6 months.
• These results contribute to strategies for educating patients on the nature of their
headaches.
• The need to consider volatility of headache characteristics when selecting outcome
measures for prospective clinical trials is highlighted.
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Figure Legends 
Figure 1. Flow of participants through the study 
Figure 2. Month-to-month variation in headache characteristics in migraine and non-migraine 
groups. (A) Frequency of headaches. (B) Average headache intensity. (C) Average 
activity interference due to headache 
Figure 3. Transition matrices of headache intensity showing the probability of transitioning 
from a current headache intensity state (denoted by rows) to the next-day headache 
intensity state (denoted by columns). (A) Migraine group. (B) Non-migraine group 
(p < 0.001) 
Figure 4. Simulated day-to-day clinical course of headache intensity of 12 hypothetical 
individuals with headaches over 30 days (numerical rating scale; 0, no headache, to 
3, severe headache. (A) Migraine group. (B) Non-migraine group (p < 0.001) 
Figure 5. Transition matrices of activity interference caused by headache for migraine group 
showing the probability of transitioning from a current activity interference state 
(denoted by rows) to the next-day activity interference state (denoted by columns). 
(A) Migraine group. (B) Non-migraine group (p < 0.001)
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Figure 6. Simulated day-to-day clinical course of activity interference of 12 hypothetical 
individuals with headaches over 30 days (activity interference rated using a scale; 
0, not at all, to 4, extremely. (A) Migraine group. (B) Non-migraine group (p < 
0.001) 
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Figure 1. Flow of participants through the study 
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A 
Initial State of 
Headache Intensity Subsequent State of Headache Intensity 
No Headache Mild Moderate Severe 
No Headache 0.82 0.09 0.06 0.03 
Mild 0.61 0.25 0.12 0.02 
Moderate 0.48 0.15 0.21 0.16 
Severe 0.36 0.06 0.26 0.32 
B 
Initial State of 
Headache Intensity Subsequent State of Headache Intensity 
No Headache Mild Moderate Severe 
No Headache 0.76 0.11 0.09 0.04 
Mild 0.45 0.37 0.14 0.04 
Moderate 0.36 0.20 0.31 0.13 
Severe 0.24 0.11 0.26 0.39 
Figure 3.Transition matrices of headache intensity showing the probability of transitioning from a current 
headache intensity state, denoted by rows, to the next-dayheadache intensity state, denoted by 
columns. (A) Migraine group. (B) Non-migraine group(p< 0.001) 
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Figure 4.Simulated day-to-day clinical course of headache intensity of 12 hypothetical individuals with 
headaches over 30 days (numerical rating scale a scale; 0, no headache,to 3, severe headache. 
(A) Migraine group. (B) Non-migraine group (p < 0.001)
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A 
Initial State of 
Activity 
Interference 
Caused by 
Headache 
Subsequent State of Activity Interference Caused by Headache 
Not at All A Little Bit Moderately Quite a Bit Extremely 
Not at All 0.85 0.08 0.04 0.02 0.01 
A Little Bit 0.63 0.18 0.12 0.06 0.01 
Moderately 0.46 0.22 0.22 0.08 0.02 
Quite a Bit 0.43 0.14 0.22 0.17 0.04 
Extremely 0.44 0.10 0.10 0.13 0.23 
B 
Initial State of 
Activity 
Interference 
Caused by 
Headache 
Subsequent State of Activity Interference Caused by Headache 
Not at All A Little Bit Moderately Quite a Bit Extremely 
Not at All 0.81 0.12 0.04 0.02 0.01 
A Little Bit 0.52 0.28 0.13 0.05 0.02 
Moderately 0.38 0.28 0.20 0.11 0.03 
Quite a Bit 0.31 0.19 0.19 0.24 0.07 
Extremely 0.26 0.15 0.12 0.20 0.27 
Figure 5. Transition matrices of activity interference caused by headache for migraine group showing the 
probability of transitioning from a current activity interference state, denoted by rows, to the next-
day activity interference state, denoted by columns. (A) Migraine group. (B) Non-migraine group 
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Figure 6.Simulated day-to-day clinical course of activity interference of 12hypothetical individuals with 
headaches over 30 days (activity interference rated using a scale; 0, not at all, to 4, extremely. (A) 
Migraine group. (B) Non-migraine group (p < 0.001) 
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Table 1. Baseline characteristics of participants [mean (SD) or n (%) where indicated)] (n = 85) 
Migraine 
(n = 40) 
Non-Migraine 
(n = 45) 
p values* 
Demographic characteristics 
Age 40.83 (12.87) 33.89 (12.11) 0.013 
Gender (female) (n, %) 32 (80.00%) 40 (88.89%) 0.26 
Body mass index 24.81 (4.93) 24.34 (5.83) 0.70 
Headache characteristics 
History of headache (years since first 
episode) 
20.44 (12.90) 13.44 (12.76) 0.014 
Frequency of headache in a month  4.93 (5.89) 9.74 (7.66) 0.002 
Episode duration, minimum (hours) 12.45 (16.00) 13.28 (17.61) 0.82 
Episode duration, maximum (hours) 58.30 (35.69) 84.97 (168.60) 0.31 
Average headache intensity per month 
(0–10)† 
6.46 (1.65) 5.57 (1.64) 0.014 
Clinical characteristics 
Receiving pharmacologic treatment (n, 
%) 
Paracetamol 14 (35.00%) 17 (37.78%) 0.79 
Non-steroidal anti-inflammatory 
drug 
18 (45.00%) 20 (44.44%) 0.96 
Tricyclic antidepressant 6 (15.00%) 3 (6.67%) 0.21 
Triptan 19 (47.50%) 10 (22.22%) 0.014 
Botulinum toxin 8 (20.00%) 11 (24.44%) 0.62 
Beta blocker 4 (10.00%) 3 (6.67%) 0.58 
Selective serotonin reuptake 
inhibitor 
5 (12.50%) 6 (13.33%) 0.91 
Proton pump inhibitor 4 (10.00%) 6 (13.33%) 0.63 
Anticonvulsant 5 (12.50%) 7 (15.56%) 0.69 
Receiving physical treatment (n, %) 8 (20.00%) 12 (26.70%) 0.47 
Pain on manual examination of the 
upper cervical joints (n, %) 
4 (10.00%) 26 (57.78%) <0.001 
Positive flexion rotation test (n, %) 4 (10.00%) 17 (37.78%) 0.003 
Extensor under load test (percent 
change on symptomatic side) 
6.17 (8.16) 11.87 (15.34) 0.035 
NOTE. Bold numbers indicate statistical significance (p < 0.05) 
* p values for Student t-test for continuous variables; p values for Chi-square test for categorical variables
† Headache intensity: Numerical rating scale 0–10; 0 = no pain, 10 = worst possible pain
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Table 2. Univariate logistic regression analysis showing relationships between possible predictors of non-
improvement in headache characteristics in the SHORT-TERM 
Variable 
HIT-6 Headache Frequency  Headache Intensity 
Nagelkerke 
R2 
 p value Nagelkerke 
R2 
 p value Nagelkerke 
R2 
 p value 
Demographic characteristics 
Age 0.011 0.46 0.037 0.196 0.019 0.38 
Sex 0.002 0.78 0.003 0.70 0.001 0.80 
BMI 0.001 0.86 0.143 0.035 0.042 0.24 
Clinical characteristics 
Receiving pharmacologic 
treatment 
0.013 0.42 0.017 0.36 0.003 0.73 
Receiving physical treatment 0.066 0.11 0.020 0.35 0.015 0.45 
Frequency in a month 0.003 0.72 0.007 0.57 0.006 0.62 
Average headache intensity last 
month 
0.008 0.54 0.036 0.20 0.065 0.10 
Average activity interference 0.000 0.90 0.000 0.90 0.000 0.98 
Pain on manual examination of the 
upper cervical joints 
0.043 0.17 0.005 0.62 0.000 0.89 
Positive flexion rotation test 0.001 0.86 0.007 0.55 0.004 0.70 
Percent change on symptomatic 
side on extensor under load 
test 
0.000 0.91 0.019 0.39 0.004 0.68 
Pain and sensitization 
SF-MPQ-2 Total score 0.004 0.65 0.000 0.91 0.000 0.90 
CSI Total score 0.011 0.46 0.059 0.11 0.008 0.55 
Disability 
HIT-6 Score at baseline 0.114 0.028 0.019 0.35 0.000 0.97 
HDI Total Score at baseline 0.012 0.45 0.025 0.29 0.003 0.71 
HDQ Total Score at baseline 0.109 0.025 0.038 0.19 0.001 0.85 
WHODAS Overall Score at 
baseline 
0.113 0.029 0.175 0.018 0.014 0.42 
Emotional state 
DASS-21 Depression Score 0.021 0.33 0.006 0.625 0.007 0.61 
DASS-21 Anxiety Score 0.015 0.39 0.005 0.633 0.004 0.71 
DASS-21 Stress Score 0.013 0.45 0.064 0.106 0.001 0.85 
Other health measures 
SCQ Overall Score 0.013 0.44 0.029 0.277 0.000 0.95 
PSQI Total Score 0.011 0.47 0.010 0.496 0.027 0.28 
Physical activity level 0.058 0.099 0.025 0.289 0.000 0.94 
_____________________ 
Abbreviations: BMI, body mass index; CSI, Central Sensitization Inventory; DASS-21, Depression Anxiety Stress Scales-21; HDI, The Henry 
Ford Headache Disability Inventory; HDQ, Headache Disability Questionnaire; HIT-6, Headache Impact Test-6; PSQI, Pittsburgh Sleep Quality 
Index; SCQ, the Self-Administered Comorbidity Questionnaire; SF-MPQ-2, Short-form McGill Pain Questionnaire-2; WHODAS, World Health 
Organization Disability Assessment Schedule 
Bold numbers indicate possible predictors with p < 0.2 
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Table 3. Univariate logistic regression analysis showing relationships between possible predictors of non-
improvement in headache characteristics in the MEDIUM-TERM 
Variable 
HIT-6 Headache Frequency Headache Intensity 
Nagelkerke 
R2 
 p value Nagelkerke 
R2 
 p value Nagelkerke 
R2 
 p value 
Demographic characteristics 
Age 0.040 0.17 0.002 0.79 0.067 0.09 
Sex 0.001 0.82 0.001 0.84 0.040 0.22 
BMI 0.009 0.53 0.041 0.23 0.109 0.06 
Clinical characteristics 
Receiving pharmacologic 
treatment 
0.005 0.64 0.026 0.26 0.000 0.96 
Receiving physical treatment 0.026 0.27 0.010 0.51 0.001 0.85 
Frequency in a month 0.001 0.85 0.004 0.68 0.067 0.09 
Average headache intensity last 
month 
0.070 0.07 0.068 0.09 0.016 0.38 
Average activity interference 0.052 0.11 0.008 0.56 0.001 0.82 
Neck impairments 
Pain on manual examination of the 
upper cervical joints 
0.057 0.10 0.017 0.37 0.002 0.76 
Positive flexion rotation test 0.017 0.36 0.510 0.12 0.004 0.67 
Percent change on symptomatic 
side on extensor under load 
test 
0.007 0.55 0.012 0.50 0.000 0.99 
Pain and sensitization 
SF-MPQ-2 Total score 0.002 0.76 0.022 0.34 0.018 0.37 
CSI Total score 0.000 0.92 0.005 0.65 0.051 0.13 
Disability 
HIT-6 Score at baseline 0.049 0.13 0.011 0.48 0.029 0.24 
HDI Total Score at baseline 0.001 0.83 0.000 0.97 0.087 0.06 
HDQ Total Score at baseline 0.104 0.026 0.015 0.42 0.008 0.55 
WHODAS Overall Score at 
baseline 
0.040 0.17 0.004 0.69 0.059 0.13 
Emotional state 
DASS-21 Depression Score 0.005 0.61 0.012 0.50 0.035 0.27 
DASS-21 Anxiety Score 0.018 0.36 0.002 0.74 0.010 0.52 
DASS-21 Stress Score 0.030 0.24 0.003 0.72 0.079 0.07 
Other health measures 
SCQ Overall Score 0.014 0.42 0.005 0.61 0.005 0.62 
PSQI Total Score 0.000 0.89 0.013 0.43 0.009 0.53 
Physical activity level 0.078 0.05 0.007 0.57 0.004 0.65 
_____________________ 
Abbreviations: BMI, body mass index; CSI, Central Sensitization Inventory; DASS-21, Depression Anxiety Stress Scales-21; HDI, The Henry 
Ford Headache Disability Inventory; HDQ, Headache Disability Questionnaire; HIT-6, Headache Impact Test-6; PSQI, Pittsburgh Sleep Quality 
Index; SCQ, the Self-Administered Comorbidity Questionnaire; SF-MPQ-2, Short-form McGill Pain Questionnaire-2; WHODAS, World Health 
Organization Disability Assessment Schedule 2.0 
Bold numbers indicate possible predictors with p < 0.2 
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Table 4. Multivariate logistic regression predicting likelihood of non-improvement in headache 
characteristics in the SHORT-TERM 
Outcome Predictor variables B (SE) Wald test p value OR (95% CI) 
Headache 
frequency 
Headache group 0.36 (0.81) 0.20 0.66 1.44 (0.29–7.08) 
Age 0.03 (0.03) 0.77 0.38 1.03 (0.97–1.09) 
BMI 0.17 (0.11) 2.42 0.12 1.18 (0.96–1.46) 
CSI Total Score -0.04 (0.04) 1.17 0.28 0.96 (0.89–1.03) 
HDQ Total Score 0.004 (0.03) 0.03 0.87 1.00 (0.95–1.06) 
WHODAS Overall Score 0.10 (0.06) 2.45 0.12 1.10 (0.98–1.25) 
DASS-21 Stress Score 0.05 (0.12) 0.19 0.66 1.05 (0.84–1.33) 
Chi square 12.96, p = 0.07; Nagelkerke R2: 0.273 
HIT-6 
score 
Headache group -0.68 (0.72) 0.89 0.34 0.51 (0.12–2.08) 
Receiving physical treatment 1.63 (0.89) 3.36 0.07 5.10 (0.89–29.09) 
Pain on manual examination of the 
upper cervical joints 1.23 (0.81) 2.30 0.13 3.43 (0.70–16.90) 
HIT-6 Score at baseline -0.06 (0.07) 0.65 0.42 0.94 (0.81–1.09) 
HDQ Total Score at baseline -0.01 (0.03) 0.03 0.87 1.00 (0.94–1.06) 
WHODAS Overall Score at baseline -0.02 (0.03) 0.52 0.47 0.98 (0.92–1.04) 
Physical activity level at baseline 0.72 (0.51) 2.01 0.16 2.05 (0.76–5.55) 
Chi square 14.70,  p = 0.040; Nagelkerke R2: 0.277 
Headache 
intensity 
Headache group 0.33 (0.64) 0.27 0.60 1.39 (0.40–4.84) 
Average headache intensity -0.34 (0.20) 2.75 0.10 0.71 (0.48–1.06) 
Chi square 3.10,  p = 0.21; Nagelkerke R2: 0.072 
_____________________ 
Abbreviations: BMI, body mass index; CSI, Central Sensitization Inventory; DASS-21, Depression Anxiety Stress Scales-21; HDQ, Headache 
Disability Questionnaire; HIT-6, Headache Impact Test-6; WHODAS, World Health Organization Disability Assessment Schedule 2.0 
Bold numbers indicate statistical significance (p < 0.05) 
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Table 5. Multivariate logistic regression predicting likelihood of non-improvement in headache 
characteristics in the MEDIUM-TERM 
Outcome Predictor variables B (SE) Wald test p value OR (95% CI) 
Headache 
frequency 
Headache group 0.21 (0.62) 0.11 0.74 1.23 (0.36–4.20) 
Average headache intensity 0.31 (0.19) 2.63 0.11 1.36 (0.94–1.97) 
Positive flexion rotation test -0.97 (0.66) 2.18 0.14 0.38 (0.10–1.38) 
Chi square 5.37 p = 0.15; Nagelkerke R2: 0.112 
HIT-6 
score 
Headache group -0.59 (0.70) 0.72 0.40 0.55 (0.14–2.16) 
Age 0.05 (0.03) 3.65 0.06 1.05 (1.00–1.11) 
Average headache intensity -0.14 (0.26) 0.29 0.59 0.87 (0.52–1.45) 
Average activity interference -0.28 (0.69) 0.16 0.69 0.76 (0.20–2.92) 
Pain on manual examination of the 
upper cervical joints 1.72 (0.81) 4.48 0.034 5.58 (1.14–27.42) 
HIT-6 Score at baseline 0.01 (0.07) 0.02 0.89 1.01 (0.87–1.17) 
HDQ Total Score at baseline -0.04 (0.04) 1.31 0.25 0.96 (0.90–1.03) 
WHODAS Overall Score at baseline 0.02 (0.03) 0.43 0.51 1.02 (0.96–1.09) 
Physical activity level 1.06 (0.56) 3.64 0.06 2.89 (0.97–8.61) 
Chi square 18.34, p = 0.031; Nagelkerke R2: 0.323 
Headache 
intensity 
Headache group -0.004 (0.76) 0.00 1.00 1.00 (0.23–4.41) 
Age 0.03 (0.03) 0.63 0.43 1.03 (0.96–1.09) 
BMI 0.10 (0.09) 1.11 0.29 1.10 (0.92–1.32) 
Frequency of headaches 0.09 (0.06) 2.28 0.13 1.10 (0.97–1.24) 
CSI Total Score -0.04 (0.03) 1.11 0.29 0.96 (0.90–1.03) 
HDI Total Score 0.02 (0.02) 0.69 0.41 1.02 (0.98–1.06) 
WHODAS Overall Score 0.005 (0.05) 0.01 0.93 1.00 (0.90–1.12) 
DASS-21 Stress Score 0.15 (0.12) 1.63 0.20 1.17 (0.92–1.47) 
Chi square 12.61, p = 0.13; Nagelkerke R2: 0.266 
_____________________ 
Abbreviations: BMI, body mass index; CSI, Central Sensitization Inventory; DASS, Depression Anxiety Stress Scales-21; HDI, The Henry Ford 
Headache Disability Inventory; HDQ, Headache Disability Questionnaire; HIT-6, Headache Impact Test-6; WHODAS, World Health 
Organization Disability Assessment Schedule 2.0 
Bold numbers indicate statistical significance (p < 0.05) 
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CHAPTER SEVEN 
Responsiveness of Disability Questionnaires 
in Migraine and Non-Migraine Headaches 
Chapter Seven has been submitted as: 
Aguila ME, Leaver AM, Ng K, Rebbeck T. Responsiveness of disability questionnaires in 
migraine and non-migraine headaches. Submitted to Quality of Life Research 
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Abstract 
Purpose To examine the responsiveness of disability questionnaires for migraine and other 
frequently presenting non-migraine headaches in primary care (tension-type headache and 
cervicogenic headache). 
Methods Data were collected from a longitudinal cohort study distinguishing migraine and 
non-migraine headaches. Participants fulfilled the International Classification of Headache 
Disorders-3 beta criteria for migraine, tension-type headache and/or cervicogenic headache. 
Participants completed the Headache Impact Test-6, Headache Disability Inventory, Henry 
Ford Headache Disability Inventory, Headache Disability Questionnaire, and the World 
Health Organization Disability Assessment Schedule 2.0 at baseline and at 1, 3 and 6 months. 
Participants also filled out a headache diary daily for 6 months. Internal responsiveness of the 
questionnaires was evaluated by calculating effect size, and external responsiveness by 
receiver operating characteristic curve analysis of change scores with headache frequency. 
Results Headache Impact Test-6 and Headache Disability Questionnaire had the best internal 
responsiveness for individuals with migraine and non-migraine. At short-term, effect sizes 
(84% confidence intervals) ranged from 0.31 (0.07–0.56) to 0.47 (0.11–0.82). At medium-
term, effect sizes ranged from 0.40 (0.06–0.74) to 0.60 (0.26–0.94). Headache Disability 
Questionnaire generally had the best external responsiveness to change in headache 
frequency at both short- and medium-term [areas under the curve (95% confidence intervals) 
0.52 (0.32–0.72) to 0.69 (0.49–0.89)]. 
Conclusions Headache Impact Test-6 and Headache Disability Questionnaire were the most 
responsive disability questionnaires for individuals with migraine and non-migraine 
headaches. These results add to the evidence on the usefulness of these measures in routine 
assessment of outcomes in clinical practice. 
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Introduction 
Headaches that most frequently present to primary care include migraine [1] and non-
migraine headaches such as tension-type headache [1] and cervicogenic headache [2]. These 
headaches are associated with significant impact on the individuals [3, 4], who experience 
disability when their headache and associated symptoms are active, as well as between 
headache episodes. Disability must therefore be assessed in individuals with headaches 
because it cannot be fully explained by headache frequency, intensity and symptoms [5]. 
Disability assessed using self-report questionnaires is among the outcomes recommended for 
headache research [6–9]. A number of these questionnaires are specific to migraine and 
assess disability during, but not between, migraine episodes [10]. Aside from migraine-
specific questionnaires, there are headache-specific questionnaires that are applicable across 
different episodic or chronic headache types. These questionnaires include the Headache 
Impact Test-6TM (HIT-6) [11], The Henry Ford Headache Disability Inventory (HDI) [12], 
and the Headache Disability Questionnaire (HDQ) [13]. In addition to these headache-
specific questionnaires, generic disability questionnaires [e.g. 14, 15], including the World 
Health Organization Disability Assessment Schedule 2.0 (WHODAS) [16], have also been 
used. The above questionnaires differ in their constructs, reference time periods and scoring, 
however all are reliable and valid measures of disability for individuals with headache [6, 10, 
11, 14, 17]. To date, however, evidence is still lacking regarding which of these 
questionnaires are most responsive, and therefore can be recommended to clinicians for their 
ability to detect improvement or worsening of symptoms across migraine and non-migraine 
headaches. 
Responsiveness of self-report questionnaires is important to clinicians and patients 
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because it denotes ability to measure true change over time. Internal responsiveness describes 
the ability of a measure to detect change over a particular time period [18], whilst external 
responsiveness measures this change in relation to an external reference measure of health 
status [18]. Thus far, only the responsiveness of the HIT-6 has been evaluated in specific 
headache populations [11]. The HIT-6 has been shown to be responsive to self-reported 
change in severity [19] and headache frequency and duration [20] in migraine and to self-
reported change and headache frequency in tension-type headache [21]. Other disability 
questionnaires measuring slightly different constructs than HIT-6 (see Table 1) are available 
for headache populations. The responsiveness of HDQ has been shown to be acceptable in a 
general headache population who are seeking physiotherapy treatment [22] and the 
responsiveness of WHODAS has been shown to be acceptable in a population with chronic 
conditions, including migraine [23]. However, the responsiveness of these questionnaires has 
not been compared across headache types nor compared with HIT-6. Comparing the 
responsiveness of these questionnaires between migraine and non-migraine headache 
populations could build on early evidence from our previous work indicating greater day-to-
day variability in disability in migraine compared to non-migraine headaches (forthcoming 
publication). Investigating the responsiveness of HIT-6 compared with that of other disability 
questionnaires in different headache types could reveal the ability of the questionnaires to 
capture clinically meaningful changes and, therefore, the utility of these questionnaires as 
outcome measures. 
Therefore the primary aim of the study was to examine the responsiveness of 
disability questionnaires for headache types presenting frequently in primary care, namely 
migraine and non-migraine headaches. A secondary aim of the study was to explore whether 
responsiveness of questionnaires differed between headache types. 
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Methods 
Participants and study design 
Data were collected from a longitudinal cohort study distinguishing migraine and non-
migraine headaches. This research was granted ethics approval by the Human Research 
Ethics Committee of The University of Sydney (Project Number 2014/536). 
Recruitment of participants with recurrent headaches for the longitudinal cohort study 
was done through advertisements posted at University, consumer support groups, community 
bulletins, social media, and primary care and neurology clinics. Volunteers were eligible if 
they were aged 18-65 years, had headaches for at least a year and had at least one headache 
episode in the previous month. 
Participants in the migraine group were those who were diagnosed as having migraine 
by their attending neurologist/physician, whose headache features fulfilled the International 
Classification of Headache Disorders (ICHD)-3 beta criteria for migraine [24] and in whom 
other headache types were excluded as diagnosis. Participants in the non-migraine headache 
group were those diagnosed as having tension-type or cervicogenic headache by a clinician 
and whose headache features fulfilled the ICHD 3 beta criteria for tension-type headache or 
cervicogenic headache. 
Volunteers were excluded from either of the headache groups if their headaches were 
due to any known secondary cause (other than cervicogenic) such as tumour, substance 
withdrawal, surgery, etc. or if they had a pacemaker or fibrillator. 
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Procedures 
All participants underwent initial telephone screening to confirm their eligibility. All eligible 
participants completed self-administered questionnaires which covered information on 
demographics and disability. Written informed consent was provided by all participants prior 
to participation. Participants also provided baseline information on headache characteristics 
including history, frequency of episodes, typical duration of each episode, and headache 
intensity in the last month using the numerical rating scale (with anchors at 0 and 10: 0 = no 
pain, 10 = worst pain possible). Participants then filled out an electronic diary administered 
using the Research Electronic Data Capture (REDCap) application (Research Electronic Data 
Capture, Nashville, Tennessee, USA) [25] hosted at The University of Sydney. Participants 
recorded the presence of headaches daily for 6 months. Disability questionnaires were also 
completed at baseline, 1 month, 3 months and 6 months. 
Outcomes 
Disability Disability was measured using the Headache Impact Test-6TM (HIT-6) [11], Henry 
Ford Headache Disability Inventory (HDI) [12], Headache Disability Questionnaire [13], and 
the 12-item version of the World Health Organization Disability Assessment Schedule 2.0 
(WHODAS) [16]. The characteristics of these questionnaires are described in Table 1. 
Headache frequency Frequency of headache episodes was counted from the number 
of headache days reported in diary entries and summarized as number of headache episodes 
per month. External responsiveness for headache frequency was calculated using 50% 
reduction in headache frequency as the external criterion. This external criterion was selected 
because it was among the recommended outcome measures in headache trials [6, 8, 9] and 
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was the primary indicator of recovery nominated as most important by patients [26, cited in 
13]. This was used as the external criterion for external responsiveness. (See statistical 
analysis.) 
Statistical analyses 
Demographic and baseline headache characteristics were summarized as mean and standard 
deviation (SD) and frequency and percentage as appropriate. Additionally, questionnaire 
scores at baseline, and at 1, 3 and 6 months were summarized as mean and SD. 
Internal and external responsiveness were calculated for short-term and medium-term 
changes for all questionnaire scores. Internal responsiveness was calculated using effect size 
= mean change between baseline and follow-up scores (at 3 months for short-term and at 6 
months for medium-term) divided by the standard deviation of the baseline score [27]. Effect 
sizes of 0.2, 0.5 and 0.8 were interpreted as small, medium and large, respectively [18]. 
Statistical significance of effect size was established based on non-overlapping 84% 
confidence intervals (CI), equivalent to Z test of means at the 0.05 level [28]. External 
responsiveness was calculated using receiver operating characteristic (ROC) curve analysis. 
ROC curves were plotted for each disability measure against the external criterion for short-
term change (from 1 month to 3 months) and medium term change (from 1 month to 6 
months). The area under the curve (AUC) and 95% CI were then calculated to determine the 
capacity of each questionnaire to discriminate between participants who improved on the 
external criteria and those who did not. AUC values were interpreted as follows: ≥ 0.90 as 
excellent; ≥ 0.80 and < 0.90 as good; ≥ 0.70 and < 0.80 as fair; and < 0.70 as poor [29]. ROC 
curves between HIT-6 and the other disability questionnaires were compared using the 
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DeLong approach [30]. Data were excluded from analyses if any of the follow up 
questionnaires was missing. 
The calculated sample size for this study had 80% power to detect an effect size of 
0.7, within the range of previously published responsiveness effect size of HIT-6 for chronic 
migraine [20], at significance level of 0.05, whilst allowing for about 20% attrition. Statistical 
analyses were conducted using Statistical Package for Social Sciences® statistical software, 
version 24 (SPSS Inc., Chicago, Illinois, USA) for Windows and Microsoft Excel (Microsoft 
Corporation, Redmond, Washington, USA; 2010), and Analyse-it for Microsoft Excel 
(standard edition) (Analyse-it Software, Ltd, Leeds, England, UK; 2009). 
Results 
Participants 
Eighty five eligible participants were included in the longitudinal study. Of these, 68 
participants, 33 from the migraine group and 35 from the non-migraine group, had complete 
baseline and follow-up questionnaires and therefore were included in analyses. Sixty 
participants (88.2%) were female. Mean age (standard deviation, SD) was 37.74 (13.06) 
years. Participants in the migraine group had longer history of headache, less frequent 
episodes and more severe headache intensities than the non-migraine group (Table 2). 
Questionnaire responses 
Mean scores on all questionnaires at baseline and the three follow-up periods are shown in 
Table 3. HIT-6 scores ranged from substantial to severe categories for the migraine group and 
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from moderate to substantial categories for the non-migraine group. None of the mean scores 
were at the lowest 10% or highest 10% of the total score range for all the questionnaires. 
Internal responsiveness 
At short-term, internal responsiveness based on effect sizes (84% CI) was highest for HDQ 
[0.37 (0.13–0.61)] and HIT-6 [0.31 (0.07–0.56)] for the total cohort (Table 4). Similarly, 
HDQ and HIT-6 had the highest internal responsiveness for the migraine group [0.47 (0.11–
0.82) and 0.34 (-0.01–0.69), respectively] and for the non-migraine group [0.31 (-0.02–0.65) 
and 0.32 (-0.02–0.66), respectively]. These effect sizes are interpreted as small. The overlap 
in confidence intervals of effect sizes for HIT-6 and HDQ indicates no statistically significant 
difference between these two questionnaires in short-term internal responsiveness. 
At medium-term, internal responsiveness based on effect sizes (84% CI) was highest 
for HIT-6 [0.52 (0.27–0.76) and HDQ [0.41 (0.16–0.65)] for the total cohort (Table 4). 
Similarly, HIT-6 and HDQ had the highest internal responsiveness for the migraine group 
[0.47 (0.12–0.83) and 0.46 (0.11–0.81), respectively] and for the non-migraine group [0.60 
(0.26–0.94) and 0.40 (0.06–0.74), respectively]. These effect sizes are interpreted as small to 
medium. The overlap in confidence intervals for HIT-6 and HDQ indicates no statistically 
significant difference between these two questionnaires in medium-term internal 
responsiveness based on effect sizes. 
External responsiveness 
At short-term, HDQ was the most responsive to change in headache frequency, considering 
the total cohort, with AUC value (95% CI) of 0.61 (0.47–0.74) (Table 4). This AUC value is 
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interpreted as poor but better than chance probability of differentiating between participants 
who improved and those who did not improve on headache frequency. For the migraine 
group, HIT-6 was the most responsive disability questionnaire, with AUC value (95% CI) of 
0.53 (0.29–0.77). This value is also interpreted as poor. For the non-migraine group, HDQ 
was the most responsive, with AUC value (95% CI) of 0.69 (0.49–0.89), interpreted as fair. 
At medium-term, HDQ was the most responsive to change in headache frequency for 
the total cohort as well as the migraine and non-migraine groups. HDQ AUC values ranged 
from 0.52–0.55, interpreted as poor in differentiating between participants who improved and 
those who did not improve on headache frequency. 
There were no significant differences for the AUC of the HIT-6 compared with the 
other questionnaires for short-term and medium-term (P > 0.05) (Table 4). These results were 
consistent for the whole cohort, for the migraine group, and for the non-migraine group. 
Discussion 
Results of this study indicate that HIT-6 and HDQ were the most responsive disability 
questionnaires for individuals with migraine and non-migraine headaches with clinical 
characteristics similar to the cohorts in this study. As expected, responsiveness was better for 
headache-specific than generic questionnaires. Additionally, responsiveness was better at 
medium-term than short-term. These results suggest that either HIT-6 or HDQ may be used 
in assessing outcomes at 6 months in individuals with migraine and non-migraine headaches 
undergoing their usual headache management. 
The relative ranking of responsiveness for HIT-6 and HDQ differed for internal and 
external responsiveness and between headache groups. However, these two questionnaires 
consistently ranked first or second on any responsiveness calculation and headache group. 
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Additionally, there were no statistically significant differences in their responsiveness scores. 
Collectively, these findings show that either HIT-6 or HDQ could be used in assessing 
clinically important changes for migraine or non-migraine at 3 or 6 months. 
Interestingly, HIT-6 showed the largest effect size for migraine and non-migraine 
headaches at medium-term. These results support previous evidence on the responsiveness of 
HIT-6 for people with recurrent headaches, in general [11], and for chronic migraine [20] and 
tension-type headache in particular [21]. Results of this study also present new evidence on 
the responsiveness of HDQ for both migraine and non-migraine headaches. The 
comparatively high responsiveness of HDQ could be due to the scale options in the individual 
items, allowing detection of small clinical changes. For example, one HDQ item asks “When 
you have a headache while you work (or school), how much is your ability to work reduced?” 
and presents options ranging from 0 (no reduction) to 10 (100% reduction) [13]. The HDQ 
thus provides a greater range of options than the scales in the other disability questionnaires. 
Further, HDQ had the best external responsiveness for the whole cohort, indicating that HDQ 
related better than the other questionnaires with short-term and medium-changes in headache 
frequency. This finding may reflect the fact that the HDQ includes items on frequency 
(number of days) of specific headache symptoms and associated disability [13] while the 
others do not. 
The external responsiveness of the questionnaires was nearly no better than chance at 
differentiating between those who improved on headache frequency and those who did not 
after 3 or 6 months. These findings could be specific for individuals with clinical 
characteristics similar to the cohorts in this study or could be due to the natural course of 
these headaches in the absence of intervention in this study. 
Results of external responsiveness may have also been different if other external 
criteria were used. For example, higher external responsiveness scores for HDQ (ROC = 
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0.76) were demonstrated in a general headache population when global change scores as 
perceived by patients was used as the external criterion [22]. In another study, small to large 
effect sizes were demonstrated for WHODAS in a population with chronic conditions when 
improvement in severity of condition, categorized as mild, moderate or severe, was used as 
the external criterion [23]. However we are confident that our choice of external criterion is 
the most relevant to patients, as indicated by patients’ perception of its importance as an 
outcome measure [26, cited in 13]. In addition, a reduction in headache frequency is among 
the recommended external criteria based on guidelines for headache trials [6–9]. 
Findings of this study must therefore be considered whilst recognising a number of 
methodological limitations. The heterogeneity of the non-migraine group restricts any 
conclusion that can be drawn about the relative responsiveness of the questionnaires for 
specific headache types. Whilst this study did not aim to compare responsiveness of 
questionnaires between specific headache types, future studies could address such aim by 
building on results of this present study. The sample size was relatively small and may not 
have been adequate to detect effect sizes smaller than that hypothesised for this study. The 
short observation period could have restricted the differences in responsiveness of 
questionnaires between migraine and non-migraine groups. Therefore the responsiveness of 
these questionnaires should be explored for longer-term changes in larger, homogenous 
headache groups in controlled treatment efficacy trials. 
Nevertheless, given the equal responsiveness of the HIT-6 and HDQ in migraine and 
non-migraine headaches, clinicians could use either questionnaire, depending on the aspect of 
disability of interest. For example, HDQ could be preferred when the goal is to measure the 
percentage decrease in efficiency of tasks while HIT-6 may be preferred when the goal is to 
measure the frequency of activity limitation. 
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Conclusions 
In this study comparing responsiveness of disability questionnaires, HIT-6 and HDQ were the 
most responsive to short-term and medium-term clinically relevant changes. These findings 
are applicable to individuals with migraine and non-migraine headaches undergoing their 
usual headache treatment. These findings add to the evidence on the usefulness of HIT-6 and 
HDQ in routine assessment of outcomes in the clinics. 
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Table 2. Baseline characteristics of participants (n = 68)† 
 Migraine 
(n = 33) 
 Non-Migraine 
(n = 35) 
 Mean (SD) or n (%)  Mean (SD) or n (%) 
Demographic characteristics    
Age 39.91 (13.30)  35.69 (12.68) 
Gender (female) 28 (84.8%)  32 (91.4%) 
Clinical characteristics    
History of headache (years since first episode) 20.24 (12.51)  14.33 (14.90) 
Frequency of headache in a month  4.89 (6.12)  9.31 (7.18) 
Episode duration , minimum (hours) 15.12 (17.86)  12.58 (18.31) 
Episode duration , maximum (hours) 64.73 (38.47)  95.13 (189.30) 
Average headache intensity last month  (0-10)‡ 6.41 (1.74)  5.80 (1.57) 
Taking medication for headache 30 (90.9%)  31 (81.6%) 
Receiving physical therapy for headache 6 (18.2%)  10 (28.6%) 
Receiving alternative treatment for headache 14 (42.4%)  15 (42.9%) 
 
Abbreviation: SD, standard deviation 
 
† For continuous variables, values are presented as mean (SD); for categorical variables, values are presented as 
frequency (%). 
‡ Headache intensity: Numerical rating scale 0–10; 0 = no pain, 10 = worst possible pain 
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CHAPTER EIGHT 
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Conclusions 
8.1 Overview of findings 
The current standard in defining, classifying and diagnosing migraine and non-migraine 
headaches involves differentiating each headache type based on headache characteristics 
following the International Classification of Headache Disorders (ICHD) (1).The ICHD is 
continuously being reviewed and revised according to evidence regarding pathophysiology 
and characteristics of the headache type. Thus the application of ICHD, and therefore 
classification and diagnosis of migraine and non-migraine headaches, may be augmented by a 
better understanding of their pathophysiology and clinical characteristics. This thesis 
verifiesthe ICHD as the standard for classifying headaches. It submits new evidence on the 
potential of gamma-aminobutyric acid (GABA) as a biomarker for migraine and on the day-
to-day volatility and six-month clinical course of migraine and non-migraine headaches. This 
thesis also presents additional data on clinical characteristics that differentiate migraine from 
non-migraine headaches beyond the ICHD diagnostic criteria, such as impairments in 
cervical muscle behaviour measured using the deep cervical extensor test and self-reported 
disability measured using the Headache Disability Questionnaire or the Headache Impact 
Test-6 as part of a combination of clinical characteristics differentiating migraine. 
The aim of this thesis was to characterise migraine on the basis of its neurochemical profile 
and clinical features not listed as diagnostic criteria in the ICHD, compared with non-
migraine headaches (TTH and CGH) that frequently present in primary care. Chapter Two 
verified that ICHD is generally used to define patient populations of migraine and non-
migraine headaches in defined in clinical trials. Cutting-edge evidence is presented in 
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Chapters Three, Four and Six. First, GABA is a potential diagnostic biomarker for migraine, 
given the higher concentration found in people with migraine compared with headache-free 
controls (Chapter Three) and its association with pain and disability (Chapter Four). This is 
the first time that the potential of GABA as a migraine biomarker is demonstrated, providing 
direction for future research to investigate the pathophysiology of migraine, leading to 
targeted management. Second, the day-to-day volatility of headache intensity and disability is 
worse in migraine compared to non-migraine headaches as presented in Chapter Six. This is 
the first time that the day-to-day volatility of migraine is depicted in detail, carrying 
significance for addressing patients’ concern about the unpredictability of their headaches. 
Evidence in addition to existing knowledge is presented in Chapter Five. Evidence is 
presented suggesting that a combination of less pain on manual examination of the upper 
cervical spine, less change in deep cervical extensors thickness during contraction, less 
frequent headaches, and higher disability distinguished migraine from non-migraine 
headaches. Chapter Six also showed that the disability changed in migraine and non-migraine 
headaches, with a tendency to decline, over six months. This medium-term reduction in 
disability was associated with the absence of painful cervical joint dysfunction. Chapter 
Seven found that the best way to measure this change in disability over time could be using 
the Headache Impact Test-6 (HIT-6) or the Headache Disability Questionnaire (HDQ). The 
findings of this thesis addressgaps in the understanding of migraine, with implications 
including expanding details in headache definitions, improving clinical practice, as well 
asinforming future research. Ultimately, this thesis advances the search for effective 
treatments and better health outcomes for people with migraine. 
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8.2 Implications of the thesis 
8.2.1. Implications for headache definitions 
The evidence presented by this thesis provides impetus for the definitions of migraine and 
non-migraine headache to be explained in more detail and broadened. The systematic review 
in Chapter Two is the first study to provide an understanding of the characteristics of study 
populations in treatment efficacy trials for migraine and non-migraine headaches. Whilst 
89.5% of the trials reported adherence to the ICHD criteria in selecting the study populations, 
details on the definition of study populations were unclear. First, 44.5% of the trials included 
in the review did not report the method used to arrive at a headache diagnosis. Second, the 
specific diagnostic criteria present among the study populations at baseline were generally 
not provided. Such details are important, as they provide a clear description of study 
populations, improving the transparency on the possible inclusion of people with overlapping 
features or coexistent headache types. Such details could enable clinicians to decide on the 
applicability of evidence to their patients (2), enhancing research translation. (3). Results of 
this review therefore suggest that minimum standards for reporting characteristics of study 
populations at baseline would be beneficial. Specifying the extent to which study populations 
demonstrated ICHD diagnostic criteria at baseline should be among these minimum 
standards. More detailed reporting of characteristics of study populations allow clarity of 
headache populations in trials and ensure transparency and generalisabiltiy of evidence to 
clinical practice(1, 4). This consideration of minimum standards could be a course of action 
forguideline developers,who are involved in refining existing guidelines for clinical trials in 
specific headache types (5-7). 
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The definition of migraine could be expanded by differentiating migraine as being associated 
with more severe disability than non-migraine headaches. Whilst the ICHD presents migraine 
as a more severe headache type than TTH based on headache intensity (1), the results of the 
cross-sectional study demonstrated that migraine is more severe than non-migraine headaches 
based on disability. Greater disability differentiates migraine from non-migraine headaches 
when disability is considered in isolation or in combination with cervical musculoskeletal 
impairments. Results of the cross-sectional cohort study also validate that cervical joint 
dysfunction is less in migraine than in non-migraine headaches and present preliminary 
evidence that cervical muscle behaviour is also impaired in migraine. Cervical 
musculoskeletal impairments in migraine may be investigated further to determine their 
utility in defining migraine. Nevertheless, the additional evidence presented in this thesis on 
characteristics of migraine that may be useful in differential diagnosis therefore contributes to 
the continued efforts of the headache community to clarify characteristics of headache types 
to improve clinical practice and research.  
8.2.2. Implications for clinical practice 
The findings of Chapters Four, Five and Six have important implications in clinical practice 
namely, headache assessment and differential diagnosis, prognosis and management. The 
findings of this thesis show that the clinical characteristics that are relevant to assess and 
consider in prognosis and management include cervical musculoskeletal impairments and 
disability. 
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8.2.2.1. Assessment of cervical musculoskeletal impairments 
Measuring cervical joint dysfunction will enable clinicians to characteriseand potentially 
distinguish migraine from non-migraine headaches. The findings presented in Chapter Five 
further validate that migraine has less upper cervical joint dysfunction than non-migraine 
headaches as demonstrated by less frequent pain on manual provocation of the upper cervical 
joints (p< 0.001) and less frequent positive flexion rotation test (p = 0.004). These findings 
were consistent with previous reports of greater joint dysfunction in non-migraine headaches 
compared to migraine (8-10). Taken together, clinicians can be confident that examination of 
cervical joint dysfunction by palpation and the flexion rotation test should be retained to 
assist with characterisation and differential diagnosis of migraine from non-migraine 
headaches. 
Cervical joint dysfunction was also one of the factors in a multifactorial model that explained 
32.3 % of the variation in non-improvement in disability in the medium-term (p = 0.031) 
(Chapter Six). Painful joint dysfunction was associated with 6 times higher odds of non-
improvement in disability [odds ratio (95% confidence interval) = 5.58 (1.14 to 27.42] (p = 
0.040). Clinicians should therefore treatcervical dysfunction when present to potentially 
improve the outcome in disability. 
In contrast, measurement of cervical muscle impairment by clinicians to assist in differential 
diagnosis of headaches was not supported by this thesis. However, its assessment may direct 
management. We investigated a new test, the deep cervical extensor test (11), in Chapter Five 
that measured muscle behaviour of deep cervical extensors during low-load contractions, 
detected using real-time ultrasound imaging, We found no difference in muscle behaviour 
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between headache types when directly compared. However, there is some preliminary 
evidence to explore this test further, given that this test contributed significantly (discriminant 
function coefficient = 0.47) to a combination of measures distinguishing migraine from non-
migraine (Chapter Five). This test had not been evaluated in other cross-sectional studies to 
date. Given the lack of difference demonstrated between headache groups, examination of the 
behaviour of cervical extensors for the purposes of differential diagnosis cannot be 
recommended at this point in time. However, as pointed out earlier, there is evidence that it 
could be included amongst a battery of tests to characterise and possibly differentially 
diagnose migraine. 
Assessment of other domains of cervical muscle impairment such as muscle function, i.e., 
strength and endurance, to assist in the differentiation of migraine from non-migraine 
headaches was also not supported by this thesis. However assessment of impairment to direct 
treatment would be supported. Chapter Five found no difference in strength or endurance of 
either cervical flexors or extensors between migraine and non-migraine headaches. 
Unexpectedly, it was found that people with migraine also displayed these impairments 
compared with controls. This supports the only other study that demonstrated reduced 
strength in cervical muscles in episodic migraine compared to controls (12). Thus evidence 
from this thesis indicates that impairments in cervical muscle function may also be present in 
migraine. Considering this evidence, clinicians should assess cervical muscle function 
impairment in migraine to identify possible targets for treatment. 
Finally, clinicians are recommended to examine cervical musculoskeletal impairment in 
combination with other clinical characteristics such as headache frequency and higher 
disability scores. The findings of Chapter Five support that the combination of these tests 
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results in distinguishing migraine from non-migraine headaches with a sensitivity of 80% and 
specificity of 75.6%. Clinicians now have additional evidence to consider when differentially 
diagnosing, especially when the presenting case is ambiguous as to being pure migraine or a 
non-migraine headache (Chapter Five). 
a. Assessment of multidimensional pain and central sensitisation
symptoms
Implications of results of Chapter Four include measuring the multidimensional nature of 
pain and central sensitisation symptoms to gain greater insight into the patient experience of 
migraine as well as providing an association with the diagnosis and neurochemical 
profile.These characteristics can be easily measured using self-report questionnaires such as 
the Short-form McGill Pain Questionnaire-2 (SF-MPQ-2) (13) and the Central Sensitization 
Inventory (CSI) (14), respectively. Responses to these questionnairesprovide rich information 
on the sensory and emotional dimensions of the pain experience (13, 15) and underlying 
pathophysiological mechanisms (14, 16). Consequently, clinicians are provided with a deeper 
understanding of the patient’s headache experience, ultimately facilitating a more specific, 
patient-centred approach to treatment. 
In addition, both SF-MPQ-2 and CSI are useful in diagnosis and have an association with the 
neurochemical profile of migraine. Individuals with CSI scores of ≥ 22.5 out of 100 are 
nearly five times more likely to be indicative of migraine than no headache, with sensitivity 
of 95% and specificity of 80% (Chapter Four). This cut-off score of 22.5 is lower than 
previously published cut-off score of 40 for central sensitisation syndromes in general (17), 
As such, this lower cut-off score means that migraine can be strongly suspected in individuals 
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with CSI scores of ≥ 22.5, improving the clinical utility of this index. Additionally, the fair 
correlations of pain and central sensitisation scores with increased GABA levels in migraine 
(Chapter Three) suggest that information from SF-MPQ-2 and CSI could be used to 
understand the neurochemical profile of patients in the absence of spectroscopy data. 
However, whether the association between multidimensional pain and central sensitisation 
and brain GABA levels is specific for migraine, or true for any recurrent headache or chronic 
pain condition,will be investigated in prospective research. 
b. Assessment of disability
The findings of Chapters Five, Six and Seven support that clinicians should assess disability 
for several reasons: to differentiate migraine, to predict the course of headache and to assess 
outcome. Firstly, Chapter Five found that people with migraine had greater disability than 
non-migraine. Disability is best assessed using the Headache Disability Questionnaire (HDQ) 
(18), The Henry Ford Headache Disability Inventory (HDI) (19),or Headache Impact Test -6 
(HIT-6) (20) because they showed good discriminative ability for migraine. For example, 
scores on HDQ ≥ 27.5 out of 90 distinguish people with migraine from non-migraine 
headaches, with sensitivity = 80.0%, specificity = 74.1%, and positive likelihood ratio = 3.09. 
Similarly, total scores on HDI ≥19 out of 100 distinguish having migraine, with sensitivity = 
80.0%, specificity = 67.1%, and positive likelihood ratio = 1.72. Scores on HIT-6, when 
combined with results of musculoskeletalimpairment and headache frequency,also showed 
good discriminative validity for migraine from non-migraine headaches (sensitivity = 80.0%, 
specificity = 75.6%). 
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Further, clinicians should also assess disability because it may be associated with poor 
prognosis and therefore could be targeted to potentially change the course of the headache. 
The findings  in Chapter Six demonstrated that higher disability at baseline was one factor in 
a multifactorial model that explained 32.3 % of the variation in non-improvement in 
disability in the medium-term (p = 0.031). Further, the results presented in Chapter Six 
showed that disability changed over the medium-term in migraine and non-migraine 
headaches. Given this, assessment of disability at baseline may assist clinicians with 
understanding the prognosis and course of headache. 
Finally the findings of Chapter Seven support the use of disability questionnaires by 
clinicians to measure outcome. Clinically relevant changes in disability may be measured 
using the HIT-6 or HDQ, with acceptable responsiveness [effect sizes (95% confidence 
interval) ranging from 0.40 (0.06 to 0.74) to 0.69 (0.49 to 0.89)].Chapter Seven thus builds on 
the evidence presented in Chapter Five on the usefulness of HIT-6 and HDQ, not only to 
characterise disability in migraine and non-migraine headaches,but also to measure clinically 
relevant change over time in migraine (21, 22) and non-migraine headaches (23). 
c. Implications for patient education
Overall, the results of this thesis have implications for patient education with regard to 
diagnosis, prognosis and management. As a result of findings of  Chapters Three, Four and 
Five, clinicians can have greater confidence to differentiate migraine on the basis of clinical 
and characteristics, including disability profile, and can communicate this to their patients. 
Clinicians will be able to educate patients with migraine about the nature of their headaches 
with greater clarity. The factors associated with non-improvement in disability and the high 
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day-to-day volatility especially of migraine headaches presented in Chapter Six could be 
included in patient education strategies. Previous work has established the critical role of 
patient education in effective multidisciplinary headache management. Educating patients 
about the characteristics of their headaches enhances self-efficacy, motivation and treatment 
adherence, eventually resulting in improved outcomes (24-26). In particular, providing 
patients with information on the behaviour of headaches addresses their frustration because of 
the unpredictability of their headaches (27, 28) and potentially helps them align their 
expectations accordingly. Finally, the work in Chapters Five and Six demonstrated that 
cervical musculoskeletal impairments are present in 10% of participants with migraine.. 
Explaining to patients that these impairments could be targeted when present, potentially 
reducing disability (Chapter Six), may provide patients with some hope. 
8.2.3. Limitations of the thesis 
The findings of this thesis must be interpreted with caution in light of a number of 
methodological limitations of the studies. One limitation of this thesis is that the spectroscopy 
technique employed in Chapters Three and Fourmight not provide a complete profile of brain 
neurochemicals in migraine. Although MEGA-PRESS is considered to be the best available 
technique for separating and quantifying GABA, it is possible that even this best 
spectroscopy technique might not have achieved complete separation of GABA from 
macromolecules. Future advances in spectroscopy might allow more complete separation, 
and therefore more accurate measurement of GABA. As regards distinguishing migraine 
from non-migraine headaches, an important caveat in considering the findings presented in 
Chapters Five through Seven is that the heterogeneity of the non-migraine group prevents any 
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conclusion to be drawn about cervical musculoskeletal impairments and clinical course 
specifically for CGH or TTH. Prospective studies with pure headache groups that have larger 
sample sizes would be better suited to distinguish specific headache types. Larger sample 
sizes of prospective population- or clinic-based research could also allow for a more in-depth 
investigation of numerous possible predictors of non-improvement in headaches. Such 
research could build on findings of our exploratory longitudinal cohort study presented in 
Chapter Six. There is also reason for cautious interpretation of results related to self-report 
questionnaires in Chapters Four through Seven due to possible test order effects. Although 
the consistent presentation of questionnaires across participants eliminated one possible 
confounding variable, we did not test any effect the order of administration of questionnaires 
may have on the responses of the participants. Lastly, the lack of follow up measurements of 
cervical musculoskeletal impairments and the limited observation period in the study 
presented in Chapter Six do not allow any conclusion on long-term clinical courses of 
headaches and possible association of any change in cervical musculoskeletal impairments. 
These limitations may be addressed in future research. 
8.2.4. Directions for future research 
Evidence presented in this thesis has implications for future research to further elucidate the 
nature of migraine toward enhancing treatment. These include validating GABA as a 
biomarker for migraine, specifying cervical musculoskeletal impairments in headaches, and 
further characterising the clinical course and prognosis of migraine and non-migraine 
headaches. 
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8.2.4.1 Validating GABA as a biomarker for migraine 
 
The breakthrough presented in Chapters Three and Four regarding the potential of GABAas a 
biomarker for migraine may be explored further in future studies. Validating GABA as a 
migraine biomarker would address the lack of established biomarkers (29, 30)and would 
consequently allow refinement of headache definitions to be based on more objective markers 
than headache features. In the process of validating GABA as a biomarker for migraine, its 
role in migraine pathophysiology may be investigated. 
 
The first step toward validating GABA as a biomarker is to examine the association of brain 
GABA levels with other clinical characteristics of migraine (31). Such characteristics should 
include those related to the headache (such as triggers, aura, associated symptoms during the 
headache phase, e.g. nausea and photophobia, and symptoms during the postdrome phase). 
Also it may be worth exploring  the associations of brain GABA levels with personal factors, 
including multidimensional pain, central sensitisation, emotional state and lifestyle habits 
(32, 33), and other known risk factors for migraine progression [such as obesity (34), genetic 
predisposition and medication overuse (32)]. Whilst multidimensional pain and central 
sensitisation were found to be associated with brain GABA levels in this thesis (Chapter 
Four), these findings need to be cross-validated in future cross sectional studies with larger 
sample sizes. 
 
The second step in establishing GABA as a biomarker is to determine that increased 
concentration of GABA in the brain is unique to migraine. Hence concentration of GABA 
should be compared between different headache types, chronic pain conditions and pain-free 
controls in a larger cross sectional studies. This would elucidate whether the increase in 
276
GABA concentrations in migraine is specific for migraine, to headaches in general or to any 
chronic pain condition.  
A longitudinal study would enable identification of causal relationships between GABA 
levels and the onset and phases of migraine, and any change in clinical characteristics such as 
pain and disability. Identifying these causal relationships would clarify the pathophysiology 
of migraine and the mechanisms causing the increased GABA levels. Next, to identify the 
GABA-related mechanisms, preclinical studies using animal models may help inform the 
design of randomised controlled trials targeting reduction in GABA levels. Ultimately curing 
migraine with an intervention (e.g. pharmaceutical agent) aimed at the potential cause 
(increased GABA levels would confirm the role of GABA in migraine pathophysiology. 
Proving the efficacy of the intervention targeting GABA would then complete the validation 
of GABA as a migraine biomarker. 
8.2.4.2 Specifying cervical musculoskeletal impairments in headaches 
Cervical musculoskeletal impairments in migraine compared to non-migraine headaches 
demonstrated in Chapter Five need to be exploredfurther. First, larger cross-sectional cohort 
studies with pure groups for migraine, TTH and CGH would enable differentiation between 
specific headache types. Second, the discriminative validity of the combination of tests to 
differentiate migraine from non-migraine headaches should be evaluated in future cohort 
studies. To accomplish this, headache classification using the combination of manual 
examination of the upper cervical spine, real-time ultrasound measurement of the change in 
deep cervical extensors thickness during low-load contraction, frequency of headaches, and 
disability may be compared with classification using the ICHD. Such studies would hopefully 
277
resolve the conflicting findings regarding the presence of these cervical musculoskeletal 
impairments in migraine. 
8.2.4.3 Characterising the clinical course and prognosis of migraine and non-
migraine headaches better 
Lastly, the clinical course and prognosis of migraine and non-migraine headaches may be 
studied further to build on findings of Chapters Six and Seven. This may be achieved through 
a longitudinal clinical trial over at least one year, preferably longer to consider the volatility 
of headache symptoms demonstrated in the medium-term in Chapter Six. Such longitudinal 
clinical trial study should entail at least one intervention and prospective measurements of 
headache characteristics and other putative predictors repeated over time. Additional studies 
on clinical course would address the scarcity of evidence in this area and may eventually 
open avenues for specific management of headaches. 
The recommendations presented in this chapter for guideline expansion, clinical practice and 
research are envisioned to inform the design of targeted and effective treatment for migraine 
and for headaches in general. Whilst much is still left to be known about headaches, every 
effort to increase the understanding of the nature of headaches contributes toward improved 
definitions of headaches. Correct headache classification is a necessary step toward 
development of effective treatments. The application of findings presented in this thesis will 
therefore contribute to better health outcomes for patients and, ultimately, to the reduction of 
the global burden of headaches. 
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For Meg, this is, pardon the pun, MIND-BLOWING 
news!…Meg now awaits studies that will solve 
exactly how GABA links with migraine: Does GABA 
start her migraine attack? Does GABA stop it? Much 
more remains unknown, but each piece to the 
migraine puzzle raises hope for its cure. 
 
 [Excerpt from Three-Minute Thesis Presentation (3MT®) by Maria Eliza Ruiz Aguila; 
Winner, Faculty of Health Sciences 3MT® 2014] 
  
Illustration by David Val Christian B. Agoncillo, 2014 
for presentations related to studies in this thesis 
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APPENDIX 1 
Supplemental Materials for Chapter Two:  
Definitions and Participant Characteristics of Frequent 
Recurrent Headache Types in Clinical Trials: 
A Systematic Review 
Appendix 1is the peer reviewed version of supplemental materials to the following article: 
Aguila ME, Rebbeck T, Mendoza KG, De La Peña MG, Leaver AM. Definitions and 
participant characteristics of frequent recurrent headache types in clinical trials: A systematic 
review. Cephalalgia.Epub2017 Apr 25. doi: 10.1177/0333102417706974, which has been 
published in online form ahead of print at 
http://journals.sagepub.com/doi/suppl/10.1177/0333102417706974 
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Appendix A 
Search Strategy: MEDLINE OVID 
Definitions and participant characteristics of frequent recurrent headache types in clinical 
studies: A systematic review 
1 exp Headache/ 
2 exp Cluster Headache/     
3 exp Tension-Type Headache/     
4 exp Migraine Disorders/ 
5 exp Post-Traumatic Headache/ 
6 cervicogenic headache.mp. 
7 exp Headache Disorders, Primary/        
8 exp Headache Disorders/       
9 primary headache.mp.       
10 (headache* or cephalagi* or migrain*).mp 
11 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 
12 exp Clinical Trial/    
13 (clin* adj25 trial*).ti,ab.       
14 ((singl* or doubl* or trebl*  or tripl*) adj25 blind*).mp. or mask*.ti,ab. 
15 ((singl* or doubl* or trebl*  or tripl*) adj25 (blind* or mask*)).ti,ab.        
16 exp Placebos/       
17 placebo*.ti,ab. 
18 random*.ti,ab.        
19 exp Cross-Over Studies/     
20 exp Double-Blind Method/   
21 double-blind procedure*.mp.        
22 exp Randomized Controlled Trial/ 
23 exp Single-Blind Method/    
24 Single-Blind Procedure*.mp. 
25 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 
26 11 and 25 
27 limit 26 to (English language and yr="2005 -Current")        
28 limit 27 to humans 
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Appendix C 
Reference List for Studies Included in the Review 
Migraine studies 
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migraine pain in adults: A single-blind, prospective, randomized, placebo-controlled
clinical trial. Clin Ther 2007; 29: 1441–7.
2. Allais G, Bussone G, D'Andrea G, et al. Almotriptan 12.5 mg in menstrually related
migraine: A randomized, double-blind, placebo-controlled study. Cephalalgia 2011;
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3. Allais G, Romoli M, Rolando S, et al. Ear acupuncture in the treatment of migraine
attacks: A randomized trial on the efficacy of appropriate versus inappropriate
acupoints. Neurol Sci 2011; 32: S173–5.
4. Almén-Christensson A, Hammar M, Lindh-Åstrand L, et al. Prevention of menstrual
migraine with perimenstrual transdermal 17-β-estradiol: A randomized, placebo-
controlled, double-blind crossover study. Fertil Steril 2011;  96: 498–500.e1
5. Alstadhaug KB, Odeh F, Salvesen R, et al. Prophylaxis of migraine with melatonin: A
randomized controlled trial. Neurology 2010; 75: 1527–32.
6. Anand KS, Prasad A, Singh MM, et al. Botulinum toxin type a in prophylactic
treatment of migraine. Am J Ther 2006; 13: 183–7.
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APPENDIX 2 
Ethics Approvals 
Appendix 2 presents ethics approvals from The University of Sydney Human Research Ethics 
Committee for studies presented in Chapters Three through Seven. 
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The Committee had no ethical objections to the modification/s and has approved the project to 
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Project Title: Natural Course and Predictors of Recovery of Migraine and Other 
Headache Types 
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Please do not hesitate to contact Research Integrity (Human Ethics) should you require further 
information or clarification. 
 
Yours sincerely 
 
 
 
 
Dr Stephen Assinder 
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Human Research Ethics Committee 
 
 
 
This HREC is constituted and operates in accordance with the National Health and Medical 
Research Council’s (NHMRC) National Statement on Ethical Conduct in Human Research 
(2007), NHMRC and Universities Australia Australian Code for the Responsible Conduct of 
Research (2007) and the CPMP/ICH Note for Guidance on Good Clinical Practice. 
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APPENDIX 3 
Levels of Excitatory and Other Brain Chemicals in Migraine 
Detected Using Proton Magnetic Resonance Spectroscopy 
Appendix 3 presents supplementary methods and findings for Chapter Three.
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INTRODUCTION 
This report presents the levels of excitatory and other brain chemicals in migraine, to 
supplement findings presented in Chapter 3. In Chapter 3, new evidence was presented on 
elevated levels of the inhibitory brain chemical, gamma-aminobutyric acid (GABA), in 
people with migraine compared to age- and gender- matched controls and on the good 
diagnostic accuracy of GABA for classifying individuals with and without migraine. In light 
of this new evidence and the hypothesis that migraine pathophysiology involves an imbalance 
between excitatory and inhibitory mechanisms (1, 2), levels of excitatory and other brain 
neurochemicals in migraine are worth exploring. 
 
Abnormalities in the brain concentrations of N-acetyl-aspartate (NAA), glutamate (Glu), 
glutamate + glutamine (Glx), creatine (Cr), choline (Cho), and myoInositol (mI) have been 
associated with various pathological changes in the brain. NAA is considered a marker of 
neuronal integrity and lower NAA levels are interpreted as neuronal loss or injury (3, 4). Glu 
and Glx are associated with excitatory neurotransmission. Cr reflects energy metabolism and 
is also used as a reference metabolite in measuring brain chemicals because of its relative 
stability across the brain (4). Cho is typically found in cell membranes and is believed to be a 
marker of cell turnover. mI maintains glial cell volumes and elevated mI levels are 
interpreted as glial activation due to inflammation (5). 
 
Previous studies have investigated these brain chemicals in migraine. For example, decreased 
levels of NAA in the cerebellum have been reported in individuals with familial hemiplegic 
migraine compared to controls (6). There is also evidence on excitatory abnormalities in 
migraine. Elevated levels of Glu have been suggested to be related with central sensitization 
mechanisms in animal models of migraine (7). Consistent with this finding, there is evidence 
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for higher Glu levels in the anterior paracingulate cortex of individuals with migraine 
compared with controls. Similarly, low ratios of N-acetyl aspartylglutamate and Gln have 
been shown in the anterior cingulate cortex and insula in patients with migraine (8). 
Alterations in brain chemicals in migraine have also been found in the presence of 
comorbidities. For example, elevated levels of mI in the prefrontal cortex were observed in 
individuals with migraine and major depressive disorder compared to individuals with 
migraine without major depressive disorder(9).Further studies are required to replicateand 
validatethese findings to fully understand the neurochemical profile of migraine. 
 
Therefore this report presents the methods and results of proton magnetic resonance 
spectroscopy for the following brain chemicals measured during the interictal period from the 
same cohort described in Chapter 3: NAA, Glu, Glx, Cr, Cho, and mI. The aim of this report 
was to characterise migraine in terms of its neurochemical profile, in addition to the evidence 
for GABA presented in Chapter 3. 
 
MAGNETIC RESONANCE SPECTROSCOPY DATA ACQUISITION 
Imaging was conducted at the Brain and Mind Research Institute imaging centre on a 3-Tesla 
GE Discovery MR750 scanner (GE Medical Systems, Milwaukee, Wisconsin) using an 8-
channel phased array head coil. The protocol comprised three-dimensional sagittal whole-
brain scout for orientation and positioning of all subsequent scans (repetition time, TR=50ms; 
echo time, TE=4ms; 256matrix; no averaging, z=5mm thickness). To aid in the anatomical 
localisation of all sampled voxels, a T1-weighted Magnetization Prepared RApid Gradient-
Echo (MPRAGE) sequence producing 196 sagittal slices (TR=7.2ms; TE=2.8ms; flip angle = 
10°; matrix 256x256; 0.9mm isotropic voxels) was acquired. Next, single voxel 1H-MRS 
using a Point RESolved Spectroscopy (PRESS) acquisition with two chemical shift-selective 
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imaging pulses for water suppression was acquired separately from voxels placed in the 
thalamus and anterior cingulate cortex using the following parameters: TE=35ms, 
TR=2000ms, 128 averages voxel size 2x2x2cm(see Figure 1). Anatomical localisation of 
voxel placement was based on the Talairach and Tournoux brain atlas (10) and positioning 
was guided by the T1-weighted image. Prior to any post-processing, all spectra were visually 
inspected separately by two independent raters to ensure the consistency of the data. Poorly 
fitted neurochemical peaks as reflected by large Cramer–Rao Lower Bounds (CRLB) were 
excluded from further analysis (CRLB less than 20). Finally, prior to determination of 
neurochemical ratios, all spectroscopy data were corrected for grey and white matter and 
cerebrospinal fluid content within the acquisition voxel. 
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Thalamus 
 
Anterior Cingulate Cortex 
 
Figure 1. Placement of the single voxel in the thalamus (top panel) and anterior cingulate 
cortex (bottom panel) in the (A) axial, (B) coronal, and (C) sagittal planes for 
proton magnetic resonance spectroscopy analysis. 
 
 
All spectra were quantified with the LCModel software package (11, 12) using a PRESS 
TE=35 basic set of 15 neurochemicals that included NAA, Glu, Glx, Cr, cho, and mI and 
incorporated macromolecule and baseline fitting routines. The radiographers, the 
neuroimaging expert who read the spectroscopy data and the neuroradiologist were blinded to 
group allocation. 
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Other methods, including study design, participant inclusion, procedures and statistical 
analyses have been detailed in Chapter 3. 
 
RESULTS 
Spectroscopy data were of sufficient quality to allow analysis from 18 participants each from 
the control group and their matched participants in the migraine group. 
 
Profiles of NAA, Glu, Glx, Cr, Cho, and mI in migraine and controls are depicted in 
representative spectra in Figure 2. The spectra are plots of signal intensity against the 
frequency of the signal. The peaks for the neurochemicals in the spectra therefore represent 
the concentration of the neurochemicals, where the height of the peaks is proportional to the 
concentration of the neurochemicals (3). Thus the concentrations of NAA, Glu, Glx, Cr, Cho, 
and mI in migraine were not significantly different from those in matched controls (Figure 2, 
Table 1). Consequently, these brain chemicals also demonstrated poor diagnostic accuracies 
in classifying individuals as having migraine or not (Table 2). 
 
 
Figure 2.Representative spectra from the anterior cingulate cortex of a participant with 
migraine (right) and a matched control (left). 
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Table 1. Median and interquartile range of concentrations (in institutional units) of N-acetyl-
aspartate, glutamate, glutamate + glutamine, creatine, choline, and myoInositol in 
the thalamus and anterior cingulate cortex in in people with migraine and controls 
 
 Migraine Control p values 
Thalamus    
N-acetyl-aspartate 17.35 (16.06–18.18) 17.59 (16.96–18.14) 0.647 
Glutamate 15.84 (14.41–16.87) 16.33 15.18–17.66) 0.215 
Glutamate + glutamine 17.08 (15.86–18.22) 17.61 (16.65–18.67) 0.528 
Creatine 3.64 (1.35–5.36) 3.71 (2.37–5.26) 0.845 
Choline 3.04 (2.77–3.33) 3.12 (2.88–3.44) 0.679 
MyoInositol 7.06 (6.18–7.88) 7.10 (6.42–8.09) 0.112 
Anterior cingulate cortex    
N-acetyl-aspartate 15.28 (14.14–17.60) 15.25 (13.56–16.31) 0.841 
Glutamate 21.08 (17.88–23.22) 19.85 (17.93–22.75) 0.478 
Glutamate + glutamine 25.63 (22.41–28.05) 24.13 (20.12–28.26) 0.167 
Creatine 4.43 (3.13–6.33) 3.84 (3.16–4.58) 0.455 
Choline 3.08 (2.74–3.62) 3.35(3.15–3.65) 0.575 
MyoInositol 11.32 (10.47–12.37) 11.78 (8.47–12.61) 0.067 
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Table 2. Areas under the curve (95% confidence intervals) from receiver operating 
characteristic curve analyses evaluating N-acetyl-aspartate, glutamate, glutamate + 
glutamine, creatine, choline, and myoInositol in the thalamus and anterior cingulate 
cortex in in people with migraine and controls 
 
 Area Under the Curve 
(95% CI) 
p values 
Thalamus   
N-acetyl-aspartate 0.43 (0.25–0.62) 0.46 
Glutamate 0.41 (0.22–0.59) 0.32 
Glutamate + glutamine 0.39 (0.21–0.57) 0.24 
Creatine 0.51 (0.32–0.70) 0.94 
Choline 0.43 (0.24–0.62) 0.46 
MyoInositol 0.47 (0.28–0.66) 0.74 
Anterior cingulate cortex   
N-acetyl-aspartate 0.57 (0.38–0.75) 0.48 
Glutamate 0.56 (0.37–0.74) 0.56 
Glutamate + glutamine 0.58 (0.39–0.77) 0.41 
Creatine 0.61 (0.42–0.79) 0.27 
Choline 0.39 (0.20–0.58) 0.24 
MyoInositol 0.52 (0.32–0.72) 0.815 
__________________________ 
Abbreviation: CI, confidence interval; ROC, receiver operating characteristic 
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These findings differ from previous reports on brain chemicals in migraine, possibly due to 
different methods, region of measurement, and characteristics of the cohort in the studies. 
Still, these findings add to the scarce evidence on the neurochemical basis and 
pathophysiology of migraine. Considering the elevated levels of GABA detected in the same 
migraine cohort, these findings on NAA, Glu, Glx, Cr, Cho, and mI suggest the relative 
importance of GABA in the pathophysiology and diagnosis of migraine compared to these 
chemicals. Further cross-sectional and longitudinal studies could investigate these brain 
chemicals and their changes over time in different brain regions hypothesised to be involved 
in migraine, in individuals with migraine with different characteristics from participants of 
this study, and during the ictal period. 
 
CONCLUSIONS 
Our results demonstrate no significant difference in metabolic profile for NAA, Glu, Glx, Cr, 
Cho, and mI in individuals with migraine during the interictal period compared with matched 
controls. These findings, taken together with elevated levels of GABA detected in the same 
migraine cohort presented in Chapter 3, contribute to the characterisation of the 
neurochemical profile of migraine and provide basis to further explore neurochemical 
alterations and their probable link with the pathophysiology of migraine. 
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APPENDIX 4 
Project Protocol: 
Can Neurochemicals Distinguish Headache Types? 
Appendix 4 presents the project protocol for studies in Chapters Three and Four. 
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Project Title: 
CAN NEUROCHEMICALS DISTINGUISH 
HEADACHE TYPES? 
Project Protocol 
TABLE OF CONTENTS 
1.0 Project sequence ................................................................................................................ 2 
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2.3Telephone screening for inclusion criteria ..................................................................... 4 
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1.0 Project Sequence 
1.1 Telephone screening (Check if volunteer fulfils inclusion and exclusion criteria) 
1.2 Inclusion and enrolment of eligible participants 
1.3 Sending of forms and questionnaires 
1.3.1 Forms 
1.3.1.1 Participant information statement 
1.3.1.2 Participant consent form 
1.3.1.3 Instructions to get to Brain and Mind Research Institute 
1.3.2 Questionnaires 
1.3.2.1 Demographic and headache details 
1.3.2.2 Short-form McGill Pain Questionnaire-2 
1.3.2.3 Central Sensitization Inventory 
1.3.2.4 Headache Impact Test-6 
1.3.2.5 The Henry Ford Headache Disability Index 
1.3.2.6 Headache Disability Questionnaire 
1.3.2.7 Depression Anxiety Stress Scales-21 
1.4 Schedule for clinical screening and MRI: non-headache day for participants with 
migraine 
1.5 Clinical screening 
1.5.1 Participant examination: 
1.5.1.1 Check information on questionnaires for completeness and 
confirm details for accuracy 
1.5.1.2 Ask other questions, as necessary 
1.5.2 Clinical examination: 
1.5.2.1 Range of motion measurement 
1.5.2.2 Test for mechanosensitivity of neural tissue 
1.5.2.3 Spurling's Test 
1.5.2.4 Palpation 
1.5.2.5 Flexion rotation test 
1.5.2.6 Neurological tests 
1.5.3 Confirmation of inclusion as participant 
1.6 Spectroscopy 
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 2.0 Initial telephone screening for patient groups 
 
Potential subjects are recruited by advertisement or from referring doctors as per the ethics 
document. Potential subjects will initially be screened over the telephone by either Marilie or 
Andrew. During the current (pilot phase) subjects will be recruited with migraine or as controls.  
 
2.1 General screening and demographic details 
 
Name:  
 
Found about study by: 
DOB:      Gender:  F M 
 
 
Contact:    Address: 
 
 
Phone: 
Email:  
 
2.2 Initial screening for either migraine or control group 
Have you experienced headaches?  Yes   No   
 Proceed to 
1.3 
Telephone 
screening 
for migraine 
Proceed to 
1.4 
Telephone 
screening 
for control 
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2.3 Telephone screening for migraine 
ICHD-II criteria 1.1 Migraine 
without aura  
Sample screening question Participant response 
A. At  least 5 attacks fulfilling criteria 
B-D 
How often do you have headaches? 
(Or how many headaches have you have had so far?) 
 
B. Headache attacks lasting 4-72 
hours (untreated or unsuccessfully 
treated)  
How long do your headaches typically last?   
C. Headache has at least two of the 
following characteristics: 
 Unilateral location 
 Pulsating quality 
 Moderate or severe pain 
intensity 
 Aggravation by or causing 
avoidance of routine physical 
activity (eg walking or climbing 
stairs) 
Can you describe your headache/ how does it feel? (If 
needing further prompting: would you describe it as 
sickening?splitting? nauseating?) 
Where do you feel your headache usually? 
How would you rate the average intensity of your 
headacheon a scale of 0 (no pain at all) to 10/10(worst 
possible pain?)  
What happens to your headachewith exercise such as 
walking or climbing stairs? Does it get better or worse?  
 
D. During headache at least one of the 
following 
 Nausea and/or vomiting 
 Photophobia 
 Phonophobia 
Do you experience any other symptoms with your 
headache? Can you describe them?  
 
Or more leading questions:  
Do you ever feel nauseas or vomit when you have a 
headache? 
Are you sensitive to light or sound during a headache?  
 
(Other info) What do you need to do to relieve your headache and the 
other symptoms? 
 
Do you take any medication for your headache? What meds?  
What do you think triggers your headaches? (Or more 
leading: Do you think your headache is associated with 
chocolate intake, alcohol consumption, hormonal changes, 
etc.?) 
 
Do you have a family member who has migraine?  
E. Not attributed to another disorder Have you been diagnosed with any other condition that may 
be related to your headache? 
Have you received treatment any other condition that may 
be related to your headache? 
 
 
ICHD-II criteria 1.1 Migraine with 
aura  
Sample screening question Participant response 
A. At  least 2 attacks fulfilling criteria 
B-D 
How often do you have headaches?  
B. Aura consisting of at least one of 
the following, but  
 No motor weakness; 
 
 Fully reversible visual 
symptoms  
o positive features: 
flickering lights, spots or 
lines 
o negative features: loss of 
vision 
 Fully reversible sensory 
symptoms  
o positive features: pins 
and needles 
o negative features: 
numbness 
 Fully reversible dysphasic 
speech disturbance  
Do you experience any other symptoms with your 
headache? Can you describe them?  
 
Do you feel these before or after your headache? 
 
Or more leading questions:  
Do you have visual symptoms with your headache such as 
flickering lights, etc. 
Do you feel pins and needles? Numbness?  
Does your speech get affected during attacks? 
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ICHD-II criteria 1.1 Migraine with 
aura  
Sample screening question Participant response 
C. At least two of the following: 
 Homonymous visual 
symptoms and/or unilateral 
sensory symptoms 
 At least one aura symptom 
develops gradually over > 
5minutes and/or different 
aura symptoms occur in 
succession over > 5minutes 
 Each symptom lasts > 5 and 
less than <60 minutes 
Are your visual symptoms sensory on one side or both 
sides? 
How long does it take for the visual / sensory / speech 
symptom (aura) to develop? 
How long does the visual / sensory / speech symptom 
(aura) last? 
 
 
 
D. Headache fulfilling criteria B-D for 
migraine without aura begins 
during the aura or follows aura 
within 60 minutes 
Once you have the visual / sensory / speech symptom (aura), 
how long does it take before you get a headache? Can you 
describe this headache? 
 
(Other info) What do you need to do to relieve your headache and the 
other symptoms? 
 
Do you take any medication for your headache? What meds?  
What do you think triggers your headaches? (Or more 
leading: Do you think your headache is associated with 
chocolate intake, alcohol consumption, hormonal changes, 
etc.?) 
 
Do you have a family member who has migraine?  
E. Not attributed to another disorder Have you been diagnosed with any other condition that may 
be related to your headache? 
Have you received treatment any other condition that may 
be related to your headache? 
 
 
Fulfilled criteria for migraine?  
 Yes: Included in migraine group 
 No: Excluded 
 
2.4 Telephone screening for controls 
 
2.4.1 Have you had a headache in the past 3 
months? 
Yes   No   
2.4.2 If you experience headaches, are they 
regular? (N.B. “regular” ~ once in 3mos) 
Yes   No   
2.4.3 Do you experience significant pain? Yes   No   
2.4.4 Do you experience significant neck pain?  Yes   No   
2.4.5 Do you have any other chronic 
complaints, say pain that lasts for more 
than 3 months? 
Yes   No   
Responded “no” to screening questions 1.4.1 to 1.4.5?  
 Yes: Included as control 
 No: Excluded 
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2.5 Telephone screening for exclusion criteria 
 
I need to ask a few more questions to make sure that you can undergo MRI scanning. 
• Do you have entrapment neuropathy? 
Myelopathy?Stent? Epilepsy?  
Yes   No   
• Are you pregnant?  Yes   No   
• Have you had cervical spine surgery? 
Whiplash or trauma to the head or neck? 
Amputation? 
Yes   No   
• Do you use a wheelchair?  Yes   No   
• Have you had any health complaints in the 
last 5 days?  
Yes   No   
• Have you been diagnosed with severe 
depression, since symptoms of depression 
influence neurochemistry in the cortical 
regions of interest in this study? 
Yes   No   
• Did you take any medicine for a neck 
condition or headache in the previous 6 
hours? 
Yes   No   
• Do you have any metal in your body? This 
may be a reason for not going through MRI 
scanning. Do you have any metal in your 
head? An aneurysm clip? Cochlear implants? 
Neurostimulators in your head? Braces on 
your teeth? Head tattoos? Metal piercings in 
your head? Do you have any metal in your 
heart? Have you done any welding, because 
that might leave metal in your eyes? 
Yes   No   
• Do you have claustrophobia or fear of 
enclosed spaces? Are you afraid of tight 
spaces? 
Yes   No   
• Do you think you do not have reasonable 
command of English to understand 
instructions?   
Yes   No   
 
Responded “yes” to any of the exclusion criteria? 
 Yes: Excluded  
 No: Included  
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If individual meets inclusion and exclusion criteria (for either migraine or control), proceed to explain 
that they are eligible for study.  Explain briefly the following:  
• Will you be interested to participate in our project? This is a study about natural 
chemicals in your brain that might be associated with different types of headache.  
We think there might be different natural chemicals in your brain when you have 
migraines and when you do not have migraines.  We are doing this study to better 
understand these natural chemicals in the brain and maybe eventually better 
decide on treatment for headaches. 
• You might be interested in the findings 
• You will be required to undertake a series of brain scans at the Brain & Mind 
Research Institute on Mallett St., Camperdown 
If individual has more questions or if he/she is interested to participate in the study, say that 
you will send further information and some questionnaires that need to be filled out before 
the MRI appointment. These may be sent by email or post, according to preference. 
• patient information statement (PIS) 
• consent form 
• baseline demographic information (other than that collected above) 
• baseline questionnaires (SF-MPQ-2, DASS-21, Headache Disability Questionnaire, 
Headache Impact Test-6, Headache Disability Inventory) 
• information about how to access the BMRI (where to parkand meet etc) 
Once participant has had time to read the PIS, explain that we will telephone to book the MRI time.   
Remind that he/she should come to the appointment with the questionnaires completed.  
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3.0 Participant forms and questionnaires 
3.1 Patient information statement and consent form 
PARTICIPANT INFORMATION STATEMENT 
Can neurochemicals distinguish headache types? 
(1) What is the study about?
You are invited to participate in a study of brain chemicals that are associated with 
different types of headache. We will measure the levels of chemicals in different parts 
of your brain to determine whether any changes are specific to different types of 
headache.  You are eligible to participate in this study if you experience frequent 
headaches, or you never experience headaches.  
You are not eligible to participate if you have any of the following: 
• Any disease or injury affecting the neck
• Epilepsy
• A physical condition that prevents you from being positioned in the scanner,
such as being in a wheelchair
• Severe depression
• Any metal in your head or neck, including orthodontic braces for your teeth,
or neck tattoos
• Claustrophobia
If you are not certain whether you are eligible, please ask the researchers. You will have 
to complete a questionnaire to ensure there are no contraindications to your 
participation. This is routine before any scanning. 
(2) Who is carrying out the study?
The study is being conducted by Professors Kathryn Refshauge, Jim Lagopoulos and 
Patrick Brennan and Drs Trudy Rebbeck and Andrew Leaver, at The University of 
Sydney. 
(3) What does the study involve?
You will be required to attend the Brain and Mind Research Institute at Mallett St, 
Camperdown, to undertake a series of brain scans. We will first ask you a series of 
questions about your headache status and general health. We will then scan your brain 
using a particular type of imaging equipment, proton magnetic resonance spectroscopy, 
to enable us to measure the concentration of five different chemicals in four regions of 
your brain. Some people may experience some mild anxiety when placed in the MRI 
scanner.  However, the imaging staff involved with this study are trained to deal with 
these issues and will be available for immediate support. We will reimburse you for 
travel and inconvenience. 
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(4) How much time will the study take? 
 
Your involvement in the study will take 1 hr. We will follow up your progress in 3 
months, and measure the level of these chemicals again as well as your headache 
status. 
 
(5) Can I withdraw from the study? 
 
Being in this study is completely voluntary - you are not under any obligation to consent 
and - if you do consent - you can withdraw at any time without affecting your 
relationship with The University of Sydney. 
 
(6) Will anyone else know the results? 
 
All aspects of the study, including results, will be strictly confidential and only the 
researchers will have access to information on participants. 
A report of the study may be submitted for publication, but individual participants will 
not be identifiable in such a report. 
 
(7) Will the study benefit me? 
 
We cannot and do not guarantee or promise that you will receive any benefits from the 
study. 
 
(8) Can I tell other people about the study? 
 
You can tell other people about the study. If they are interested in participating, they 
would be welcome to ring one of the researchers named on this Participant Information 
Sheet. 
 
(9) What if I require further information about the study or my involvement in it? 
 
When you have read this information, one of the chief investigators will discuss it with 
you further and answer any questions you may have.  If you would like to know more at 
any stage, please feel free to contact: 
 
Ms Maria Eliza Aguila 
9351 9453 
magu5636@uni.sydney.edu.au 
 
Associate Professor Jim Lagopoulos 
93510783 
Jim.Lagopoulos@sydney.edu.au 
 
Dr Andrew Leaver 
9351 9545 
Andrew.Leaver@sydney.edu.au 
 
(10) What if I have a complaint or any concerns? 
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Any person with concerns or complaints about the conduct of a research study can 
contact The Manager, Human Ethics Administration, University of Sydney on +61 2 8627 
8176 (Telephone); +61 2 8627 8177 (Facsimile) or ro.humanethics@sydney.edu.au 
(Email). 
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PARTICIPANT CONSENT FORM 
 
 
I, ...........................................................................................[PRINT NAME], give consent to my 
participation in the research project 
 
TITLE: Can neurochemicals distinguish headache types? 
 
In giving my consent I acknowledge that: 
 
1. The procedures required for the project and the time involved have been explained to me 
and any questions I have about the project have been answered to my satisfaction. 
 
 
2. I have read the Participant Information Statement and have been given the opportunity to 
discuss the information and my involvement in the project with the researcher/s. 
 
 
3. I understand that being in this study is completely voluntary – I am not under any obligation 
to consent. 
 
 
4. I understand that my involvement is strictly confidential. I understand that any research data 
gathered from the results of the study may be published however no information about me 
will be used in any way that is identifiable. 
 
5. I understand that I can withdraw from the study at any time, without affecting my 
relationship with the researcher(s) or the University of Sydney now or in the future. 
 
 
I consent to:  
Receiving Feedback YES  NO  
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If you answered YES to the “Receiving Feedback” question, please provide your details i.e. mailing 
address, email address. 
 
Feedback Option 
 
Address:  _______________________________________________________ 
 
_______________________________________________________ 
 
Email: _______________________________________________________ 
 
 
 
 
 
 
 
 
.................................. ................................................... 
Signature  
 
 
 
.................................. .................................................... 
Please PRINT name 
 
 
.................................................................................. 
Date 
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3.2Demographic details 
 
_____________________________________________________________________ 
Marital status:   singleロmarriedロdivorcedロwidowedロ 
Highest education level:  Primary ロ     secondary ロtertiaryロ 
Occupation:  
 
Height:  Weight: 
 
 
Medications: 
 
Drug name Dose Frequency Length of time 
taken 
Time/ date last 
taken  
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3.3Headache duration, location, intensity and frequency 
 
 
2.3.1 How long have you been experiencing headaches?  ______________________ months/ years 
 
Please shade areas on the head and body charts below to indicate where you are currently experiencing pain 
including headaches.  If you have pain in more than one location, indicate additional locations also.  
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You should then rate the headache intensity using the following two 0 – 10 scales:  
 
2.3.2 Average headache pain intensity over the last month (Circle the most appropriate)   
 
0 1 2 3 4 5 6 7 8 9 10 
No pain                           Worst possible pain 
          
   
2.3.3 Average headache intensity over the last 24 hours (Circle the most appropriate)   
 
0 1 2 3 4 5 6 7 8 9 10 
No pain                    Worst possible pain  
         
2.3.4 How often do you experience headaches _________times  per month   
          
2.3.5 Global perceived effect 
With respect to your headache pain, compared to when you first entered the study, how would you describe 
your headaches these days? 
 (Circle the most appropriate)   
 
-5 -4 -3 -2 -1 0 1 2 3 4 5 
Vastly worse    Unchanged                 Completely recovered 
 
  
RIGHT RIGHT LEFT LEFT 
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3.4  Pain questionnaires 
Short-Form McGill Pain Questionnaire-2(SF-MPQ-2)1 
This questionnaire provides you with a list of words that describe some of the different qualities of pain and related 
symptoms. Please put an X through the numbers that best describe the intensity of each of the pain and related 
symptoms you felt during the past week. Use 0 if the word does not describe your pain or related symptoms. 
 
1. Throbbing pain none 0 1 2 3 4 5 6 7 8 9 10 worst possible 
              
2. Shooting pain none 0 1 2 3 4 5 6 7 8 9 10 worst possible 
              
3. Stabbing pain none 0 1 2 3 4 5 6 7 8 9 10 worst possible 
              
4. Sharp pain none 0 1 2 3 4 5 6 7 8 9 10 worst possible 
              
5. Cramping pain none 0 1 2 3 4 5 6 7 8 9 10 worst possible 
              
6. Gnawing pain none 0 1 2 3 4 5 6 7 8 9 10 worst possible 
              
7. Hot-burning pain none 0 1 2 3 4 5 6 7 8 9 10 worst possible 
              
8. Aching pain none 0 1 2 3 4 5 6 7 8 9 10 worst possible 
              
9. Heavy pain none 0 1 2 3 4 5 6 7 8 9 10 worst possible 
              
10. Tender none 0 1 2 3 4 5 6 7 8 9 10 worst possible 
              
11. Splitting pain none 0 1 2 3 4 5 6 7 8 9 10 worst possible 
              
12. Tiring-exhausting none 0 1 2 3 4 5 6 7 8 9 10 worst possible 
              
13. Sickening none 0 1 2 3 4 5 6 7 8 9 10 worst possible 
              
14. Fearful none 0 1 2 3 4 5 6 7 8 9 10 worst possible 
               
15. Punishing-cruel none 0 1 2 3 4 5 6 7 8 9 10 worst possible 
               
16. Electric-shock pain none 0 1 2 3 4 5 6 7 8 9 10 worst possible 
               
17. Cold-freezing pain none 0 1 2 3 4 5 6 7 8 9 10 worst possible 
               
18. Piercing none 0 1 2 3 4 5 6 7 8 9 10 worst possible 
               
19. Pain caused by light  
touch 
none 0 1 2 3 4 5 6 7 8 9 10 worst possible 
              
               
20. Itching none 0 1 2 3 4 5 6 7 8 9 10 worst possible 
               
21. Tingling or ‘pins and  
needles’ 
none 0 1 2 3 4 5 6 7 8 9 10 worst possible 
              
               
22. Numbness none 0 1 2 3 4 5 6 7 8 9 10 worst possible 
1SF-MPQ-2 © R. Melzack and the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT), 2009. All 
Rights Reserved.With permission. 
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CENTRAL SENSITIZATION INVENTORY2: PART A 
Please circle the best response to the right of each statement 
1 I feel unrefreshed when I wake up in the 
morning  
Never Rarely Sometimes Often Always 
2 My muscles feel stiff and achy  Never Rarely Sometimes Often Always 
3 I have anxiety attacks  Never Rarely Sometimes Often Always 
4 I grind or clench my teeth  Never Rarely Sometimes Often Always 
5 I have problems with diarrhea and/or 
constipation  
Never Rarely Sometimes Often Always 
6 I need help in performing my daily activities Never Rarely Sometimes Often Always 
7 I am sensitive to bright lights  Never Rarely Sometimes Often Always 
8 I get tired very easily when I am physically 
active  
Never Rarely Sometimes Often Always 
9 I feel pain all over my body  Never Rarely Sometimes Often Always 
10 I have headaches Never Rarely Sometimes Often Always 
11 I feel discomfort in my bladder and/or burning 
when I urinate  
Never Rarely Sometimes Often Always 
12 I do not sleep well Never Rarely Sometimes Often Always 
13 I have difficulty concentrating Never Rarely Sometimes Often Always 
14 I have skin problems such as dryness, itchiness, 
or rashes  
Never Rarely Sometimes Often Always 
15 Stress makes my physical symptoms get worse Never Rarely Sometimes Often Always 
16 I feel sad or depressed Never Rarely Sometimes Often Always 
17 I have low energy Never Rarely Sometimes Often Always 
18 I have muscle tension in my neck and shoulders Never Rarely Sometimes Often Always 
19 I have pain in my jaw Never Rarely Sometimes Often Always 
20 Certain smells, such as perfumes, make me feel 
dizzy and nauseated  
Never Rarely Sometimes Often Always 
21 I have to urinate frequently Never Rarely Sometimes Often Always 
22 My legs feel uncomfortable and restless when I 
am trying to go to sleep at night  
Never Rarely Sometimes Often Always 
23 I have difficulty remembering things Never Rarely Sometimes Often Always 
24 I suffered trauma as a child Never Rarely Sometimes Often Always 
25 I have pain in my pelvic area  Never Rarely Sometimes Often Always 
Total = 
CENTRAL SENSITIZATION INVENTORY: PART B 
Have you been diagnosed by a doctor with any of the following disorders? 
Please check the box to the right for each diagnosis and write the year of the diagnosis 
No Yes Year Diagnosed 
1 Restless leg syndrome 
2 Chronic fatigue syndrome 
3 Fibromyalgia 
4 Temporomandibular joint disorder (TMJ) 
5 Migraine or tension headaches 
6 Irritable bowel syndrome 
7 Multiple chemical sensitivities 
8 Neck injury (including whiplash) 
9 Anxiety or panic attacks 
10 Depression 
2From Mayer, T.G.,Neblett, R., Cohen, H., Howard, K.J., Choi, Y.H., Williams, M.J., Perez, Y., &Gatchel, R.J. (2012).  The 
development and psychometric validation of the Central Sensitization Inventory.  Pain Practice, 12(4), 276-285.  With 
permission. 
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3.5  DASS-21 
DASS21 Name: Date: 
Please read each statement and circle a number 0, 1, 2 or 3 which indicates how much the statement applied to 
you over the past week.  There are no right or wrong answers.  Do not spend too much time on any statement. 
The rating scale is as follows: 
0  Did not apply to me at all 
1  Applied to me to some degree, or some of the time 
2  Applied to me to a considerable degree, or a good part of time 
3  Applied to me very much, or most of the time 
1 I found it hard to wind down 0      1   2   3 
2 I was aware of dryness of my mouth 0      1   2   3 
3 I couldn't seem to experience any positive feeling at all 0      1   2   3 
4 I experienced breathing difficulty (eg, excessively rapid breathing,breathlessness in 
the absence of physical exertion) 
0      1   2   3 
5 I found it difficult to work up the initiative to do things 0      1   2   3 
6 I tended to over-react to situations 0      1   2   3 
7 I experienced trembling (eg, in the hands) 0      1   2   3 
8 I felt that I was using a lot of nervous energy 0      1   2   3 
9 I was worried about situations in which I might panic and makea fool of myself 0      1   2   3 
10 I felt that I had nothing to look forward to 0      1   2   3 
11 I found myself getting agitated 0      1   2   3 
12 I found it difficult to relax 0      1   2   3 
13 I felt down-hearted and blue 0      1   2   3 
14 I was intolerant of anything that kept me from getting on withwhat I was doing 0      1   2   3 
15 I felt I was close to panic 0      1   2   3 
16 I was unable to become enthusiastic about anything 0      1   2   3 
17 I felt I wasn't worth much as a person 0      1   2   3 
18 I felt that I was rather touchy 0     1   2   3 
19 I was aware of the action of my heart in the absence of physical exertion (eg, sense 
of heart rate increase, heart missing a beat) 
0      1   2   3 
20 I felt scared without any good reason 0      1   2   3 
21 I felt that life was meaningless 0      1   2   3 
Participants with a score of > 21 on the Depression Scale of on the DASS 21 will be excluded.  
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3.6  Headache disability questionnaires 
HEADACHE DISABILITY QUESTIONNAIRE 
Name:………………………………… Date:………/………./……….  Score            / 90 
Please read each question and circle the response that best applies to you 
1. How would you rate the usual pain of your headache on a scale from 0 to 10? 
0 
NO 
PAIN 
1 2 3 4 5 6 7 8 9 10 WORST PAIN 
2. When you have headaches, how often is the pain severe? 
NEVER 1-9% 10-19% 20-29% 30-39% 40-49% 50-59% 60-69% 70-79% 80-89% 90-100% ALWAYS 
0 1 2 3 4 5 6 7 8 9 10
3. On how many days in the last month did you actually lie down for an hour or more because of your headaches? 
NONE 1-3 4-6 7-9 10-12 13-15 16-18 19-21 22-24 25-27 28-31 EVERY DAY 
0 1 2 3 4 5 6 7 8 9 10 
4. When you have a headache, how often do you miss work or school for all or part of the day? 
NEVER 1-9% 10-19% 20-29% 30-39% 40-49% 50-59% 60-69% 70-79% 80-89% 90-100% ALWAYS 
0 1 2 3 4 5 6 7 8 9 10
5. When you have a headache while you work (or school), how much is your ability to work reduced? 
NOT 1-9% 10-19% 20-29% 30-39% 40-49% 50-59% 60-69% 70-79% 80-89% 90-100% UNABLE TO 
WORK 0 1 2 3 4 5 6 7 8 9 10 
REDUCED 
6. How many days in the last month have you been kept from performing housework or chores for at least half of the day because of 
your headaches? 
NONE 1-3 4-6 7-9 10-12 13-15 16-18 19-21 22-24 25-27 28-31 EVERY DAY 
0 1 2 3 4 5 6 7 8 9 10 
7. When you have a headache, how much is your ability to perform housework or chores reduced? 
NOT 1-9% 10-19% 20-29% 30-39% 40-49% 50-59% 60-69% 70-79% 80-89% 90-100% UNABLE
TO PERFORM 0 1 2 3 4 5 6 7 8 9 10 
REDUCED 
8. How many days in the last month have you been kept from non-work activities (family, social or recreational) because of your
headaches? 
NONE 1-3 4-6 7-9 10-12 13-15 16-18 19-21 22-24 25-27 28-31 EVERY DAY 
0 1 2 3 4 5 6 7 8 9 10 
9. When you have a headache, how much is your ability to engage in non-work activities (family, social or recreational) reduced? 
NOT 1-9% 10-19% 20-29% 30-39% 40-49% 50-59% 60-69% 70-79% 80-89% 90-100% UNABLE
TO PERFORM 0 1 2 3 4 5 6 7 8 9 10 
REDUCED 
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HIT-6TM HEADACHE IMPACT TEST
This questionnaire was designed to help you describe and communicate the way you feel and what you cannot 
do because of headaches. 
To complete, please check one box for each question. 
1.When you have headaches, how often is the pain severe?
 Never  Rarely  Sometimes  Very Often  Always 
2.How often do headaches limit your ability to do usual daily activities including household
work, work, school, or social activities? 
 Never  Rarely  Sometimes  Very Often  Always 
3. When you have a headache, how often do you wish you could lie down? 
 Never  Rarely  Sometimes  Very Often  Always 
4.In the past 4 weeks, how often have you felt too tired to do work or daily activities because of your headaches? 
 Never  Rarely  Sometimes  Very Often  Always 
5.In the past 4 weeks, how often have you felt fed up or irritated because of your headaches? 
 Never  Rarely  Sometimes  Very Often  Always 
6. In the past 4 weeks, how often did headaches limit your ability to concentrate on work or daily activities?
 Never  Rarely  Sometimes  Very Often  Always 
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 
(6 points each) (8 points each) (10 points each) (11 points each) (13 points each) 
To score, add points for answers in each column 
Please share your HIT-6 results with your doctor.
Total Score: _____________ 
Higher scores indicate 
greater impact on your life. 
Score range is 36-78.
Copyright © 2000 QualityMetric Incorporated and Glaxo Wellcome Group Companies.  All rights reserved. 
HIT-6™ United Kingdom (English) Version 1.0 
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THE HENRY FORD HEADACHE DISABILITY INVENTORY3 
Please read carefully: The purpose of the scale is to identify difficulties that you may be experiencing because of your headache. Please check off 
“YES”, “SOMETIMES”, or “NO” to each item. Answer each question as it pertains to your headache only. 
YES SOMETIMES NO 
E1. Because of my headaches I feel handicapped. □ □ □
F2. Because of my headaches I feel restricted in performing 
my routine daily activities. 
□ □ □
E3. No one understands the effect that my headaches have on 
my life. 
□ □ □
F4. I restrict my recreational activities (eg, sports, hobbies) 
because of my headaches. 
□ □ □
E5. My headaches make me angry. □ □ □
E6. Sometimes I feel that I am going to lose control because of 
my headaches. 
□ □ □
F7. Because of my headaches I am less likely to socialize. □ □ □
E8. My spouse (significant other), or family and friends, have 
no idea what I am going through because of my headaches. 
□ □ □
E9. My headaches are so bad that I feel that I am going to go 
insane. 
□ □ □
E10. My outlook on the world is affected by my headaches. □ □ □
E11. I am afraid to go outside when I feel that a headache is 
starting. 
□ □ □
E12. I feel desperate because of my headaches. □ □ □
F13. I am concerned that I am paying penalties at work or at 
home because of my headaches. 
□ □ □
E14. My headaches place stress on my relationships with 
family or friends. 
□ □ □
F15. I avoid being around people when I have a headache. □ □ □
F16. I believe my headaches are making it difficult for me to 
achieve my goals in life. 
□ □ □
F17. I am unable to think clearly because of my headaches. □ □ □
F18. I get tense (eg, muscle tension) because of my 
headaches. 
□ □ □
F19. I do not enjoy social gatherings because of my 
headaches. 
□ □ □
E20. I feel irritable because of my headaches. □ □ □
F21. I avoid traveling because of my headaches. □ □ □
E22. My headaches make me feel confused. □ □ □
E23. My headaches make me feel frustrated. □ □ □
F24. I find it difficult to read because of my headaches. □ □ □
F25. I find it difficult to focus my attention away from my 
headaches and on other things. 
□ □ □
3From Jacobson, G.P., Ramadan, N.M., Aggarwal, S.K., & Newman, C.W. (1994). The Henry Ford Hospital Headache Disability
Inventory (HDI). Neurology, 44, 837-842.With permission. 
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4.0  Where do I go for the MRI?  
 
Please come to the Brain & Mind Research Institute, 94 Mallett Street, Camperdown, where a 
member of the research team (Ms. Marilie Aguila, Dr Andrew Leaver or Dr Trudy Rebbeck) will 
meet you at the foyer of Building F.   
 
By public transport, get off at Central station, walk to the bus stop Railway Square D, Sydney and 
then catch a bus (438, 439, 440, or 461, any bus that will go on Paramatta Road). Get off at 
Parramatta Rd NrMallett St. The BMRI is a short walk from there. 
 
If you are driving, there are a number of parking spots on Australia St. near the BMRI that are all 
day parking, although these are limited and may be full early.   
 
 
Contact:  Ms Maria Eliza Aguila, T 02 9351 9010, M 0405-756675 
  Brain & Mind Research Institute T 02 9351 0672   
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4.0 Clinical screening 
 
CLINICAL NOTES for assessing physiotherapist  
 
Subjective Examination 
 
Clarify body chart as provided by patient:  
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Do the painful areas become painful together or separately?  
 
  
RIGHT RIGHT LEFT LEFT 
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History:  
• Have you seen a neurologist?   Yes   No   
If yes, what was the diagnosis given? ____________________   
• Have you taken any medication to reduce the 
pain?  
Yes   No   
• Have you received physical treatment for the 
pain? 
Yes   No   
If yes, what are these? ____________________   
• Have you received alternative treatment for 
the pain? 
Yes   No   
If yes, what are these? ____________________ No   
 
Pain behaviour:  
• Do movements affect your pain? Yes   No   
• Do certain positions affect your pain? Yes   No   
 
Other: general health etc 
• Are you comfortable to go through MRI 
scanning?  
Yes   No   
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Clinical Examination 
 
Cervical ROM:            
Movement Range Comment 
Flexion  
 
 
Extension  
 
 
Left lateral flexion   
 
 
Right lateral flexion  
 
 
Left rotation 
 
  
Right rotation  
 
  
 
Test for Mechanosensitivity of Neural Tissue: 
Tests for mechanosensitivity of the upper cervical neural tissues will be done following the protocol 
described in Hall &Elvey (2004) In J.D. Boyling& G.A. Jull (Eds.), Grieve's modern manual therapy: The 
vertebral column (3rd ed.). (pp. 413-431). Edinburgh: Churchill Livingstone and Hall, T., Briffa, K., & Hopper, 
D. (2008).  Clinical Evaluation of Cervicogenic Headache: A Clinical Perspective.   J Man ManipTher, 16(2): 
73–80.  
 Yes 
 No 
 
Spurling's:  Extension/Lateral Flexion: +/- rotation + compression   
 
Positive ロ Negativeロ 
 
Positive Spurling’s? 
 Yes: Excluded  
 No: Confirm inclusion as participant 
 
 
Palpation: 
Manual examination of the upper cervical joints will be done following the protocol of Zito, Jull & Story, 
2006 
 
0/C1 Provoked   VAS: Relieved VAS: 
C1/C2 Provoked   VAS: Relieved VAS: 
C2/C3 Provoked   VAS: Relieved VAS: 
C3/C4 Provoked   VAS: Relieved VAS: 
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Cervical Flexion Rotation Test: 
Cervical flexion rotation test will be done following the protocol described in Hall, Briffa, Hopper, & 
Robinson, 2010. 
 
Positive ロ Negative ロ 
 
Neurological Tests: 
Two or more neurologic signs present? 
 Yes: Excluded  
 No: Confirm inclusion as participant 
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APPENDIX 5 
Project Protocol: 
Natural Course and Predictors of Recovery of 
Migraine and Other Headache Types 
Appendix 5 presents the project protocol for studies in Chapters Five through Seven. 
371
Project Title: 
NATURAL COURSE AND PREDICTORS OF RECOVERY 
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1.0 Project Sequence 
1.1 Telephone screening (Check if volunteer fulfils inclusion and exclusion criteria) 
1.2 Inclusion and enrolment of eligible participants 
1.3 Send questionnaires and forms 
1.3.1 Forms 
1.3.1.1 Baseline questionnaire (demographic and headache details) 
1.3.1.2 Participant information statement 
1.3.1.3 Participant consent form 
1.3.1.4 Instructions to get to clinical assessment venue 
1.3.2 Headache / Pain 
1.3.2.1 McGill Pain Questionnaire 
1.3.2.2 Central Sensitization Inventory 
1.3.3 Disability 
1.3.3.1 Headache Impact Test-6 
1.3.3.2 The Henry Ford Headache Disability Index 
1.3.3.3 Headache Disability Questionnaire 
1.3.3.4 WHO Disability Assessment Schedule 2.0 
1.3.4 Self-rated Health and Physical Activity 
1.3.4.1 Self-Administered Comorbidity Questionnaire 
1.3.4.2 Depression Anxiety Stress Scales-21 
1.3.4.3 Pittsburgh Sleep Quality Index 
1.3.4.4 Long Form International Physical Activity Questionnaire 
1.4 Schedule for assessment: preferably 3 days after most recent headache episode 
1.5 Baseline Assessment 
1.5.1 Participant examination: 
1.5.1.1 Check information on questionnaires for completeness and 
confirm details for accuracy 
1.5.1.2 Ask other questions 
1.5.2 Clinical examination: 
1.5.2.1 Range of motion measurement 
1.5.2.2 Flexion rotation test 
1.5.2.3 Cranio-cervical flexion test 
1.5.2.4 Strength test:Cervical flexors 
1.5.2.5 Endurance test: Cervical flexors 
1.5.2.6 Palpation of neck structures 
1.5.2.7 Cervical extensor test 
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1.5.2.8 Strength test : Cervical extensors 
1.5.2.9 Endurance test: Cervical extensors 
1.5.2.10 Real-time ultrasound imaging  
1.5.3 Assignment to groups 
1.5.3.1 Migraine  
1.5.3.2 Non-migraine 
1.5.3.2.1 Tension-type headache 
1.5.3.2.2 Cervicogenic headache  
1.5.3.2.3 Post-traumatic headache, including persistent headache 
attributed to whiplash 
1.5.3.3 Mixed or unclassifiable? 
1.6 REDCap headache diary for 6 months 
1.7 Follow up at 1 month, 3 months and 6 months after enrolment 
1.7.1.1 REDCap headache diary 
1.7.1.2 McGill Pain Questionnaire 
1.7.1.3 Central Sensitization Inventory 
1.7.1.4 Headache Impact Test-6 
1.7.1.5 The Henry Ford Headache Disability Index  
1.7.1.6 Headache Disability Questionnaire 
1.7.1.7 WHO Disability Assessment Schedule 2.0 
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2.0 Initial telephone screening for participant groups 
 
Potential participants are recruited by advertisement or from referring doctors as per the ethics 
document. Potential participants will initially be screened over the telephone by Marilie (headache 
or control groups) and Kanzah (control group).  
 
2.1 Demographic details 
 
Name:  
 
Found about study by: 
DOB:      Sex:   F           M 
 
 
Contact: Address: 
 
 
Phone: 
Email:  
 
Is the volunteer aged 18-65 years old?  
 Yes: Proceed to screening for inclusion criteria 
 No: Excluded 
 
 
2.2 Initial screening for either headache or control group 
 
Have you experienced headaches?  Yes   No   
 Proceed to 2.3.1 
Telephone 
screening for 
headache groups 
Proceed to 2.3.2 
Telephone 
screening for 
control 
 
2.3 Telephone screening for inclusion criteria 
 
2.3.1 Telephone screening for inclusion criteria for headache groups 
 
Do you experience recurrent headaches?    Yes   No 
Did you experience headache in the last month?    Yes   No 
Have you had your headache for more than a year?   Yes   No 
 
Responded “yes” to screening questions 2.3.1? 
 Yes: Included in headache group; proceed to screening for exclusion criteria 
for headache group 
 No: Excluded 
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2.3.2 Telephone screening for inclusion criteria for control group 
 
Have you had a headache in the past 3 months?   Yes   No 
If you experience headaches, are they regular? (N.B. 
“regular” ~ once in 3mos) 
  Yes   No 
Did you have any recent head or neck surgery?   Yes   No 
Do you experience significant neck pain?    Yes   No 
Do you have other conditions requiring medical attention or 
that affect performance of daily activities (e.g. diabetes 
mellitus, malignant cancers, demyelinating, inflammatory and 
degenerative neurological conditions, class3 obesity (BMI 
>40), severe cardiac or pulmonary disease, infectious or 
inflammatory arthropathies) 
  Yes   No 
Do you have severe mobility impairment necessitating 
dependence on mobility aids for ambulation? 
  Yes   No 
 
 
Responded “no” to screening questions 2.3.2?  
 Yes: Included as control; proceed to screening for exclusion criteria for 
control group 
 No: Excluded 
 
2.4 Telephone screening for exclusion criteria 
 
I need to ask a few more questions to make sure that you are eligible to participate in this research 
project. 
 
2.4.1 Telephone screening for exclusion criteria for headache groups 
 
Do you have a known reason for your headache such as 
dehydration or a substance or its withdrawal? 
  Yes   No 
Have you not had a craniotomy?   Yes   No 
Do you have no access to internet using a computer or a 
mobile phone? 
  Yes   No 
Do you have a pacemaker or fibrillator?   Yes   No 
Will you not be willing to fill out an online headache diary for 
6 months? 
  Yes   No 
Do you think you do not have reasonable command of English 
to understand instructions?   
  Yes   No 
 
Responded “yes” to any of the screening questions 2.4.1? 
 Yes: Excluded  
 No: Included in headache group 
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2.4.2 Telephone screening for exclusion criteria for control group 
 
I need to ask a few more questions to make sure that you are eligible to participate in this research 
project. 
 
Do you have a pacemaker or fibrillator?   Yes   No 
Do you think you do not have reasonable command of English 
to understand instructions?   
  Yes   No 
 
Responded “yes” to any of the screening questions 2.4.2? 
 Yes: Excluded  
 No: Included in control group 
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If the volunteer meets the inclusion and exclusion criteria, proceed to explain that they are eligible 
for study.  Explain briefly the following:  
• Will you be interested to participate in our project? This is a study about 
differentiating migraine from other types of headaches.  If you experience recurrent 
headaches, we will monitor changes in your headaches, and determine what affects 
your headaches. 
We are doing this study to better understand the similarities and differences between 
headache types and maybe eventually to better decide on diagnosis and treatment 
for headaches. 
• You might be interested in the findings. 
• You will be required to undertake a series of clinical tests, including real-time 
ultrasound imaging at the Arthritis and Musculoskeletal Research Group Laboratory 
at The University of Sydney Cumberland Campus in Lidcombe. If more convenient, 
they may also do the assessment at a city clinic(Sydney Specialist Physiotherapy 
Centre, Level 1, 50 York St. Sydney). 
If the individual has more questions or if he/she is interested to participate in the study, say that you 
will send further information and some questionnaires that need to be filled out before the clinical 
assessment. These may be sent by email or post, according to their preference. 
• participant information statement (PIS) 
• consent form 
• baseline questionnaire on demographic (and headache information for headache 
groups) 
• baseline questionnaires 
o McGill Pain Questionnaire 
o Central Sensitization Inventory 
o Headache Impact Test-6 
o The Henry Ford Headache Disability Index 
o Headache Disability Questionnaire 
o WHO Disability Assessment Schedule 2.0 
o Self-Administered Comorbidity Questionnaire 
o Depression Anxiety Stress Scales-21 
o Pittsburgh Sleep Quality Index 
o Long Form International Physical Activity Questionnaire 
• information about how to get to The University of Sydney Cumberland Campus or 
to alternative assessment site (where to parkand meet etc) 
Once participant has had time to read the PIS, explain that we will do the assessment, preferably 
done within 3 days of the last headache episode of participants with headaches.  Inform the 
participant that you need the neck and shoulders exposed. Suggest for the participant to come in 
singlet.  Remind that he/she should come to the appointment with the questionnaires completed.  
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3.0 Participant questionnaires 
 
3.1 Participant information statement and consent form 
 
PARTICIPANT INFORMATION STATEMENT 
 
Distinguishing Migraine from Other Headache Types 
 
(1) What is the study about? 
 
You are invited to participate in a study which will investigate if migraine is different 
from other headaches. We will monitor changes in your headaches, and determine 
whether physical activity, movement or neck muscle function affects your headache.  
This study will also investigate the usefulness of clinical tests to distinguish different 
types of headaches.  
You are eligible to participate in this study if you experience recurring headaches.  
 
You are not eligible to participate if you have recurring headaches due to dehydration, a 
substance or substance withdrawal, if you have had craniotomy, or if you have no 
access to internet using a computer or a mobile phone.   
 
If you are not certain whether you are eligible, please ask the researchers.  
 
(2) Who is carrying out the study? 
 
The study is being conducted by Dr Trudy Rebbeck, Dr Andrew Leaver, Mrs Maria 
Eliza Aguila, Prof Patrick Brennan, Prof Jim Lagopoulos, and Prof Kathryn 
Refshaugeat The University of Sydney. 
 
(3) What does the study involve? 
 
You will be required to attend an assessment session.  We will first ask you to answer 
some questions about your headache, its effects on your life and general health.  We 
will then perform a series of clinical tests to analyse your neck muscles and movements. 
These tests are part of standard clinical assessment for neck pain. We will also measure 
the size of your neck muscles using ultrasound imaging.  Images and videos will be 
obtained during some of these tests to aid in analysing movements. You will also be 
asked to record details of each of your headache episodes such as headache intensity, 
duration, triggers, and associated symptoms, over 6 months since your first assessment 
using an electronic web-based diary. You will also answer headache and disability 
questionnaires at 1 month, 3 months and 6 months after the assessment.     
 
(4) How much time will the study take? 
 
Your involvement in the study will take a maximum of 1.5 hours for the assessment in 
the laboratory or clinic.  You will then record features of your headache episodes on an 
electronic web-based headache diary on days when you have headache for 6 months 
after the assessment session.   Filling out this diary will take about 10 minutes each 
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time. The headache and disability questionnaires on follow up will take about 20 
minutes to answer. 
 
(5) Can I withdraw from the study? 
 
Being in this study is completely voluntary.  You are not under any obligation to 
consent and, if you do consent, you can withdraw at any time without affecting your 
relationship with the investigators or The University of Sydney. 
 
(6) Will anyone else know the results? 
 
All aspects of the study, including results, will be strictly confidential and only the 
researchers will have access to information on participants. Images and videos obtained 
in this study will be used for purposes of analysis of neck muscles and movements only.  
 
A report of the study may be submitted for publication, but individual participants will 
not be identifiable in such a report. 
 
(7) Will the study benefit me? 
 
We cannot and do not guarantee or promise that you will receive any benefits from the 
study. 
 
(8) Can I tell other people about the study? 
 
You can tell other people about the study. If they are interested in participating, they 
would be welcome to ring one of the researchers named on this Participant Information 
Sheet. 
 
(9) What if I require further information about the study or my involvement in it? 
 
When you have read this information, one of the chief investigators will discuss it with 
you further and answer any questions you may have.  If you would like to know more at 
any stage, please feel free to contact: 
 
Ms Maria Eliza Aguila 
9351 9010 
maria.aguila@sydney.edu.au 
 
Dr Trudy Rebbeck 
9351 9534 
trudy.rebbeck@sydney.edu.au 
 
Dr Andrew Leaver 
9351 9545 
andrew.leaver@sydney.edu.au 
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(10) What if I have a complaint or any concerns? 
 
Any person with concerns or complaints about the conduct of a research study can 
contact The Manager, Human Ethics Administration, University of Sydney on +61 2 
8627 8176 (Telephone); +61 2 8627 8177 (Facsimile) or 
ro.humanethics@sydney.edu.au (Email). 
 
 
This information sheet is for you to keep 
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PARTICIPANT CONSENT FORM 
 
 
I, ...........................................................................................[PRINT NAME], give consent to my 
participation in the research project 
 
TITLE:  Distinguishing Migraine from Other Headache Types 
 
In giving my consent, I acknowledge that: 
 
1. The procedures required for the project and the time involved have been explained to me and any 
questions I have about the project have been answill bed to my satisfaction. 
2. I have read the Participant Information Statement and have been given the opportunity to discuss the 
information and my involvement in the project with the researcher/s. 
3. I understand that being in this study is completely voluntary – I am not under any obligation to 
consent. 
4. I understand that my involvement is strictly confidential. I understand that any research data 
gathered from the results of the study may be published however no information about me will be 
used in any way that is identifiable. 
5. I understand that I can withdraw from the study at any time, without affecting my relationship with 
the researcher(s) or the University of Sydney now or in the future. 
6. I consent to:  
• Receiving Feedback YES  NO  
 
If you answill bed YES to the “Receiving Feedback” question, please provide your details i.e. 
mailing address, email address. 
 
Feedback Option 
 
Address:  _________________________________________________ 
 
_________________________________________________ 
 
Email: _________________________________________________ 
 
 
................................... ................................................... 
Signature  
 
 
 
.................................. .................................................... 
Please PRINT name 
 
 
.................................................................................. 
Date 
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3.2 Baseline Questions 
3.2.1 Demographic details 
 
PERSONAL DETAILS 
 
1. Name _________________________________________________ 
2. Sex   □   Male □   Female  
3. Height (cm) _____________________________________________   
4. Weight (kg) _____________________________________________ 
5. Marital status   □   Single □   Married / Defacto   
□   Divorced / Widowed / Separated 
6. Country of birth ____________________________________ 
7. Highest education level  □   Primary   □   Secondary 
□   Certificate 
□   Diploma or advanced diploma 
□   Bachelor degree 
□   Graduate  
□   Bachelor degree 
□   Graduate diploma or graduate certificate 
□   Postgraduate degree 
8. Occupation ___________________________________________ 
9. Medications: 
 
Drug name Dose Frequency Length of 
time taken 
Time/ date 
last taken  
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3.2.2 Headache duration, location, intensity and frequency 
 
QUESTIONS ON HEADACHE 
 
10. How long have you been experiencing headaches?  ______________________ 
months/ years 
11. Have you been seen by a health professional for your headaches?  
□   Yes □   No 
12. Have you been given a headache diagnosis?    
□   Yes □   No 
If yes,  
a. What is your headache diagnosis?  
□   Tension-type headache 
□   Migraine, please specify ________________ 
□   Cervicogenic headache 
□   Post-traumatic headache, please specify _______________ 
□   Other, please specify ________________ 
b. Who diagnosed your headache type? 
□   GP □   Neurologist □   Other, please specify ________ 
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13. Please shade areas on the head and body charts below to indicate where you 
are currently experiencing pain including headaches. If you have pain in more 
than one location, indicate additional locations also. 
 
Please proceed to question 14, next page. 
RESEARCH TEAM USE ONLY: 
Frequency: 
Duration: 
Intensity: 
Associated symptoms: 
Triggers: 
History: 
Previous treatment: 
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You should then rate the headache intensity using the following two 0 – 10 scales: 
14. Average headache pain intensity over the last month (Circle the most
appropriate)
0 1 2 3 4 5 6 7 8 9 10 
No pain Worst 
possible 
pain   
15. Average headache intensity over the last 24 hours (Circle the most appropriate)
0 1 2 3 4 5 6 7 8 9 10 
No 
pain 
Worst 
possible 
pain    
16. How many times in a day do you experience headaches?  _________times  per
day
17. How many times in a month do you experience headaches?  ______ times  per
month
RIGHT RIGHT LEFT LEFT 
387
3.3 Pain questionnaires 
3.3.1 Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2) 
This questionnaire provides you with a list of words that describe some of the different qualities of pain and related 
symptoms. Please put an X through the numbers that best describe the intensity of each of the pain and related symptoms 
you felt during a typical headache episode. Use 0 if the word does not describe your pain or related symptoms. 
1. Throbbing pain none 0 1 2 3 4 5 6 7 8 9 10 worst possible
2. Shooting pain none 0 1 2 3 4 5 6 7 8 9 10 worst possible
3. Stabbing pain none 0 1 2 3 4 5 6 7 8 9 10 worst possible
4. Sharp pain none 0 1 2 3 4 5 6 7 8 9 10 worst possible
5. Cramping pain none 0 1 2 3 4 5 6 7 8 9 10 worst possible
6. Gnawing pain none 0 1 2 3 4 5 6 7 8 9 10 worst possible
7. Hot-burning pain none 0 1 2 3 4 5 6 7 8 9 10 worst possible
8. Aching pain none 0 1 2 3 4 5 6 7 8 9 10 worst possible
9. Heavy pain none 0 1 2 3 4 5 6 7 8 9 10 worst possible
10. Tender none 0 1 2 3 4 5 6 7 8 9 10 worst possible
11. Splitting pain none 0 1 2 3 4 5 6 7 8 9 10 worst possible
12. Tiring-exhausting none 0 1 2 3 4 5 6 7 8 9 10 worst possible
13. Sickening none 0 1 2 3 4 5 6 7 8 9 10 worst possible
14. Fearful none 0 1 2 3 4 5 6 7 8 9 10 worst possible
15. Punishing-cruel none 0 1 2 3 4 5 6 7 8 9 10 worst possible
16. Electric-shock pain none 0 1 2 3 4 5 6 7 8 9 10 worst possible
17. Cold-freezing pain none 0 1 2 3 4 5 6 7 8 9 10 worst possible
18. Piercing none 0 1 2 3 4 5 6 7 8 9 10 worst possible
19. Pain caused by light touch none 0 1 2 3 4 5 6 7 8 9 10 worst possible
20. Itching none 0 1 2 3 4 5 6 7 8 9 10 worst possible
21. Tingling or ‘pins and 
needles’
none 0 1 2 3 4 5 6 7 8 9 10 worst possible
22. Numbness none 0 1 2 3 4 5 6 7 8 9 10 worst possible
SF-MPQ-2 © R. Melzack and the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials 
(IMMPACT), 2009. All Rights Reserved. 
Information regarding permission to reproduce the SF-MPQ-2 can be obtained at www.immpact.org. 
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22. Pulsating none 0 1 2 3 4 5 6 7 8 9 10 worst possible 
               
22. Band-like none 0 1 2 3 4 5 6 7 8 9 10 worst possible 
               
22. Tightness none 0 1 2 3 4 5 6 7 8 9 10 worst possible 
               
22. Excruciating none 0 1 2 3 4 5 6 7 8 9 10 worst possible 
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3.3.2 Central Sensitization Inventory1: Part A 
Please circle the best response to the right of each statement 
1 I feel unrefreshed when I wake up in the morning Never Rarely Sometimes Often Always 
2 My muscles feel stiff and achy Never Rarely Sometimes Often Always 
3 I have anxiety attacks  Never Rarely Sometimes Often Always 
4 I grind or clench my teeth  Never Rarely Sometimes Often Always 
5 I have problems with diarrhea and/or constipation Never Rarely Sometimes Often Always 
6 I need help in performing my daily activities  Never Rarely Sometimes Often Always 
7 I am sensitive to bright lights  Never Rarely Sometimes Often Always 
8 I get tired very easily when I am physically active Never Rarely Sometimes Often Always 
9 I feel pain all over my body  Never Rarely Sometimes Often Always 
10 I have headaches Never Rarely Sometimes Often Always 
11 I feel discomfort in my bladder and/or burning 
when I urinate  
Never Rarely Sometimes Often Always 
12 I do not sleep well Never Rarely Sometimes Often Always 
13 I have difficulty concentrating Never Rarely Sometimes Often Always 
14 I have skin problems such as dryness, itchiness, or 
rashes  
Never Rarely Sometimes Often Always 
15 Stress makes my physical symptoms get worse Never Rarely Sometimes Often Always 
16 I feel sad or depressed Never Rarely Sometimes Often Always 
17 I have low energy Never Rarely Sometimes Often Always 
18 I have muscle tension in my neck and shoulders Never Rarely Sometimes Often Always 
19 I have pain in my jaw Never Rarely Sometimes Often Always 
20 Certain smells, such as perfumes, make me feel 
dizzy and nauseated  
Never Rarely Sometimes Often Always 
21 I have to urinate frequently Never Rarely Sometimes Often Always 
22 My legs feel uncomfortable and restless when I 
am trying to go to sleep at night  
Never Rarely Sometimes Often Always 
23 I have difficulty remembering things Never Rarely Sometimes Often Always 
24 I suffered trauma as a child Never Rarely Sometimes Often Always 
25 I have pain in my pelvic area Never Rarely Sometimes Often Always 
Total = 
CENTRAL SENSITIZATION INVENTORY: PART B 
Have you been diagnosed by a doctor with any of the following disorders? 
Please check the box to the right for each diagnosis and write the year of the diagnosis 
No Yes Year Diagnosed 
1 Restless leg syndrome 
2 Chronic fatigue syndrome 
3 Fibromyalgia 
4 Temporomandibular joint disorder (TMJ) 
5 Migraine or tension headaches 
6 Irritable bowel syndrome 
7 Multiple chemical sensitivities 
8 Neck injury (including whiplash) 
9 Anxiety or panic attacks 
10 Depression 
1With permission.From Mayer, T.G., Neblett, R., Cohen, H., Howard, K.J., Choi, Y.H., Williams, M.J., 
Perez, Y., &Gatchel, R.J. (2012).The development and psychometric validation of the Central Sensitization 
Inventory.Pain Practice, 12(4), 276-285. 
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3.4 Disability questionnaires 
3.4.1 HIT-6TM Headache Impact Test 
This questionnaire will be designed to help you describe and communicate the way you feel and what you 
cannot do because of headaches. 
To complete, please check one box for each question. 
1. When you have headaches, how often is the pain severe?
 Never  Rarely  Sometimes  Very Often  Always 
2. How often do headaches limit your ability to do usual daily activities including household
work, work, school, or social activities?
 Never  Rarely  Sometimes  Very Often  Always 
3. When you have a headache, how often do you wish you could lie down?
 Never  Rarely  Sometimes  Very Often  Always 
4. In the past 4 weeks, how often have you felt too tired to do work or daily activities because of your
headaches?
 Never  Rarely  Sometimes  Very Often  Always 
5. In the past 4 weeks, how often have you felt fed up or irritated because of your headaches?
 Never  Rarely  Sometimes  Very Often  Always 
6. In the past 4 weeks, how often did headaches limit your ability to concentrate on work or daily
activities?
 Never  Rarely  Sometimes  Very Often  Always 
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 
(6 points each) (8 points each) (10 points each) (11 points each) (13 points each) 
To score, add points for answers in each column 
Please share your HIT-6 results with your doctor. 
Total Score: ____________________ 
Higher scores indicate 
greater impact on your life. 
Score range is 36-78. 
© 2001 QualityMetric Incorporated and the GlaxoSmithKline Group of Companies. All rights 
reserved. 
HIT-6™ US Original (English) Version 1.0 
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3.4.2 The Henry Ford Headache Disability Index2 
Please read carefully: The purpose of the scale is to identify difficulties that you may be 
experiencing because of your headache. Please check off “YES”, “SOMETIMES”, or “NO” 
to each item. Answer each question as it pertains to your headache only. 
YES SOMETI
MES 
NO 
E1. Because of my headaches I feel handicapped. □ □ □ 
F2. Because of my headaches I feel restricted in performing 
my routine daily activities. 
□ □ □ 
E3. No one understands the effect that my headaches have on 
my life. 
□ □ □ 
F4. I restrict my recreational activities (eg, sports, hobbies) 
because of my headaches. 
□ □ □ 
E5. My headaches make me angry. □ □ □ 
E6. Sometimes I feel that I am going to lose control because 
of my headaches. 
□ □ □ 
F7. Because of my headaches I am less likely to socialize. □ □ □ 
E8. My spouse (significant other), or family and friends, have 
no idea what I am going through because of my headaches. 
□ □ □ 
E9. My headaches are so bad that I feel that I am going to go 
insane. 
□ □ □ 
E10. My outlook on the world is affected by my headaches. □ □ □ 
E11. I am afraid to go outside when I feel that a headache is 
starting. 
□ □ □ 
E12. I feel desperate because of my headaches. □ □ □ 
F13. I am concerned that I am paying penalties at work or at 
home because of my headaches. 
□ □ □ 
E14. My headaches place stress on my relationships with 
family or friends. 
□ □ □ 
F15. I avoid being around people when I have a headache. □ □ □ 
F16. I believe my headaches are making it difficult for me to 
achieve my goals in life. 
□ □ □ 
F17. I am unable to think clearly because of my headaches. □ □ □ 
F18. I get tense (eg, muscle tension) because of my 
headaches. 
□ □ □ 
F19. I do not enjoy social gatherings because of my 
headaches. 
□ □ □ 
E20. I feel irritable because of my headaches. □ □ □ 
F21. I avoid traveling because of my headaches. □ □ □ 
E22. My headaches make me feel confused. □ □ □ 
E23. My headaches make me feel frustrated. □ □ □ 
F24. I find it difficult to read because of my headaches. □ □ □ 
F25. I find it difficult to focus my attention away from my 
headaches and on other things. 
□ □ □ 
2With permission.From Jacobson, G.P., Ramadan, N.M., Aggarwal, S.K., & Newman, C.W. (1994). The Henry Ford 
Hospital Headache Disability Inventory (HDI). Neurology, 44: 837-842.  
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3.4.3 Headache Disability Questionnaire 
 
Name:………………………………… Date:………/………./……….   Score                    / 90 
 
Please read each question and circle the response that best applies to you 
 
1. How would you rate the usual pain of your headache on a scale from 0 to 10? 
0 
NO 
PAIN 
1 2 3 4 5 6 7 8 9 10 WORST PAIN 
2. When you have headaches, how often is the pain severe? 
NEVER 1-9% 10-19% 20-29% 30-39% 40-49% 50-59% 60-69% 70-79% 80-89% 90-100% ALWAYS 
0 1 2 3 4 5 6 7 8 9 10  
3. On how many days in the last month did you actually lie down for an hour or more because of your headaches? 
NONE 1-3 4-6 7-9 10-12 13-15 16-18 19-21 22-24 25-27 28-31 EVERY DAY 
0 1 2 3 4 5 6 7 8 9 10  
4. When you have a headache, how often do you miss work or school for all or part of the day? 
NEVER 1-9% 10-19% 20-29% 30-39% 40-49% 50-59% 60-69% 70-79% 80-89% 90-100% ALWAYS 
0 1 2 3 4 5 6 7 8 9 10  
5. When you have a headache whilst you work (or school), how much is your ability to work reduced? 
NOT 1-9% 10-19% 20-29% 30-39% 40-49% 50-59% 60-69% 70-79% 80-89% 90-100% UNABLE TO 
WORK 0 1 2 3 4 5 6 7 8 9 10 
REDUCED          
6. How many days in the last month have you been kept from performing housework or chores for at least half of the 
day because of your headaches? 
NONE 1-3 4-6 7-9 10-12 13-15 16-18 19-21 22-24 25-27 28-31 EVERY DAY 
0 1 2 3 4 5 6 7 8 9 10  
7. When you have a headache, how much is your ability to perform housework or chores reduced? 
NOT 1-9% 10-19% 20-29% 30-39% 40-49% 50-59% 60-69% 70-79% 80-89% 90-100% UNABLE   
TO PERFORM 0 1 2 3 4 5 6 7 8 9 10 
REDUCED          
8. How many days in the last month have you been kept from non-work activities (family, social or recreational) 
because of your headaches? 
NONE 1-3 4-6 7-9 10-12 13-15 16-18 19-21 22-24 25-27 28-31 EVERY DAY 
0 1 2 3 4 5 6 7 8 9 10  
9. When you have a headache, how much is your ability to engage in non-work activities (family, social or 
recreational) reduced? 
NOT 1-9% 10-19% 20-29% 30-39% 40-49% 50-59% 60-69% 70-79% 80-89% 90-100% UNABLE  
TO PERFORM 0 1 2 3 4 5 6 7 8 9 10 
REDUCED          
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Page 1 of 2 (12-item, self-administered) 
WHODAS 2.0 
WORLD HEALTH ORGANIZATION 
3.4.4 Disability Assessment Schedule 2.0 
 
12-item version, self-administered 
 
This questionnaire asks about difficulties due to health conditions. Health conditions include 
diseases or illnesses, other health problems that may be short or long lasting, injuries, mental 
or emotional problems, and problems with alcohol or drugs. 
 
Think back over the past 30 days and answer these questions, thinking about how much 
difficulty you had doing the following activities. For each question, please circle only one 
response.  
. 
 
In the past 30 days, how much difficulty did you have in: 
S1  Standing for long periods such as 
30 minutes? 
None  Mild  Moderate  Severe  Extreme 
or 
cannot 
do 
S2  Taking care of your 
householdresponsibilities? 
None  Mild  Moderate  Severe  Extreme 
or 
cannot 
do 
S3 Learning a new task, for 
example, learning how to get to a 
new place? 
None  Mild  Moderate  Severe  Extreme 
or 
cannot 
do 
S4  How much of a problem did you 
have joining in community 
activities (for example, 
festivities, religious or other 
activities) in the same way as 
anyoneelse can? 
None  Mild  Moderate  Severe  
 
Extreme 
or 
cannot 
do 
 
S5 How much have you been 
emotionallyaffected by your 
health problems? 
None  Mild  Moderate  Severe  Extreme 
or 
cannot 
do 
 
Please continue to next page... 
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Page 2 of 2 (12-item, self-administered) 
WHODAS 2.0 
WORLD HEALTH ORGANIZATION 
DISABILITY ASSESSMENT SCHEDULE 2.0 
 
In the past 30 days, how much difficulty did you have in: 
S6 Concentrating on doing 
something forten minutes? 
None  Mild  Moderate  Severe  Extreme 
or cannot 
do\ 
S7 Walking a long distance such 
as akilometre [or equivalent]? 
None  Mild  Moderate  Severe  Extreme 
or cannot 
do 
S8 Will behing your whole body? None  Mild  Moderate  Severe  Extreme 
or cannot 
do 
S9  Getting dressed?  None  Mild  Moderate  Severe  Extreme 
or cannot 
do 
S10 Dealing with people you do 
not know? 
None  Mild  Moderate  Severe  Extreme 
or cannot 
do 
S11 Maintaining a friendship? None  Mild  Moderate  Severe  Extreme 
or cannot 
do 
S12 Your day-to-day work? None  Mild  Moderate  Severe  Extreme 
or cannot 
do 
 
H1 Overall, in the past 30 days, how many dayswill be 
these difficulties present? 
Record number of days 
_____ 
H2 In the past 30 days, for how many days will be you 
totally unableto carry out your usual activities or work 
because of any health condition? 
Record number of days 
_____ 
H3 In the past 30 days, not counting the days that you will 
be totally unable, for how many days did you cut back 
or reduce your usual activities or work because of any 
health condition? 
Record number of days 
_____ 
 
This completes the questionnaire. Thank you. 
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3.5 Health Questionnaires 
3.5.1 The Self-Administered Comorbidity Questionnaire3 
Instructions: 
The following is a list of common problems. Please indicate if you currently have the problem in the first 
column. If you do not have the problem, skip to the next problem.  
If you do have the problem, please indicate in the second column if you receive medications or some other type 
of treatment for the problem. 
In the third column indicate if the problem limits any of your activities. 
Finally, indicate all medical conditions that are not listed under “other medical problems” at the end of the page. 
 Do you have the problem? 
Do you receive 
treatment for it? 
Does it limit your 
activities? 
PROBLEM 
No 
(0) 
Yes  
(1) 
No 
(0) 
Yes 
(1) 
No 
(0) 
Yes 
(1) 
Heart disease N Y N Y N Y 
High blood pressure N Y N Y N Y 
Lung disease N Y N Y N Y 
Diabetes N Y N Y N Y 
Ulcer or stomach disease N Y N Y N Y 
Kidney disease N Y N Y N Y 
Liver disease N Y N Y N Y 
Anemia or other blood disease N Y N Y N Y 
Cancer N Y N Y N Y 
Depression N Y N Y N Y 
Osteoarthritis, degenerative arthritis N Y N Y N Y 
Back pain N Y N Y N Y 
Rheumatoid arthritis N Y N Y N Y 
Other medical problems  
(please write in) 
      
 N Y N Y N Y 
 N Y N Y N Y 
   
3With permission.From Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN. The Self-Administered 
Comorbidity Questionnaire: A new method to assess comorbidity for clinical and health services research. 
Arthritis Rheum. 2003 Apr 15;49(2):156-63. PubMed PMID:12687505 . 
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3.5.2 Depression Anxiety Stress Scales – 21 items 
 
DASS21 Name: Date: 
Please read each statement and circle a number 0, 1, 2 or 3 which indicates how much the statement applied to you over the 
past week.  There are no right or wrong answers.  Do not spend too much time on any statement. 
The rating scale is as follows: 
0  Did not apply to me at all 
1  Applied to me to some degree, or some of the time 
2  Applied to me to a considerable degree, or a good part of time 
3  Applied to me very much, or most of the time 
1 I found it hard to wind down 0      1      2      3 
2 I will be aware of dryness of my mouth 0      1      2      3 
3 I couldn't seem to experience any positive feeling at all 0      1      2      3 
4 I experienced breathing difficulty (eg, excessively rapid breathing,breathlessness in the 
absence of physical exertion) 
0      1      2      3 
5 I found it difficult to work up the initiative to do things 0      1      2      3 
6 I tended to over-react to situations 0      1      2      3 
7 I experienced trembling (eg, in the hands) 0      1      2      3 
8 I felt that I will be using a lot of nervous energy 0      1      2      3 
9 I will be worried about situations in which I might panic and makea fool of myself 0      1      2      3 
10 I felt that I had nothing to look forward to 0      1      2      3 
11 I found myself getting agitated 0      1      2      3 
12 I found it difficult to relax 0      1      2      3 
13 I felt down-hearted and blue 0      1      2      3 
14 I will be intolerant of anything that kept me from getting on withwhat I will be doing 0      1      2      3 
15 I felt I will be close to panic 0      1      2      3 
16 I will be unable to become enthusiastic about anything 0      1      2      3 
17 I felt I will ben't worth much as a person 0      1      2      3 
18 I felt that I will be rather touchy 0      1      2      3 
19 I will be aware of the action of my heart in the absence of physical exertion (eg, sense of heart 
rate increase, heart missing a beat) 
0      1      2      3 
20 I felt scared without any good reason 0      1      2      3 
21 I felt that life will be meaningless 0      1      2      3 
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3.5.3 Pittsburgh Sleep Quality Index 
 
INSTRUCTIONS:  
The following questions relate to your usual sleep habits during the past month only. Your 
answers should indicate the most accurate reply for the majority of days and nights in the past 
month. Please answer all questions.  
1 During the past month, what time have you usually gone to bed at night?  
BED TIME ___________ 
2 During the past month, how long (in minutes) has it usually taken you to fall asleep each 
night?  
NUMBER OF MINUTES ___________ 
3 During the past month, what time have you usually gotten up in the morning?  
GETTING UP TIME ___________ 
4 During the past month, how many hours of actual sleep did you get at night? (This may 
be different than the number of hours you spent in bed.)  
HOURS OF SLEEP PER NIGHT ___________  
For each of the remaining questions, check the one best response. Please answer all questions.  
5 During the past month, how often have you had trouble sleeping because you . . .  
a) Cannot get to sleep within 30 minutes  
Not during the past 
month____ 
Less than once a 
week ____ 
Once or twice a 
week ____ 
Three or more times a 
week ____ 
b) Wake up in the middle of the night or early morning  
Not during the past 
month____ 
Less than once a 
week ____ 
Once or twice a 
week ____ 
Three or more times a 
week ____ 
c) Have to get up to use the bathroom  
Not during the past 
month____ 
Less than once a 
week ____ 
Once or twice a 
week ____ 
Three or more times a 
week ____ 
Page 1 of 4  
  
Participant’s Initials 
____ Participant ID __________  Date ______________  Time ________ 
AM 
PM  
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d) Cannot breathe comfortably  
Not during the past 
month____ 
Less than once a 
week ____ 
Once or twice a 
week ____ 
Three or more times a 
week ____ 
e) Cough or snore loudly  
Not during the past 
month____ 
Less than once a 
week ____ 
Once or twice a 
week ____ 
Three or more times a 
week ____ 
f) Feel too cold  
Not during the past 
month____ 
Less than once a 
week ____ 
Once or twice a 
week ____ 
Three or more times a 
week ____ 
g) Feel too hot  
Not during the past 
month____ 
Less than once a 
week ____ 
Once or twice a 
week ____ 
Three or more times a 
week ____ 
h) Had bad dreams  
Not during the past 
month____ 
Less than once a 
week ____ 
Once or twice a 
week ____ 
Three or more times a 
week ____ 
i) Have pain  
Not during the past 
month____ 
Less than once a 
week ____ 
Once or twice a 
week ____ 
Three or more times a 
week ____ 
j) Other reason(s), please describe _________________________________________________ 
___________________________________________________________________________ 
How often during the past month have you had trouble sleeping because of this?  
Not during the past 
month____ 
Less than once a 
week ____ 
Once or twice a 
week ____ 
Three or more times a 
week ____ 
 
6 During the past month, how would you rate your sleep quality overall?  
Very good ____________  
Fairly good ____________ 
Fairly bad  ____________ 
Very bad  ____________  
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7 During the past month, how often have you taken medicine to help you sleep (prescribed 
or "over the counter")?  
Not during the past 
month____ 
Less than once a 
week ____ 
Once or twice a 
week ____ 
Three or more times a 
week ____ 
8 During the past month, how often have you had trouble staying awake whilst driving, 
eating meals, or engaging in social activity?  
Not during the past 
month____ 
Less than once a 
week ____ 
Once or twice a 
week ____ 
Three or more times a 
week ____ 
9 During the past month, how much of a problem has it been for you to keep up enough 
enthusiasm to get things done?  
No problem at all     ____________  
Only a very slight problem    ____________ 
Somewhat of a problem    ____________ 
A very big problem     ____________  
10 Do you have a bed partner or room mate?  
No bed partner or room mate    ____________  
Partner/room mate in other room   ____________ 
Partner in same room, but not same bed  ____________ 
Partner in same bed     ____________  
If you have a room mate or bed partner, ask him/her how often in the past month 
you have had...  
a) Loud snoring  
Not during the past 
month____ 
Less than once a 
week ____ 
Once or twice a 
week ____ 
Three or more times a 
week ____ 
b) Long pauses between breaths whilst asleep  
Not during the past 
month____ 
Less than once a 
week ____ 
Once or twice a 
week ____ 
Three or more times a 
week ____ 
c) Legs twitching or jerking whilst you sleep  
Not during the past 
month____ 
Less than once a 
week ____ 
Once or twice a 
week ____ 
Three or more times a 
week ____ 
400
Page 4 of 4  
d) Episodes of disorientation or confusion during sleep  
Not during the past 
month____ 
Less than once a 
week ____ 
Once or twice a 
week ____ 
Three or more times a 
week ____ 
e) Other restlessness whilst you sleep; please describe 
 ________________________________________________________________________
___________________________________________________________________________ 
Not during the past 
month____ 
Less than once a 
week ____ 
Once or twice a 
week ____ 
Three or more times a 
week ____ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 1989, University of Pittsburgh. All rights reserved. Developed by Buysse,D.J., 
Reynolds,C.F., Monk,T.H., Berman,S.R., and Kupfer,D.J. of the University of Pittsburgh 
using National Institute of Mental Health Funding.  
Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ: Psychiatry Research, 28:193-
213, 1989. 
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3.5.4 International Physical Activity Questionnaire 
 
We are interested in finding out about the kinds of physical activities that people do as part of 
their everyday lives. The questions will ask you about the time you spend being physically 
active in a usual week. Please answer each question even if you do not consider yourself to 
be an active person. Please think about the activities you do at work, as part of your house 
and yard work, to get from place to place, and in your spare time for recreation, exercise or 
sport. 
 
Think about all the vigorous and moderate activities that you do in a usual week. Vigorous 
physical activities refer to activities that take hard physical effort and make you breathe much 
harder than normal. Moderate activities refer to activities that take moderate physical effort 
and make you breathe somewhat harder than normal. 
 PART 1: JOB-RELATED PHYSICAL ACTIVITY 
 
The first section is about your work. This includes paid jobs, farming, volunteer work, course 
work, and any other unpaid work that you do outside your home. Do not include unpaid work 
you might do around your home, like housework, yard work, general maintenance, and caring 
for your family. These are asked in Part 3. 
 
1. Do you currently have a job or do any unpaid work outside your home? 
 
  Yes  
 
 No Skip to PART 2: TRANSPORTATION 
 
The next questions are about all the physical activity you do on a usual weekas part of your 
paid or unpaid work. This does not include traveling to and from work. 
 
2. On a usual week, on how many days do you do vigorous physical activities like heavy 
lifting, digging, heavy construction, or climbing up stairsas part of your work? Think 
about only those physical activities that you do for at least 10 minutes at a time. 
 
_____ days per week 
 
 No vigorous job-related physical activity Skip to question 4 
 
3. How much time do you usually spend on one of those days doing vigorous physical 
activities as part of your work? 
 
_____ hours per day 
_____ minutes per day 
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4. Again, think about only those physical activities that you do for at least 10 minutes at a 
time. During ausual week, on how many days do you do moderate physical activities 
like carrying light loads as part of your work? Please do not include walking. 
 
_____ days per week 
 
 No moderate job-related physical activity Skip to question 6 
 
5. How much time do you usually spend on one of those days doing moderate physical 
activities as part of your work? 
 
_____ hours per day 
_____ minutes per day 
 
6. On a usual week, on how many days do you walk for at least 10 minutes at a time as 
part of your work? Please do not count any walking you do to travel to or from work. 
 
_____ days per week 
 
 No job-related walking Skip to PART 2: TRANSPORTATION 
 
7. How much time do you usually spend on one of those days walking as part of your work? 
 
_____ hours per day 
_____ minutes per day 
 
PART 2: TRANSPORTATION PHYSICAL ACTIVITY 
 
These questions are about how you traveled from place to place, including to places like 
work, stores, movies, and so on. 
 
8. On a usual week, on how many days do you travel in a motor vehicle like a train, bus, 
car, or tram? 
 
_____ days per week 
 
 No traveling in a motor vehicle Skip to question 10 
 
9. How much time do you usually spend on one of those days traveling in a train, bus, car, 
tram, or other kind of motor vehicle? 
 
_____ hours per day 
_____ minutes per day 
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Now think only about the bicycling and walking you might do to travel to and from work, to 
do errands, or to go from place to place. 
 
10. On a usual week, on how many days do you bicycle for at least 10 minutes at a time to 
go fromplace to place? 
 
_____ days per week 
 
 No bicycling from place to place Skip to question 12 
 
11. How much time do you usually spend on one of those days to bicycle from place to 
place? 
 
_____ hours per day 
_____ minutes per day 
 
12. During a usual week, on how many days do you walk for at least 10 minutes at a time to 
go from place to place? 
 
_____ days per week 
 
 No walking from place to place Skip to PART 3: 
HOUSEWORK, HOUSE 
MAINTENANCE, AND 
CARING FOR FAMILY 
 
13. How much time do you usually spend on one of those days walking from place to place? 
 
_____ hours per day 
_____ minutes per day 
 
 
PART 3: HOUSEWORK, HOUSE MAINTENANCE, AND CARING FOR FAMILY 
 
This section is about some of the physical activities you might do in a usual week in and 
around your home, like housework, gardening, yard work, general maintenance work, and 
caring for your family. 
 
14. Think about only those physical activities that you do for at least 10 minutes at a time. On 
a usual week, on how many days do you do vigorous physical activities like heavy 
lifting, chopping wood, shoveling snow, or digging in the garden or yard? 
 
_____ days per week 
 
 No vigorous activity in garden or yard Skip to question 16 
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15. How much time do you usually spend on one of those days doing vigorous physical 
activities in the garden or yard? 
 
_____ hours per day 
_____ minutes per day 
 
16. Again, think about only those physical activities that you did for at least 10 minutes at a 
time. On a usual week, on how many days do you do moderate activities like carrying 
light loads, sweeping, will behing windows, and raking in the garden or yard? 
 
_____ days per week 
 
 No moderate activity in garden or yard Skip to question 18 
 
17. How much time do you usually spend on one of those days doing moderate physical 
activities in the garden or yard? 
 
_____ hours per day 
_____ minutes per day 
 
18. Once again, think about only those physical activities that you do for at least 10 minutes 
at a time. On a usual week, on how many days do you do moderate activities like 
carrying light loads, will behing windows, scrubbing floors and sweeping inside your 
home? 
 
_____ days per week 
 
 No moderate activity inside home Skip to PART 4: 
RECREATION, SPORT AND 
LEISURE-TIME PHYSICAL 
ACTIVITY 
 
19. How much time do you usually spend on one of those days doing moderate physical 
activities inside your home? 
 
_____ hours per day 
_____ minutes per day 
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PART 4: RECREATION, SPORT, AND LEISURE-TIME PHYSICAL ACTIVITY 
 
This section is about all the physical activities that you do in a usual week solely for 
recreation, sport, exercise or leisure. Please do not include any activities you have already 
mentioned. 
 
20. Not counting any walking you have already mentioned, on a usual week, on how many 
days do you walk for at least 10 minutes at a time in your leisure time? 
 
_____ days per week 
 
 No walking in leisure time Skip to question 22 
 
21. How much time do you usually spend on one of those days walking in your leisure time? 
 
_____ hours per day 
_____ minutes per day 
 
22. Think about only those physical activities that you do for at least 10 minutes at a time. On 
a usual week, on how many days do you do vigorous physical activities like aerobics, 
running, fast bicycling, or fast swimming in your leisure time? 
 
_____ days per week 
 
 No vigorous activity in leisure time Skip to question 24 
 
23. How much time do you usually spend on one of those days doing vigorous physical 
activities in your leisure time? 
 
_____ hours per day 
_____ minutes per day 
 
24. Again, think about only those physical activities that you did for at least 10 minutes at a 
time. On a usual week, on how many days do you do moderate physical activities like 
bicycling at a regular pace, swimming at a regular pace, and doubles tennis in your 
leisure time? 
 
_____ days per week 
 
 No moderate activity in leisure time Skip to PART 5: TIME 
SPENT SITTING 
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25. How much time do you usually spend on one of those days doing moderate physical 
activities in your leisure time? 
_____ hours per day 
_____ minutes per day 
 
 
PART 5: TIME SPENT SITTING 
 
The last questions are about the time you spend sitting whilst at work, at home, whilst doing 
course work and during leisure time. This may include time spent sitting at a desk, visiting 
friends, reading or sitting or lying down to watch television. Do not include any time spent 
sitting in a motor vehicle that you have already told me about. 
 
26. On a usual week, how much time do you usually spend sitting on a weekday? 
 
_____ hours per day 
_____ minutes per day 
 
27. On a usual week, how much time do you usually spend sitting on a weekend day? 
 
_____ hours per day 
_____ minutes per day 
 
 
This is the end of the questionnaire, thank you for participating. 
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4.0 Where do I go for clinical assessment? 
 
Please come to the Arthritis and Musculoskeletal Research Group Laboratory (AMRG Lab) 
on the second floor of S Block, Room 218 of the University of Sydney (Cumberland 
Campus) in Lidcombe.  The address of University of Sydney (Cumberland Campus) is 75 
East Street, Lidcombe NSW 2141. 
 
 
 
 
A member of the research team (Ms. Marilie Aguila, Dr Andrew Leaver or Dr Trudy 
Rebbeck) will meet you at the receiving area of the AMRG Lab which you will find as soon 
as you enter S218.  
 
Here are some suggestions to get to the Cumberland campus by public transport: 
 
By train 
The nearest railway station to the Cumberland campus is Lidcombe station. It takes 
approximately 20-30 minutes to walk to campus from the station. We recommend using the 
available bus services. 
By bus 
• The Metrobus M92 service (Parramatta to Sutherland via Cumberland Campus)  
• The 915 bus (Lidcombe/TAFE/University) service. 
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Bus stop locations 
• From Lidcombe Station: On the eastern Commonwealth Bank side  
• From Cumberland Campus: Going to Lidcombe, the bus stop is located outside 
Gate 1. Travelling from Lidcombe station or towards Bankstown the bus stop is on 
East Street, located on the opposite side of road from the campus between Gates 1 & 
2. 
If you are driving, there are a number of parking spots inside the campus. 
 
 
 
Current visitor parking fees are $5.00 per entry for Gate 2 & $4.00 per day for Gate 3. 
 
Contact:  Ms Marilie Aguila  T 02 9351 9010   M 0405-756675 
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Alternative clinical assessment venue: 
Sydney Specialist Physiotherapy Centre 
Level 1, 50 York Street, Sydney 2000 
 
 
Please refer to http://www.transportnsw.info/ for trip planning and public transportation 
timetables.  
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5.0 Clinical assessment 
 
5.1 Subjective Examination 
5.1.1 Check information on baseline questionnaire for completeness and 
confirm details for accuracy 
5.1.2 Other questions: general health etc.: 
 
1. Do you have headache today?  Yes      No 
If yes:  
When did it start? How long has this episode been going on?  _____________ 
How would you describe the headache? ______________________________ 
How would you rate the intensity of the headache on a scale of 0 to 10, 0 
being no pain and 10 being the worst possible pain? _______________ 
2. When will be your last headache episode?  
_______________________________________ 
3. How long does a headache episode last if it is untreated or if it is not successfully treated?  
Minimum _____ hours ______ minutes 
Maximum  _____ hours ______ minutes 
4. Does your headache go away 
between episodes? 
   Yes      No 
5. What symptoms accompany your headaches?   
Does it always come with your headache?  
How would you rate the intensity of that symptom?(Mild? Moderate? Severe?) 
 
Accompanying symptoms How often Intensity 
Never Occasionally Often Mild Moderate Severe 
Nausea       
Vomiting        
Light sensitivity       
Noise sensitivity       
Lightheaded/dizzy       
Unsteadiness       
Blurred vision       
Eye swelling       
Loss of appetite       
Yawning       
Fatigue       
Confused thinking       
Other.______________________       
6. Do you have neck pain or stiffness    Yes      No 
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with your headache 
7. Do you feel any sensation for a period of minutes to an hour before the onset of your
headache?
a. visual aura (e.g. blind spots, flashing or zigzag lights) □   Yes□   No
b. feeling of pins/needles or numbness □ Yes□   No
c. feeling of weakness □ Yes□   No
d. feeling of difficulty speaking □ Yes□   No
If you have any of these aura symptoms, can you describe how long each symptom 
lasts? _______________________________________________________________ 
8. What do you think causes your headache or makes it worse?
a. Certain foods (e.g. chocolate, cheeses)  
b. Alcohol (e.g. red wine, beer, spirits)  
c. Awkward head or neck postures or neck movement  
d. Sustained neck postures (e.g. reading)  
e. Pressure over the neck or base of skull on the headache side  
f. Medication  
g. Routine physical activity or walking stairs  
h. Lifestyle factors (e.g. excessive sleep, fasting or dieting)  
i. Exercises/sports  
j. Environmental factors (e.g. strong odours, smoke, weather
changes)
 
k. Stress or anxiety  
l. Fatigue  
m. Hormonal changes  
n. Other.  Please describe_____________________________  
o. Does not know what brings on headache / Does not see any
pattern
 
9. Do you know what started your headache?
What do you think started your headache?
Does not know  
Knows what started headache (Please describe below)  
_____________________________________________________________ 
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10. What relieves your headache?  
a. Medication(Are these the same ones you listed on the baseline 
questionnaire?) 
 
b. Heat/ice applications  
c. Physical activity  
d. Neck exercise or change of position  
e. Alcohol  
f. Relaxation  
g. Massage  
h. Sleeping/rest  
i. Unknown  
j. Other. Please describe ________________________________  
11. Have you received physical 
treatment for your headache? 
   Yes      No 
  If yes, what are these? ____________________________________ 
12. Have you received alternative 
treatment for your headache? 
   Yes      No 
  If yes, what are these? ____________________________________ 
13. Have you been diagnosed with any 
other condition that may be related 
to your headache? 
   Yes      No 
14. Have you had any imaging or 
laboratory test done on your neck? 
   Yes      No 
If yes, what will be the test and what will be the result? 
__________________________ 
15. Do other members of your family suffer from similar headaches?    
 Yes (please specify relation) 
________________________ 
 No  Unsure  
16. Are you comfortable to go through clinical 
tests typically done forneck pain? 
   Yes      No 
17. Are you comfortable to go through 
ultrasound imaging? 
   Yes      No 
18. Are you willing to fill out an online 
headache diary for 6 months? 
   Yes      No 
5.2 Clinical Examination 
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5.2.1 Cervical ROM 
Procedure for Measuring Neck Motion with the CROM (Reproduced from CROM Procedure 
Manual)  
 
“The CROM Instrument is aligned on the nose bridge and ears and is fastened to the head 
by a Velcro strap (see Figure 1).The rotation meter is magnetic and responds quickly to the 
shoulder-mounted magnetic yoke, accurately measuring cervical rotation. Because the 
rotation meter is controlled by the magnetic yoke, shoulder substitution is eliminated. 
 
 
Figure 1. CROM with rotation arm and magnetic yoke 
 
 
 
 
 
 
 
 
 
 
 
 
Three dial angle meters are used to take most of the measurements. The sagittal plane meter 
and the lateral flexion meter are gravity meters. The rotation meter is magnetic and 
responds quickly to the shoulder-mounted magnetic yoke, accurately measuring cervical 
rotation. Because the rotation meter is controlled by the magnetic yoke, shoulder substitution 
is eliminated. 
 
Cervical Flexion and Extension 
Instruct the participant to sit erect in astraight-back chair sitting upright with the sacrum 
against the back of the chair, the thoracic spine away from the back of the chair, arms 
hanging at sides and feet flat on the floor. Next, instruct the participant to position the CROM 
instrument as if putting on a pair of glasses. Ensure the CROM sitting on ears. Fasten the 
Velcro straps snuggly in line with the bows. You will not need the magnetic yoke, rotation 
armforward head arm or vertebra locator for these measurements. 
 
To assure full flexion in this multi-joint area, the participant 
should start in neutral posture.First,instruct the participant to 
“bring your chin to your chest as far as you can comfortably 
go” (suboccipital flexion). Then ask “Can you go any 
further?” in order toobtain full cervical flexion(see Figure 2). 
To take the reading on the sagittal plane meter, read through 
the meter’s beveled edge; from this angle the pointer will be 
magnified to the dial edge. Record this measurement in the 
appropriate space on the recording sheet. 
 
 
To measure cervical extension, first instruct the participant to 
Figure 2: Cervical flexion 414
“Look up to the ceiling as far as you comfortably can. Then have the participant extend 
further until full extension is achieved. “Can you go any further?” Record this measurement 
also. 
 
Lateral Flexion 
Instruct the participant to sit erect on a straight-back chairwith the sacrum against the back of 
the chair, thethoracic spine away from the back of the chair, arms hanging at sides and feet 
flat on the floor. To eliminate rotation during lateral flexion, the participant should focus on a 
point on a wall straight ahead. The sagittal plane meter will read zero if the participant is 
looking straight ahead. The lateral flexion meter will also read zero if the head is not laterally 
flexed. If the lateral flexion meter does not read zero, record the reading as lateral flexion at 
rest. You will not need the magnetic yoke, rotation arm, forward head arm nor vertebra 
locator for these measurements. 
 
Instruct the participant to flex the head laterally to the left, keeping the shoulders level and 
without rotating the head (see Figure 3). Monitor for shoulder elevation by lightly placing 
your hand on the right shoulder, and correct manually any head motion outside the coronal 
plane. Note and record the measurement from the lateral flexion meter. 
 
Now instruct the participant to flex the head laterally to the right, again keeping the shoulders 
level without rotating the head (see Figure 4). As before, monitor for left shoulder elevation 
and correct head motion. Note and record the measurement from the lateral flexion meter. 
 
 
Figure 3: Left lateral flexion   Figure 4: Right lateral flexion 
415
WARNING: The magnetic yoke should not be used if the participant has an implanted 
pacer or defibrillator. 
 
Rotation 
 
You will need to use the CROM instrument plus the magnetic yoke and rotation arm for these 
measurements. To obtain an accurate rotation measurement, first determine which direction is 
north. (You can find magnetic (map) north by noting the direction of the red needle on the 
rotation meter when it is at least four feet from the magnetic yoke.) 
 
Next, place the magnetic yoke on the participant’s shoulders with the arrow pointing 
north.(See Figure 5.) 
 
Figure 5: Magnetic yoke pointing north 
 
 
Instruct the participant to sit erect on a straight-back chair with the sacrum against the back of 
the chair, the thoracic spine away from the back of the chair, arms hanging at sides and feet 
flat on the floor. The lateral flexion and sagittal plane meters must read zero for the rotation 
meter to be level; if necessary, assist the participant into the correct position. As the 
participant faces straight ahead, grasp the rotation meter between your thumb and index 
finger and turn the meter until one of the pointers is at zero. 
 
Instruct the participant to focus on a horizontal line on the wall so the head is not tipped 
during rotation. Ask participant to straighten up if required. Have the participant turn the 
head as far to the left as possible (see Figure 6), and to ensure that no shoulder rotation 
occurs, lightly stabilize the right shoulder with your hand. (Note: if the head and shoulders 
are rotated together the pointer will not move because the magnetic yoke positioned on the 
shoulders eliminates shoulder substitution). Record this measurement in the appropriate place 
on the recording sheet. 
 
Whilst you lightly stabilize the left shoulder, instruct the participant to turn the head as far as 
possible to the right (see Figure 7). Record this measurement also.” 
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Figure 6: Left rotation Figure 7: Right rotation 
Movement Range (degrees) Comment 
Flexion 
Extension 
Left lateral flexion 
Right lateral flexion 
Left rotation 
Right rotation 
5.2.2 Cervical flexion rotation test 
NOTE: Do the flexion rotation test using the CROM device. 
Cervical flexion rotation test will be done following the protocol described in Hall T, 
Robinson K (2004)4.  
The cervical flexion rotation test assesses dysfunction at the C1-C2 segment (Hall & 
Robinson, 2004)4. This test will be done following the protocol of Stratton and Bryan (1994) 
as described by Hall and Robinson (2004)4 and using the CROM to measure the range of 
passive cervical rotation.  
The participant is asked to wear the CROM device and lies supine and relaxed. The patient’s 
head is pre-positioned so that the cervical spine is in end range of flexion. Keeping the 
4 Hall T, Robinson K (2004) The flexion-rotation test and active cervical mobility—A comparative 
measurement study in cervicogenic headache. Man Ther 9:197–202. 
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cervical spine maximally flexed, the head is then passively rotated to the left and the right. 
The assessor then instructs the participant as follows: “Let me do all the work. You just have 
to relax and let me know if the movement produces or increases pain or headache”. End of 
range is at that point when a firm resistance is felt by the assessor or when the participant 
complains of pain or headache, whichever comes first. It is important to do this test with the 
least provocation of headache or other related symptoms. The examinerthen measures of the 
range of rotation to determinewhether the FRT is positive or negative. 
 
A positive test is defined where the range of movement at which restriction, pain or headache 
sets in is ≤ 32o.5. 
 
  Positive Left:   ______ degrees 
Right: ______ degrees 
  Negative 
 
5.2.3 Cranio-cervical flexion test (CCFT) 
Cranio-cervical flexion test will be done following the protocol of Jull et at., 20086 
This will be done in two stages. 
Stage 1: Analysis of performance of the craniocervical flexion (CCF) action. 
The participant is positioned in supine, crook lying with theirears aligned with the shoulder or 
parallel with the plinth. Initially, check that participant has the range passively—hence the 
examiner performs passive CCF first. The dial should increase to at least 30mmHg. Ensure 
the movement is NOT provocative of headache symptoms to proceed. If provocative of 
symptoms, DO NOT proceedwith the test. Note that sometimes if you adjust the participant 
position to slightly elevate shoulders, the test may become asymptomatic (presumably 
because reducing stretch on sensitive neural tissue).  
Instruct the participant to “Slowly slide the back of your head up the bed to nod your 
chin.”The examiner analyses the movement to ensure that it is head rotation with negligible 
activity in the sternocleidomastoid or anterior scalene muscles. This movement is analysed by 
observing and/or palpating the activity in the superficial flexors during the flexion. 
  
5Ogince M, Hall T, Robinson K (2007) The diagnostic validity of the cervical flexion-rotation test in C1/2-
related cervicogenic headache. Man Ther 12:256–262. 
 
6 Jull GA, O'Leary SP, Falla DL (2008) Clinical assessment of the deep cervical flexor muscles: The 
craniocervical flexion test. J Manipulative PhysiolTher 31:525–533. 
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 Then ask the participant to do this movement using the 
pressure biofeedback unit (PBU). The PBU is partially 
inflated and positioned such that its top is on the back of 
the head (Figure 8). With the participant in starting 
position, inflate the PBU to 20mmHg. Ask the 
participant to do the nodding movement to elevate the 
target pressure from 20 to 22 mmHg (top of red/pink 
band). 
Figure 8. Participant starting position for CCFT 
 
Signs of abnormal muscle behaviour or activation patterns of the deep cervical flexors are as 
indicated below, and the corrective strategies in the adjacent column.  
Abnormal Action Corrective Cues 
Retraction strategy: Head rotation does not 
increase with increases in pressure targets 
and the movement becomes more a head 
retraction action than craniocervical flexion 
Passively correct the movement pattern by 
moving the participant’s head through 
craniocervical flexion. 
Early activation of SCM:  Superficial 
cervical flexors are overly active especially 
at the early stage of the movement  
Use the following verbal cues: “eye look 
down”, “Look at the ceiling and slowly look 
down to just above your knees” 
Compensation with hyoid muscles.  
 
 
Inhibit activity of the hyoid muscles using 
this verbal cue: “Put your tongue on the roof 
of your mouth, lips together and teeth 
apart)”  
The head does not return to the starting 
position. This is indicated on the dial by 
being less than or greater than 20mmHg.  
First, check the cuff position and inflation 
of the PBU. Make sure the top edge of the 
cuff is just under the occiput. Make sure that 
the cuff is inflated adequately. 
Second, check head position. Is this due to a 
lack of proprioception? Passively move the 
participant’s head to neutral or to the 
starting position and then check the cuff 
reading again 
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Record the reason for ‘failure of the test’ and verbally or manually correct the action. Allow 
the participant 1-2 repetitions to correct the action then proceed to stage 2. 
Stage 2: Testing isometric endurance of the deep cervicalflexors at test stages that the 
participant is able to achieve withthe correct craniocervical flexion action. 
Proceed with this stage when the participant can correctly perform the craniocervical flexion 
movement. Otherwise, provide corrective cues to address the abnormal action. 
The participantdoes the head nod action to 22mmHg and holds the head nod for 5 seconds. If 
the participant canperform at least 3 repetitions of 5-second holds withoutsubstitution 
strategies, the test is progressed to the nextpressure target.Repeat the process in 2 mmHg 
increments, until 30 mmHg. Use “top of green band” as cue for 24 mmHg, top of yellow 
band for 26 mmHg, top of blue band for 28 mmHg, and black line next to blue band for 30 
mmHg. At each stage, make sure that the correct head nod action is done for all pressure 
increments and that no substitutions are occurring, and the SCM or AS are not overly active. 
Once a level is reached when the participant cannot hold the head nod for 5 seconds for 
repetitions (eg 26mmHg), go back to the previous level (eg 24mmHg). Ask the participant to 
do 10- second hold at this pressure increment for 3 repetitions.If the participant can perform 
as many repetitions of 10-second holds of the head nod without substitution strategies.  
The examiner should watch out for signs of reduced endurance of the deep cervical flexors 
during the head nod: the superficial flexor muscles are overly active, the head is jerky despite 
holding the neck in flexion, the pressure of the PBU is not held steady and/or decreases. 
Record the pressurelevel(s) that the participant can hold steady for 10 seconds and the 
number of repetitions at that level, with minimal superficial muscle activity and without 
substitution strategies.If the test will be not performed because of provocation of headache, 
record accordingly. 
22 mmHg: 
24 mmHg: 
26 mmHg: 
28 mmHg: 
30 mmHg: 
Number of repetitions of 10 sec-holda: ________ 
Number of repetitions of 10 sec-hold: ________ 
Number of repetitions of 10 sec-hold: ________ 
Number of repetitions of 10 sec-hold: ________ 
Number of repetitions of 10 sec-hold: ________ 
 Unable to do test 
 
a Must be able to do at least 3 good repetitions to progress to the next pressure target 
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5.2.4 Strength test: Cervical flexors 
Maximal isometric force in the neck flexor and extensor muscles will be measured using the 
Lafayette Manual Muscle Tester (Model 01163) handheld dynamometer using a protocol by 
Silvermann et al 19917, also described in Dumas et al., 20018.This technique has been shown 
to have good reliability (ICC>0.74). Two trials will be done and the highest score will be 
used for statistical analysis. 
The participant will be positioned supine, with the chin nodded (that is, maintaining 
craniocervical neutral). The examiner places his/her hand under the participant’s occiput at 
the beginning of the test. The participant is instructed to lift the head just off the examiner’s 
hand by gently pushing against the dynamometer then pushing progressively harder whilst 
the examiner holds the device still (isometric hold, make test). Contraction is held for about 
3–5 seconds (or until the dynamometer beeps twice). Two trials will be done with adequate 
rests between trials. 
The mean of both repetitions will be used for statistical analysis. 
Strength Test Force (kg) Comment 
Trial 1 Trial 2 Highest Score 
Neck flexors 
7Silverman JL, Rodriquez AA, Agre JC (1991) Quantitative cervical flexor strength in healthy subjects and in 
subjects with mechanical neck pain. Arch Phys Med Rehabil 72:679–681. 
8 Dumas JP, Arsenault AB, Boudreau G, Magnoux E, Lepage Y, Bellavance A, Loisel P. (2001) Physical 
impairments in cervicogenic headache: traumatic vs. nontraumatic onset. Cephalalgia 21:884–893. 
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5.2.5 Endurance test: Cervical flexors 
Cervical flexor endurance will be measured following the protocol of Harris et al., 20059; 
also cited in Edmonston et al., 200810. 
This technique will be appropriate for participants with headaches showed excellent test-
retest reliability (ICC = 0 93) when used with individuals with postural neck pain 9.  
The test will be performed with the participant in crook-lying on a plinth, with hands on the 
abdomen (Figure 9).  
Figure 9. Starting position for endurance test of 
the neck flexors 
Guide the participant’s head through slight upper neck flexion (head nod). The amount of 
flexion is just enough so that the head lifts about 2.5 cm above the plinth. After two trials and 
with the participant able to do the correct movement, the participant is ready to do the test. 
The examiner then places his/her hand on the plinth just below the occiput. The 
participantslowly flexes his or her upper neck and lifts his or her head just off the examiner's 
handwhilst retaining the upper neck flexion (Figure 10).  
Figure 10. Head position for endurance test of 
the neck flexors 
9Harris KD, Heer DM, Roy TC, Santos DM, Whitman JM, Wainner RS (2005) Reliability of a measurement of 
neck flexor muscle endurance. Physical therapy 85:1349–1355. 
10Edmondston SJ, Wallumrød ME, Macléid F, Kvamme LS, Joebges S, Brabham GC (2008) Reliability of 
isometric muscle endurance tests in subjects with postural neck pain. J Manipulative PhysiolTher 31:348–354. 
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Verbal feedback to maintain the head in slight flexion is provided (“tuck your chin in” or 
“hold your head up”). The test will be terminated if the participant is unable to maintain the 
flexed position, or is limited by exacerbation of pain or headache or discomfort,or at 1 
minute, whichever comes first. The holding time will be measured in minutes and seconds. 
Endurance Test Time (mins:secs) Comment 
Neck flexors 
5.2.6 Palpation 
Manual examination of the upper cervical joints will be done following the protocol of 
Maitland, 198211 and Zito, Jull & Story, 200612. 
Participant position: Participant is in prone with forehead resting on one palm (hands 
overlapped) and neck positioned in neutral mid-flexion-extension position. 
Examiner position: Standing at the head of the treatment table. 
Palpate the suboccipital area overlying and superior to the atlas with the tips of the middle 
three fingers.  To do this, the pressure of the finger tips should be directed towards the 
participant's eyes and the tissue should be palpated by both a medial-lateral movement and a 
postero-anterior movement (Figure 11). 
Figure 11. Palpation of the suboccipital area 
Continue palpation by using the full length of the pads of the middle and ring fingers of each 
hand in the laminar-trough area (that is from the lateral surface of spinous process to the 
lateral margin of the articular pillar), from C1 to C4. The technique involves moving both 
11Maitland GD (1982) Palpation examination of the posterior cervical spine: The ideal, average and 
abnormal.Aust J Physiother 28:3–12. 
12Zito G, Jull G, Story I (2006) Clinical tests of musculoskeletal dysfunction in the diagnosis of cervicogenic 
headache. Man Ther 11:118–129. 
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hands in rhythm with each other, moving the skin up and down with the pads of the fingers as 
far as the skin allows, whilst gently sinking into the muscle bellies and other soft tissue. The 
purpose is to feel for areas of thickness, swelling and tightness in the soft tissue and also for 
abnormalities of the general bony contour. Perform two or three up and down movements in 
the upper cervical area, then slide the fingers caudally 2 or 3 centimetres and the process is 
repeated until the level of C4 is reached. 
 
Once the general andmore gross impression has been gained through the full pads of the 
fingers, the procedure should be repeated but this time using the tip of the pad of only one 
finger of each hand. 
 
Ask the participant if any of the movements provoke or relieve the headache. Then ask the 
participant to rate any local or referred pain provoked during the manual examinationat any 
joint. The participant then rates the pain using a 0–10 verbal analogue scale, where 0 is no 
pain and 10 is the worst pain possible. 
 
Headache provoked?  Yes   No  
     
If yes, at which level?  0/C1  VAS:  
  C1/C2  VAS:  
  C2/C3  VAS:  
  C3/C4  VAS:  
 
 
5.2.7 Cervical extensor test 
 
Cervical extensor test will be performed as described on page 213 of Jull G, Sterling M, Falla 
D, Treleaven J, O’Leary S. (2008)13.   
Background 
Cervical muscle behaviour is commonly assessed in people with neck pain. Reliable 
protocols for cervical flexor motor performance have been established and there is increasing 
body of evidence supporting the coexistence of neck pain and cervical flexor muscle 
behavioure.g. 14. Whilst protocols for measuring cervical extensor muscle endurance and 
13Jull G, Sterling M, Falla D, Treleaven J, O’Leary S. (2008). Whiplash, headache, and neck pain: research-
based directions for physical therapies. Churchill Livingstone/Elsevier, Edinburgh. 
 
14O’Leary S, Falla D, Jull G (2011)The relationship between superficial muscle activity during the cranio-
cervical flexion test and clinical features in participants with chronic neck pain. Manual Therapy 16:452-455. 
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strength have been established e.g. 15, to date, reliable protocols for assessing cervical extensor 
motor control have not. 
Associations between deep extensor (multifidus) muscle cross sectional area and motor 
activation of the lumbar multifidus and pain have been demonstrated in participants with 
lower back pain16. This same association is believed by some clinicians to be a feature of 
neck pain, but has yet to be demonstrated. 
Deep Extensor Muscle Behaviour 
Cervical Extensor Test 
The cervical extensor test will be performed as described by Jull et al (2008)17.  This test is 
understood to bias activation of the deep cervical extensors (namely the semispinalis cervicis 
and multifidus groups) with some validity obtained under fMRI18. The cervical extensor test 
will be scored through video analysis of the performance of the participant according to 
maintenance of the start position, eccentric phase and concentric phase. The following scores 
will be reported: Overall score, Phase 1 (Maintenance of start position) score,Phase 2 
(Eccentric phase) score, Phase 3 (Concentric phase) score, and aggregate score which is the 
total of the phase scores. The participant is required to expose the neck, upper back and 
shoulder. A singlet top will provide sufficient exposure. 
Start position 
The participant will be instructed on adopting a prone position on the plinth with their head 
over the edge of the bed (see Figure 12).The participant is instructed on holding this position 
for 10 seconds then performing a slow neck flexion (see Figure 13) and extension procedure 
without involving head extension beyond neutral. 
Instruction (Video filming commences) 
Participant instructions 
One standard instruction will be issued to the participant: “I will place your head in a 
position called the start position. Look at a point directly below your head on the floor. Can 
you hold this position for 10 seconds first then perform the movement. The movement to 
perform is to curl your neck slowly downwards so that you are looking underneath the plinth, 
then slowly curl your neck back up to the start position without lifting your chin. Ensure you 
15Edmondston SJ, Wallumrød ME, Macléid F, Kvamme LS, Joebges S, Brabham GC (2008) Reliability of 
isometric muscle endurance tests in subjects with postural neck pain. J Manipulative PhysiolTher 31:348–354. 
16Hides JA, Stokes MJ, Saide MJ, Jull GA, Cooper DH (1994) Evidence of lumbar multifidus muscle wasting 
ipsilateral to symptoms in patients with acute/subacute low back pain. Spine 19:165.–172. 
17 Jull G, Sterling M, Falla D, Treleaven J, O’Leary S. (2008). Whiplash, headache, and neck pain: research-
based directions for physical therapies. Churchill Livingstone/Elsevier, Edinburgh (beginning page. 213). 
18O'Leary S, Cagnie B, Reeve A, Jull G, Elliott JM (2011) Is there altered activity of the extensor muscles in 
chronic mechanical neck pain? A functional magnetic resonance imaging study.Archives of physical medicine 
and rehabilitation 92:929–934. 
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finish so that your eyes are looking at the ground where they started.” The participant will be 
given verbal feedback and manual correction for two test movements. 
The participant will be asked to repeat this 10 times. 
Testing 
The participant assumes the “Start Position” with manual and verbal correction by the 
examiner as required. 
The participant will be asked to hold the starting position for 10 seconds. The “hold time” 
will be recorded by the assessor using a stopwatch. The assessor will count each second of 
this period aloud. At the conclusion of the “hold time”, the assessor will repeat the 
instructions through each stage of the test movement. 
“Look at a point directly below your head on the floor. 
Now slowly curl your neck downwards so that you are looking underneath the plinth. 
Now slowly curl your neck back up to the start position without lifting your chin. 
Your eyes should be looking at the same point on the ground as where they started. 
Now repeat 10 times.” 
The assessor then counts each repetition that the participant performs.(Video filming 
concludes.) 
. 
 
Video Analysis 
Concurrent video analysis will be conducted. The video camera will be positioned on a tripod 
perpendicular to the participant to obtain a lateral view. The distance between the camera and 
the participant, tripod height, camera inclination and zoom setting will be standardised. 
Ensure that the legs of the plinth (at the head of the plinth) and the tripod are on their 
designated markers on the floor. 
Figure 12: Start position (Phase 1) Figure 13: Neck flexion during Phase 2 
(eccentric phase) 
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Optimal settings to be determined 
Camera distance Position the head at start position in centre grid of camera screen 
Tripod height (As set) 
Camera inclination Position the head at start position in centre grid of camera screen 
Zoom 100% 
 
Rate overall performance using the following scale: 
Normal 9-10 repetitions of correct pattern 
Mostly normal: 5-8 repetitions of correct pattern 
Mostly abnormal 1-4 repetitions of correct pattern 
Abnormal Unable to perform 1 repetition correctly 
 
Number of repetitions until failure (loss of optimal motor performance) _________out of 10 
Overall performance  Normal   Mostly 
normal 
  Mostly 
abnormal 
  Abnormal 
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Assessment Notes: 
Rating of each phase: Encircle the cell that describes the performance at each phase. 
 
Phase 1: Maintenance of start position 
0 1 2 3 Comment 
Maintains 
start position 
Mostly 
maintains 
start position 
Mostly does 
not maintain 
position 
Definitely 
does not  
maintain start 
position 
Drifts into Flexion 
Drifts into UCE 
 
Phase 2: Eccentric phase 
0 1 2 3 Comment  
Normal 
control 
Mostly 
normal 
Mostly 
abnormal 
Abnormal  Forward translation of head             
Dominant CCF  motion 
Movement is jerky or quick 
Full range of neck flexion 
not achieved 
 
Phase 3: Concentric phase 
0 1 2 3 Comment  
Normal 
control  
Mostly 
normal  
Mostly 
abnormal 
Abnormal 
 
Head not returned to starting 
position 
Low cervical spine not 
returned to the starting 
position 
Dominant CCE motion 
Movement is jerky or quick  
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Cause of failure, if any (Tick all that apply, based on video.)  
 Lower cervical spine drifts into flexion at starting position 
 Forward translation of the head during eccentric phase 
 Movement is jerky during eccentric phase 
 Participant does not lift head back up to start position during concentric phase 
 The head returns to the starting position by the low cervical spine remains in flexion 
(sags) during concentric phase 
 Inability to maintain a neutral craniocervical flexion/extension position 
 Participant in a position of craniocervical extension through or at the end of repetition 
 Visually prominent semispinalis capitis muscle 
 Other: (Please describe.) _______________________________________________ 
 
 
Failure of optimal motor performance of this task is understood to occur for many reasons.  
Some of the reasons suggested are outlined in the following table with description of how this 
will appear visually. 
Table. Common reasons for failure of the CET 
 
Reason for failure Description 
1. Starting Position  
Lower cervical spine drifts into flexion An inability to maintain a neutral cervical spine 
posture against gravity i.e., the lower cervical 
spine will sag into flexion 
2. Eccentric Phase  
Forward translation of the head Participant cannot control flexion of the lower 
cervical spine against gravity (eccentric 
extensor action). Instead the head translates 
downward rather than curling downward. 
Movement is jerky  
3. Concentric Phase  
Return of head position Participant does not lift head back up to start 
position as they fatigue. A difference of 5 
degrees is considered not returning to the start 
position. 
Return of low cervical spine position The head returns to the starting position but the 
low cervical spine remains in flexion (sags) 
4. Overall Performance  
Dominance of craniocervical extension 
action 
Inability to maintain a neutral craniocervical 
flexion/extension position, participant in a 
position of craniocervical extension through or 
at the end of repetition. Visually prominent 
semispinalis capitus muscle 
Number of repetitions of accurate 
performance 
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5.2.8 Strength test: Cervical extensors 
Cervical extensor strength will be measured using a Lafayette Manual Muscle Tester (Model 
01163) handheld dynamometer using a protocol similar to that used by Silvermann et al 
199119 also described in Dumas et al., 200120. This technique has been shown to have good 
reliability (ICC>0.74). 
The participant lies in prone. The dynamometer is placed on the back of the head. The 
participant will be asked to lift his or her head off the bed. The examiner will place his or her 
hand under the participant’s forehead to ensure the head remains off the bed for the test. The 
participant will be asked to first gently push against the dynamometer then to push 
progressively harder whilst the examiner holds the device still (isometric hold, make test). 
Contraction will be performed against the dynamometer for about 3-5s (until dynamometer 
beeps twice).  Two trials will be done.  
The mean of both repetitions will be used for statistical analysis.  
Strength Test Force (kg) Comment 
 Trial 1 Trial 2 Highest Score  
Neck 
extensors 
    
   
19Silverman JL, Rodriquez AA, Agre JC (1991) Quantitative cervical flexor strength in healthy subjects and in 
subjects with mechanical neck pain. Arch Phys Med Rehabil 72:679–681. 
 
20 Dumas JP, Arsenault AB, Boudreau G, Magnoux E, Lepage Y, Bellavance A, Loisel P. (2001) Physical 
impairments in cervicogenic headache: traumatic vs. nontraumatic onset. Cephalalgia 21:884–893. 
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5.2.9 Endurance test: Cervical extensors 
Cervical extensor endurance will be measured following the protocol of Edmonston et al 
200821. 
The endurance test for the cervical extensors is a modification of a test described 
byLjungquist et al (1999)22, also adapted from the Biering-Sorensen lumbar extensor test. 
The participantwill lie in prone with the head over the edge of the plinth. Arms are kept to the 
side. The examiner supports the participant’s head A strap will be placed at the level of T6 to 
support theupper thoracic spine. A band will be fixed aroundthe head with a fluid 
inclinometer attached to the band overthe occiput. A 2-kg weight will be suspended from 
theheadband so that the weight will be located just short of thefloor. The participant's head 
will be positioned in neutral position and the test begins when the examiner removes the 
support of the participant's head. (see Figure 14). 
The participantholds the cervical spine horizontal with the chinretracted. The test is 
terminated if the neck position changes by more than 5° from the horizontalas measured by 
the inclinometer, or if the participant could no longer hold the position due to pain or 
discomfort, or at 3 minutes and 20 seconds, whichever comes first. Theholding time will be 
measured in minutes and seconds. 
Endurance Test Time (mins:secs) Comment 
Neck extensors 
21Edmondston SJ, Wallumrød ME, Macléid F, Kvamme LS, Joebges S, Brabham GC (2008) Reliability of 
isometric muscle endurance tests in subjects with postural neck pain. J Manipulative PhysiolTher 31:348–354. 
22Ljungquist T, Fransson B, Harms‐Ringdahl K, Björnham Å, Nygren Å (1999) A physiotherapy test package 
for assessing back and neck dysfunction—Discriminative ability for patients versus healthy control subjects. 
Physiotherapy Research International 4:123–140. 
Figure 14. Starting position for endurance 
test for the cervical extensors 
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5.2.10 Real-time ultrasound imaging 
Measurement of cervical multifidus using real time ultrasound 
Configuration of the ultrasound machine 
For the measurement of cervical multifidus, a 5-10MHz transducer (adjusted to 5MHz for big 
build, 7.5 MHz for medium build, and 10MHz for small build) transducer is used to make 
measurements of muscle size and shape (VF 8- 3 +); depth is set at 4cm (may need to adjust 
for a larger neck size i.e. 5 cm) and focus adjusted to the level of the midpoint of the muscle. 
Gain, dynamic range, TGC and contrast is adjusted to optimise visualisation of the fascial 
planes. 
Participant positioning 
A standardised position of the participant is to be ensured for reproducibility of 
measurements across participants. The participant is seated in a chair with the feet flat on the 
floor facing the bed. The participant’s head is rested on pillows.  
Identification of the cervical multifidus 
The spinous process of the C4level is identified by palpation and marked with a pen. 
Imaging of the neck 
Imaging of the neck is carried out by placing the transducer perpendicular to the long axis of 
the posterior neck at the C4 level. The left and right side of the neck is imaged separately by 
sliding the transducer left/right until an image is obtained where the spinous process is 
horizontally level with the uppermost part of the articular pillar. Multifidus is identified by 
the following landmarks: inferiorly the bony outline of the lamina, laterally by the facet joint, 
superiorly by the fascial plane, medially by the spinous process. The clearest image is 
ensured by maintaining the transducer 90 degrees to the fascia of the underlying muscle or 
varying the tilt of the transducer until the clearest fascial plane is present. In the presence of 
two facial planes, measurements are taken from the facial plane closest in level to the spinous 
process. 
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Measurements 
• Lateral dimension  
The lateral dimension is measured as the distance between the echogenic spinous 
process/highest point of the spinous process and the point where the two fascial planes meet 
adjacent to the supero/medial border of the facet. 
• Antero-posterior dimension 
The anterior-posterior dimension is measured by bisecting the lateral distance, measuring 
from leading edge to leading edge-top edge of fascial plane superiorly (lower of the two 
when two present), to the top edge of the lamina (brightest part).  
 
• How to use the equipment: Siemens RTUS machine 
1. Press power button 
2. Allow a few minutes for machine to start 
3. Press New participant 
4. To choose “neck” protocol, go to exam and double click “NECK” 
5. Enter participant data 
6. Press ok 
7. This will take you to “Live image” 
8. Apply a liberal amount of gel on the transducer head 
9. Place transducer over spinous process at C4 level 
10. When ready, press “Freeze” and then “Print store” to capture the image 
11. Then place the transducer over the cervical multifidus at C4 level on the 
left side 
12. When ready, press “Freeze” and then “Print store” to capture the image 
13. Turn menu button (central) x1 to left 
14. Choose “clip capture” 
15. Scroll down far left toggle to “time capture” 
16. Choose 8 secs by scrolling toggle up 
17. Adjust clip speed if necessary on left button corner of screen  
18. Keep the transducer on the cervical multifidus and ask the participant to 
lift his/her head off the pillow, and capture this image by pressing 
“Freeze” and then “Clip store”. 
19. Then place the transducer over the cervical multifidus at C4 level on the 
right side 
20. When ready, press “Freeze” and then “Print store” to capture the image 
21. Keep the transducer on the cervical multifidus and ask the participant to 
lift his/her head off the pillow, and capture this image by pressing 
“Freeze” and then “Clip store”. 
22. To create new participant data, press “live screen” and repeat steps 3-5 
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23. To retrieve clip, go to participant data (2nd button top left on key board) 
and click on latest entry 
24. To save image on USB, plug in USB (port is located at the back of 
machine on right), USB will appear on screen under “export/import” 
Neck Protocol Pre-set Parameters: 
VF 8 3+ Persist 4 
Neck R/S 3 
36 dB Map 3 
7.3 MHz Tint 1 
DR 55dB DTCE Med 
Edge 2 32 fps 
 
• Instructions for measuring 
• Measuring D1: Lateral dimension 
1. Press calliper first, then move the mouse to place on the echogenic 
spinous process/highest point of the spinous process, not past the 
convexity of the spinous process. Note, at times the best frame may not 
display the spinous process on the screen, with it being on the edge or just 
off the screen. If this is the case, choose the highest point of the spinous 
process at the point it leaves the screen or follow the lamina up. 
2. Press set. 
3. Move calliper using the mouse to the second pointwhere the two fascial 
planes meet adjacent to the supero/medial border of the facet, medial to 
the convex curve of the facet joint. Note, you may follow the lamina up to 
the facet joint to reach this same point. 
4. Press set. 
5. This will display as D1 on the screen. Record this in the table provided.  
 
• Measuring D2: Bisecting point of D1 
 
6. Calculate (D1)/2 (i.e. ½ the D1 distance) 
7. Press calliper and place on one of the lateral dimension points  
8. Press set. 
9. Follow the lateral dimension line across by the distance measured in step 
6. 
10. Press set. 
11. This will display as D2 on the screen. Record this in the table provided. 
 
• Measuring D3: Perpendicular bisector of D1 
12. Press calliper and place on the D2 point which halves the D1 line (the 
point from step 9). 
13. Press set. 
14. Move the mouse down to the top edge of the lamina (highest brightest 
part). This will be close to the fascial layer for rotatores. 
15. Press set. 
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16. This will display at D3. Record this in the table provided. 
 
• Measuring D4: ‘Shortest’ AP dimension (closest to multifidus AP dimension) 
17. Press calliper then move the mouse to the top edge of the lamina (highest 
brightest part) at the point perpendicularly below your D2 point (the 
bottom of the D3 line). 
18. Press set 
19. Move the calliper using the mouse along the D3 line until you meet 
theleading edge (top edge) of the first facial plane that you can see, 
usually situated close to the D1 line or in line with the facet joint and 
spinous process. This first facial plane will not be present on all video 
clips. If this is the case, simply record N/A or comment in the table 
provided. 
20. Press set. 
21. This will display as D4. Record this in the table provided. If the first facial 
plane is not present in the clip, simply record N/A or comment in the table 
provided. 
 
• Measuring D5: “Longest” AP dimension   (closest to multifidus plus semi-
spinalis) 
22. Press calliper and move the mouse to the top edge of the lamina (highest 
brightest part), the same point as in step 17. 
23. Press set. 
24. Move the calliper using the mouse to the leading edge (top edge) of the 
first fascial plane that you see above the facet joint or spinous process.  
Note, in some video clips, there may be two fascial planes (quite close 
together) present above the facet joint or spinous process. 
25. Press set. 
26. This will display as D5. Record this using the table provided. 
 
• Measuring contracted dimensions:  
27. Click patient browser again. This should display the original clip. 
 
 Choosing the frame: Muscle contracted 
28. Watch the clip once more to determine when multifidus is contracting. 
29. Move the clip to the time given in the table. The time is located at the top 
of the screen, next to the date. 
 
 Measuring D1–D5 FOR CONTRACTED STATE 
30. Repeat steps 1–26. 
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• Data collection_RTUS cervical multifidus EXAMPLE: 
 
 
 
 
 Left Right 
Relaxed Contracted Relaxed Contracted 
Lateral dimension     
Antero-posterior dimension (D4)     
Antero-posterior dimension (D5)     
Muscle shape (Lat / AP)     
Multiplied linear dimension  
(Lat x AP) 
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• How to use the equipment: GE Logiq Portable Ultrasound Machine 
1. Press power button (top centre of keyboard) 
2. Allow a few minutes for machine to start 
3. Press “New Patient” (left side of control panel). 
4. A login window will appear.  Leave the password blank and move the 
trackball to “log on”. Press “Set /B Pause” button (lower right off centre of 
control panel) to select “log on” on screen. 
5. Enter participant data: Patient ID, Last Name, First Name. If these cells are 
not blank, move trackball to “New Patient” on screen and then press “Set 
/B Pause” button (lower right off centre of control panel) 
6. Check that Category on left side of screen has “Small Parts” depressed.   
7. Press “New Patient” button on control panel again. This will take you to 
the live image screen. 
8. Check that the following parameters are correct: 
• Neck (protocol) 
• B mode 
• Fq 8.0Hz 
• Gn 62 
• E/A 3/2 
• Map N/0 
• D 3.0cm 
• DR 66 
• FR 65Hz 
• AO 100% 
9. Apply a liberal amount of gel on the transducer head. 
10. Place transducer over spinous process at C4 level. 
11. When ready, press “Freeze” and then “P1” to capture the image. 
12. Then place the transducer over the cervical multifidus at C4 level on the 
left side. 
13. When ready, press “Freeze” and then “P1” to capture the image. 
14. Keep the transducer on the cervical multifidus and ask the participant to 
lift his/her head off the pillow, and capture this image by pressing 
“Freeze” and then “P1”. 
15. Then place the transducer over the cervical multifidus at C4 level on the 
right side. 
16. When ready, press “Freeze” and then “P1” to capture the image 
17. Keep the transducer on the cervical multifidus and ask the participant to 
lift his/her head off the pillow, and capture this image by pressing 
“Freeze” and then “P1”. 
18. To retrieve clips from live image screen: 
a. Press “Freeze” button (lower right of control panel) so that it is lit 
up.   
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b. Press unmarked button (lower left off centre of control panel). This 
will make the cursor appear. 
c. Move trackball to desired image. 
d. Press “Set /B Pause” button (lower right off centre of control 
panel). 
19. To retrieve clips from home screen: 
a. Press “New Patient” (left side of control panel). 
b. Choose the participant name or ID of interest from the list at the 
bottom of the screen. 
c. Press “Set /B Pause” button (lower right off centre of control 
panel). 
d. Move trackball to “Image History” on upper left of screen.  Press  
“Set /B Pause” button to select image. 
20. To measure: 
a. Press “Measure” button above trackball. 
b. Move the trackball to position the active caliper at the point of 
interest. 
c. Press “Set /B Pause” button to fix caliper at start point. 
d. Move the trackball along the distance or depth. 
e. Press “Set /B Pause” button to fix first caliper at end point. 
21. To save image on hard disk: 
a. Press unmarked button (lower left off centre of control panel). This 
will make the cursor appear. 
b. Move cursor using trackball to image of interest then click “Set /B 
Pause” button. 
c. Move trackball to Menu on right bottom corner of screen then click 
“Set /B Pause” button. 
d. Select “Save as”. 
e. In “Save in” box, choose “HD (E:\export)” from dropdown 
choices. 
f. Write file name as “(Participant ID_left/right_resting/contracting”) 
e.g. IS-000_left_resting 
g. Use the following parameters for the rest of the details: 
i. Image only 
ii. Compression: None 
iii. Quality: 100 
iv. Save as type: Jpeg (*.jpg) 
22. To save image on removable disk: 
a. Plug in removable disk (USB port at the back) 
b. Follow instructions for saving to hard disk but choose to save in 
removal disk. 
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5.3 Classification to Headache Groups 
5.3.1 Checklist for Migraine Group 
 
ICHD-3 beta criteria 2.3.1. Migraine without 
aura 
Participant response 
A. At  least 5 attacks fulfilling criteria B-D  
B. Headache attacks lasting 4-72 hours (untreated 
or unsuccessfully treated)  
 
C. Headache has at least two of the following 
characteristics: 
 Unilateral location 
 Pulsating quality 
 Moderate or severe pain intensity 
 Aggravation by or causing avoidance of 
routine physical activity (eg walking or 
climbing stairs)  
 
D. During headache at least one of the following 
 Nausea and/or vomiting 
 Photophobia 
 Phonophobia 
 
E. Not better accounted for by another ICHD-3 
diagnosis  
 
 
 
ICHD-3 beta criteria 2.3.2. Migraine with 
aura  
Participant response 
A. At  least 2 attacks fulfilling criteria B and 
C 
 
B. One or more of the following fully 
reversible aura symptoms:  
 Visual (e.g. flickering lights, spots or 
lines, loss of vision) 
 Sensory (e.g. pins and needles, 
numbness) 
 Speech and/or language   
 Motor 
 Brainstem 
 Retinal 
 
C. At least two of the following: 
 At least one aura symptom develops 
gradually over > 5minutes, and/or two 
or more symptoms occur in 
succession  
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ICHD-3 beta criteria 2.3.2. Migraine with 
aura  
Participant response 
 Each individual aura symptom lasts 5-
60 minutes 
 At least one aura symptom is 
unilateral  
 The aura is accompanied, or followed 
within 60 minutes, by headache 
D. Not better accounted for by another 
ICHD-3 diagnosis, and transient 
ischaemic attack has been excluded 
 
 
ICHD-3 beta criteria 2.3.3. Chronic 
migraine 
Participant response 
A. Headache (tension-type like and/or 
migraine-like) on > 15 days per 
month for > 3 months and fulfilling 
criteria B and C 
 
B. At least 5 attacks fulfilling criteria 
B-D for migraine without aura 
and/or criteria B and C for migraine 
with aura  
 
C. Headache attacks lasting 4-72 
hours (untreated or unsuccessfully 
treated)  
 
D. Headache has at least two of the 
following characteristics: 
 Unilateral location 
 Pulsating quality 
 Moderate or severe pain 
intensity 
 Aggravation by or causing 
avoidance of routine physical 
activity (eg walking or climbing 
stairs)  
 
E. During headache at least one of the 
following 
 Nausea and/or vomiting 
 Photophobia 
 Phonophobia 
 
F. One or more of the following fully  
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ICHD-3 beta criteria 2.3.3. Chronic 
migraine 
Participant response 
reversible aura symptoms:  
 Visual (e.g. flickering lights, 
spots or lines, loss of vision) 
 Sensory (e.g. pins and needles, 
numbness) 
 Speech and/or language   
 Motor 
 Brainstem 
 Retinal 
G. At least two of the following: 
 At least one aura symptom 
develops gradually over > 
5minutes, and/or two or more 
symptoms occur in succession  
 Each individual aura symptom 
lasts 5-60 minutes 
 At least one aura symptom is 
unilateral 
 The aura is accompanied, or 
followed within 60 minutes, by 
headache 
 
H. On > 8 days per month for > 3 
months, fulfilling any of the 
following: 
 Criteria C and D for migraine 
without aura  
 Criteria B and C for migraine 
with aura 
 Believed by the participant to 
be migraine at onset and 
relieved by a triptan or ergot 
derivative 
 
I. Not better accounted for by another 
ICHD-3 diagnosis 
 
 
Fulfilled criteria for migraine?  
 Yes: Included in Migraine Group 
 No: Consider inclusion in Other Non-Migrainous Headaches Group 
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5.3.2 Checklist for Other Non-Migrainous Headaches Group 
5.3.2.1 Tension-type headache 
 
ICHD-3 beta criteria 2.4.1.1. Infrequent episodic 
tension-type headache 
Participant response 
A. At least 10 episodes of headache occurring on <1 
day per month on average (<12 days per year) 
and fulfilling criteria B-D 
 
B. Lasting from 30 minutes to 7 days  
C. At least two of the following: 
 Bilateral location 
 Pressing or tightening (non-pulsating) quality 
 Mild or moderate intensity 
 Not aggravated by routine physical activity 
such as walking or climbing stairs 
 
D. Both of the following: 
 No nausea or vomiting 
 No more than one of photophobia or 
phonophobia 
 
E. Not better accounted for by another ICHD-3 
diagnosis 
 
 
ICHD-3 beta criteria 2.4.1.2. Frequent 
chronic tension-type headache 
Participant response 
A. At least 10 episodes of headache occurring 
on 1-14 days per month on average for > 30 
months (> 12 days and < 180 days per year) 
and fulfilling criteria B-D 
 
B. Lasting from 30 minutes to 7 days  
C. At least two of the following: 
 Bilateral location 
 Pressing or tightening (non-pulsating) 
quality 
 Mild or moderate intensity 
 Not aggravated by routine physical 
activity such as walking or climbing 
stairs 
 
D. Both of the following: 
 No nausea or vomiting 
 No more than one of photophobia or 
phonophobia 
 
E. Not better accounted for by another ICHD-3 
diagnosis 
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ICHD-3 beta criteria 2.4.1.3. Chronic 
tension-type headache 
Participant response 
A. > 15 days per month on average for >3 
months (> 180 days per year), 
fulfilling criteria B-D 
 
B. Lasting hours to days or unremitting  
C. At least two of the following: 
 Bilateral location 
 Pressing or tightening (non-
pulsating) quality 
 Mild or moderate intensity 
 Not aggravated by routine physical 
activity such as walking or 
climbing stairs 
 
D. Both of the following: 
 No more than one of photophobia, 
phonophobia or mild nausea 
 Neither moderate or severe nausea 
or vomiting 
 
E. Not better accounted for by another 
ICHD-3 diagnosis 
 
 
5.3.2.2 Cervicogenic headache 
 
ICHD-3 beta criteria 2.4.2. Cervicogenic 
headache 
Participant response 
A. Any headache fulfilling criterion C  
B. Clinical, laboratory and/or imaging 
evidence of a disorder or lesion within the 
cervical spine or soft tissues of the neck, 
known to be able to cause headache 
 
C. Evidence of causation demonstrated by at 
least two of the following: 
 Headache has developed in temporal 
relation to the onset of the cervical 
disorder or appearance of the lesion 
 Headache has significantly improved or 
resolved in parallel with improvement 
in or resolution of the cervical disorder 
or lesion 
 Cervical range of motion is reduced and 
headache is made significantly worse by 
provocative manoeuvres 
 Headache is abolished following 
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ICHD-3 beta criteria 2.4.2. Cervicogenic 
headache 
Participant response 
diagnostic blockade of a cervical 
structure or its nerve supply 
D. Not better accounted for by another ICHD-3 
diagnosis 
 
 
 
 Yes: Included in Other Non-Migrainous Headaches Group 
 No: Consider inclusion as mixed type or unclassifiable   
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6.0 REDCap headache diary for 6 months 
 
7.0 Follow up at 1 month, 3 months and 6 months after enrolment 
7.1 REDCap headache diary 
7.2 McGill Pain Questionnaire 
7.3 Central Sensitization Inventory 
7.4 Headache Impact Test-6 
7.5 The Henry Ford Headache Disability Index  
7.6 Headache Disability Questionnaire 
7.7 WHO Disability Assessment Schedule 2.0 
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APPENDIX 6 
Summary of Media Coverage for the Study 
Presented in Chapter 3 
This summary was provided by The University of Sydney Media Office. 
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WED 17 FEBRUARY 2016
Media coverage on migraine and GABA study
Executive summary
The following is a summary of the media coverage gained on the study 'Elevated levels of GABA+ in migraine detected using 1H­MRS'
NMR in Biomedicine, May 2015.
The study was released to the media in October 2015 with Maria Aguila as the media spokesperon.
The media coverage gained reached an estimated audience of 2,028,208, with the biggest audience share from TV.
*Note: This report may not capture all online articles.
A cure for debilitating migraines could be a step closer thanks to a world-first ...
13 Oct 2015 6:20 PMChannel 7, Perth, Seven News, Rick Ardon and Susannah Carr
Duration: 1 min 32 secs • ASR AUD 14,523 • WA • Australia • Radio & TV • ID: M00063542601
A cure for debilitating migraines could be a step closer thanks to a world-first breakthrough by
University of Sydney researchers. They've discovered a chemical imbalance of a substance
called GABA in the brain of sufferers, and are now looking to develop new ways to treat the
condition.
Audience
191,000 ALL, 80,000 MALE 16+, 94,000 FEMALE 16+
Interviewees
Maria Aguila, University of Sydney|Marnee McKay, Migraine Sufferer
Also broadcast from the following 1 station
GWN7 (Perth)
COPYRIGHT This report and its contents are for the internal research use of Mediaportal subscribers only and must not
be provided to any third party by any means for any purpose without the express permission of Isentia and/or the relevant
copyright owner. For more information contact copyright@isentia.com
DISCLAIMER Isentia makes no representations and, to the extent permitted by law, excludes all warranties in relation to
the information contained in the report and is not liable for any losses, costs or expenses, resulting from any use or misuse
of the report.
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A cure for migraine could be one step closer thanks to a breakthrough by researchers at ...
13 Oct 2015 6:28 PMChannel 7, Melbourne, Seven News, Jennifer Keyte
Duration: 2 mins 0 sec • ASR AUD 50,286 • VIC • Australia • Radio & TV • ID: M00063540742
A cure for migraine could be one step closer thanks to a breakthrough by researchers at the
University of Sydney.
Audience
327,000 ALL, 128,000 MALE 16+, 179,000 FEMALE 16+
Interviewees
Maria Aguila, University of Sydney|Marnee McKay, Migraine Sufferer
Also broadcast from the following 9 stations
Prime7 Albury (Albury), Prime7 Ballarat (Ballarat), Prime7 Bendigo (Bendigo), Prime7 Gippsland (Sale), Prime7
Mildura (Mildura), Prime7 Shepparton (Shepparton), Prime7 Swan Hill (Swan Hill), Prime7 Warrnambool
(Warrnambool), Southern Cross Darwin (Darwin)
A cure for debilitating migraines could be a step closer thanks to a world-first ...
13 Oct 2015 6:30 PMChannel 7, Brisbane, Seven News, Sharyn Ghidella and Bill McDonald
Duration: 1 min 51 secs • ASR AUD 37,070 • QLD • Australia • Radio & TV • ID: M00063541425
A cure for debilitating migraines could be a step closer thanks to a world-first breakthrough by
University of Sydney researchers. They've discovered a chemical imbalance of a substance
called GABA in the brain of sufferers, and are now looking to develop new ways to treat the
condition.
Audience
405,000 ALL, 133,000 MALE 16+, 224,000 FEMALE 16+
Interviewees
Maria Aguila, University of Sydney|Marnee McKay, Migraine Sufferer
Also broadcast from the following 9 stations
Seven Bundaberg (Bundaberg), Seven Cairns (Cairns), Seven Central (Alice Springs), Seven Mackay (Mackay),
Seven Mt Isa (Mt Isa), Seven Rockhampton (Rockhampton), Seven Sunshine Coast (Sunshine Coast), Seven
Toowoomba (Toowoomba), Seven Townsville (Townsville)
COPYRIGHT For the internal research use of Mediaportal subscribers only. Not to be provided to any third party for any purpose without the express
permission of Isentia. For further information contact copyright@isentia.com
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Research at the University of Sydney into migraines has found a chemical called Gamma ...
13 Oct 2015 6:47 PMChannel 7, Sydney, Seven News, Mark Fergusson
Duration: 2 mins 0 sec • ASR AUD 87,548 • NSW • Australia • Radio & TV • ID: M00063541157
Research at the University of Sydney into migraines has found a chemical called Gamma which
causes them. Migraines cost the economy $7b a year.
Audience
406,000 ALL, 133,000 MALE 16+, 232,000 FEMALE 16+
Interviewees
Maria Aguila, University of Sydney|Marnee McKay, Migraine Sufferer
Also broadcast from the following 15 stations
Prime7 ACT (Canberra), Prime7 Armidale (Armidale), Prime7 Coffs Harbour (Coffs Harbour), Prime7 Cooma
(Cooma), Prime7 Dubbo (Dubbo), Prime7 Gold Coast (Gold Coast), Prime7 Griffith (Griffith), Prime7 Moree
(Moree), Prime7 Newcastle (Newcastle), Prime7 North Coast (Lismore), Prime7 Orange (Orange), Prime7
Tamworth (Tamworth), Prime7 Taree (Manning River), Prime7 Wagga Wagga (Wagga Wagga), Prime7
Wollongong (Wollongong)
Migraine breakthrough: One step closer to solving the painful puzzle
13 Oct 2015 7:14 PMCountryman by Dr Andrew Rochford, 7 News
332 words • ASR AUD 4,710 • University of Sydney Internet • ID: 480273767
Read on source website
Audience
N/A UNIQUE DAILY VISITORS, N/A AV. STORY AUDIENCE
Australian researchers at the University of Sydney have made a breakthrough in ...
14 Oct 2015 6:35 PMSouthern Cross Tasmania, Hobart, Southern Cross Nightly News, Jo Palmer
Duration: 1 min 54 secs • ASR AUD 4,477 • TAS • Australia • Radio & TV • ID: M00063557029
Australian researchers at the University of Sydney have made a breakthrough in understanding
migraines.
Audience
63,000 ALL, 22,000 MALE 16+, 32,000 FEMALE 16+
Interviewees
Maria Aguila, University of Sydney|vox pops
COPYRIGHT For the internal research use of Mediaportal subscribers only. Not to be provided to any third party for any purpose without the express
permission of Isentia. For further information contact copyright@isentia.com
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FED:CheckUp medicaL column for October 16
16 Oct 2015AAP Newswire, Australia, National, AAP
669 words • ASR N/A • Photo: No • Type: AAP NewswireClassification:  • National • Australia • Press • ID: 481958842
View original  - Full text: 669 word(s), ~2 mins
Audience
N/A CIRCULATION
Researching the baffling migraine
19 Oct 2015District Reporter Camden, Camden, General News
Page 7 • 475 words • ASR AUD 189 • Photo: No • Type: News ItemClassification:  • Size: 230.00 cm² • NSW • Australia • Press
• ID: 484405048
View original  - Full text: 475 word(s), ~1 min
Audience
16,900 CIRCULATION
Chemical imbalance linked to migraines
21 Oct 2015 3:00 AMlifehealthinsuranceNEWS.com.au by lifehealthinsurancenews.com.au editor
324 words • ASR N/A • University of Sydney Internet • ID: 484419993
Read on source website
Audience
N/A UNIQUE DAILY VISITORS, N/A AV. STORY AUDIENCE
COPYRIGHT For the internal research use of Mediaportal subscribers only. Not to be provided to any third party for any purpose without the express
permission of Isentia. For further information contact copyright@isentia.com
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What I Live With: The Untold Toll Of Migraines Experienced By 1 In 10 Australians
22 Oct 2015 10:37 AMhuffingtonpost.com.au by huffingtonpost.com.au editor
939 words • ASR AUD 7,004 • University of Sydney Internet • ID: 484893677
Read on source website
Audience
N/A UNIQUE DAILY VISITORS, N/A AV. STORY AUDIENCE
Headache over for migraine researchers?
26 Oct 2015Newcastle Herald, Newcastle NSW, General News
Page 21 • 121 words • ASR AUD 471 • Photo: No • Type: News ItemClassification:  • Size: 45.00 cm² • NSW • Australia • Press
• ID: 486621869
View original  - Full text: 121 word(s), <1 min
Audience
32,731 CIRCULATION
Headache may be over for migraine researchers
31 Oct 2015Western Advocate, Bathurst NSW, General News, Margaret Scheikowski
Page 13 • 537 words • ASR AUD 1,146 • Photo: No • Type: News ItemClassification:  • Size: 264.00 cm² • NSW • Australia •
Press • ID: 489790935
View original  - Full text: 537 word(s), ~2 mins
Audience
2,707 CIRCULATION
COPYRIGHT For the internal research use of Mediaportal subscribers only. Not to be provided to any third party for any purpose without the express
permission of Isentia. For further information contact copyright@isentia.com
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FED:CheckUp medicaL column for October 16
    A weekly round-up of news affecting your health
    By Margaret Scheikowski and Angelo Risso
    WALK UNNATURALLY TO BURN MORE KILOJOULES
    If you want to burn more kilojoules when you're walking, just do "weird" things.
    That's the advice of the co-author of an engineering study which found that varying your walking speed
can burn up more energy than maintaining a steady pace.
    The very act of changing speeds burns energy, says Professor Manoj Srinivasan from The Ohio State
University.
    "Walking at any speed costs some energy but when you're changing the speed, you're pressing the gas
pedal, so to speak.
    "Changing the kinetic energy of the person requires more work from the legs and that process certainly
burns more energy."
    Other ways for walkers to burn more kilojoules involve doing it in a way that feels unnatural.
    "Just do weird things," he says.
    "Walk with a backpack, walk with weights on your legs. Walk for a while, then stop and repeat that.
    "Walk in a curve as opposed to a straight line."
    SLEEPY DRIVERS AS DANGEROUS AS DRUNK ONES
    Tired? Behind the wheel? You might as well be drink-driving.
    A Queensland University of Technology study found young drivers were more likely to drive drowsy than
drunk, despite the act being equally as dangerous.
    The study examined 114 drivers under 30 and 177 drivers over 30, finding young drivers were both more
likely to 'sleepy drive' and to disapprove of enforcement practices for sleepy driving.
    "What this shows is that drivers, in particular young drivers, don't view equally the dangers of drink
driving and sleepy driving despite the crash risks being similar," researcher Chris Watling said.
    "Given younger drivers are over-represented in crash statistics and more likely to be impaired by
sleepiness, it is vital we look to increase their perception of the dangers of driving while sleepy."
    Research shows a blood alcohol content of 0.05 is the same as 17 consecutive hours awake, while 20
hours awake is the equivalent of a 0.1.
    NDIS GUIDE FOR MENTAL HEALTH CARERS
    Navigating Australia's new National Disability Insurance Scheme isn't easy.
    But people who provide unpaid care and support to a family member or friend with a psychosocial
disability related to a mental condition can now be helped by a new guide.
    Psychosocial disability describes the experience of people with impairments and participation restrictions
related to mental health conditions.
    The guide, developed by Mental Health Australia and Carers Australia, can be accessed at
http://mhaustralia.org/ and http://www.carersaustralia.com.au/
    HEADACHE OVER FOR MIGRAINE RESEARCHERS?
    Migraines have been puzzled over for years but the code may finally have been cracked.
    University of Sydney researchers have found higher levels of the gamma-aminobutyric acid (GABA)
chemical are present in the brains of migraine sufferers.
    GABA is the brain's most abundant inhibitory brain chemical and plays a major role in a person's pain
threshold.
    This lends support to the idea migraines are caused by chemical imbalances in the brain.
    "For such a debilitating condition, very little is known about migraine so this is a big step forward and
could lead to better diagnosis and treatment of the disease in the future," lead researcher Maria Aguila
said.
    "GABA could be used to help us identify migraine sufferers and track responses to drug trials and
measuring GABA levels over a period of time could well reveal what's causing attacks."
       GROW MEDICINES IN YOUR BACKYARD?
    Two scientists seeking to re-engineer plant proteins to tackle diabetes, obesity and cancer could be a
step closer to their goal.
    David Craik from the University of Queensland and Marilyn Anderson from La Trobe University have
taken out the prestigious $1 million Ramaciotti Biomedical Research Award to produce "next generation"
biodrugs incorporated into plant products such as seeds and teas.
    This could enable patients to cheaply grow medicines in their own backyard, saving millions of lives
across the developing world.
    "This type of blue-sky research falls outside the realm of work typically funded by government or industry
so we are particularly grateful," Professor Craik said.
    AAP mss/mmr
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Researching the
baffling migraine
Migraines have baffled scientists for years -
no-one knows why they come or how they go
- but researchers at the University of Sydney
have taken a significant step forward in
understanding the debilitating condition.
A new study, reveals higher levels of the
chemical gamma-aminobutyric acid in the
brain of migraine sufferers, supporting the
theory that migraines are linked to a chemical
imbalance in the brain. 
"The finding paves the way for the dis-
covery of new, effective treatments for
migraines," said lead researcher Maria
Aguila, PhD candidate in the Faculty of
Health Sciences.
"For such a debilitating condition, very
little is known about migraine so this is a big
step forward and could lead to better diagno-
sis and treatment of the disease in the future,"
she said. 
Gamma-aminobutyric acid or GABA as it
is commonly known, is the most abundant
inhibitory brain chemical and has long been
suspected to play a role in migraines because
of its ability to influence pain. This study is
the first to accurately measure GABA levels
in the living brain. 
While the expert are still at a loss to
understand  "what causes migraine, how it
starts and ends, or why the triggers appear to
differ from one person to the next" the latest
finding can assist with more specific
research,  Ms Aguila said.
"For example, GABA could be used to
help us identify migraine sufferers and track
responses to drug trials, and measuring
GABA levels over a period of time could
well reveal what's causing attacks."
The study compared the levels of GABA
in twenty chronic migraine sufferers to an
age and gender matched control group who
did not experience any form of regular
headaches. Brain scans were conducted when
the participants were not having a migraine.
Associate Professor in Neuroimaging,
Jim Lagopoulos said the ability to directly
measure these chemicals in the brain would
not have been possible several years ago.
"These advances not only allow us to
d f d l h i b i h
study fundamental changes in brain chem-
istry that are associated with migraine, but
they also open a whole new world with
respect to monitoring a patient's response to
treatment and compliance," he said.
The researchers were unable to tell if the
increase in GABA is related to a recent
migraine attack or signalling a new one as the
scanning process is currently too complex to
carry out during a migraine attack.
Fast facts on migraine -
z Migraine is the third most com-
mon disease in the world; 
z It is estimated to affect 1 in 7
adults;
z It is up to three times more com-
mon in women than men;
z Often starting at puberty,
migraine most affects those
aged between 35 and 45 years; 
z Current diagnosis is based on a
complex checklist of signs and
symptoms, and;
z Migraine is believed to be under-
reported and under diagnosed
globally.
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Headacheover formigraine researchers?
MIGRAINEShavebeenpuzzled over for years but the
codemay finally havebeen cracked.University of Sydney
researchers have foundhigher levels of the gamma-
aminobutyric acid (GABA) chemical in the brains of
migraine sufferers. GABA is thebrain’smost abundant
inhibitory brain chemical andplays amajor role in a
person’s pain threshold. This lends support to the idea that
migraines are causedby chemical imbalances in thebrain.
The finding could lead to better diagnosis and treatment.
‘‘GABAcould be used to help us identifymigraine sufferers
and track responses to drug trials andmeasuringGABA
levels over a period of time couldwell revealwhat’s
causing attacks,’’ lead researcherMaria Aguila said.
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Headache may be over for migraine researchers
Checkup
Margaret Scheikowski
MIGRAINES have been puzzled overfor years but the code may finallyhave been cracked.
University of Sydney researchers have
found higher levels of the gamma-
aminobutyric acid (GABA) chemical are
present in the brains of migraine sufferers.
GABA is the brain’s most abundant
inhibitory brain chemical and plays a
major role in a person’s pain threshold.
This lends support to the idea migraines
are caused by chemical imbalances in the
brain.
“For such a debilitating condition, very
little is known about migraine, so this is a
big step forward and could lead to better
diagnosis and treatment of the disease in
the future,” lead researcher Maria Aguila
said.
“GABA could be used to help us identify
migraine sufferers and track responses to
drug trials and measuring GABA levels
over a period of time could well reveal
what’s causing attacks.” 
■ ■ ■
TWO scientists seeking to re-engineer
plant proteins to tackle diabetes, obesity
and cancer could be a step closer to their
goal.
David Craik from the University of
Queensland and Marilyn Anderson from
La Trobe University have taken out the
prestigious $1 million Ramaciotti
Biomedical Research Award to produce
“next generation” biodrugs incorporated
into plant products such as seeds and teas.
This could enable patients to cheaply
grow medicines in their own backyard,
saving millions of lives across the develop-
ing world.
“This type of blue-sky research falls out-
side the realm of work typically funded by
government or industry so we are particu-
larly grateful,” Professor Craik said.
■ ■ ■
NAVIGATING Australia’s new National
Disability Insurance Scheme isn’t easy.
But people who provide unpaid care
and support to a family member or friend
with a psychosocial disability related to a
mental condition can now be helped by a
new guide.
Psychosocial disability describes the
experience of people with impairments
and participation restrictions related to
mental health conditions.
The guide, developed by Mental Health
Australia and Carers Australia, can be
accessed at http://mhaustralia.org/ and
http://www.carersaustralia.com.au/
■ ■ ■
LOGIE-WINNING actor John Wood is
fronting a new campaign to raise aware-
ness about shingles, which will affect one
in three adults.
The condition, involving the painful
outbreak of rash or blisters, is estimated to
have doubled among the over-60s in
recent years, says Chronic Pain Australia.
Half will go on to experience longer-
term nerve pain, lasting 3.5 years on aver-
age.
Wood was bedridden for 13 weeks when
he first had shingles as a teenager and had
it again while filming Blue Heelers in his
50s.
“I want to make sure that those at high-
est risk, people over 60, know about the
potential pain and suffering that shingles
can cause and have a conversation with
their doctor about their risk,” he said.
■ ■ ■
SHINGLES often has vague symptoms
such as mild to severe pain in a particular
area, or a rash, leading people to dismiss
the possibility until it’s too late to treat the
nerve damage.
People with gut problems are taking
part in a world-first trial of an Australian
seaweed extract.
University of Wollongong researchers
are investigating whether the extract can
help prevent the onset of chronic disorders
such as Type 2 Diabetes.
Seaweed dietary fibres are known to
improve the gut and digestive condition of
animals and reduce metabolic stress such
as experienced in the pre-diabetic condi-
tion.
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CAMPERDOWN
Brain is linked to the pain
MIGRAINE STUDY’S FINDINGS
IT’S A disease that has baf-
fled health professionals for
years, but University of Syd-
ney research has findings
that support the theory that
migraines are linked to a
chemical imbalance in the
brain.
A new study reveals high-
er levels of the chemical
gamma-aminobutyric acid
in the brain of migraine suf-
ferers and paves the way for
the discovery of new, effec-
tive treatments, said lead re-
searcher Maria Aguila, PhD
candidate in the Faculty of
Health Sciences.
“For such a debilitating
condition, very little is
known about migraine so
this is a big step forward and
could lead to better diag-
nosis and treatment of the
disease in the future.”
Gamma-aminobutyric 
acid, or GABA as it is com-
monly known, has long been
suspected to play a role in
migraines due to its ability
to influence pain. 
“We still don’t know what
causes migraine, how it
starts and ends … but this
discovery means that we can
now be much more specific
with our research going for-
ward,” said Ms Aguila.
“For example, GABA
could be used to help us
identify migraine sufferers
and track responses to drug
trials, and measuring GABA
levels over a period of time
could well reveal what’s
causing attacks.”
The study compared the
levels of GABA in 20 chronic
migraine sufferers to an age-
and gender-matched control
group who did not experi-
ence any form of regular
headache. 
Brain scans were conduc-
ted when the participants
were not having a migraine.
The researchers were un-
able to tell if the increase in
GABA is related to a recent
migraine attack or signal-
ling a new one, as the scan-
ning process is currently too
complex to carry out during
a migraine attack.
ONE IN SEVEN HIT
 Migraine is the third most 
common disease in the world
 It is estimated to affect one 
in seven adults
 It is up to three times more 
common in women than men
 Often starting at puberty, 
migraine most affects those 
aged between 35 and 45
 Current diagnosis is based 
on a complex checklist of 
signs and symptoms
Migraine is believed to be 
under-reported and under 
diagnosed globally
University of Sydney researchers believe that migraines may
be linked to a chemical imbalance in the brain.
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APPENDIX 7 
 
Cover Art Published in Journal of Pain 
 
 
 
 
 
 
Appendix 7 presents the cover art published in The Journal of Pain Volume 17, Issue 10 
(October 2016) (http://www.jpain.org/issue/S1526-5900(16)X0011-9). The cover illustration 
was a stylised image from an output of the editing process of GABA from the study in 
Chapter Four published in the same issue: [Aguila ME, Rebbeck T, Leaver AM, Lagopoulos 
J, Brennan PC, HübscherM,Refshauge KM. The association between clinical characteristics 
of migraine and brain GABA levels: An exploratory study. J Pain 2016; 17:1058–67. 
doi:10.1016/j.jpain.2016.06.008]  
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APPENDIX 8 
 
The Clinical Significance of Immediate Symptom Responses to 
Manual Therapy Treatment for Neck Pain:  
Observational Secondary Data Analysis of a Randomized Trial 
 
 
 
 
 
Appendix 8 is the peer reviewed version of the following article: Trott, CA, Aguila, MER, 
Leaver, AM, The clinical significance of immediate symptom responses to manual therapy 
treatment for neck pain: Observational secondary data analysis of a randomized trial. Man 
Ther. 2014; 19:549–554.doi: 10.1016/j.math.2014.05.011, which has been published in final 
form athttp://www.mskscienceandpractice.com/article/S1356-689X(14)00113-1/fulltext; with 
permission from Elsevier. 
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ABSTRACT 
Objective 
Toexplore aspects of symptom responses to manual therapy treatment for neck pain.  
 
Methods  
An observational study based on data collected in a randomized trial.181 participants 
seeking care from a physiotherapist or chiropractor for a new episode of neck pain 
were included. Outcome variables included recovery timeand participant-perceived 
effect of treatment (GPE) at 3-months.  
 
Results  
There was a significant reduction of ≥1.4points (95%CI 1.2 to 1.5) in pre- and post-
treatment pain scores at each occasion of treatment. There was also small but 
significant increases in pain of ≤0.7points (95%CI 0.4 to 1.0) between each treatment 
session, without regression to the preceding pre-treatment level. The relationships 
between immediate post-treatment effects and longer-term outcomes were explored 
using multivariate regression analyses. There was significant univariate association 
between recovery time and cumulative post-treatment changes in pain from the 
second, third and fourth (Exp(B)=1.2) treatment sessions, as well as the presence of 
post-treatment headache (Exp(B)=0.7) and other minor adverse symptoms 
(Exp(B)=0.6). There was significant univariate association between GPE at 3-months 
and cumulative pain responses from first (B=0.2), second (B=0.3), third (B=0.3) and 
fourth (B=0.4) treatment sessions. The change in pain after session 1 was 
independently associated with GPE (B=0.2). There was a consistently significant 
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difference of ≥0.7points (95%CI 0.43 to 0.89) in the different methods of reporting 
pain.  
 
 
Conclusions  
Our results show that manual therapy for neck pain involves a “two-steps forward, 
one-step back” recovery pattern. Whilst minor adverse events are undesirable, they do 
not seem to be significantly associated with long-term recovery.  
 
KEY WORDS 
Manual Therapy, Neck Pain, Manipulation Spinal, Pain Measurement 
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INTRODUCTION 
Neck pain is a common musculoskeletal condition experienced by up to 15% of 
people at any given time, and afflicting most people at some stage of their lives 
(Haldeman et al., 2008; Hoy et al., 2010). Manual therapy is one of the few effective 
treatments for neck pain, with demonstrated benefits in improving pain and function, 
at least in the short term (Korthals-de Bos et al., 2003; Hurwitz et al., 2008; Driessen 
et al., 2012). The clinical course of neck pain appears to have fluctuating periods of 
aggravation and remission, with recurrence a common feature of the condition (Cote 
et al., 2004; Haldeman et al., 2008; Hush et al., 2011). Based on current evidence, it 
would appear that manual therapy is of most value in reducing symptoms, restoring 
function and hastening recovery during an episode of acute neck pain.  
 
Although acknowledged as an effective treatment, the therapeutic mechanisms 
underpinning manual therapy are not fully understood, and many different theoretical 
and philosophical approaches exist amongst and between the disciplines that practice 
manual therapy. One of the most widely recognized approaches to manual therapy 
practice is the approach developed by Australian physiotherapist Geoffrey Maitland. 
One of the key features of Maitland’s approach was the emphasis on monitoring and 
reassessing symptoms during and after application of a technique, as a means guiding 
choice of technique, dosage and treatment progression (Maitland, 1970; Maitland, 
1986). This approach differed from the approaches of many of Maitland’s 
contemporaries who tended to focus more on biomechanical principles to guide 
treatment decisions (Larson, 2005). 
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The use of patient-reported numerical ratings of current pain intensity to guide 
treatment selection and to monitor treatment outcomes is now widespread in modern 
manual therapy practice. Numerical rating scales for pain are also widely used as 
primary outcome measures in clinical trials of manual therapy, as a means of 
determining recovery from an episode of neck pain.The construct of recovery, 
howver, is complex and multidimensional, encompassing many different elements 
that are not necessarily captured by a single number. Focus group interviews of 
people with back pain for example, have shown that people with pain scores of zero 
do not necessarily consider themselves recovered, and some who consider themselves 
recovered can still register pain scores above zero (Hush et al., 2009).Inconsistencies 
have been demonstrated between verbal reports of pain and the standardized 
questionnaires that measure pain and disability in people with low back pain (Ong et 
al., 2006; De Souza and Frank, 2007).Better understanding of the relationship 
between pain scores and patient-relevant indices of recovery, and the ability to 
identify possible biases in patient reports of sympotms might improve monitoring of 
clinical and research outcomes in people with neck pain. 
 
Several studies have previously investigated the relevance of within-session changes 
in symptoms in patients undergoing manual therapy treatment. There is some 
evidence that symptom changes that occur within a treatment session are maintained 
between treatment sessions (Hahne et al., 2004; Tuttle, 2005; Tuttle et al., 2006; 
Tuttle, 2009), and tend to continue throughout the duration of care (Cook et al., 2012). 
There is also some evidence to suggest that changes in pain and disability scores 
during treatment correlate with self-reported rate of recovery(O’Halloran et al., 2013). 
This suggests a relationship between positive treatment responses and recovery in the 
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very short term. The relationship between positive within-session treatment responses 
and longer-term recovery, however, is lacking. Further, the previous studies into the 
within- session responses to manual therapy concentrated primarily on the positive 
effects of manual therapy, such as improvement in pain and range of motion. Manual 
therapy can also result in a range of minor adverse effects (Hurwitz et al., 2005) most 
commonly increased neck pain and headache. Less is known about the effect of these 
adverse effects on recovery.   
 
 The aim of this study was to explore aspects of the immediate symptom responses to 
manual therapy treatment, in people with neck pain. Specifically, this study aimed to 
investigate 
1. The typical clinical course of reported symptoms during a short episode of 
manual therapy care 
2. The relationship between the immediate changes in reported pain following 
manual therapy and longer-term outcomes 
3. The influence of minor adverse effects of manual therapy on longer-term 
outcomes  
4. The consistency between pain scores reported by patients to practitioners and 
those recorded by patients in diaries.  
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METHODS 
 
Design 
This study involved observational secondary data analysis from a randomized 
controlled trial (Leaver et al., 2010) that compared high-velocity thrust manipulation 
with non-thrust mobilization in people with a new episode of neck pain. The original 
randomized controlled trial demonstrated no difference in outcomes between the 
manipulation and mobilization groups. We were therefore able to combine both 
treatment groups for an observation study. 
Participants in the randomized controlled trial kept a daily diary of pain scores and the 
participating practitioners recorded pre- and post-treatment pain scores at each 
treatment session. This provided an opportunity to explore the relationship between 
the short-term effects of manual therapy treatments and longer-term patient relevant 
outcomes, as well as other features of manual therapy care. The study was approved 
by the University of Sydney Human Research Ethics Committee and all participants 
provided written informed consent. 
 
Participants 
The study was conducted in 11 physiotherapy and chiropractic clinics in Sydney, 
Australia, between October 2006 and April 2008. Participants aged 18-70 years who 
were seeking care from a physiotherapist or chiropractor for a new episode of non-
specific neck pain were recruited by their treating practitioner. Eligible participants 
had neck pain of less than three months duration that was preceded by at least one 
month without neck pain. Participants were excluded if they had whiplash-associated 
disorder, history of neck surgery, serious pathology (e.g. malignancy, infection, 
inflammatory disorder, fracture, radiculopathy or myelopathy), primary complaint 
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other than neck pain, mild neck pain (<2/10 on a 0-10 point scale) or were unable to 
communicate in English. For the purpose of the associated randomized controlled 
trial, participants were also excluded if the treating practitioner deemed them 
unsuitable for neck manipulation. Participants from both groups (i.e. manipulation 
and mobilization) were included in the observational study. 
Procedures 
Baseline data were collected using participant questionnaires and practitioner 
assessment forms (Leaver et al., 2010). All participants were treated with up to four 
sessions of multimodal physical therapy that included manual therapy. The manual 
therapy that was provided to participants was either high velocity thrust manipulation 
or non-thrust mobilization according to the randomization schedule of the associated 
randomized controlled trial. Participants were followed for a period of three months 
after baseline assessment. The manual therapy treatments were applied pragmatically 
with the treating manual therapists selecting the target spinal segment, manual therapy 
technique and grade according to their clinical judgment. The treating practitioners 
were physiotherapists and chiropractors with post-graduate training and qualifications 
in spinal manipulative therapy, with at least two years of post-graduate experience. 
Participants completed a pain diary for three months. Diary entries were collected by 
telephone and transcribed weekly to minimize loss of data. An exit interview was 
conducted by telephone at three months to obtain participant’s pain, activity and 
global perceived effect scores. The sample size was determined by the original trial 
and was powered to explore the differences between mobilization and manipulation in 
terms of speed of recovery.  
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Variables/outcomes 
Demographic variables collected at baseline included age, sex, smoking habit, self-
rated general health (5-point categorical scale) and compensation status. Clinical 
variables collected at baseline included pain intensity (numerical rating scale 0-10), 
duration of the current episode of neck pain in days, neck-related disability (Neck 
Disability Index 0-50), past history of neck pain, use of analgesic medications and the 
presence of associated symptoms including arm pain, headache, upper back pain, 
lower back pain, dizziness and/or nausea.  
Pre-treatment and immediate post-treatment pain scores were recorded by the treating 
practitioner using a 0-10 numerical rating scale (NRS). ‘Within-session’ changes in 
pain were calculated as the difference between pre-treatment and post-treatment 
scores at each treatment session. ‘Cumulative change in pain’ relative to baseline was 
also calculated as the difference between the baseline pain score and the post-
treatment score at each treatment session. Variables recorded in the participant diary 
included average 24-hour pain scores on a daily basis for three months as well as 
Neck Disability Index (NDI) (Vernon and Mior, 1991) and Global Perceived Effect 
(GPE) (Kamper et al., 2010) at three-month follow-up. Adverse effects of treatment 
were recorded in the participant diary during the treatment period. A checklist of 
common minor adverse effects including additional neck pain, additional headache, 
dizziness, nausea, fatigue and other was used as well as open-ended questioning. 
The outcome variables were the recovery time for the episode of neck pain and the 
participants’ perception of treatment effects. Recovery time for the episode of neck 
pain was defined as the number of days it took from the day of enrolment in the study 
for a participant to report a pain score of <1 (NRS 0-10) for the first of seven 
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consecutive days. The participants’ perception of the effects of treatment was 
measured with the Global Perceived Effect scale (GPE). The GPE scale rates 
perception of recovery on a scale from -5 (Much worse) to +5 (Much better) and is a 
reliable and patient-focused indicator of recovery (Kamper et al., 2010).  
 
Statistical analysis 
All data were analyzed using Statistical Package for Social Sciences (SPSS)® 
statistical software, version 21 (SPSS Inc., Chicago, Illinois, USA) for Windows. 
Baseline demographic and clinical characteristics were reported as frequencies (%) or 
using descriptive statistics.The clinical course of neck pain during the two-week 
episode of care was reported by plotting pre- and post-treatment pain scores for each 
treatment session during the episode of care. Repeated measures t-test was used to 
compare pre- and post-treatment scores within and between sessions. 
 
The relationships between immediate positive and adverse post-treatment effects and 
longer-term outcomes were explored using multivariate regression. Specifically, the 
relationship between post-treatment effects and recovery time was explored using 
Cox regression. The relationship between post-treatment effects and the perceived 
effects of treatment at three-month follow-up was explored using linear regression. 
For both regression models, the univariate relationships between the within-session 
changes in pain (including the cumulative changes in pain scores from baseline at 
each treatment session) and adverse events were calculated. In the multivariate 
analysis, all variables associated  (p<0.1) with faster recovery or better-perceived 
treatment outcomes were included in the regression models. Variables that no longer 
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associated with recovery were removed in a stepwise manner. Where there was strong 
correlation (Pearson r>0.4) between the predictor variables, the earliest associated 
post-treatment response and the adverse effect with the strongest association were 
included in the multivariate model. Clinical and demographic variables, previously 
shown (Leaver et al., 2013) to be associated with either faster recovery (better self-
rated general health, shorter duration of symptoms, being a smoker, and absence of 
concomitant upper back pain or headache) or higher disability (concomitant upper or 
lower back pain, older age, and previous sick leave for neck pain) were also included 
in the multivariate models. Data and residuals were explored to ensure that all 
assumptions for the use of linear regression analysis were met (Zuur et al., 2010).  
 
The consistency between post-treatment pain scores recorded by the treating therapist 
and those recorded by the patients in their diaries 24-hours after a treatment session 
was tested using paired-samples t-tests.   
 
RESULTS 
Participant characteristics  
One hundred and eighty-one participants were recruited. Of the 237 patients screened, 
56 were excluded due to either not meeting the eligibility criteria (n = 46) or declining 
to participate (n = 10). Five participants withdrew from the study before the three-
month follow-up point. These participants were included in the survival analysis and 
were censored at the date of last data collection. Two of the participants who were 
lost to follow-up completed their course of treatment and were included in all 
analyses that were related to the two-week treatment period. Three participants 
withdrew from the study without completing the course of treatment and were 
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excluded from all analyses. Baseline participant characteristics are presented in Table 
1. The cohort had an average age of 39 years, with two-thirds of participants being 
female. Participants had moderate neck pain (NRS 6.2), moderate disability (NDI 
16/50) and were seeking treatment on average three weeks into the episode of neck 
pain. Concomitant symptoms occurred frequently, particularly pain affecting the 
upper limb (79.6%), head (64.6%) and upper back (63.5%).  
Clinical course of neck pain during a episode of manual therapy care 
The clinical course of neck pain over the two-week treatment period, determined by 
serial pre- and post-treatment pain scores featured a ‘descending saw-tooth’ pattern of 
recovery (Figure 1). On each occasion of treatment there was a statistically significant 
improvement in pain within the session, resulting in a trajectory of cumulative 
improvement across the treatment period. There was also a consistent pattern of small 
but statistically significant increases in neck pain between each treatment session. 
These small relapses did not, on any occasion reach the level of the preceding pre-
treatment score.   
Relationship between within session changes in symptoms and outcome 
 
There was significant (p<0.1) univariate association between time taken to recover 
from the episode of neck pain and several of the response to treatment variables 
including; cumulative post-treatment change in pain from baseline after the second 
(Exp (B)=1.2, 95% CI 1.1 to 1.3), third (Exp (B)=1.2, 95% CI 1.1 to 1.3) and fourth 
(Exp (B)=1.2, 95% CI 1.1 to 1.4) treatment sessions, as well as post-treatment 
headache (Exp (B)=0.7) and other minor adverse symptoms (Exp (B)=0.6). There 
was moderate correlation between the cumulative post-treatment change in pain 
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scores from baseline at each of the treatment sessions (Pearson’s r 0.49, p<0.01). The 
score from the earliest treatment session with univariate association, Session 2, was 
included in the multivariate analysis. There was strong correlation between reports of 
post-treatment headache and other minor adverse effects (Pearson’s r 1.0, p<0.01). 
The presence of post-treatment headache was used in the multivariate analysis 
because it had the strongest univariate association. None of the response to treatment 
variables remained independently associated with recovery time after controlling for 
duration of symptoms, self-rated general health, and baseline headache. 
 
There was significant (p<0.1) univariate association between the perceived effects of 
treatment at three months and cumulative post-treatment change in pain from baseline 
after the first (B=0.2, 95% CI 0.0 to 0.4), second (B=0.3, 95% CI 0.1 to 0.4), third 
(B=0.3, 95% CI 0.1 to 0.4) and fourth (B=0.4, 95% CI 0.2 to 0.5) treatment sessions. 
The association between the perceived effects of treatment at three months and 
reported adverse effects was not statistically significant. The earliest cumulative 
change in post-treatment pain score with univariate association to GPE, Session 1, 
was included in the multivariate analysis. The post-treatment change in pain from 
Session 1 remained independently associated (B=0.2, 95% CI 0.01 to 0.4) with the 
perceived effects of treatment at three months after controlling for concomitant upper 
back pain, lower back pain, older age, and previous sick leave for neck pain. 
 
Consistency of patient-reported pain scores 
 
There was a significant difference (p<0.05) between the pain scores reported to the 
treating practitioners and the scores recorded by participants in their diaries. On each 
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occasion of treatment, the average 24-hour pain scores recorded in the diaries was on 
average approximately one point (0-10 NRS) higher than the scores reported to the 
treating practitioner (Table 2).  
 
 
 
DISCUSSION 
A detailed investigation of the change in symptoms reported by patients and 
practitioners in response to manual therapy for neck pain has provided clinically 
relevant findings and has raised further clinical questions. These findings include new 
information about the clinical course during an episode of manual therapy care, as 
well as new information about the consistency between patient and practitioner 
reports of changes in pain. This study also provides further confirmation of the value 
of within-treatment changes in symptom levels and a means of predicting longer-term 
outcomes.  
 
Unlike previous studies that describe a rather pessimistic outlook for patients with 
neck pain (Carroll et al., 2008; Hush et al., 2011), these results suggest that the 
prognosis is quite favorable for those with a new episode of neck pain who are 
identified by experienced manual therapists as suitable for manual treatments. These 
participants experienced large and rapid improvement in neck symptoms over the 
course of manual therapy treatment. The significant improvements in pain between 
treatment sessions were consistent with previous research exploring manual therapy 
in musculoskeletal pain (Cook et al., 2012), however by tracking changes in reported 
symptoms from treatment to treatment rather than using strict time-contingent review 
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points, we also saw a pattern of recovery that would have otherwise not been evident. 
There was a distinct pattern of a large improvement in reported pain scores within a 
treatment session, followed by a slight relapse between sessions and this pattern was 
consistent across the entire course of treatment. It is tempting to attribute the observed 
pattern of recovery entirely to the beneficial effects of the treatment provided. 
However our study did not include a no-treatment or placebo control and is therefore 
limited in its ability to account for the non-specific interaction effects of the 
treatment. A placebo-controlled trial with a similar review schedule would help to 
identify whether natural recovery or regression to the mean play a role in the 
identified pattern. Another limitation is the use of pain as the sole indicator of short-
term treatment success. The findings would have been strengthened by periodically 
exploring other short-term outcomes measures like range of motion or function. 
 
There is also reason for caution in interpreting the observed pattern of recovery due a 
possible systematic bias in reporting of symptoms. The pain scores reported by 
treating therapists were on average one point lower on the numerical rating scale than 
scores independently recorded by patients over the following day. There are several 
possible explanations for this finding. This discrepancy might represent the same 
tendency for slight relapse following treatment suggested by the between-session 
changes recorded by the practitioners. Alternatively, it is possible that patients under-
reported their post-treatment pain to the therapist out of a desire to please or seem 
grateful. The use of blinded assessors for collection of pre- and post-treatment 
outcomes might have yielded different results. It is also possible that the mode of 
reporting, verbal versus written, has a systematic influence on the levels of pain 
reported by the participants. Despite being a simple and apparently one-dimensional 
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scale, the relationship between a numeral rating of pain and perceptions of recovery is 
complex (Hush et al., 2009). A qualitative research model could possibly be 
employed to further explore some of the questions raised by our observations of the 
difference in patient and therapists reports of pain.  
 
Despite the differences in symptoms reported by the patients to the practitioners and 
those recorded by the patients, both sets of pain scores demonstrated significant and 
progressive improvements with each treatment session. This is important information 
for patients who are being treated with manual therapy for neck pain. Evidence-based 
guidelines for neck and low back pain and (van Tulder et al., 2006; Childs et al., 
2008) emphasize the importance of providing accurate and assuring information to 
patients and setting expectations of recovery. For a patient, information that a brief 
course of treatment is likely to be effective and that their recovery will probably 
involve “two-steps forward, one-step back” is potentially helpful. Improving a 
patient’s understanding of the context of a slight relapse between treatment sessions 
might help provide additional reassurance and decrease negative affective 
interpretations of relapses.  
 
The other important finding for manual therapists and their patients was the 
association between the immediate responses to manual therapy treatment and longer-
term outcomes. This is consistent with other studies that have demonstrated the 
predictive value of within-session responses on treatment outcomes (Hahne et al., 
2004; Tuttle, 2005; Tuttle, 2009; O’Halloran et al., 2013), but adds information about 
the broader value of treatment responses beyond the treatment period. There was an 
independent association between within-session improvements in pain and the 
478
perceived effects of treatment at three months after controlling for clinical and 
demographic variables previously found (Leaver et al., 2013) to be associated with 
neck-related disability. There was also a univariate association between the rate of 
recovery and the cumulative improvement in pain scores at the second, third and 
fourth treatment sessions. Whilst a progressive improvement in symptoms during a 
course of treatment does not predict the rate of recovery independent of the duration 
of pain, general health or absence of headache, it can still be a useful guide for 
clinicians about expected progress. There is an intuitive link between short-term and 
longer-term improvement, which can be incorporated into discussions with patients 
about their expected course of recovery.  
 
Minor adverse events such as headache during the treatment period are of course 
undesirable, however our results suggest that the occurrence of such events does not 
necessarily affect longer-term recovery. There was no independent association 
between experiencing minor adverse events during the treatment period and recovery 
time or the perceived effects of treatment at three months. A recent randomized 
controlled trial(Walker et al., 2013) has shown that adverse events are common in 
both manual therapy treatment groups and placebo controls, suggesting that these 
events may be a feature of the condition rather than due to the effects of treatment. 
The reporting of minor increases in pain or concomitant symptoms after manual 
therapy might even relate to the tendency for minor regression of improvement 
between treatments that our results demonstrate. This information can be used to 
shape patients’ understanding that experiencing minor adverse events may be a part of 
the recovery process and does not reflect impeded recovery.   
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Our results demonstrate than an episode of manual therapy care for patients with non-
specific neck pain results in rapid resolution of symptoms and a positive prognostic 
outlook. By communicating the normality and relatively benign nature of minor 
relapses and minor adverse events during treatment, therapists can assist in shaping 
realistic patient expectations about recovery from the episode of neck pain. Although 
discrepancies and imperfections exist in the reporting styles of pain, treatment 
responses contain valuable information about longer-term outcomes and play a role in 
predicting overall treatment perception and recovery. 
 
Conclusion  
Our results demonstrate that recovery from an episode of neck pain features a pattern 
of significant improvements in pain coinciding with manual treatments, with small 
relapses in pain scores between treatments. There is a relationship between immediate 
improvements in pain during manual therapy treatment and speed of recovery, as well 
as longer-term perceived benefits of treatment.Our findings also indicate that minor 
adverse events or relapses during treatment are not associated with delayed recovery. 
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Table 1.Baseline characteristics (n=181) 
 
Age (years)  38.8 ±10.7 
Sex-Female 117 (64.6%) 
Current smoker 17 (9.4) 
Neck pain duration (days) 19.5 ± 20.1 
Neck-related disability (NDI) 15.5 ± 7.4 
Past history of neck pain 114 (63.0%) 
Past sick leave for neck pain 57 (31.5%) 
Upper limb pain 144 (79.6%) 
Upper back pain 115 (63.5%) 
Lower back pain 71 (39.2%) 
Headache 117 (64.6%) 
Dizziness 56 (30.9%) 
Nausea 41 (22.7%) 
Data are Mean ± SD or N(%);NDI=Neck Disability Index (0-50) 
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Table 2.Differences between pain scores immediately reported to practitioner and 
pain scores entered in participant diary the following day 
 
Treatment 
session 
Immediate post-
treatment pain 
recorded by 
practitioner. NRS 
Mean (SD) 
Average 24-hour 
pain recorder by 
patient the following 
day. NRS 
Mean (SD) 
Mean difference 
NRS between 
practitioner and 
patient score. 
(95%CI) 
Treatment 1 4.2 (1.8) 5.4 (2.0) 1.2* (0.86 to 1.48) 
Treatment 2 3.2 (1.8) 4.2 (2.2) 1.0* (0.70 to 1.31) 
Treatment 3 2.5 (1.8) 3.2 (2.0) 0.7* (0.43 to 0.89) 
Treatment 4 1.6 (1.6) 2.6 (2.1) 1.0* (0.71 to 1.26) 
*p<0.1; NRS=Numerical rating scale (0-no pain, 10-worst possible pain) 
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NRS = Numerical rating scale; Rx = treatment number  
Figure 1. Clinical course of neck pain (Numerical Rating Score 0–10) during an 
episode of manual therapy treatment demonstrating the “descending saw-tooth” 
pattern of immediate improvement followed by slight relapse.    
 
6.45
4.2 4.74 3.18 3.89 2.53 3 1.6401
23
45
67
8
Pre-Rx 1 Post-Rx 1 Pre-Rx 2 Post-Rx 2 Pre-Rx 3 Post-Rx 3 Pre-Rx 4 Post-Rx4Pain 
N
RS
 (0
-1
0)
 re
co
rd
ed
 b
y 
th
e 
tr
ea
tin
g 
hh
485
